WO2009126691A1 - Inhibitors of fatty acid amide hydrolase - Google Patents

Inhibitors of fatty acid amide hydrolase Download PDF

Info

Publication number
WO2009126691A1
WO2009126691A1 PCT/US2009/039872 US2009039872W WO2009126691A1 WO 2009126691 A1 WO2009126691 A1 WO 2009126691A1 US 2009039872 W US2009039872 W US 2009039872W WO 2009126691 A1 WO2009126691 A1 WO 2009126691A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
ring
composition
membered
compound
Prior art date
Application number
PCT/US2009/039872
Other languages
French (fr)
Inventor
Mark L. Behnke
Alfredo C. Castro
Catherine A. Evans
Louis Grenier
Michael J. Grogan
Tao Liu
Daniel A. Snyder
Thomas T. Tibbitts
Original Assignee
Infinity Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40912141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009126691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Pharmaceuticals, Inc filed Critical Infinity Pharmaceuticals, Inc
Priority to AU2009233711A priority Critical patent/AU2009233711B2/en
Priority to CA2721060A priority patent/CA2721060A1/en
Priority to JP2011504146A priority patent/JP5637982B2/en
Priority to CN200980119527.3A priority patent/CN102046179B/en
Priority to EP09729529A priority patent/EP2282742A1/en
Publication of WO2009126691A1 publication Critical patent/WO2009126691A1/en
Priority to IL208536A priority patent/IL208536A0/en
Priority to US12/901,421 priority patent/US8957049B2/en
Priority to US14/599,192 priority patent/US20150368278A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Definitions

  • Fatty acid amide hydrolase also referred to as oleamide hydrolase and anandamide amidohydrolase, is an integral membrane protein that degrades fatty acid primary amides and ethanolamides, including oleamide and anandamide. FAAH degrades neuromodulating fatty acid amides at their sites of action and is intimately involved in their regulation.
  • FAAH has been demonstrated to be involved in a number of biological processes and its inhibition has been shown to be effective in treating a variety of conditions. For example, inhibiting FAAH has been shown to be useful in treating chronic pain, acute pain, neuropathic pain, anxiety, depression, feeding behaviors, movement disorders, glaucoma, neuroprotection and cardiovascular disease.
  • current inhibitors of FAAH lack the target selectivity, biological activity and/or bioavailability needed for in vivo studies and therapeutic use. Thus, to date, the therapeutic potential of FAAH inhibitors remains essentially unexplored.
  • FAAH fatty acid amide hydrolase
  • Ring A is a C3_io carbocyclyl or C ⁇ -io aryl group.
  • Ring A is phenyl.
  • Ring A is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group.
  • Ring A is monocyclic, while in other embodiments Ring A is bicyclic.
  • R A is Ring B, i.e., providing compounds which are encompassed by formula (II):
  • Ring B is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group. In some embodiments, Ring B is monocyclic, while in other embodiments Ring B is bicyclic.
  • SEQ ID NO. 1 Homo sapiens FAAH amino acid sequence:
  • inhibitors of FAAH that contain at least one Lewis acidic boron head group, such as, for example, a boronic acid, boronic ester, borinic acid or borinic ester head group.
  • Lewis acidic boron head group such as, for example, a boronic acid, boronic ester, borinic acid or borinic ester head group.
  • Such compounds include compounds of formula (I):
  • Z 1 is -OH or -OR 3 ; and Z 2 and Ring A taken together form an optionally substituted 5- to 7-membered ring;
  • L 1 is a covalent bond, an optionally substituted straight or branched Ci_ 6 alkylene, or an optionally substituted straight or branched C 2 _6 alkenylene moiety;
  • Ring A is optionally substituted C 3 _ 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl;
  • R A is hydrogen, halogen, -OR 7 , -CF 3 , -CN, -NO 2 , -SO 2 R 7 , -SOR 7 , -C(O)R 7 , -CO 2 R 7
  • Ring B is optionally substituted C 3 -Io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 1 is, independently, halogen, -OR 8 , -CF 3 , -CN, -NO 2 , -SO 2 R 8 , - SOR 8 , -C(O)R 8 , -CO 2 R 8 , -C(O)N(R 8 ) 2 , -N 3 , -N 2 R 8 , -N(R 8 ) 2 , -B(OH 2 ), optionally substituted C i_8 alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _
  • Ci_g heteroalkyl optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _g heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 3 and R 4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _g heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 5
  • R A is Ring B, i.e., compounds encompassed by formula (II):
  • Z 1 , Z 2 , L 1 , X, Ring A, Ring B, R 1 , R 2 , n and m are as defined herein.
  • Ring A is a C 3 _ 10 carbocyclyl or C ⁇ -io aryl group. In some embodiments, Ring A is phenyl. In other embodiments, Ring A is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group. In some embodiments, Ring A is monocyclic, while in other embodiments Ring A is bicyclic. In certain embodiments, Ring B is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group. In some embodiments, Ring B is monocyclic, while in other embodiments Ring B is bicyclic. For example, in certain embodiments, Ring B is a 5-6 membered monocyclic heteroaryl group, while in other embodiments, Ring B is a 9-10 membered bicyclic heteroaryl group.
  • Certain compounds of the present invention can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., stereoisomers and/or diastereomers.
  • provided compounds, and pharmaceutically acceptable compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers.
  • the compounds of the invention are enantiopure compounds.
  • mixtures of stereoisomers or diastereomers are provided.
  • certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated.
  • the invention additionally encompasses the compounds as individual isomers substantially free of other isomers and, alternatively, as mixtures of various isomers, e.g., racemic mixtures of stereoisomers.
  • a particular enantiomer is preferred, it may, in some embodiments be provided substantially free of the corresponding enantiomer, and may also be referred to as "optically enriched.”
  • “Optically-enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer.
  • Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses.
  • HPLC high pressure liquid chromatography
  • Jacques, et al. Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, EX. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (EX. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
  • Ci_6 alkyl is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1 - 6, Ci_5, Ci_4, Ci_3, Ci_2, C 2 _6, C 2 _ 5 , C 2 -4, C 2 _ 3 , C 3 -O, C3_5, C3_ 4 , C 4 _6, C 4 -S, and C5_6 alkyl.
  • boronic acid refers to any chemical compound comprising a - B(OH) 2 moiety.
  • Arylboronic acid compounds readily form oligomeric anhydrides by dehydration of the boronic acid moiety (see, for example, Snyder et al., J. Am. Chem. Soc. (1958) 80: 3611).
  • boronic acid is expressly intended to encompass free boronic acids, oligomeric anhydrides, including, but not limited to, dimers, trimers, and tetramers, and mixtures thereof.
  • boronic ester is art understood terms referring to a -B(OR) 2 moiety, a -B(R)OH moiety and a -B(R)OR moiety, respectively, wherein R is a group other than hydrogen (e.g., for example, an optionally substituted Ci_g alkyl, optionally substituted C 2 -s alkenyl, optionally substituted C 2 -8 alkynyl, optionally substituted C 1 -
  • halo and halogen refer to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).
  • alkyl refers to a monoradical of a straight-chain or branched saturated hydrocarbon group having from 1 to 8 carbon atoms ("C 1 -S alkyl”). In some embodiments, an alkyl group can have from 1 to 6 carbon atoms (“C 1 ⁇ alkyl”).
  • an alkyl group can have from 1 to 4 carbon atoms ("Ci_ 4 alkyl").
  • Ci_ 4 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
  • Ci_6 alkyl groups include the aforementioned Ci_ 4 alkyl groups as well as pentyl, isopentyl, neopentyl, hexyl and the like. Additional examples of alkyl groups include heptyl, octyl and the like. Unless otherwise specified, each instance of an "optionally substituted" alkyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • alkenyl refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms and one or more carbon-carbon double bonds (“C 2 _8 alkenyl”).
  • an alkenyl group can have from 2 to 6 carbon atoms ("C 2 _ 6 alkenyl”).
  • an alkenyl group can have from 2 to 4 carbon atoms (“C 2 ⁇ t alkenyl”).
  • the one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
  • Examples of C 2 - 4 alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, butadienyl and the like.
  • Examples of C 2 - 6 alkenyl groups include the aforementioned C 2 - 4 alkenyl groups as well as pentenyl, pentadienyl, hexenyl and the like. Additional examples of alkenyl include heptenyl, octenyl, octatrienyl and the like. Unless otherwise specified, each instance of an "optionally substituted" alkenyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • alkynyl refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms and one or more carbon-carbon triple bonds (“C 2 _8 alkynyl”).
  • an alkynyl group can have from 2 to 6 carbon atoms ("C 2 _ 6 alkynyl”).
  • an alkynyl group can have from 2 to 4 carbon atoms ("C 2 _ 4 alkynyl”).
  • the one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
  • Examples of C 2 - 4 alkynyl groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl and the like.
  • Examples of C2-6 alkenyl groups include the aforementioned alkynyl groups as well as pentynyl, hexynyl and the like. Additional examples of alkynyl include heptynyl, octynyl and the like. Unless otherwise specified, each instance of an "optionally substituted" alkynyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • heteroalkyl refers to an alkyl group, as defined herein, wherein one or more carbon atoms are replaced with one or more heteroatoms selected from optionally substituted nitrogen, oxygen and sulfur.
  • heteroalkyl refers to a monoradical of a straight-chain or branched hydrocarbon group having from 1 to 8 carbon atoms and one or more heteroatoms (“C 1 -S heteroalkynyl”).
  • C 1 -S heteroalkynyl Unless otherwise specified, each instance of an “optionally substituted” heteroalkyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • heteroalkenyl refers to an alkenyl group, as defined herein, wherein one or more carbon atoms are replaced with one or more heteroatoms selected from optionally substituted nitrogen, oxygen and sulfur.
  • heteroalkenyl refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms, one or more carbon-carbon double bonds, and one or more heteroatoms (“C 2 _8 heteroalkenyl”).
  • each instance of an “optionally substituted” heteroalkenyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • heteroalkynyl refers to an alkynyl group, as defined herein, wherein one or more carbon atoms are replaced with one or more heteroatoms selected from optionally substituted nitrogen, oxygen and sulfur.
  • heteroalkynyl refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms, one or more carbon-carbon triple bonds, and one or more heteroatoms (“C 2 _8 heteroalkynyl”).
  • each instance of an “optionally substituted” heteroalkynyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • alkylene refers to a diradical of a straight-chain or branched saturated hydrocarbon group having from 1 to 6 carbon atoms ("C 1 ⁇ alkylene”). In some embodiments, an alkylene group can have from 1 to 4 carbon atoms ("C 1 ⁇ t alkylene”). In some embodiments, an alkylene group can have from 1 to 2 carbon atoms (“Ci_ 2 alkylene”). Examples of Ci_ 2 alkylene groups include methylene and ethylene. Examples of C 1 .
  • 4 alkylene groups include the aforementioned Ci_ 2 alkylene groups as well as trimethylene (1,3- propanediyl), propylene (1,2-propanediyl), tetramethylene (1,4-butanediyl), butylene (1,2- butanediyl), 1 ,3-butanediyl, 2-methyl-l,3-propanediyl and the like.
  • Ci_6 alkylene groups include the aforementioned Ci_ 4 alkylene groups as well as pentamethylene (1,5- pentanediyl), pentylene (1,2-pentanediyl), hexamethylene (1,6-hexanediyl), hexylene (1,2- hexanediyl), 2,3-dimethyl-l,4-butanediyl and the like.
  • an alkylene group is an ⁇ , ⁇ -diradical.
  • ⁇ , ⁇ -diradical alkylene groups include methylene, ethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene.
  • alkenylene refers to a diradical of a straight-chain or branched hydrocarbon group having from 2 to 6 carbon atoms and one or more carbon-carbon double bonds (“C 2 _6 alkenylene”).
  • an alkenylene group can have from 2 to 4 carbon atoms ("C 2 -4 alkenylene”).
  • an alkenylene group can have 2 carbon atoms, i.e., ethenediyl.
  • the one or more carbon-carbon double bonds can be internal (such as in 1 ,4-but-2-enediyl) or terminal (such as in 1,4-but-l-enediyl).
  • Examples of C2-4 alkenylene groups include ethenediyl, 1 ,2-propenediyl, 1 ,3-propenediyl, 1 ,4- but-1-enediyl, 1 ,4-but-2-enediyl and the like.
  • Examples Of C 2 -O alkenylene groups include the aforementioned C2-4 alkenylene groups as well as 1,5-pent-l-enediyl, 1 ,4-pent-2-enediyl, 1,6- hex-2-enediyl, 2,5-hex-3-enediyl, 2-methyl-l,4-pent-2-enediyl and the like.
  • an alkenylene group is an ⁇ , ⁇ -diradical.
  • Examples of ⁇ , ⁇ -diradical alkenylene groups include ethenediyl, 1,3-propenediyl, 1 ,4-but-2-enediyl, 1,5-pent-l-enediyl, l,6-hex-3- enediyl and the like.
  • alkynylene refers to a diradical of a straight-chain or branched hydrocarbon group having from 2 to 6 carbon atoms and one or more carbon-carbon triple bonds ("C 2 -6 alkynylene”). In some embodiments, an alkynylene group can have from 2 to 4 carbon atoms ("C 2 -4 alkynylene”). In some embodiments, an alkynylene group can have 2 carbon atoms, i.e., ethynediyl.
  • the one or more carbon-carbon triple bonds can be internal (such as in 1 ,4-but-2-ynediyl) or terminal (such as in 1,4-but-l-ynediyl).
  • C2-4 alkynylene groups include ethynediyl, propynediyl, 1,4-but-l-ynediyl, 1 ,4-but-2-ynediyl and the like.
  • C 2 -6 alkynylene groups include the aforementioned C 2-4 alkynylene groups as well as 1,5-pent-l-ynediyl, 1 ,4-pent-2-ynediyl, l,6-hex-2-ynediyl, 2,5-hex-3- ynediyl, 3-methyl-l,5-hex-l-ynediyl and the like.
  • an alkynylene group is an ⁇ , ⁇ -diradical.
  • Examples of ⁇ , ⁇ -diradical alkynylene groups include ethynediyl, propynediyl, 1 ,4-but-2-ynediyl, 1,5-pent-l-ynediyl, 1 ,6-hex-3-ynediyl and the like.
  • perhaloalkyl refers to an alkyl group having from 1 to 3 carbon atoms, wherein all of the hydrogen atoms are each independently replaced with fluoro or chloro. In some embodiments, all of the hydrogen atoms are each replaced with fluoro. In some embodiments, all of the hydrogen atoms are each replaced with chloro. Examples of perhaloalkyl groups include -CF 3 , -CF 2 CF 3 , -CF 2 CF 2 CF 3 , -CCl 3 , -CFCl 2 , -CF 2 Cl and the like.
  • alkoxy refers to an - O-alkyl group having from 1 to 8 carbon atoms ("Ci- 8 alkoxy”). In some embodiments, an alkoxy group can have from 1 to 6 carbon atoms ("Ci-6 alkoxy”). In some embodiments, an alkoxy group can have from 1 to 4 carbon atoms ("Ci- 4 alkoxy”). Examples of Ci_ 4 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy and the like.
  • Ci_ 6 alkoxy groups include the aforementioned Ci_ 4 alkoxy groups as well as pentyloxy, isopentyloxy, neopentyloxy, hexyloxy and the like. Additional examples of alkoxy groups include heptyloxy, octyloxy and the like. Unless otherwise specified, each instance of an "optionally substituted" alkoxy group is independently unsubstituted or substituted with 1-5 groups as described below.
  • perhaloalkoxy refers to an alkoxy group having from 1 to 3 carbon atoms, wherein all of the hydrogen atoms are each independently replaced with fluoro or chloro. In some embodiments, all of the hydrogen atoms are each replaced with fluoro. In some embodiments, all of the hydrogen atoms are each replaced with chloro. Examples of perhaloalkoxy groups include -OCF 3 , -OCF 2 CF 3 , - OCF 2 CF 2 CF 3 , -OCCl 3 , -OCFCl 2 , -OCF 2 Cl and the like.
  • alkylthio refers to an -S-alkyl group having from 1 to 8 carbon atoms. In some embodiments, an alkylthio group can have from 1 to 6 carbon atoms. In some embodiments, an alkylthio group can have from 1 to 4 carbon atoms. Examples of Ci_ 4 alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio and the like.
  • Ci_6 alkylthio groups include the aforementioned Ci_ 4 alkylthio groups as well as pentylthio, isopentylthio, hexylthio and the like. Additional examples of alkylthio groups include heptylthio, octylthio and the like. Unless otherwise specified, each instance of an "optionally substituted" alkylthio group is independently unsubstituted or substituted with 1-5 groups as described below.
  • carbocyclyl or “carbocycle” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms ("C 3 -Io carbocyclyl”).
  • a carbocyclyl group can have from 3 to 8 ring carbon atoms ("C 3 _8 carbocyclyl”).
  • a carbocyclyl group can have from 3 to 6 ring carbon atoms (“C 3 _6 carbocyclyl”).
  • Examples of C 3 _6 carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl and the like.
  • Examples of C3-8 carbocyclyl groups include the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl, cycloheptadienyl, cycloheptatrienyl, cyclooctyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl and the like.
  • C 3 _io carbocyclyl groups include the aforementioned C 3 -S carbocyclyl groups as well as octahydro-lH-indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and the like.
  • a carbocyclyl group can be monocyclic ("monocyclic carbocyclyl") or bicyclic (e.g., containing a fused, bridged or spiro ring system), and can be saturated or can contain one or more carbon-carbon double or triple bonds.
  • Carbocyclyl also refers to a phenyl group (as defined below) fused to a monocyclic carbocyclyl group.
  • carbocyclyl groups include 1,2,3,4-tetrahydronaphthalene (e.g., 1,2,3,4-tetrahydronaphthalen- 1-yl, l,2,3,4-tetrahydronaphthalen-5-yl, and the like), 2,3-dihydro-l ⁇ -indene (e.g., 2,3- dihydro-lH-inden-1-yl, 2,3-dihydro-lH-inden-4-yl, and the like), indene (e.g., lH-inden-1- yl, lH-inden-7-yl, and the like), 5,6,7,8-tetrahydroquinoline (e.g., 5,6,7,8-tetrahydroquinolin- 5-yl, 5,6,7,8-tetrahydroquino
  • carbocyclyl or carbocycle can refer to a monocyclic, saturated carbocyclyl group ("cycloalkyl") having from 3 to 8 ring carbon atoms ("C 3 -S cycloalkyl”).
  • a cycloalkyl group can have from 3 to 6 ring carbon atoms ("C 3 _6 cycloalkyl”).
  • a cycloalkyl group can have from 5 to 6 ring carbon atoms ("C5-6 cycloalkyl”).
  • C5-6 cycloalkyl groups include cyclopentyl and cyclohexyl.
  • C 3 _6 cycloalkyl groups include the aforementioned C5-6 cycloalkyl groups as well as cyclopropyl and cyclobutyl.
  • Examples of C 3 _g cycloalkyl groups include the aforementioned C 3 6 cycloalkyl groups as well as cycloheptyl and cyclooctyl.
  • each instance of an "optionally substituted" cycloalkyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • heterocyclyl or “heterocycle” refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur.
  • a heterocyclyl group can have from 3 to 7 ring atoms selected from carbon atoms and 1 to 3 heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur.
  • a heterocyclyl group can have from 5 to 7 ring atoms selected from carbon atoms and 1 or 2 heteroatoms, each heteroatom independently selected from nitrogen, oxygen and sulfur.
  • a heterocyclyl group can have from 5 to 6 ring atoms selected from carbon atoms and 1 to 3 heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur.
  • the point of attachment can be a carbon or the optionally substituted nitrogen atom, as valency permits.
  • heterocyclyl groups with 1-2 ring heteroatoms include oxiranyl, aziridinyl, oxetanyl, azetidinyl, pyrrolidinyl, dihydropyrrolyl, tetrahydrofuranyl, dihydrofuranyl, dioxolanyl,tetrahydrothiophenyl, dihydrothiophenyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyridinyl, dihydropyridinyl, piperazinyl, tetrahydropyranyl, dioxanyl, morpholinyl, azepanyl, diazepanyl, diazepinyl, oxepanyl, dioxepanyl, oxazepanyl, oxazepin
  • heterocyclyl groups with 1-3 heteroatoms include the aforementioned heterocyclyl groups as well as triazolidinyl, oxadiazolidinyl, triazinanyl and the like.
  • Heterocycyl groups can be monocyclic (as in the aforementioned examples), bicyclic, or tricyclic.
  • Bicyclic heterocyclyl groups can include one or more heteroatoms in one or both rings.
  • heterocyclyl groups examples include tetrahydroindolyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1 ,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole and the like.
  • Heterocyclyl or “heterocycle” also refers to a radical of a 5- to 10-membered fused ring system having ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen and sulfur, wherein one ring is aromatic and the other is non-aromatic. In some embodiments, at least one heteroatom is present in either the aromatic or non-aromatic ring, while in other embodiments, at least one heteroatom is present in both rings. In heterocyclyl groups that contain one or more optionally substituted nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • heterocyclyl groups examples include indolinyl (e.g., indolin-1-yl, indolin-4-yl, and the like), isoindolinyl (e.g., isoindolin-1-yl, isoindolin-4-yl, and the like), 4,5,6,7-tetrahydro-lH-indolyl (e.g., tetrahydro-lH-indol-2-yl, 4,5,6,7-tetrahydro-lH-indol-4-yl, and the like), dihydrobenzofuranyl (e.g., dihydrobenzofuran-3-yl, dihydrobenzofuran-5-yl, and the like), 4,5,6,7-tetrahydrobenzofuranyl (e.g., 4,5,6, 7-tetrahydrobenzofuran-2-yl, 4,5,6,7- tetrahydrobenzofuran-5-yl, and
  • each instance of an “optionally substituted” heterocyclyl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • aryl refers to a radical of an aromatic monocyclic or bicyclic ring system having 6 or 10 ring carbon atoms. Examples of such aryl groups include phenyl, 1-naphthyl and 2-naphthyl. Unless otherwise specified, each instance of an "optionally substituted” aryl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • aralkyl refers to an alkyl group substituted by an aryl group, wherein the alkyl and aryl portions independently are optionally substituted as described below.
  • heteroaryl refers to a radical of a 5- to 10-membered aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur.
  • heteroaryl groups include pyrrolyl, furanyl (furyl), thiophenyl (thienyl), pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl (pyridyl), pyridazinyl, pyrimdinyl, pyrazinyl, triazinyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl), indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl and the like
  • a heteroaryl group can be monocyclic ("monocyclic heteroaryl"), and in some embodiments a heteroaryl group can be bicyclic ("bicyclic heteroaryl").
  • bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, and the like) the point of attachment may be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2- indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
  • each instance of an "optionally substituted" heteroaryl group is independently unsubstituted or substituted with 1-5 groups as described below.
  • heteroarylkyl refers to an alkyl group substituted by a heteroaryl group, wherein the alkyl and heteroaryl portions independently are optionally substituted as described below.
  • partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
  • the term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
  • compounds of the invention may contain "optionally substituted” moieties.
  • substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
  • an "optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • Suitable monovalent substituents on R 0 are independently halogen, -(CH 2 )O 2 R*, -(CH 2 )O 2 OH, -(CH 2 )O 2 OR*, -(CH 2 ) 0 2 CH(OR*) 2 , -CN, -N 3 , -(CH 2 ) 0 2 C(O)R*, - (CH 2 )o 2 C(O)OH, -(CH 2 )O 2 C(O)OR*, -(CH 2 ) 0 2 SR*, -(CH 2 ) 0 2 SH, -(CH 2 ) 0 2 NH 2 , -(CH 2 ) 0 2 NHR*, -(CH 2 )o 2 NR* 2 , -NO 2 , -SiR* 3 , -OSiR* 3 , -C(
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -O(CR * 2 ) 2 3 O-, wherein each independent occurrence of R * is selected from hydrogen;-, Ci_6 alkyl, C 2 _6 alkenyl, C 2 _6 alkynyl, each of which may be substituted as defined below; or an unsubstituted 5- or 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a Ci_6 alkyl, C 2 _6 alkenyl, or C 2 _6 alkynyl R group include halogen, -R*, -(haloR*), -OH, -OR*, -CN, -C(O)OH, -C(O)OR*, -NH 2 , -NHR*, -NR* 2 , or - NO 2 , wherein each R* is unsubstituted or substituted with one or more halogens, and is independently Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, -CH 2 Ph, -O(CH 2 ) 0 iPh, or a 5- or 6- membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include - S(O) 2 NR ⁇ , -C(S)NR ⁇ , -C(NH)NR ⁇ , or -N(R t )S(0) 2 R t ; wherein each R f is independently hydrogen; Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, each of which may be substituted as defined below; unsubstituted -OPh; or an unsubstituted 5- or 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the definition above, two independent occurrences of taken together with the atom(s) to which they are bound form an unsubstituted 3- to 12- membered saturated, partially unsaturated, or aromatic mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a Ci_6 alkyl, C 2 _6 alkenyl, or C 2 _6 alkynyl R 1 ⁇ group are independently halogen, -R*, -OH, -OR*, -CN, -C(O)OH, -C(O)OR*, -NH 2 , -NHR*, -NR* 2 , or -NO 2 , wherein each R* is unsubstituted or substituted with one or more halogens, and is independently Ci_ 4 alkyl, C 2 _ 4 alkenyl, C 2 _ 4 alkynyl, -CH 2 Ph, -O(CH 2 ) 0 iPh, or a 5- or 6- membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • prodrug refers to a derivative of a parent compound that requires transformation within the body in order to release the parent compound.
  • a prodrug has improved physical and/or delivery properties over the parent compound.
  • Prodrugs are typically designed to enhance pharmaceutically and/or pharmacokinetically based properties associated with the parent compound.
  • the advantage of a prodrug can lie in its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it enhances absorption from the digestive tract, or it may enhance drug stability for long-term storage.
  • the compounds of the invention readily undergo dehydration to form oligomeric anhydrides by dehydration of the boronic acid moiety to form dimers, trimers, and tetramers, and mixtures thereof. These oligomeric species hydrolyze under physiological conditions to reform the boronic acid.
  • the oligomeric anhydrides are contemplated as a "prodrug" of the compounds described herein, and may be used in the treatment of disorder and/or conditions a wherein the inhibition of FAAH provides a therapeutic effect.
  • Exemplary prodrugs of the compounds described herein include, but are not limited to, compounds wherein Z 1 and Z 2 taken together form a 5- to 8-membered ring having at least one heteroatom atom selected from optionally substituted nitrogen, oxygen and sulfur directly attached to boron (B), wherein the ring is comprised of carbon atoms and optionally one or more additional heteroatoms independently selected from optionally substituted nitrogen, oxygen and sulfur.
  • prodrugs of the compounds described herein are trifluoroborate prodrugs which hydrolyze to the boronic acid (i.e., -BF3 hydrolyzing to -B(OH) 2 ) at acidic pH.
  • Salt forms of the boronic acid e.g., Na + , Li + , Mg 2+ , Ca 2+ , and the like
  • Amino acids can be used to form prodrugs, such as, for example, serine and cysteine protected boronic acids.
  • 1,2 and 1,3 hydroxy sugars can be used to form prodrugs, such as, for example, glycerol, erythritol, threitol, ribitol, arabinitol, xylitol, allitol, altritol, galactitol, sorbitol, mannitol, and iditol protected boronic acids.
  • prodrugs such as, for example, glycerol, erythritol, threitol, ribitol, arabinitol, xylitol, allitol, altritol, galactitol, sorbitol, mannitol, and iditol protected boronic acids.
  • prodrugs include, but are not limited to, maltitol, lactitol, and isomalt; other monosaccharides which include hexoses (e.g., allose, altrose, glucose, mannose, gulose, idose, galactose, talose) and pentoses (e.g., ribose, arabinaose, xylose, lyxose); pentaerythritols and structural derivatives thereof, such as methylated, ethylated, acetate, ethoxylate, and propoxylate derivatives; and phenolic polyols such as 1,2,4 benzenetriol, 5-methyl benzene 1, 2, 3-triol, 2,3,4- trihydroxybenzaldehyde, and 3,4,5-trihydroxybenzamide.
  • Prodrugs also include NMIDA- derivatives.
  • tautomer includes two or more interconvertable compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa).
  • the exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base.
  • Exemplary tautomerizations include keto-to-enol; amide-to-imide; lactam-to-lactim; enamine- to-imine; and enamine-to-(a different) enamine tautomerizations.
  • isomers includes any and all geometric isomers and stereoisomers.
  • isomers include cis- and trans-isomcrs, E- and Z- isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
  • an isomer/enantiomer may, in some embodiments, be provided substantially free of the corresponding enantiomer, and may also be referred to as "optically enriched.”
  • “Optically- enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer.
  • the compound of the present invention is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer.
  • Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New
  • Z 1 is -OH or -OR 3 and Z 2 is -OH, -
  • Ci_g alkyl optionally substituted Ci_g alkyl, optionally substituted C 2 - 8 alkenyl, optionally substituted C 2 -8 alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl group.
  • Z 1 is -OH and Z 2 is -OH. In certain embodiments, Z 1 is -OH and Z 2 is -OR 4 .
  • Z 1 is -OR 3 and Z 2 is -OR 4 .
  • Z 1 is -OH or -OR 3
  • Z 2 is optionally substituted Ci_8 alkyl, optionally substituted C 2 - 8 alkenyl, optionally substituted C 2 - 8 alkynyl or an optionally substituted C3-10 carbocyclyl.
  • Z 1 is -OH or -OR 3
  • Z 2 is optionally substituted Ci_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, or an optionally substituted 3-10 membered heterocyclyl.
  • Z 1 is -OH or -OR 3
  • Z 2 is an optionally substituted C ⁇ -io aryl
  • Z 1 is -OH or -OR 3
  • Z 2 is an optionally substituted 5-10 membered heteroaryl.
  • Z 1 and Z 2 taken together with the boron atom to which they are bound, form a 5-membered ring having at least one O, S, N or NR 5 atom directly attached to the boron atom.
  • exemplary 5-membered rings include, but are not limited to:
  • each R 5 is as defined above and herein.
  • Z 1 and Z 2 taken together with the boron atom to which they are bound, form a 6-membered ring having at least one O, S, N or NR 5 atom directly attached to the boron atom.
  • Exemplary 6-membered rings include, but are not limited to:
  • Z 1 and Z 2 form an 8-membered ring having at least one O, S, N or NR 5 atom directly attached to the boron atom.
  • Exemplary 8-membered ring structures include, but are not limited to:
  • each R 5 is as defined above and herein.
  • Z 1 is -OH or -OR 3
  • Z 2 and Ring A taken together form an optionally substituted 5- to 7-membered ring.
  • Z 1 is -OH or -OR 3
  • Z 2 and Ring A taken together form an optionally substituted 6-membered ring.
  • Exemplary ring structures include, but are not limited to:
  • Ring A is as defined above and herein.
  • L 1 is a covalent bond, an optionally substituted straight or branched Ci_ 6 alkylene or an optionally substituted straight or branched C2-6 alkenylene moiety.
  • L 1 is a covalent bond.
  • Ring A is an optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl.
  • Ring A is monocyclic or bicyclic. In certain embodiments, Ring A is aromatic. In certain embodiments, Ring A is saturated or partially unsaturated.
  • Ring A is an optionally substituted C 6 or Cs monocyclic aryl group.
  • monocyclic ring systems include, but are not limited to:
  • Ring A is an optionally substituted phenyl ring system of formula:
  • Ring A is phenyl and has at least one fluorine substituent (i.e., n is at least one and R 1 is F). In certain embodiments, Ring A has at least two fluorine substituents (i.e., n is at least 2 and each R 1 is F). In certain embodiments, Ring A has at least three fluorine substituents (i.e., n is at least 3 and each R 1 is F). In certain embodiments, at least one R 1 group is fluoro in the ortho position relative to the boron atom. However, in certain embodiments, compounds containing fluorine substituents on Ring A are specifically excluded (i.e., when R 1 is F). In certain embodiments, compounds containing fluorine substituents ortho to the boron atom on Ring A are specifically excluded (i.e., when R 1 is F at the ortho position of Ring A with respect to the boron atom).
  • Ring A is an optionally substituted phenyl ring system of any one of formulae:
  • Ring A is an optionally substituted phenyl ring system having an XR A group para to the boron atom, i.e., a phenyl ring of any one of formulae:
  • Ring A is an optionally substituted phenyl ring system having an -XR A group meta to the boron atom, i.e., a phenyl ring of any one of formulae:
  • Ring A is an optionally substituted phenyl ring system having an -XR A group ortho to the boron atom, i.e., a phenyl ring of any one of formulae:
  • Ring A is phenyl
  • X is a covalent bond
  • R A is hydogen, i.e., Ring A is an optionally substituted phenyl ring system of formula:
  • R 1 and n are as defined above and herein.
  • ring systems include:
  • each R 1 is as defined above and herein.
  • Ring A is an optionally substituted saturated or partially unsaturated C 3 -Io or C 3 -S monocyclic ring system.
  • monocyclic ring systems include, but are not limited to:
  • Ring A is an optionally substituted 5-8 membered or 5-6 membered monocyclic heteroaryl group.
  • aromatic monocyclic ring systems include, but are not limited to, 5-membered rings of any of following formulae:
  • R 14 is hydrogen, -SO 2 R 11 , -SOR 11 , -C(O)R 11 , -CO 2 R 11 , -C(O)N(R . I 1 hO 2 , -C(O)NH(R I I 1 h 1 ), - C(O)NH 2 , optionally substituted Ci_g alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _g heteroalkynyl, optionally substituted C 3 _ 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -io aryl, or optionally substituted 5-10 membered heteroaryl, and each instance of R 11 is, independently, optionally substituted Ci_g alkyl, optionally substituted C 2 _g
  • Ring A is an optionally substituted thiophenyl group. In certain embodiments, Ring A is a thiophenyl group of the formula:
  • Ring A is an optionally substituted pyridinyl group. In certain embodiments, Ring A is pyridinyl group of the formula:
  • Ring A is an optionally substituted saturated or partially unsaturated 3-8 membered or 5-8-membered monocyclic heterocyclyl group.
  • saturated or partially unsaturated monocyclic ring systems include, but are not limited to:
  • Ring A is an optionally substituted bicyclic aryl group.
  • bicyclic ring systems include, but are not limited to:
  • Ring A is a bicyclic group of any of formulae:
  • Ring A is an optionally substituted bicyclic Cs-io carbocyclyl group.
  • both rings of the bicyclic Cg-io carbocyclyl group are saturated or partially saturated.
  • one ring of the bicyclic Cg-io carbocyclyl group is saturated or partially saturated and the other ring is aromatic.
  • Such bicyclic Cg-io carbocyclyl ring systems include, but are not limited to:
  • Ring A is an optionally substituted 6-10 membered bicyclic heteroaryl group. In certain embodiments, Ring A is an optionally substituted 9-10 membered bicyclic heteroaryl group. In certain embodiments, Ring A is an optionally substituted 9 membered bicyclic heteroaryl group. In certain embodiments, the optionally substituted 9- membered bicyclic heteroaryl is a 6,5-fused heteroaryl ring. In certain embodiments, the optionally substituted 10-membered bicyclic heteroaryl is a 6,6-fused heteroaryl ring.
  • Ring A is a 6,5-fused heteroaryl ring of any of formulae:
  • Ring A is a 6,6-fused heteroaryl ring of any of formulae:
  • Ring A is an optionally substituted bicyclic 6-10 membered heterocyclyl group.
  • both rings of the bicyclic 6-10 membered heterocyclyl group are saturated or partially saturated.
  • one ring of the bicyclic 6-10 membered heterocyclyl group is saturated or partially saturated and the other ring is aromatic.
  • Such bicyclic heterocyclyl ring systems include, but are not limited to:
  • bicyclic Ring A having one or more floating substituents e.g., -R 1 and/or -X-R A
  • the floating substituent may be present on any substitutable carbon atom on either ring of the fused ring system.
  • X is a covalent bond. In certain embodiments, X is -0-.
  • X is -NR 6 -. In certain embodiments, X is -S-.
  • X is an optionally substituted Ci_ 6 alkylene. In other embodiments, X is an optionally substituted Ci_4 alkylene. In yet other embodiments, X is an optionally substituted Ci_ 2 alkylene. In certain embodiments, X is -(CH 2 ) 4 -. In certain embodiments, X is -(CH 2 ) 3 -. In certain embodiments, X is -(CH 2 ) 2 -. In certain embodiments,
  • X is an optionally substituted Ci_6 alkylene, wherein one methylene unit is replaced with -O-. In certain embodiments, X is -CH 2 O- or -OCH 2 -.
  • X is an optionally substituted Ci_ 6 alkylene, wherein one methylene unit is replaced with -NR 6 -. In certain embodiments, X is -CH 2 NR 6 - or -NR 6 CH 2 -.
  • X is a covalent bond, C(O), -0-, -CH 2 O-, -OCH 2 -, -NR 6 -, or -CH 2 NR 6 -, or -NR 6 CH 2 -. In certain embodiments, X is a covalent bond, -0-, or optionally substituted Ci_ 6 alkylene.
  • R A is hydrogen, halogen, -OR 7 , -CF 3 , -CN, -NO 2 , - SO 2 R 7 , -SOR 7 , -C(O)R 7 , -CO 2 R 7 , -C(O)N(R 7 ) 2 , -CHO, -N 3 , -N 2 R 7 , -N(R 7 ) 2 , or Ring B having formula:
  • Ring B is optionally substituted C 3 _ 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -io aryl, or optionally substituted 5-10 membered heteroaryl, and R 2 , R 7 and m are as defined herein.
  • R A is hydrogen.
  • R A is Ring B, as defined above and herein.
  • Ring B is optionally substituted C 3 _i 0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl.
  • Ring B is monocyclic or bicyclic. In certain embodiments, Ring B is aromatic.
  • Ring B is an optionally substituted C 6 or Cg monocyclic aryl group.
  • monocyclic aryl ring systems include, but are not limited to:
  • Ring B is an optionally substituted phenyl ring of formula:
  • each of R 2 and m is as defined above and herein.
  • Ring B is an optionally substituted phenyl ring of any one of formulae:
  • R 2 is as defined above and herein.
  • both of Ring B and Ring A are phenyl.
  • Ring B is an optionally substituted saturated or partially unsaturated C3_io or Cs_8 monocyclic carbocyclyl group.
  • monocyclic ring systems include, but are not limited to:
  • Ring B is an optionally substituted 5-8 membered or 5-6 membered monocyclic heteroaryl group.
  • Ring B is an optionally substituted 5-membered heteroaryl group.
  • monocyclic heteroaryl systems include, but are not limited to, any of formulae:
  • R 16 is hydrogen, -SO 2 R 11 , -SOR 11 , -C(O)R 11 , -CO 2 R 11 , -C(O)NH 2 , -C(O)NH(R 11 ), - C(O)N(R 1 %, optionally substituted Ci_g alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _ 8 heteroalkynyl, optionally substituted C 3 _i 0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl, and each instance of R 11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C
  • Ring B is an optionally substituted 6-membered monocyclic heteroaryl group.
  • monocyclic heteroaryl systems include, but are not limited to, 6- membered rings of any of formulae: wherein each o R 2 and m is as defined above and herein.
  • Ring B is an optionally substituted saturated or partially unsaturated monocyclic 3 to 10 membered heterocyclyl group.
  • saturated or partially unsaturated monocyclic heterocyclyl systems include, but are not limited to:
  • each of R , R , 16 and m is as defined above and herein.
  • Ring B is an optionally substituted C 10 bicyclic aryl group (i.e., naphthyl) having the formula:
  • each of R 2 and m is as defined above and herein.
  • Ring B is a bicyclic Cg-io carbocyclyl group.
  • both rings of the bicyclic C 8 -io carbocyclyl group are saturated or partially saturated.
  • one ring of the bicyclic Cs-io carbocyclyl group is saturated or partially saturated and the other ring is aromatic.
  • Such bicyclic ring systems include, but are not limited to: wherein each of R and m is as defined above and above and described herein.
  • Ring B is an optionally substituted 6-10 membered bicyclic heteroaryl group. In certain embodiments, Ring B is an optionally substituted 9-10 membered bicyclic heteroaryl group. In certain embodiments, an optionally substituted 9-membered bicyclic heteroaryl group is a 6,5-fused bicyclic heteroaryl group. In certain embodiments, an optionally substituted 10-membered bicyclic heteroaryl group is a 6,6-fused bicyclic heteroaryl group.
  • heteroaryl systems include, but are not limited to, 6,5-fused ring systems of any of formulae:
  • Ring B is an optionally substituted saturated or partially saturated 9-10 membered bicyclic heterocyclyl group.
  • bicyclic heterocyclyl systems include, but are not limited to:
  • each of R , R , 16 and m is as defined above and herein.
  • bicyclic Ring B having one or more floating substituents that the floating substituent may be present on any substitutable carbon atom on either ring of the fused bicyclic ring system.
  • each instance of R 1 is, independently, halogen, -OR 8 , -CF 3 ,
  • Ci_8 alkyl optionally substituted C 2 _8 alkenyl, optionally substituted C 2 _
  • each instance of R 1 is, independently, halogen, -OR 8 , -CF 3 , - CN, -NO 2 , -SO 2 R 8 , -SOR 8 , -C(O)R 8 , -CO 2 R 8 , -C(O)N(R 8 ) 2 , -N 3 , -N 2 R 8 , or - N(R 8 ) 2 , optionally substituted Ci_8 alkyl, optionally substituted C 2 _8 alkenyl, or optionally substituted C 2 _ 8 alkynyl.
  • each instance of R 1 is, independently, halogen, -OR 8 or optionally substituted Ci_8 alkyl.
  • R 1 is halogen.
  • R 1 is -F or -Cl.
  • R 1 is -Cl.
  • R 1 is -F.
  • at least one R 1 is ortho to the boron atom.
  • at least one R 1 is meta to the boron atom.
  • at least one R 1 is para to the boron atom.
  • At least one R 1 is alpha to the boron atom. In other embodiments, at least one R 1 is beta to the boron atom. In yet other embodiments, at least one R 1 is gamma to the boron atom.
  • n is 0, 1, 2 or 3. In some embodiments, n is 0, 1 or 2. In other embodiments, n is 1 or 2. In yet other embodiments, n is 3. In yet other embodiments, n is 2. In still yet other embodiments, n is 1. In still yet other embodiments, n is 0.
  • Ring A is not substituted with an R 1 group, but instead is substituted with hydrogen. It is also understood that when n is 0, X is a covalent bond and R A is hydrogen, then Ring A is unsubstituted.
  • each instance of R 2 is, independently, halogen, -OR 9 , -CF 3 , -CN, -NO 2 , -SO 2 R 9 , -SOR 9 , -C(O)R 9 , -CO 2 R 9 , -C(O)N(R 9 ) 2 , -N 3 , -N 2 R 9 , -N(R 9 ) 2 , optionally substituted Ci_g alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C 2 _ 8 heteroalkenyl, optionally substituted C 2 _8 heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-
  • each instance of R 2 is, independently, halogen, -OR 9 , -CF 3 , - CN, -NO 2 , -SO 2 R 9 , -SOR 9 , -C(O)R 9 , -CO 2 R 9 , -C(O)N(R 9 ) 2 , -N 3 , -N 2 R 9 , -N(R 9 ) 2 , optionally substituted Ci_8 alkyl, optionally substituted C 2 _8 alkenyl, or optionally substituted C 2 _8 alkynyl.
  • each instance of R 2 is, independently, halogen or -OR 9 .
  • R 2 is halogen.
  • R 2 is -F or -Cl.
  • R 2 is -Cl.
  • R 2 is -F.
  • At least one R 2 is ortho to X. In other embodiments, at least one R 2 is meta to X. In yet other embodiments, at least one R 2 is para to X.
  • At least one R 2 is alpha to X. In other embodiments, at least one R 2 is beta to X. In yet other embodiments, at least one R 2 is gamma to X.
  • m is O, 1, 2, 3, 4 or 5. In some embodiments, m is O, 1, 2 or 3. In some embodiments, m is 0, 1 or 2. In other embodiments, m is 1 or 2. In yet other embodiments, m is 3. In still other embodiments, m is 2. In still yet other embodiments, m is 1. In still other embodiments, m is 0. It is understood that when m is 0, then Ring B is not substituted with an R 2 group, but instead is substituted with hydrogen.
  • the present invention provides compounds of formula (I):
  • Ring A is an optionally substituted Cio bicyclic aryl or an optionally substituted 9-10 membered bicyclic heteroaryl.
  • Ring A is an optionally substituted Cio bicyclic aryl group.
  • Ring A is an optionally substituted naphthyl group.
  • Ring A is an optionally substituted 9-10 membered bicyclic heteroaryl group. In certain embodiments, Ring A is an optionally substituted 10- membered bicyclic heteroaryl group. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl containing 1 to 2 N atoms. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl containing 1 N atom. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl containing 2 N atoms.
  • Ring A is an optionally substituted isoquinoline group. In certain embodiments, Ring A is an optionally substituted quinolinyl group. In certain embodiments, Ring A is an optionally substituted quinoxalinyl group.
  • the present invention provides 6,6-fused bicyclic compounds of formula (III):
  • Z 1 is -OH or -OR 3 and Z 2 is -OH, -OR 4 , an optionally substituted Ci_ 8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl; (ii) Z 1 and Z 2 taken together form a 5- to 8-membered ring having at least one O, S, N or
  • Z 1 is -OH or -OR 3 , and Z 2 and Ring A taken together form an optionally substituted 5- to 7-membered ring;
  • W 1 and W 2 are independently selected from CR 12 , C and N;
  • R A is hydrogen, halogen, -OR 7 , -CF 3 , -CN, -NO 2 , -SO 2 R 7 , -SOR 7 , -C(O)R 7 , -CO 2 R 7 , - C(O)N(R 7 ) 2 , -N 3 , -N 2 R 7 , -N(R 7 ) 2 , or Ring B having formula:
  • Ring B is optionally substituted C 3 -Io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 - I o aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 1 is, independently, halogen, -OR 8 , -CF 3 , -CN, -NO 2 , -SO 2 R 8 , - SOR 8 , -C(O)R 8 , -CO 2 R 8 , -C(O)N(R 8 ) 2 -N 3 , -N 2 R 8 , -N(R 8 ) 2 , -B(OH 2 ), optionally substituted C i_ 8 alkyl, optionally substituted C 2 _ 8 alkenyl, optionally substituted C 2 _ 8 alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _
  • Ci_ 8 heteroalkyl optionally substituted C 2 _ 8 heteroalkenyl, optionally substituted C 2 _ 8 heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 3 and R 4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _g heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 5
  • the present invention provides 6,6-fused bicyclic compounds of the formula (III-a), (III-b), (III-c), (III-d) or (III-e):
  • n is 0. In certain embodiments, n is 1 or 2. In certain embodiments, n is 1.
  • R 1 is optionally substituted Ci_8 alkyl. In certain embodiments, R 1 Is -CH 3 .
  • R A is hydrogen.
  • R A is Ring B.
  • Ring B is an optionally substituted aryl, optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, optionally substituted 1,2,3,4-tetrahydroquinolinyl, optionally substituted cyclopentyl or optionally substituted cyclohexyl.
  • m is 0. In certain embodiments, m is 1 or 2. In certain embodiments, m is 1.
  • R 2 is halogen, -OR 9 , -CN, -NO 2 , or -N(R 9 ) 2 .
  • R 2 is -Cl, -CN, -NO 2 , -OH, -OCH 3 , -OC 4 H 9 , or -N(CH 3 ) 2 .
  • at least one of W 1 and W 2 is N.
  • W 1 is N and W 2 is C or CR 12 . In certain embodiments, W 2 is N and W 1 is C or CR 12 . In some embodiments, W 1 is N and W 2 is CH. In some embodiments, W 2 is N and W 1 is CH.
  • W 1 is N and W 2 is C, CH or CR 12 , or wherein W 2 is N and W 1 is C, CH or CR 12 , the following compounds are specifically excluded: (i) compounds wherein n is 0, X is a covalent bond and R A is hydrogen; (ii) compounds wherein n is 1, R 1 is fluoro, X is -CH 2 -, and R A is hydrogen; and/or (iii) compounds wherein n is 1, R 1 is chloro, X is a covalent bond, and R A is hydrogen.
  • both W 1 and W 2 are N.
  • both W 1 and W 2 are N, the following compounds are specifically excluded:
  • both W 1 and W 2 are, independently, C or CR 12 . In certain embodiments, both W 1 and W 2 are CH. In certain embodiments, wherein both W 1 and W 2 are C, CH or CR 12 , the following compounds are specifically excluded: (i) compounds wherein n is 0, X is a covalent bond and R A is hydrogen, -OH, -
  • W 1 is C or CH and W 2 is N, providing 6,6-fused bicyclic compounds of the formula (III-e):
  • examples of such compounds include compounds of any of formulae (III-el), (IH-e2), (III-e3), (III-e4) and (III-e5):
  • both W 1 and W 2 are N, providing 6,6-fused bicyclic compounds of the formula (III-f):
  • examples of such compounds include compounds of any of formulae (III-fl), (IH-f2), (HI-O) or (IH-f4):
  • both W 1 and W 2 are C or CH, providing 6,6-fused bicyclic compounds of formula (III-g):
  • Ring A is an optionally substituted 9-membered bicyclic heteroaryl group. In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl group. In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl group containing 2-3 heteroatoms selected from O, S, N and NR 14 , wherein:
  • R 14 is, independently, hydrogen, -SO 2 R 11 , -SOR 11 , -C(O)R 11 , -CO 2 R 11 , -C(0)N(R ⁇ ) 2 , - C(O)NH(R 11 ), -C(O)NH 2 , optionally substituted Ci_ 8 alkyl, optionally substituted C 2 _ 8 alkenyl, optionally substituted C 2 _ 8 alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C 2 _8 heteroalkenyl, optionally substituted C 2 _ 8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 - I o aryl, or optionally substituted 5-10 membered heteroaryl; and each instance of R 11 is, independently, optionally substituted Ci_ 8 alkyl, optionally substituted C 2 _ 8 alkenyl, optional
  • Ring A is a 6,5-fused bicyclic heteroaryl group containing 2 heteroatoms selected from O, S, N and NR 14 . In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl group containing 3 heteroatoms selected from O, S, N and NR 14 . In certain embodiments, Ring A is an optionally substituted benzoxazolyl, optionally substituted benzthiazolyl, optionally substituted benzimidazolyl, an optionally substituted indazolyl or an optionally substituted imidazopyridinyl group.
  • the present invention provides compounds of formula (IV):
  • Z 1 is -OH or -OR 3 and Z 2 is -OH, -OR 4 , an optionally substituted Ci_ 8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C 1 - 8 heteroalkyl, optionally substituted C 2 -8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C 3 _ 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -io aryl, or optionally substituted 5-10 membered heteroaryl; (ii) Z 1 and Z 2 taken together form a 5- to 8-membered ring having at least one O, S, N or
  • Z 1 is -OH or -OR 3 , and Z 2 and Ring A taken together form an optionally substituted 5- to 7-membered ring; each of Y 3 , Y 4 and Y 5 is independently selected from C, CR 13 , N, NR 14 , O and S, with the proviso that at least one of Y 3 , Y 4 or Y 5 is a heteroatom selected from N, NR 14 , O or S; Y 6 is C or N;
  • R A is hydrogen, halogen, -OR 7 , -CF 3 , -CN, -NO 2 , -SO 2 R 7 , -SOR 7 , -C(O)R 7 , -CO 2 R 7 , - C(O)N(R 7 ) 2 , -N 3 , -N 2 R 7 , -N(R 7 ) 2 , or Ring B having formula:
  • Ring B is optionally substituted C 3 _ 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 1 is, independently, halogen, -OR 8 , -CF 3 , -CN, -NO 2 , -SO 2 R 8 , - SOR 8 , -C(O)R 8 , -CO 2 R 8 , -C(O)N(R 8 ) 2 , -N 3 , -N 2 R 8 , -N(R 8 ) 2 , -B(OH 2 ), optionally substituted Ci_ 8 alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _g hetero
  • the present invention provides compounds of any of formulae (IV-a), (IV-b), (IV-c), (IV-d) or (IV-e):
  • n is 0. In certain embodiments, n is 1 or 2. In certain embodiments, n is 1.
  • R 1 is halogen. In certain embodiments, R 1 is -F. In certain embodiments, R 1 is -Br.
  • R A is hydrogen. In certain embodiments, R A is -CF3.
  • R A is Ring B.
  • Ring B is an optionally substituted phenyl, optionally substituted pyrrolidinone or an optionally substituted piperidinyl.
  • n is 0. In certain embodiments, m is 1 or 2. In certain embodiments, m is 1.
  • R 2 is optionally substituted Ci_g alkyl, optionally substituted C 6 _
  • R 2 is -C 3 H 7 , -
  • two of Y 3 , Y 4 and Y 5 are, independently, heteroatoms selected from N, NR 14 , O or S, and Y 6 is C.
  • one of Y 3 , Y 4 , Y 5 is a heteroatom selected from N, NR 14 , O or S, and Y 6 is C or N.
  • one of Y 3 , Y 4 , Y 5 is a heteroatom selected from N, NR 14 , O or S, and Y 6 is N.
  • Y 3 is O or S.
  • Y 3 is O.
  • Y is S.
  • Y 6 is C.
  • Y 3 is O or S
  • Y 4 is C
  • Y 5 is N and Y 6 is C.
  • Y 4 is C
  • Y 5 is N and Y 6 is C
  • the following compounds are specifically excluded:
  • Y 3 is O or S
  • Y 4 and Y 5 are, independently, C or CR 13 and Y 6 is C.
  • Y 4 and Y 5 are, independently, C or CR 13 and Y 6 is C, the following compounds are specifically excluded:
  • Y 3 and Y 4 are, independently, N or NR 14 , Y 5 is C or CR 13 and Y 6 is C. In certain embodiments, wherein Y 3 and Y 4 are, independently, N or NR 14 , Y 5 is C or CR 13 and Y 6 is C, the following compounds are specifically excluded:
  • Y 3 and Y 5 are, independently, N or NR 14 , Y 4 is C or CR 13 , and Y 6 is C. In certain embodiments, wherein Y 3 and Y 5 are, independently, N or NR 14 , Y 4 is C or CR 13 , and Y 6 is C, the following compounds are specifically excluded:
  • Y 3 and Y 6 are, independently, N and Y 4 and Y 5 are, independently, C or CR 13 . In certain embodiments, wherein Y 3 and Y 6 are, independently, N and Y 4 and Y 5 are, independently, C or CR 13 , the following compounds are specifically excluded: (i) compounds wherein n is 0, X is a covalent bond, and R A is hydrogen. In certain embodiments, Y 3 is N or NR 14 , and Y 4 , Y 5 and Y 6 are, independently, C or CR 13 . In certain embodiments, wherein Y 3 is N or NR 14 , and Y 4 , Y 5 and Y 6 are, independently, independently,
  • the present invention provides compounds of the formula (IV-f):
  • the present invention provides compounds of the formula (IV- g):
  • the present invention provides compounds of formula (IV-h):
  • the present invention provides compounds of either of formulae (IV-i) or (IV-k):
  • the present invention provides compounds of the formulae (IV- m) or (IV-n):
  • the present invention provides compounds of formula (II):
  • R . 1 , r R > 2 , n and m are as defined above and herein.
  • Ring B is optionally substituted 3-10 membered heterocyclyl or optionally substituted 5-10 membered heteroaryl ⁇ i.e., referred to as "Het-B").
  • Het-B Such ring systems are depicted and described in detail above and herein.
  • the present invention provides compounds of formula (V):
  • Z 1 is -OH or -OR 3 and Z 2 is -OH, -OR 4 , an optionally substituted Ci_ 8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_
  • Z 1 and Z 2 taken together form a 5- to 8-membered ring having at least one O, S, N or NR 5 atom directly bonded to the boron atom; or
  • Z 1 is -OH or -OR 3 , and Z 2 and Ring A taken together form an optionally substituted 5- to 7-membered ring;
  • W 3 is C, CR 15 , or N;
  • Het-B is an optionally substituted 3-10 membered heterocyclyl or an optionally substituted 5-10 membered heteroaryl ring; each instance of R 1 is, independently, halogen, -OR 8 , -CF 3 , -CN, -NO 2 , -SO 2 R 8 , -
  • R 9 SOR 9 , -C(O)R 9 , -CO 2 R 9 , -C(O)N(R 9 ) 2 , -N 3 , -N 2 R 9 , -N(R 9 ) 2 , optionally substituted C 1- * alkyl, optionally substituted C 2 -8 alkenyl, optionally substituted C 2 -8 alkynyl, optionally substituted C i_8 heteroalkyl, optionally substituted C 2 -8 heteroalkenyl, optionally substituted C 2 -8 heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -w aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 3 and R 4 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted
  • each n is 0. In certain embodiments, each n is independently 1 or 2. In certain embodiments, each n is 1.
  • R 1 is halogen, -OR 8 , -CF3, optionally substituted Ci_8 alkyl or optionally substituted 5-membered heteroaryl.
  • R 1 is -Cl, -F, -OCH 3 , - OCH 2 CH 2 C 6 H 5 , -O(CH 2 ) 3 CH 3 , -CH 2 C(CH 3 ) 2 , or an optionally substituted oxadiazolyl.
  • R 2 is selected from -OR 9 , -N(R 9 ) 2 , optionally substituted C 1 -
  • R 2 is selected from optionally substituted Ci_s alkyl, optionally substituted C 6 - I o aryl, or optionally substituted 5-10 membered heteroaryl.
  • R 2 is selected from -CH 3 , -CH 2 CH 3 , -CH 2 C(CH 3 ) 2 , -
  • CH 2 CH 2 CH 2 (C O)-(oxadiazole), optionally substituted pyridinyl, -C 6 Hs 1 optionally substituted phenyl, optionally substitututed benzyl, -CH 2 CH 2 Ph 1 optionally substituted furanyl, optionally substituted imidazolyl, optionally substituted thiazolyl, -OCH 3 , -OCH 2 CH 35 -CH 2 OCH 3 , - CH 2 OCH 2 CH 3 , -CH 2 CH 2 CH 2 OCH 3 , -CH 2 NHBoC, -CH 2 CH 2 NHBoC, -CH 2 CH 2 NHAc, -
  • R 2 is selected from -(CH 2 ) 4 CH 3 , -CH 2 CH 2 CF 2 CF 3 , optionally substituted pyridinyl and optionally substituted phenyl. In certain embodiments, R 2 is selected from -(CH 2 ) 4 CH 3 , -CH 2 CH 2 CF 2 CF 3 , -pyridinyl
  • W 3 is C or CR 15 . In certain embodiments, W 3 is C or CH. In certain embodiments, W 3 is CH. In certain embodiments, W 3 is N.
  • the present invention provides compounds of formula (V-a):
  • V-a or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, Het-B, R 1 , R 2 , m and n are as defined above and herein.
  • Ring A is substituted ortho, meta, ox para to the boron atom with the group X-HetB, are provided in compounds of any of formulae (V-b), (V-c) or (V-d):
  • V-d or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, Het-B, R 1 , R 2 , m and n are as defined above and herein.
  • Exemplary Het-B rings include, but are not limited to,
  • Y 1 , Y 2 , Y 7 , Y 8 , W 4 , W 5 , W 6 , W 7 and p are as defined below, and R 2 and m are as defined above and herein.
  • the present invention provides compounds of formula (V-e):
  • V-e or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, Het-B, R 1 , R 2 , m and n are as defined above and herein, and Y 1 is O, S or NR 16 .
  • Y 1 is O or S. In certain embodiments, Y 1 is O. In certain embodiments, Y 1 is S.
  • the present invention provides compounds of any of formulae (V-el), (V-e2), (V-e3), (V-e4), (V-e5), (V-e6), or (V-e7):
  • V-e7 or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, Het-B, R 1 , R 2 , m and n are as defined above and herein.
  • the present invention provides compounds of formula (V-f):
  • V-f or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein.
  • the present invention provides compounds of any of formulae (V-fl), (V-f2), (V-f3) or (V-f4):
  • V-f4 or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, Het-B, R 1 , R 2 , m and n are as defined above and herein.
  • the present invention provides compounds of formula (V-g):
  • V-g or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , and m and n are as defined above and herein.
  • the present invention provides compounds of either of formulae (V-gl) and (V-g2):
  • V-g2 or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , R 16 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein.
  • the present invention provides compounds of formula (V-h):
  • V-h or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein, and Y 2 is O, S or NR 16 .
  • the present invention provides compounds of formulae (V-hl) or (V-h2):
  • V-h2 or a pharmaceutically acceptable salt or prodrug thereof, wherein Y 2 , W 3 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein.
  • Y 2 is O or S. In certain embodiments, Y 2 is O. In certain embodiments, Y 2 is S.
  • the present invention provides compounds of any of formulae (V-h3), (V-h4), (V-h5), (V-h6), (V-h7), (V-h8), (V-h9) or (V-hlO):
  • V-hlO or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , R 16 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein.
  • the present invention provides compounds of formula (V-i):
  • V-i or pharmaceutically acceptable salts or prodrugs thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein, Y 7 and Y 8 are independently selected from N, NR 16 , O and S, and
  • W 4 is C, CR 17 or N, wherein R 17 is hydrogen, halogen, -CF 3 , optionally substituted C 1 . 8 alkyl, optionally substituted C2-8 alkenyl, or optionally substituted C2-8 alkynyl.
  • Y 7 is O or S and Y 8 is N. In certain embodiments, Y 7 is O and Y 8 is N. In certain embodiments, Y 7 is S and Y 8 is N.
  • W 4 is N.
  • W 4 is C or CR 17 . In certain embodiments, W 4 is C or CH.
  • the present invention provides compounds of formulae (V-il):
  • the present invention provides compounds of the formula (V-j):
  • V-j or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein, W 5 is N or N 16 , and the dashed line represents a single or double bond. In certain embodiments, the dashed line is a single bond. In certain embodiments, the dashed line is a double bond.
  • the present invention provides compounds of formulae (V-jl), (V-J2), (V-J3), (V-J4), (V-J5) or (V-J6):
  • V-J6 or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 ,
  • R 16 , m and n are as defined above and herein.
  • the present invention provides compounds of formula (V-k):
  • V-k or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein, and p is 1 or 2.
  • the present invention provides compounds of either of formulae (V-kl) or (V-k2):
  • V-k2 or a pharmaceutically acceptable salt or prodrug thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , m and n are as defined above and herein.
  • the present invention provides compounds of formula (V-m):
  • V-m or pharmaceutically acceptable salts or prodrugs thereof, wherein W 3 , Z 1 , Z 2 , X, R 1 , R 2 , R 16 , m, and n, are as defined above and herein, and W 6 and W 7 are selected from N or CH, with the proviso that one or both of W 6 and W 7 is N.
  • the present invention provides compounds of either of formulae (V-ml), (V-m2) or (V-m3):
  • Het-B is an optionally substituted 3-10 membered heterocyclyl ring.
  • Het-B is an optionally substituted 3-10 membered heterocyclyl ring, wherein said heterocyclyl ring has 1 to 3 heteroatoms selected from N, NR 16 , O and S, and R 16 is, independently, hydrogen, -SO 2 R 11 , -SOR 11 , -C(O)R 11 , -CO 2 R 11 , -C(0)N(R ⁇ ) 2 , - C(O)NH(R 11 ), -C(O)NH 2 , optionally substituted Ci_ 8 alkyl, optionally substituted C 2 _ 8 alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _ 8 heteroalkenyl, optionally substituted C 2 _ 8 heteroalkynyl, optionally substituted C 3
  • Het-B is an optionally substituted 5-6 membered monocyclic heterocyclyl ring. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring containing 1 heteroatom selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 5- membered monocyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an an optionally substituted 5-membered monocyclic heterocyclyl ring selected from the group consisting of optionally substituted 1 ,3-dioxolanyl, optionally substituted 4,5-dihydroisoxazolyl, optionally substituted isoxazolidinyl, optionally substituted oxazolidinyl, optionally substituted tetrahydrofuranyl, optionally substituted pyrrolidinyl and optionally substituted pyrrolyl-2,5-dione.
  • Het-B is an optionally substituted pyrrolidinyl ⁇ i.e., containing 1 heteroatom selected from N or NR 16 )
  • the following compounds are specifically excluded: (i) compounds wherein W 3 is CH, n is 0, m is 0 and X is a covalent bond or -
  • Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring containing 1 heteroatom selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 6- membered monocyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring selected from the group consisting of optionally substituted 1,3-dioxanyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted morpholinyl, and optionally substituted tetrahydropyranyl.
  • Het-B is an optionally substituted piperidinyl (i.e., containing 1 heteroatom selected from N or NR 16 )
  • Het-B is an optionally substituted piperazinyl (i.e., containing 2 heteroatoms selected from N or NR 16 )
  • Het-B is an optionally substituted morpholynyl (i.e., containing 1 heteroatom selected from O and 1 heteroatom selected from N or NR 16 )
  • Het-B is an optionally substituted tetrahydropyranyl (i.e., containing 2 O heteroatoms)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted 9-10 membered bicyclic heterocyclyl ring.
  • Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 1 heteroatom selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring selected from the group consisting of optionally substituted indolinyl, optionally substituted isoindolinyl-l,3-dione, and optionally substituted benzo[d][l,3]dioxolyl.
  • Het-B is an optionally substituted indolinyl (i.e., containing 1 heteroatom selected from N or NR 16 ), the following compounds are specifically excluded:
  • Het-B is an optionally substituted isoindolinyl-1,3- dione (i.e., containing 1 heteroatom selected from N or NR 16 ), the following compounds are specifically excluded:
  • Het-B is an optionally substituted benzo[d][l,3]dioxolyl (i.e., containing 2 O heteroatoms)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted 10-membered bicyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heterocyclyl ring containing 1 heteroatom selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 10- membered bicyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring selected from the group consisting of optionally substituted 1,2,3,4-tetrahydroquinolinyl.
  • Het-B is an optionally substituted 1,2,3,4- tetrahydroquinolinyl (i.e., containing 1 heteroatom selected from N or NR 16 ), the following compounds are specifically excluded:
  • Het-B is an optionally substituted 5-10 membered heteroaryl ring
  • Het-B is an optionally substituted 5-10 membered heteroaryl ring.
  • Het-B is an optionally substituted 5-10 membered heteroaryl ring, wherein said heteroaryl ring has 1 to 3 heteroatoms selected from N, NR 16 , O and S, and R 16 is, independently, hydrogen, -SO 2 R 11 , -SOR 11 , -C(O)R 11 , -CO 2 R 11 , -C(O)N(R ⁇ ) 2 , - C(O)NH(R 11 ), -C(O)NH 2 , optionally substituted C 1- * alkyl, optionally substituted C 2 _ 8 alkenyl, optionally substituted C 2 _ 8 alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C 2 _8 heteroalkenyl, optionally substituted C 2 _8 heteroalkynyl, optionally substituted C3_
  • Het-B is an optionally substituted 5-6 membered monocyclic heteroaryl ring. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring containing 1 heteroatom selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring containing 2 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 5- membered monocyclic heteroaryl ring containing 3 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring selected from the group consisting of optionally substituted triazolyl, optionally substituted oxadiazolyl, optionally substituted thiadiazolyl, optionally substituted imidazolyl, optionally substituted pyrazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiophenyl, optionally substituted furanyl and optionally substituted pyrrolyl.
  • Het-B is an optionally substituted oxadiazolyl group (i.e., containing one O and two N atoms)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted thiadiazolyl group (i.e., containing one S and two N atoms)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted triazolyl group (i.e., containing three heteroatoms selected from N and NR 16 ), the following compounds are specifically excluded:
  • R 1 and R 2 is a cyclohexyl group
  • Het-B is an optionally substituted oxazolyl group (i.e., containing one N atom and one O atom)
  • the following compounds are specifically excluded: (i) compounds wherein W 3 is CH, X is a covalent bond, n is 0 and m is 0; (ii) compounds wherein W 3 is CH, n is 1, R 1 is fluoro, X is -OCH 2 - or -CH 2 O-, and m is 0;
  • Het-B is an optionally substituted thiazolyl group (i.e., containing one S atom and one N atom)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted pyrazolyl group (i.e., containing two heteroatoms selected from N or NR 16 ), the following compounds are specifically excluded:
  • Het-B is an optionally substituted thiophenyl group (i.e., containing one S atom)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted furanyl group (i.e., containing one O atom)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted pyrrolyl group (i.e., containing one heteroatom selected from N or NR 16 ), the following compounds are specifically excluded:
  • Het-B is an optionally substituted 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heteroaryl ring containing 1 heteroatom selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heteroaryl ring containing 2 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 6- membered monocyclic heteroaryl ring containing 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted pyridinyl group (e.g., 2-pyridinyl, 3- pyridinyl, 4-pyridinyl).
  • pyridinyl group e.g., 2-pyridinyl, 3-
  • Het-B is not an optionally substituted 6-membered monocyclic heteroaryl ring. In certain embodiments, Het-B is not an optionally substituted pyridinyl. Alternatively, in certain embodiments, wherein Het-B is an optionally substituted pyridinyl group, the following compounds are specifically excluded:
  • Het-B is an optionally substituted 9-10 membered bicyclic heteroaryl ring. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S (e.g., a 6-5 fused heteroaryl ring). In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 1 heteroatom selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 2 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 3 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring selected from the group consisting of optionally substituted benzthiazolyl, optionally substituted benzoxazolyl, optionally substituted benzisoxazolyl, optionally substituted benzimidazolyl, optionally substituted indazolyl, optionally substituted benzofuranyl, optionally substituted benzothiophenyl and optionally substituted indolyl.
  • Het-B is an optionally substituted benzoxazolyl group (i.e., containing one N atom and one O atom)
  • the following compounds are specifically excluded: (i) compounds wherein W 3 is CH, X is a covalent bond, n is 0 and m is 0;
  • Het-B is an optionally substituted benzisoxazolyl group (i.e., containing one N atom and one O atom)
  • the following compounds are specifically excluded:
  • Het-B is an optionally substituted benzimidazolyl group (i.e., containing two heteroatoms selected from from from N or NR 16 ), the following compounds are specifically excluded:
  • Het-B is an optionally substituted indazolyl group (i.e., containing two heteroatoms selected from from N or NR 16 ), the following compounds are specifically excluded:
  • Het-B is an optionally substituted indolyl group (i.e., containing one heteroatom selected from from N or NR 16 )
  • the following compounds are specifically excluded: (i) compounds wherein W 3 is CH, X is -CH 2 -, n is 0 and m is 0;
  • Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR 16 , O and S (e.g., a 6,6-fused heteroaryl ring). In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 1 heteroatom selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 2 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 3 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 10- membered bicyclic heteroaryl ring selected from the group consisting of optionally substituted quinolinyl, optionally substituted isoquinolinyl or optionally substituted quinoxalinyl.
  • Het-B is an optionally substituted quinolinyl group (i.e., containing one heteroatom selected from from N), the following compounds are specifically excluded:
  • the present invention provides compounds of formula (VI):
  • Z 1 is -OH or -OR 3 and Z 2 is -OH, -OR 4 , an optionally substituted Ci_ 8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C i_8 heteroalkyl, optionally substituted C 2 -8 heteroalkenyl, optionally substituted C 2 -8 heteroalkynyl, optionally substituted C 3 _ 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 6 -io aryl, or optionally substituted 5-10 membered heteroaryl;
  • Z 1 and Z 2 taken together form a 5- to 8-membered ring having at least one O, S, N or NR 5 atom directly bonded to the boron atom; or (iii) Z 1 is -OH or -OR 3 , and Z 2 and Ring A taken together form an optionally substituted
  • Y 9 is an S or O
  • Het-B is an optionally substituted 3-10 membered heterocyclyl or an optionally substituted 5-10 membered heteroaryl ring; each instance of R 1 is, independently, halogen, -OR 8 , -CF 3 , -CN, -NO 2 , -SO 2 R 8 , - SOR 8 , -C(O)R 8 , -CO 2 R 8 , -C(O)N(R 8 ) 2 , -N 3 , -N 2 R 8 , -N(R 8 ) 2 , -B(OH 2 ), optionally substituted
  • each instance of R 2 is, independently, halogen, -OR 9 , -CF 3 , -CN, -NO 2 , -SO 2 R 9 , - SOR 9 , -C(O)R 9 , -CO 2 R 9 , -C(O)N(R 9 ) 2 , -N 3 , -N 2 R 9 , -N(R 9 ) 2 , optionally substituted C 1- * alkyl
  • R 3 and R 4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C 2 _g alkenyl, optionally substituted C 2 _g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C 2 _g heteroalkenyl, optionally substituted C 2 _g heteroalkynyl, optionally substituted C 3 _io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C ⁇ -io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R 5
  • the present invention provides compounds of any of formulae (VI-a), (VI-b), (VI-c), (VI-d) or (VI-e):
  • VI-C (VI-d) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y 9 , Z 1 , Z 2 , Het-B, X, R 1 , R 2 , m and n are as defined above and herein.
  • Exemplary Het-B rings include, but are not limited to,
  • Het-B of formula (VI), and subgenera thereof is selected from
  • Het-B of formula (Vl), and subgenera thereof is selected from
  • the present invention provides compounds of formula (VI-e):
  • the present invention provides compounds of any of formulae (VI-el), (VI-e2), (VI-e3), (VI-e4) or (VI-e5):
  • n is 0.
  • X is a covalent bond.
  • m is 1.
  • R 2 is selected from optionally substituted Ci_8 alkyl or optionally substituted C ⁇ -io aryl. In certain embodiments, R 2 is selected from -CH 3 , -CH 2 CH 3 , -(CH 2 ) 2 CH 3 , -(CH 2 ) 3 CH 3 , -(CH 2 ) 4 CH 3 , optionally substituted phenyl, optionally substituted benzyl, and -(CH 2 ) 2 CeH 5 .
  • Y 9 is a S atom. In certain embodiments, Y 9 is an O atom. In certain embodiments, Het-B is an optionally substituted 3-10 membered heterocyclyl ring having 2 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 5-10 membered heteroaryl ring having 2 to 3 heteroatoms selected from N, NR 16 , O and S. In certain embodiments, Het-B is an optionally substituted 5- membered heteroaryl ring having 2 to 3 heteroatoms selected from N, NR 16 , O and S.
  • Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring selected from the group consisting of an optionally substituted triazolyl, optionally substituted oxadiazolyl, optionally substituted thiadiazolyl, optionally substituted imidazolyl, optionally substituted pyrazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl and optionally substituted isoxazolyl.
  • compounds of formula (VI) or subgenera thereof, wherein Y 9 is S, X is a covalent bond, n is 0, m is 0 and Het-B is C 6 Hs or unsubstituted thiophenyl, are specifically excluded.
  • the present invention provides a pharmaceutically acceptable composition
  • a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient, medium, or carrier.
  • the present invention provides a pharmaceutically acceptable composition
  • a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in any of Tables 1 through 20, and a pharmaceutically acceptable excipient, medium, or carrier.
  • the present invention provides a pharmaceutically acceptable composition
  • a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (Vl), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples, and a pharmaceutically acceptable excipient, medium, or carrier.
  • the present invention provides a pharmaceutically acceptable composition
  • a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples having a K 1 of less than or equal to 0.01 microM or having a K 1 of between 0.01 microM and 0.1 microM ⁇ i.e., compounds with activities designated "A" and "B"), and a pharmaceutically acceptable excipient, medium, or carrier.
  • the present invention provides a pharmaceutically acceptable composition
  • a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples having a K 1 of less than or equal to 0.01 microM (i.e., compounds with activities designated "A") and a pharmaceutically acceptable excipient, medium, or carrier.
  • the present invention provides a pharmaceutically acceptable composition
  • a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient, medium, or carrier, wherein said compound is selected from the any compound depicted in the Examples.
  • compositions of the present invention additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable excipient includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof.
  • any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc
  • compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology.
  • preparatory methods include the step of bringing the active ingredient into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
  • a pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
  • a "unit dose" is discrete amount of the pharmaceutically acceptable composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one- third of such a dosage.
  • Relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and/or any additional ingredients in a pharmaceutically acceptable composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100% (w/w) active ingredient.
  • the pharmaceutically acceptable excipient is at least 95%, 96%, 97%, 98%, 99%, or 100% pure. In some embodiments, the excipient is approved for use in humans and for veterinary use. In some embodiments, the excipient is approved by United States Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.
  • USP United States Pharmacopoeia
  • EP European Pharmacopoeia
  • British Pharmacopoeia the British Pharmacopoeia
  • International Pharmacopoeia International Pharmacopoeia
  • compositions used in the manufacture of provided pharmaceutically acceptable compositions include, but are not limited to, inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Such excipients may optionally be included in the inventive formulations. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents can be present in the composition, according to the judgment of the formulator.
  • Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
  • Exemplary granulating and/or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
  • Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers ⁇ e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays ⁇ e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols ⁇ e.g.
  • natural emulsifiers ⁇ e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin
  • colloidal clays ⁇ e.g. bentonite [alum
  • stearyl alcohol cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers ⁇ e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives ⁇ e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters ⁇ e.g.
  • Cremophor polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
  • polyoxyethylene ethers e.g. polyoxyethylene lauryl ether [Brij 30]
  • poly(vinyl-pyrrolidone) diethylene glycol monolaurate
  • triethanolamine oleate sodium oleate
  • potassium oleate ethyl oleate
  • oleic acid ethyl laurate
  • Exemplary binding agents include, but are not limited to, starch (e.g. cornstarch and starch paste); gelatin; sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.); natural and synthetic gums (e.g.
  • acacia sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; etc.; and combinations thereof.
  • Exemplary preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
  • antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulf ⁇ te, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
  • Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and trisodium edetate.
  • EDTA ethylenediaminetetraacetic acid
  • citric acid monohydrate disodium edetate
  • dipotassium edetate dipotassium edetate
  • edetic acid fumaric acid, malic acid
  • phosphoric acid sodium edetate
  • tartaric acid tartaric acid
  • trisodium edetate trisodium edetate.
  • antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
  • antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
  • Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
  • Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
  • preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl.
  • the preservative is an anti-oxidant.
  • the preservative is a chelating agent.
  • Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D- gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isot
  • Exemplary lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
  • oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury
  • Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.
  • Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsif ⁇ ers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsif ⁇ ers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate,
  • the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • the conjugates of the invention are mixed with solubilizing agents such as Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol mono
  • Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active ingredients can be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active ingredient may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • opacifying agents include polymeric substances and waxes.
  • Dosage forms for topical and/or transdermal administration of a compound of this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches.
  • the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier and/or any needed preservatives and/or buffers as may be required.
  • the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body.
  • Such dosage forms may be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium.
  • the rate may be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel.
  • Suitable devices for use in delivering intradermal pharmaceutically acceptable compositions described herein include short needle devices such as those described in U.S. Patents 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662.
  • Intradermal compositions may be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof.
  • Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S.
  • Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable.
  • Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions.
  • Topically-administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent.
  • Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
  • a pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity.
  • a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers or from about 1 to about 6 nanometers.
  • Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low- boiling propellant in a sealed container.
  • Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers.
  • Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
  • Low boiling propellants generally include liquid propellants having a boiling point of below 65 0 F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition.
  • the propellant may further comprise additional ingredients such as a liquid non- ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
  • compositions of the invention formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension.
  • Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device.
  • Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate.
  • the droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers.
  • formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutically acceptable composition of the invention.
  • Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
  • Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein.
  • a pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for buccal administration.
  • Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein.
  • formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient.
  • Such powdered, aerosolized, and/or aerosolized formulations, when dispersed may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
  • a pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration.
  • Such formulations may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier.
  • Such drops may further comprise buffering agents, salts, and/or one or more other of the additional ingredients described herein.
  • Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this invention.
  • compositions suitable for administration to humans are generally suitable for administration to animals of all sorts. Modification of pharmaceutically acceptable compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation.
  • kits comprising one or more compounds of the invention (or pharmaceutically acceptable salts or prodrugs thereof), and/or one or more pharmaceutically acceptable compositions as described herein. Kits are typically provided in a suitable container (e.g., for example, a foil, plastic, or cardboard package).
  • a suitable container e.g., for example, a foil, plastic, or cardboard package.
  • an inventive kit may include one or more pharmaceutical excipients, pharmaceutical additives, therapeutically active agents, and the like, as described herein.
  • an inventive kit may include means for proper administration, such as, for example, graduated cups, syringes, needles, cleaning aids, and the like.
  • an inventive kit may include instructions for proper administration and/or preparation for proper administration.
  • the present invention also provides methods for treating an FAAH-mediated disease, disorder or condition by administering a therapeutically effective amount of a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable composition thereof, to a patient in need thereof.
  • the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable composition thereof, to a patient in need thereof.
  • a patient to which administration is contemplated includes, but is not limited to, humans
  • Treating refers to partially or completely inhibiting or reducing the condition from which the patient is suffering.
  • Treating refers to partially or completely inhibiting or reducing the condition from which the patient is suffering.
  • “Therapeutically effective amount,” as used herein, refers to the minimal amount or concentration of an inventive compound, or pharmaceutically acceptable composition thereof, that, when administered, is sufficient in treating the patient. Treating may be via prophylactic or therapeutic therapy.
  • the present invention provides a method for inhibiting FAAH in a biological sample comprising the step of contacting said sample with a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or with a compound set forth in the Examples.
  • FAAH-mediated diseases, disorders or conditions include, but are not limited to, painful conditions, inflammatory disorders, immune disorders, depression, anxiety, anxiety-related disorders, sleep disorders, feeding behaviors, movement disorders, glaucoma, neuroprotection and cardiovascular disease.
  • the FAAH-mediated disease, disorder or condition is a painful condition, disease or disorder.
  • a "painful condition, disease or disorder” includes, but is not limited to, neuropathic pain (e.g., peripheral neuropathic pain), central pain, deafferentiation pain, chronic pain (e.g., chronic nociceptive pain, and other forms of chronic pain such as post-operative pain), stimulus of nociceptive receptors, acute pain (e.g., phantom and transient acute pain), non-inflammatory pain, inflammatory pain, pain associated with cancer, wound pain, burn pain, post-operative pain, pain associated with medical procedures, arthritic pain (e.g., pain associated with rheumatoid arthritis, osteoarthritis), lumbosacral pain, musculoskeletal pain, headache, migraine, muscle ache, lower back and neck pain, toothache and the like.
  • neuropathic pain e.g., peripheral neuropathic pain
  • central pain e.g., dea
  • the painful condition, disease or disorder is neuropathic pain.
  • the term "neuropathic pain” refers to pain resulting from injury to a nerve.
  • Neuropathic pain is distinguished from nociceptive pain, which is the pain caused by acute tissue injury involving small cutaneous nerves or small nerves in muscle or connective tissue.
  • Neuropathic pain typically is long-lasting or chronic and often develops days or months following an initial acute tissue injury.
  • Neuropathic pain can involve persistent, spontaneous pain as well as allodynia, which is a painful response to a stimulus that normally is not painful.
  • Neuropathic pain also can be characterized by hyperalgesia, in which there is an accentuated response to a painful stimulus that usually is trivial, such as a pin prick.
  • Neuropathic pain conditions can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain.
  • Neuropathic pain conditions include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; neuralgia, such as post-herpetic neuralgia and trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, chemotherapy-induced pain, chemotherapy, surgery, invasive medical procedures, toxins burns, infection, or chronic inflammatory conditions.
  • Neuropathic pain can result from a peripheral nerve disorder such as neuroma; nerve compression; nerve crush, nerve stretch or incomplete nerve transsection; mononeuropathy or polyneuropathy.
  • Neuropathic pain can also result from a disorder such as dorsal root ganglion compression; inflammation of the spinal cord; contusion, tumor or hemisection of the spinal cord; tumors of the brainstem, thalamus or cortex; or trauma to the brainstem, thalamus or cortex.
  • neuropathic pain The symptoms of neuropathic pain are heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain.
  • pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
  • the painful condition, disease or disorder is non-inflammatory pain and/or inflammatory pain.
  • non-inflammatory pain include, without limitation, peripheral neuropathic pain (e.g., pain caused by a lesion or dysfunction in the peripheral nervous system), central pain (e.g., pain caused by a lesion or dysfunction of the central nervous system), deafferentation pain (e.g., pain due to loss of sensory input to the central nervous system), chronic nociceptive pain (e.g., certain types of cancer pain), noxious stimulus of nociceptive receptors (e.g., pain felt in response to tissue damage or impending tissue damage), phantom pain (e.g., pain felt in a part of the body that no longer exists, such as a limb that has been amputated), pain felt by psychiatric patients (e.g., pain where no physical cause may exist), and wandering pain (e.g., wherein the pain repeatedly changes location in the body).
  • peripheral neuropathic pain e.g., pain caused by a lesion or dysfunction in the peripheral nervous system
  • central pain e.g., pain caused
  • non-inflammatory pain and/or inflammatory pain are associated with disorders such as inflammatory diseases (e.g., autoimmune disease).
  • the FAAH-mediated disease, disorder or condition is an inflammatory disorder.
  • inflammatory disorders refers to those diseases or conditions that are characterized by signs of pain (dolor, from the generation of noxious substances and the stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of fluid), and/or loss of function (functio laesa, which may be partial or complete, temporary or permanent).
  • Inflammatory disorders include, without limitation, those affecting the blood vessels (e.g., polyarteritis, temporal arteritis); joints (e.g, arthritis: crystalline, osteo-, psoriatic, reactive, rheumatoid, Reiter's syndrome); gastrointestinal tract (e.g, Crohn's disease, ulcerative colitis); skin (e.g, dermatitis); or multiple organs and tissues (e.g, systemic lupus erythematosus).
  • blood vessels e.g., polyarteritis, temporal arteritis
  • joints e.g, arthritis: crystalline, osteo-, psoriatic, reactive, rheumatoid, Reiter's syndrome
  • gastrointestinal tract e.g, Crohn's disease, ulcerative colitis
  • skin e.g, dermatitis
  • multiple organs and tissues e.g, systemic lupus erythematosus
  • Inflammatory disorders include, but are not limited to, inflammation associated with vascular diseases, migraine headaches, tension headaches, arteritis, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, multiple sclerosis, and ischemia (e.g., myocardial ischemia), and the like.
  • the compounds and compositions may be useful for treating neuroinflammation associated with brain disorders (e.g., Parkinson's disease and Alzheimer's disease) and chronic inflammation associated with cranial radiation injury.
  • the compounds may be useful for treating acute inflammatory conditions (e.g., conditions resulting from infection) and chronic inflammatory conditions (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease).
  • acute inflammatory conditions e.g., conditions resulting from infection
  • chronic inflammatory conditions e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease
  • the compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia.
  • Inflammation takes on many forms and includes, but is not limited to, acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative, fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial, metastatic, necrotic, obliterative, parenchymatous, plastic, productive, proliferous, pseudomembranous, purulent, sclerosing, seroplastic, serous, simple, specific, subacute, suppurative, toxic, traumatic, and/or ulcerative inflammation.
  • the FAAH-mediated disease, disorder or condition is an immune disorder.
  • Immune disorders such as auto-immune disorders, include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, haemolytic autoimmune anaemias, multiple sclerosis, amyotrophic lateral sclerosis, amylosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin inflammation disorders (e.g., psoriasis, eczema, burns, dermatitis), enuresis, eosinophilic disease, gastrointestinal disorders (
  • the immune disorder is a gastrointestinal disorder.
  • the immune disorder is inflammatory bowel disease (e.g., Crohn's disease and/or ulcerative colitis), peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, Crohn's disease, gastritis, diarrhea, irritable bowel syndrome and ulcerative colitis.
  • the immune disorder is inflammatory bowel disease (IBD).
  • the FAAH-mediated disease, disorder or condition is a skin disorder.
  • the skin disorder is pruritus (itch), psoriasis, eczema, burns or dermatitis.
  • the skin disorder is psoriasis.
  • the skin disorder is pruritis.
  • the FAAH-mediated disease, disorder or condition is anxiety.
  • “Anxiety,” as used herein, includes, but is not limited to anxiety and anxiety disorders or conditions, such as, for example, clinical anxiety, panic disorder, agoraphobia, generalized anxiety disorder, specific phobia, social phobia, obsessive-compulsive disorder, acute stress disorder, and post-traumatic stress disorder; and adjustment disorders with anxious features, anxiety disorders associated with depression, anxiety disorders due to general medical conditions, and substance-induced anxiety disorders.
  • This treatment may also be to induce or promote sleep in a patient (e.g., for example, a patient with anxiety).
  • the FAAH-mediated disease, disorder or condition is a sleep disorder.
  • sleep disorders include, but are not limited to, insomia, sleep apnea, restless legs syndrome (RLS), delayed sleep phase syndrome (DSPS), periodic limb movement disorder (PLMD), hypopnea syndrome, rapid eye movement behavior disorder (RBD), shift work sleep disorder (SWSD), and sleep problems (e.g., parasomnias) such as nightmares, night terrors, sleep talking, head banging, snoring, and clenched jaw and/or grinding of teeth (bruxism).
  • the FAAH-mediated disease, disorder or condition is depression.
  • Depression includes, but is not limited to, depressive disorders or conditions, such as, for example, major depressive disorders (unipolar depression), dysthymic disorders (chronic, mild depression) and bipolar disorders (manic-depression).
  • the depression may be clinical or subclinical depression.
  • the FAAH-mediated disease, disorder or condition is feeding behavior.
  • “Feeding behavior,” as used herein, includes but is not limited to, eating disorders (e.g., anorexias and cachexias of various natures, over-eating leading to obesity), weight loss associated with cancer, weight loss associated with other general medical conditions, weight loss associated with failure to thrive, and other wasting conditions.
  • eating disorders e.g., anorexias and cachexias of various natures, over-eating leading to obesity
  • weight loss associated with cancer e.g., weight loss associated with other general medical conditions
  • weight loss associated with failure to thrive e.g., and other wasting conditions.
  • the compounds disclosed herein can also be used to reduce body fat and for treating or preventing obesity in a mammal.
  • the compounds disclosed herein can also be used for preventing or treating the diseases associated with these health conditions.
  • the FAAH-mediated disease, disorder or condition is a movement disorder. In other embodiments, the FAAH-mediated disease, disorder or condition is glaucoma. In yet other embodiments, the FAAH-mediated disease, disorder or condition is neuroprotection. In still yet other embodiments, the FAAH-mediated disease, disorder or condition is cardiovascular disease.
  • the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, to a patient in need thereof.
  • the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples.
  • the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, having a K 1 of less than or equal to 0.01 microM or having a K 1 of between 0.01 microM and 0.1 microM (i.e., compounds with activities designated "A" or "B").
  • the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, having a K 1 of less than or equal to 0.01 microM (i.e., compounds with activities designated "A").
  • Provided compounds may be administered using any amount and any route of administration effective for treatment.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular composition, its mode of administration, its mode of activity, and the like.
  • compositions of the present invention are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease, disorder, or condition being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
  • Provided compounds and compositions of the present invention may be administered by any route.
  • provided compounds and compositions are administered via a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
  • routes including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal,
  • Specifically contemplated routes are systemic intravenous injection, regional administration via blood and/or lymph supply, and/or direct administration to an affected site.
  • the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration), etc.
  • the oral and/or nasal spray and/or aerosol route is most commonly used to deliver therapeutic agents directly to the lungs and/or respiratory system.
  • the invention encompasses the delivery of a provided pharmaceutically acceptable composition by any appropriate route taking into consideration likely advances in the sciences of drug delivery.
  • the exact amount of a compound required to achieve a therapeutically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like.
  • the desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
  • the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
  • a therapeutically effective amount of an inventive compound for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 1000 mg of an inventive compound per unit dosage form. It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutically acceptable compositions to an adult.
  • the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
  • an inventive compound or composition as described above and herein, can be administered in combination with one or more additional therapeutically active agents.
  • compositions can be administered concurrently with, prior to, or subsequent to, one or more other additional therapeutically active agents.
  • each agent will be administered at a dose and/or on a time schedule determined for that agent.
  • the additional therapeutically active agent utilized in this combination may be administered together in a single composition or administered separately in different compositions.
  • the particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved.
  • a “therapeutically active agent” or “active agent” refers to any substance that is useful for therapy, including prophylactic and therapeutic treatment.
  • the invention encompasses the delivery of provided pharmaceutically acceptable compositions in combination with agents that may improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. It will also be appreciated that therapy employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered in combination with an antiinflammatory, anti-anxiety and/or anti-depressive agent, etc.), and/or they may achieve different effects (e.g., control of any adverse side-effects).
  • Exemplary active agents include, but are not limited to, anti-cancer agents, antibiotics, anti-viral agents, anesthetics, anti-coagulants, inhibitors of an enzyme, steroidal agents, steroidal or non-steroidal anti-inflammatory agents, antihistamine, immunosuppressant agents, antineoplastic agents, antigens, vaccines, antibodies, decongestants sedatives, opioids, pain- relieving agents, analgesics, anti-pyretics, hormones, prostaglandins, progestational agents, anti- glaucoma agents, ophthalmic agents, anti-cholinergics, anti-depressants, anti-psychotics, hypnotics, tranquilizers, anti-convulsants, muscle relaxants, anti-spasmodics, muscle contractants, channel blockers, miotic agents, anti-secretory agents, anti-thrombotic agents, anticoagulants, anti-cholinergics, ⁇ -adrenergic blocking agents, diuretics, cardiovascular active agents,
  • Active agents include small organic molecules such as drug compounds ⁇ e.g. , compounds approved by the Food and Drugs Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins and cells.
  • CFR Code of Federal Regulations
  • the additional therapeutically active agent is a pain-relieving agent. In other embodiments, the additional therapeutically active agent is an anti-inflammatory agent.
  • Methods of determining the activity of compounds of the present invention for various therapeutic uses are well known in the art. These include, but are not limited to, high throughput screening to identify compounds that bind to and/or modulate the activity of isolated FAAH, as well as animal and cellular models of therapies.
  • Assays for compounds described herein are amenable to high throughput screening.
  • Assays useful for screening the compounds of the present invention may detect the binding of the inhibitor to FAAH or the release of a reaction product (e.g., fatty acid amide or ethanolamine) produced by the hydrolysis of a substrate such as oleoylethanolamide or ananadamide.
  • the substrate may be labeled to facilitate detection of the released reaction products.
  • U.S. Pat. No. 5,559,410 discloses high throughput screening methods for proteins
  • U.S. Pat. Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.
  • test compounds can be administered to the subject animals in the mouse hot-plate test and the mouse formalin test and the nociceptive reactions to thermal or chemical tissue damage measured (for example, see U.S. Pat. No. 6,326,156 which teaches methods of screening for antinociceptive activity; see also Cravatt et al. Proc. Natl. Acad. Sci. U.S.A. (2001) 98:9371-9376).
  • Two pharmacologically validated animal models of anxiety are the elevated zero maze test, and the isolation-induced ultrasonic emission test.
  • the zero maze consists of an elevated annular platform with two open and two closed quadrants and is based on the conflict between an animal's instinct to explore its environment and its fear of open spaces, where it may be attacked by predators (see, for example, Bickerdike, M. J. et al., Eur. J. Pharmacol, (994) 271, 403-411; Shepherd, J. K. et al., Psychopharmacology, (1994) 116, 56-64).
  • Clinically used anxiolytic drugs such as the benzodiazepines, increase the proportion of time spent in, and the number of entries made into, the open compartments.
  • a second test for an anti-anxiety compound is the ultrasonic vocalization emission model, which measures the number of stress-induced vocalizations emitted by rat pups removed from their nest (see, for example, Drei, T. R. et al., Pharmacol. Biochem. Behav., 24, 1263-1267 (1986); Miczek, K. A. et al., Psychopharmacology, 121, 38-56 (1995); Winslow, J. T. et al., Biol. Psychiatry, 15, 745-757 (1991).
  • the effect of the compound of the invention in the treatment of depression can be tested in the model of chronic mild stress induced anhedonia in rats.
  • This model is based on the observation that chronic mild stress causes a gradual decrease in sensitivity to rewards, for example consumption of sucrose, and that this decrease is dose-dependently reversed by chronic treatment with antidepressants.
  • the method has previously been described and more information with respect to the test appears from Willner, Paul, Psychopharmacology, 1997, 134, 319-329.
  • Another test for antidepressant activity is the forced swimming test (Nature 266, 730-
  • mice are administered an agent, preferably by the intraperitoneal route or by the oral route, 30 or 60 minutes before the test.
  • the animals are placed in a crystallizing dish filled with water and the time during which they remain immobile is clocked.
  • the immobility time is then compared with that of the control group treated with distilled water.
  • Imipramine 25 mg/kg. can be used as the positive control.
  • the antidepressant compounds decrease the immobility time of the mice thus immersed.
  • Another test for antidepressant activity is the caudal suspension test on the mouse (Psychopharmacology, 85, 367-370, 1985).
  • animals are preferably treated with the study compound by the intraperitoneal route or by the oral route 30 or 60 minutes before the test.
  • the animals are then suspended by the tail and their immobility time is automatically recorded by a computer system.
  • the immobility times are then compared with those of a control group treated with distilled water. Imipramine 25 mg/kg can be used as the positive control.
  • Antidepressant compounds decrease the immobility time of the mice.
  • Maruani et al. (U.S. Pat. No. 6,344,474) teach two such assays.
  • One method of assessing the effect on appetite behavior is to administer a FAAH inhibitor to a rat and assess its effect on the intake of a sucrose solution. This method is taught in W. C. Lynch et al., Physiol. Behav., 1993, 54, 877-880.
  • compounds of any offormulae (III), (IV), (V), or (VI), or subgenera thereof, as described above and herein, are associated with a serine residue of a protein:
  • Resi — Ser — ReS 2 is a protein having a length between about 400 to about 600 residues.
  • Ser is meant a serine residue.
  • Ser is Ser 2 4i of FAAH protein.
  • the protein is rat FAAH.
  • the protein is human FAAH (SEQ ID NO. 1).
  • the active site of the protein has a Lys at 142; a Ser at 217; and a Ser at 241.
  • the compound binds at Ser 2 4i.
  • Resi is meant the residue(s) closer to the N-terminus than Ser.
  • Res 2 is meant the residue(s) closer to the C-terminus than Ser.
  • Resi has a serine residue that is 24 amino acids closer to the N terminus than (Ser) and a lysine residue that is 99 amino acids closer to the N terminus than (Ser).
  • Z 1 and Z 2 are both -OH.
  • the compound is a boronic acid compound.
  • a number of methods are known in the art to synthesize the compounds provided herein.
  • a recognized method of synthesizing boronate esters is the reaction of an organometallic species with an organic borate, such as trimethyl borate.
  • Suitable organometallic species include, but are not limited to, alkyl lithium and Grignard reagents.
  • Other methods for the synthesis of boronates are employed when the boronate contains sensitive functionality that may not tolerate alkyl lithium reagents or Grignard reagents. These methods include palladium coupling reactions of aryl or akenyl halides and diboronates or dialkoxy boranes and hydroboration of alkenes or alkynes.
  • boronates can be readily transformed in to boronic acids by hydro lyzing the boronate under aqueous acidic conditions using a suitable acid. Suitable acids include, but are not limited to HCl, H 2 SO 4 , and HBr.
  • Another method of hydrolyzing boronates is an oxidative hydrolysis employing an oxidizing agent, such as NaIO 4 , as exemplified in Example 5.
  • the boronic acid compounds of the present invention readily form boronic esters when exposed to alcohols. The resulting boronic esters may also be used in the methods provided herein.
  • Cyclic boronates are formed when certain diols (e.g., 1,2- and 1,3-diols) are used.
  • Boronic acid compounds provided herein readily form oligomeric anhydrides by dehydration of the boronic acid moiety to form dimers, trimers, and tetramers, and mixtures thereof. These species in the presence of water and under physiological conditions convert back to the boronic acid by hydrolysis.
  • Exemplary compounds are set forth in the Examples provided below. Compounds were assayed as inhibitors of human FAAH using the method described in detail in Example 286. Activity of exemplified compounds are provided in the Examples, wherein activity designated as "A” refers to compounds having a K 1 of less than or equal to 0.01 microM, “B” refers to compounds having a K 1 of between 0.01 microM and 0.1 microM, “C” refers to compounds having a K 1 of between 0.1 microM and 1 microM, and “D” refers to compounds having a K 1 of greater than 1 microM.
  • A refers to compounds having a K 1 of less than or equal to 0.01 microM
  • B refers to compounds having a K 1 of between 0.01 microM and 0.1 microM
  • C refers to compounds having a K 1 of between 0.1 microM and 1 microM
  • D refers to compounds having a K 1 of greater than 1 microM.
  • Triisopropylborate (1.3 equiv) was then added dropwise to the clear stirring solution. After 15 min, the mixture was warmed to 0 0 C and stirred for an additional 30 min. The mixture was quenched with 2N aqueous HCl (10 equiv) and stirred for Ih at 23 0 C. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine and then dried over sodium sulfate.
  • the residue upon concentration was purified either by recrystallization/trituration (heptanes, acetonitrile, or other) or by flash silica gel chromatography ( 1 -M 0% methanol/dichloromethane) to generally produce a white solid.
  • reaction Upon completion as judged by thin layer chromatography analysis, the reaction was split between water and ethyl acetate, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The concentrated reaction mixture was purified by flash silica gel chromatography (ethyl acetate / hexanes) to provide boronic acid pinacol ester.
  • the oxadiazole was formed as in Method 7, except that the reactants are a carboxyarylboronic acid pinacol ester and either an alkyl or aryl hydrazide.
  • the thiadiazole was formed as in Method 9, except that the reactants are a carboxyarylboronic acid pinacol ester and either an alkyl or aryl hydrazide.
  • the reaction was allowed to stir for 12h at room temperature after which point it was transferred to a separatory funnel with excess dichloromethane and washed with 0.5 M citric acid (2 x 75 mL) and saturated NaHCO 3 (2 x 75 mL). The organic layer was then dried over MgSO 4 , filtered and concentrated to provide the desired ketoamide as a yellow solid in quantitative yield (680 mg) which was used directly to form the oxazole the in the following step.
  • the crude ketoamide (100 mg, 0.261 mmol) was dissolved in 2 mL concentrated H 2 SO 4 .
  • the ketoamide that was used to prepare 2 (223 mg, 0.58 mmol) was dissolved in 5 mL anhydrous tetrahydrofuran and Lawesson's reagent (282 mg, 0.70 mmol) was then added. The reaction was heated to 70 0 C for 14h after which point it was loaded directly onto silica gel and purified using silica gel chromatography using a gradient of 20-70% ethyl acetate/hexanes to provide 200 mg of the desired thiazole in 90% yield.
  • 6-Bromo-2-tetralone (4) was converted to its corresponding pincol ester boronate (5) using Method 3.
  • This ketone (6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4- dihydronaphthalen-2(lH)-one) (600 mg, 2.21 mmol) was dissolved in 10 mL 1 :1 v/v methanol/tetrahydrofuran and cooled to 0 0 C in an ice bath.
  • Sodium borohydride 250 mg, 6.63 mmol was added portion wise and the reaction was allowed to stir for 2h after which point there was no more starting material as indicated by TLC analysis.
  • This secondary alcohol 110 mg, 0.40 mmol was dissolved in 2 mL anhydrous N, N- dimethylforamide and cooled to 0 0 C in an ice bath.
  • Sodium hydride 48 mg, 1.20 mmol, 60% in dispersion oil
  • benzyl bromide 95 ⁇ L, 0.80 mmol was added and the reaction was allowed to stir at room temperature for 2h. A large amount of starting material was still remaining at this point so sodium hydride and benzyl bromide was added in 3 additional portions and the reaction was allowed to stir for an additional 48h.
  • reaction was quenched with saturated NH 4 Cl (75 mL) and transferred to a separatory funnel with excess water and ethyl acetate.
  • the water layer was washed with ethyl acetate (2 x 75mL).
  • the combined organic layers were washed with saturated NaCl (2 x 75 mL), dried over MgSO 4 , concentrated directly onto silica gel and purified by silica gel chromatography using a gradient of 5-10% ethyl acetate/hexanes to provide the desired ether as an oil (57 mg) in 39% yield.
  • the ketoamide (140 mg, 0.298 mmol) was dissolved in 4 mL anhydrous tetrahydrofuran and followed by the addition of Lawesson's reagent (145 mg, 0.358 mmol). The reaction was heated to 115 0 C in a microwave reactor for 90 min after which point the crude mixture was loaded directly onto silica gel and purified using a gradient of 25-50% ethyl acetate/hexanes to isolate 90 mg of the desired compound in 65% yield.
  • Bromobenzaldehyde 15 (3.0 g, 9.83 mmol, 1.0 equiv) dissolved in 2:1 tetrahydrofuran /water (75 ml) was treated with 2-methyl-2-butene (6.9 g, 98 mmol, 10 equiv), sodium phosphate monobasic, dihydrate, (4.6 g, 29.5 mmol, 3.0 equiv), and sodium chlorite (2.1 g, 24 mmol, 2.4 equiv). The mixture was stirred at 23 0 C for 6h and was then split between ethyl acetate (200 ml) and IN aqueous HCl (100 ml).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)

Abstract

The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

Description

INHIBITORS OF FATTY ACID AMIDE HYDROLASE
BACKGROUND
Fatty acid amide hydrolase (FAAH), also referred to as oleamide hydrolase and anandamide amidohydrolase, is an integral membrane protein that degrades fatty acid primary amides and ethanolamides, including oleamide and anandamide. FAAH degrades neuromodulating fatty acid amides at their sites of action and is intimately involved in their regulation.
FAAH has been demonstrated to be involved in a number of biological processes and its inhibition has been shown to be effective in treating a variety of conditions. For example, inhibiting FAAH has been shown to be useful in treating chronic pain, acute pain, neuropathic pain, anxiety, depression, feeding behaviors, movement disorders, glaucoma, neuroprotection and cardiovascular disease. However, current inhibitors of FAAH lack the target selectivity, biological activity and/or bioavailability needed for in vivo studies and therapeutic use. Thus, to date, the therapeutic potential of FAAH inhibitors remains essentially unexplored.
SUMMARY
Compounds described herein, and pharmaceutically acceptable compositions thereof, are effective inhibitors of fatty acid amide hydrolase (FAAH). Such compounds are encompassed by formula (I):
Figure imgf000003_0001
(I) or pharmaceutically acceptable salts or prodrugs thereof, wherein Z1, Z2, L1, X, Ring A, R1, RA and n are as defined herein. In certain embodiments, Ring A is a C3_io carbocyclyl or Cβ-io aryl group. In some embodiments, Ring A is phenyl. In other embodiments, Ring A is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group. In some embodiments, Ring A is monocyclic, while in other embodiments Ring A is bicyclic. In certain embodiments, RA is Ring B, i.e., providing compounds which are encompassed by formula (II):
Figure imgf000004_0001
(H) or pharmaceutically acceptable salts or prodrugs thereof, wherein Z1, Z2, L1, X, Ring A, Ring B, R1, R2, n and m are as defined herein. In certain embodiments, Ring B is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group. In some embodiments, Ring B is monocyclic, while in other embodiments Ring B is bicyclic.
Also provided are methods for treating conditions associated with excessive FAAH activity by administering a therapeutically effective amount of a compound provided herein, or a pharmaceutical composition thereof, to a patient in need thereof.
Also provided are methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable composition thereof, to a patient in need thereof.
Sequence Identification Numbers
SEQ ID NO. 1: Homo sapiens FAAH amino acid sequence:
MVQYEL WAALPGASGVALACCFVAAAVALRWSGRRTARGAVVRARQRQRAGLENM DRAAQRFRLQNPDLDSEALLALPLPQLVQKLHSRELAPEAVLFTYVGKAWEVNKGTNC VTSYLADCETQLSQAPRQGLL YGVPVSLKECFTYKGQDSTLGLSLNEGVP AECDSVVVH VLKLQGAVPFVHTNVPQSMFSYDCSNPLFGQTVNP WKSSKSPGGSSGGEGALIGSGGSP LGLGTDIGGSIRFPSSFCGICGLKPTGNRLSKSGLKGCVYGQEAVRLSVGPMARD VESLA LCLRALLCEDMFRLDPTVPPLPFREEVYTSSQPLRVGYYETDNYTMPSPAMRRAVLETK QSLEAAGHTLVPFLPSNIPHALETLSTGGLFSDGGHTFLQNFKGDFVDPCLGDLVSILKLP QWLKGLLAFLVKPLLPRLSAFLSNMKSRSAGKLWELQHEIEVYRKTVIAQWRALDLDV VLTPMLAPALDLNAPGRATGAVSYTMLYNCLDFPAGVVPVTTVTAEDEAQMEHYRGY FGDIWDKMLQKGMKKSVGLPVAVQCVALPWQEELCLRFMREVERLMTPEKQSS DETAILED DESCRIPTION 1. General Description of Compounds
Provided are inhibitors of FAAH that contain at least one Lewis acidic boron head group, such as, for example, a boronic acid, boronic ester, borinic acid or borinic ester head group. Such compounds include compounds of formula (I):
Figure imgf000005_0001
(I) or a pharmaceutically acceptable salt or prodrug thereof; wherein: (i) Z1 is -OH or -OR3; and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl group; (ii) Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to
8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom;
(iii) Z1 is -OH or -OR3; and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring;
L1 is a covalent bond, an optionally substituted straight or branched Ci_6 alkylene, or an optionally substituted straight or branched C2_6 alkenylene moiety;
Ring A is optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl;
X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-; RA is hydrogen, halogen, -OR7, -CF3, -CN, -NO2, -SO2R7, -SOR7, -C(O)R7, -CO2R7, - C(O)N(R7)2, -N3, -N2R7, -N(R7)2, or Ring B having formula:
Figure imgf000006_0001
wherein Ring B is optionally substituted C3-Io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted C i_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted
Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, and R10 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; n is 0, 1, 2 or 3; and m is 0, 1, 2, 3, 4 or 5.
In certain embodiments, RA is Ring B, i.e., compounds encompassed by formula (II):
Figure imgf000007_0001
or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, L1, X, Ring A, Ring B, R1, R2, n and m are as defined herein.
In certain embodiments, Ring A is a C3_10 carbocyclyl or Cβ-io aryl group. In some embodiments, Ring A is phenyl. In other embodiments, Ring A is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group. In some embodiments, Ring A is monocyclic, while in other embodiments Ring A is bicyclic. In certain embodiments, Ring B is a 3-10 membered heterocyclyl group or a 5-10 membered heteroaryl group. In some embodiments, Ring B is monocyclic, while in other embodiments Ring B is bicyclic. For example, in certain embodiments, Ring B is a 5-6 membered monocyclic heteroaryl group, while in other embodiments, Ring B is a 9-10 membered bicyclic heteroaryl group.
2. Compounds and Definitions
Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the
Elements, CAS version, Handbook of Chemistry and Physics, 75 th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March 's Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.
Certain compounds of the present invention can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., stereoisomers and/or diastereomers. Thus, provided compounds, and pharmaceutically acceptable compositions thereof, may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers. In certain embodiments, the compounds of the invention are enantiopure compounds. In certain other embodiments, mixtures of stereoisomers or diastereomers are provided. Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated. The invention additionally encompasses the compounds as individual isomers substantially free of other isomers and, alternatively, as mixtures of various isomers, e.g., racemic mixtures of stereoisomers. Where a particular enantiomer is preferred, it may, in some embodiments be provided substantially free of the corresponding enantiomer, and may also be referred to as "optically enriched." "Optically-enriched," as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, EX. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (EX. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example "Ci_6 alkyl" is intended to encompass, C1, C2, C3, C4, C5, C6, C1- 6, Ci_5, Ci_4, Ci_3, Ci_2, C2_6, C2_5, C2-4, C2_3, C3-O, C3_5, C3_4, C4_6, C4-S, and C5_6 alkyl.
As used herein a "direct bond" or "covalent bond" refers to a single bond.
As used herein, the term "boronic acid" refers to any chemical compound comprising a - B(OH)2 moiety. Arylboronic acid compounds readily form oligomeric anhydrides by dehydration of the boronic acid moiety (see, for example, Snyder et al., J. Am. Chem. Soc. (1958) 80: 3611). Thus, unless otherwise apparent from context, the term "boronic acid" is expressly intended to encompass free boronic acids, oligomeric anhydrides, including, but not limited to, dimers, trimers, and tetramers, and mixtures thereof.
The terms "boronic ester", "borinic acid" and "borinic ester" are art understood terms referring to a -B(OR)2 moiety, a -B(R)OH moiety and a -B(R)OR moiety, respectively, wherein R is a group other than hydrogen (e.g., for example, an optionally substituted Ci_g alkyl, optionally substituted C2-s alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C1-
8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_i0 carbocycyl, optionally substituted 3-10 membered heterocycyl, optionally substituted C6-10 aryl, or optionally substituted 5-10 membered heteroaryl group, or two R groups are joined to form a 5- to 8-membered ring optionally containing 1 to 4 heteroatoms selected from optionally substituted nitrogen, oxygen or sulfur).
As used herein, alone or as part of another group, "halo" and "halogen" refer to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).
As used herein, alone or as part of another group, "alkyl" refers to a monoradical of a straight-chain or branched saturated hydrocarbon group having from 1 to 8 carbon atoms ("C1-S alkyl"). In some embodiments, an alkyl group can have from 1 to 6 carbon atoms ("C1^ alkyl").
In some embodiments, an alkyl group can have from 1 to 4 carbon atoms ("Ci_4 alkyl").
Examples of Ci_4 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of Ci_6 alkyl groups include the aforementioned Ci_4 alkyl groups as well as pentyl, isopentyl, neopentyl, hexyl and the like. Additional examples of alkyl groups include heptyl, octyl and the like. Unless otherwise specified, each instance of an "optionally substituted" alkyl group is independently unsubstituted or substituted with 1-5 groups as described below.
As used herein, alone or as part of another group, "alkenyl" refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms and one or more carbon-carbon double bonds ("C2_8 alkenyl"). In some embodiments, an alkenyl group can have from 2 to 6 carbon atoms ("C2_6 alkenyl"). In some embodiments, an alkenyl group can have from 2 to 4 carbon atoms ("C2^t alkenyl"). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-4 alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, butadienyl and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl, pentadienyl, hexenyl and the like. Additional examples of alkenyl include heptenyl, octenyl, octatrienyl and the like. Unless otherwise specified, each instance of an "optionally substituted" alkenyl group is independently unsubstituted or substituted with 1-5 groups as described below. As used herein, alone or as part of another group, "alkynyl" refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms and one or more carbon-carbon triple bonds ("C2_8 alkynyl"). In some embodiments, an alkynyl group can have from 2 to 6 carbon atoms ("C2_6 alkynyl"). In some embodiments, an alkynyl group can have from 2 to 4 carbon atoms ("C2_4 alkynyl"). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C 2-4 alkynyl groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl and the like. Examples of C2-6 alkenyl groups include the aforementioned
Figure imgf000010_0001
alkynyl groups as well as pentynyl, hexynyl and the like. Additional examples of alkynyl include heptynyl, octynyl and the like. Unless otherwise specified, each instance of an "optionally substituted" alkynyl group is independently unsubstituted or substituted with 1-5 groups as described below.
As used herein, alone or as part of another group, "heteroalkyl" refers to an alkyl group, as defined herein, wherein one or more carbon atoms are replaced with one or more heteroatoms selected from optionally substituted nitrogen, oxygen and sulfur. For example, "heteroalkyl" refers to a monoradical of a straight-chain or branched hydrocarbon group having from 1 to 8 carbon atoms and one or more heteroatoms ("C1-S heteroalkynyl"). Unless otherwise specified, each instance of an "optionally substituted" heteroalkyl group is independently unsubstituted or substituted with 1-5 groups as described below.
As used herein, alone or as part of another group, "heteroalkenyl" refers to an alkenyl group, as defined herein, wherein one or more carbon atoms are replaced with one or more heteroatoms selected from optionally substituted nitrogen, oxygen and sulfur. For example, "heteroalkenyl" refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms, one or more carbon-carbon double bonds, and one or more heteroatoms ("C2_8 heteroalkenyl"). Unless otherwise specified, each instance of an "optionally substituted" heteroalkenyl group is independently unsubstituted or substituted with 1-5 groups as described below.
As used herein, alone or as part of another group, "heteroalkynyl" refers to an alkynyl group, as defined herein, wherein one or more carbon atoms are replaced with one or more heteroatoms selected from optionally substituted nitrogen, oxygen and sulfur. For example, "heteroalkynyl" refers to a monoradical of a straight-chain or branched hydrocarbon group having from 2 to 8 carbon atoms, one or more carbon-carbon triple bonds, and one or more heteroatoms ("C2_8 heteroalkynyl"). Unless otherwise specified, each instance of an "optionally substituted" heteroalkynyl group is independently unsubstituted or substituted with 1-5 groups as described below.
As used herein, alone or as part of another group, "alkylene" refers to a diradical of a straight-chain or branched saturated hydrocarbon group having from 1 to 6 carbon atoms ("C1^ alkylene"). In some embodiments, an alkylene group can have from 1 to 4 carbon atoms ("C1^t alkylene"). In some embodiments, an alkylene group can have from 1 to 2 carbon atoms ("Ci_2 alkylene"). Examples of Ci_2 alkylene groups include methylene and ethylene. Examples of C1. 4 alkylene groups include the aforementioned Ci_2 alkylene groups as well as trimethylene (1,3- propanediyl), propylene (1,2-propanediyl), tetramethylene (1,4-butanediyl), butylene (1,2- butanediyl), 1 ,3-butanediyl, 2-methyl-l,3-propanediyl and the like. Examples of Ci_6 alkylene groups include the aforementioned Ci_4 alkylene groups as well as pentamethylene (1,5- pentanediyl), pentylene (1,2-pentanediyl), hexamethylene (1,6-hexanediyl), hexylene (1,2- hexanediyl), 2,3-dimethyl-l,4-butanediyl and the like. In some embodiments, an alkylene group is an α,ω-diradical. Examples of α,ω-diradical alkylene groups include methylene, ethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene. As used herein, alone or as part of another group, "alkenylene" refers to a diradical of a straight-chain or branched hydrocarbon group having from 2 to 6 carbon atoms and one or more carbon-carbon double bonds ("C2_6 alkenylene"). In some embodiments, an alkenylene group can have from 2 to 4 carbon atoms ("C2-4 alkenylene"). In some embodiments, an alkenylene group can have 2 carbon atoms, i.e., ethenediyl. The one or more carbon-carbon double bonds can be internal (such as in 1 ,4-but-2-enediyl) or terminal (such as in 1,4-but-l-enediyl). Examples of C2-4 alkenylene groups include ethenediyl, 1 ,2-propenediyl, 1 ,3-propenediyl, 1 ,4- but-1-enediyl, 1 ,4-but-2-enediyl and the like. Examples Of C2-O alkenylene groups include the aforementioned C2-4 alkenylene groups as well as 1,5-pent-l-enediyl, 1 ,4-pent-2-enediyl, 1,6- hex-2-enediyl, 2,5-hex-3-enediyl, 2-methyl-l,4-pent-2-enediyl and the like. In some embodiments, an alkenylene group is an α,ω-diradical. Examples of α,ω-diradical alkenylene groups include ethenediyl, 1,3-propenediyl, 1 ,4-but-2-enediyl, 1,5-pent-l-enediyl, l,6-hex-3- enediyl and the like.
As used herein, alone or as part of another group, "alkynylene" refers to a diradical of a straight-chain or branched hydrocarbon group having from 2 to 6 carbon atoms and one or more carbon-carbon triple bonds ("C2-6 alkynylene"). In some embodiments, an alkynylene group can have from 2 to 4 carbon atoms ("C2-4 alkynylene"). In some embodiments, an alkynylene group can have 2 carbon atoms, i.e., ethynediyl. The one or more carbon-carbon triple bonds can be internal (such as in 1 ,4-but-2-ynediyl) or terminal (such as in 1,4-but-l-ynediyl). Examples of C2-4 alkynylene groups include ethynediyl, propynediyl, 1,4-but-l-ynediyl, 1 ,4-but-2-ynediyl and the like. Examples of C2-6 alkynylene groups include the aforementioned C 2-4 alkynylene groups as well as 1,5-pent-l-ynediyl, 1 ,4-pent-2-ynediyl, l,6-hex-2-ynediyl, 2,5-hex-3- ynediyl, 3-methyl-l,5-hex-l-ynediyl and the like. In some embodiments, an alkynylene group is an α,ω-diradical. Examples of α,ω-diradical alkynylene groups include ethynediyl, propynediyl, 1 ,4-but-2-ynediyl, 1,5-pent-l-ynediyl, 1 ,6-hex-3-ynediyl and the like.
As used herein, alone or as part of another group, "perhaloalkyl" refers to an alkyl group having from 1 to 3 carbon atoms, wherein all of the hydrogen atoms are each independently replaced with fluoro or chloro. In some embodiments, all of the hydrogen atoms are each replaced with fluoro. In some embodiments, all of the hydrogen atoms are each replaced with chloro. Examples of perhaloalkyl groups include -CF3, -CF2CF3, -CF2CF2CF3, -CCl3, -CFCl2, -CF2Cl and the like. As used herein, alone or as part of another group, "alkoxy" or "alkyloxy" refers to an - O-alkyl group having from 1 to 8 carbon atoms ("Ci-8 alkoxy"). In some embodiments, an alkoxy group can have from 1 to 6 carbon atoms ("Ci-6 alkoxy"). In some embodiments, an alkoxy group can have from 1 to 4 carbon atoms ("Ci-4 alkoxy"). Examples of Ci_4 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy and the like. Examples of Ci_6 alkoxy groups include the aforementioned Ci_4 alkoxy groups as well as pentyloxy, isopentyloxy, neopentyloxy, hexyloxy and the like. Additional examples of alkoxy groups include heptyloxy, octyloxy and the like. Unless otherwise specified, each instance of an "optionally substituted" alkoxy group is independently unsubstituted or substituted with 1-5 groups as described below.
As used herein, alone or as part of another group, "perhaloalkoxy" refers to an alkoxy group having from 1 to 3 carbon atoms, wherein all of the hydrogen atoms are each independently replaced with fluoro or chloro. In some embodiments, all of the hydrogen atoms are each replaced with fluoro. In some embodiments, all of the hydrogen atoms are each replaced with chloro. Examples of perhaloalkoxy groups include -OCF3, -OCF2CF3, - OCF2CF2CF3, -OCCl3, -OCFCl2, -OCF2Cl and the like.
As used herein, alone or as part of another group, "alkylthio" refers to an -S-alkyl group having from 1 to 8 carbon atoms. In some embodiments, an alkylthio group can have from 1 to 6 carbon atoms. In some embodiments, an alkylthio group can have from 1 to 4 carbon atoms. Examples of Ci_4 alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio and the like. Examples of Ci_6 alkylthio groups include the aforementioned Ci_4 alkylthio groups as well as pentylthio, isopentylthio, hexylthio and the like. Additional examples of alkylthio groups include heptylthio, octylthio and the like. Unless otherwise specified, each instance of an "optionally substituted" alkylthio group is independently unsubstituted or substituted with 1-5 groups as described below.
As used herein, alone or as part of another group, "carbocyclyl" or "carbocycle" refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms ("C3-Io carbocyclyl"). In some embodiments, a carbocyclyl group can have from 3 to 8 ring carbon atoms ("C3_8 carbocyclyl"). In some embodiments, a carbocyclyl group can have from 3 to 6 ring carbon atoms ("C3_6 carbocyclyl"). Examples of C3_6 carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl and the like. Examples of C3-8 carbocyclyl groups include the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl, cycloheptadienyl, cycloheptatrienyl, cyclooctyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl and the like. Examples of C3_io carbocyclyl groups include the aforementioned C3-S carbocyclyl groups as well as octahydro-lH-indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and the like. As the foregoing examples illustrate, in some embodiments a carbocyclyl group can be monocyclic ("monocyclic carbocyclyl") or bicyclic (e.g., containing a fused, bridged or spiro ring system), and can be saturated or can contain one or more carbon-carbon double or triple bonds. "Carbocyclyl" also refers to a phenyl group (as defined below) fused to a monocyclic carbocyclyl group. Examples of such carbocyclyl groups include 1,2,3,4-tetrahydronaphthalene (e.g., 1,2,3,4-tetrahydronaphthalen- 1-yl, l,2,3,4-tetrahydronaphthalen-5-yl, and the like), 2,3-dihydro-lΗ-indene (e.g., 2,3- dihydro-lH-inden-1-yl, 2,3-dihydro-lH-inden-4-yl, and the like), indene (e.g., lH-inden-1- yl, lH-inden-7-yl, and the like), 5,6,7,8-tetrahydroquinoline (e.g., 5,6,7,8-tetrahydroquinolin- 5-yl, 5,6,7,8-tetrahydroquinolin-2-yl, and the like), 4,5,6,7-tetrahydro-lH-indole (e.g., 4,5,6,7-tetrahydro-lH-indol-4-yl, 4,5,6,7-tetrahydro-lH-indol-3-yl, and the like), 4,5,6,7- tetrahydrobenzofuran (e.g., 4,5,6,7-tetrahydrobenzofuran-7-yl, 4,5,6,7-tetrahydrobenzofuran- 2-yl, and the like) and the like. Unless otherwise specified, each instance of an "optionally substituted" carbocyclyl or carbocycle group is independently unsubstituted or substituted with 1-5 groups as described below. In some embodiments, "carbocyclyl" or "carbocycle" can refer to a monocyclic, saturated carbocyclyl group ("cycloalkyl") having from 3 to 8 ring carbon atoms ("C3-S cycloalkyl"). In some embodiments, a cycloalkyl group can have from 3 to 6 ring carbon atoms ("C3_6 cycloalkyl"). In some embodiments, a cycloalkyl group can have from 5 to 6 ring carbon atoms ("C5-6 cycloalkyl"). Examples of C5-6 cycloalkyl groups include cyclopentyl and cyclohexyl. Examples of C3_6 cycloalkyl groups include the aforementioned C5-6 cycloalkyl groups as well as cyclopropyl and cyclobutyl. Examples of C3_g cycloalkyl groups include the aforementioned C3 6 cycloalkyl groups as well as cycloheptyl and cyclooctyl. Unless otherwise specified, each instance of an "optionally substituted" cycloalkyl group is independently unsubstituted or substituted with 1-5 groups as described below. As used herein, alone or as part of another group, "heterocyclyl" or "heterocycle" refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur. In some embodiments, a heterocyclyl group can have from 3 to 7 ring atoms selected from carbon atoms and 1 to 3 heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur. In some embodiments, a heterocyclyl group can have from 5 to 7 ring atoms selected from carbon atoms and 1 or 2 heteroatoms, each heteroatom independently selected from nitrogen, oxygen and sulfur. In some embodiments, a heterocyclyl group can have from 5 to 6 ring atoms selected from carbon atoms and 1 to 3 heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur. In heterocyclyl groups that contain one or more optionally substituted nitrogen atoms, the point of attachment can be a carbon or the optionally substituted nitrogen atom, as valency permits. Examples of heterocyclyl groups with 1-2 ring heteroatoms include oxiranyl, aziridinyl, oxetanyl, azetidinyl, pyrrolidinyl, dihydropyrrolyl, tetrahydrofuranyl, dihydrofuranyl, dioxolanyl,tetrahydrothiophenyl, dihydrothiophenyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyridinyl, dihydropyridinyl, piperazinyl, tetrahydropyranyl, dioxanyl, morpholinyl, azepanyl, diazepanyl, diazepinyl, oxepanyl, dioxepanyl, oxazepanyl, oxazepinyl and the like. Examples of heterocyclyl groups with 1-3 heteroatoms include the aforementioned heterocyclyl groups as well as triazolidinyl, oxadiazolidinyl, triazinanyl and the like. Heterocycyl groups can be monocyclic (as in the aforementioned examples), bicyclic, or tricyclic. Bicyclic heterocyclyl groups can include one or more heteroatoms in one or both rings. Examples of such heterocyclyl groups include tetrahydroindolyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1 ,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole and the like. "Heterocyclyl" or "heterocycle" also refers to a radical of a 5- to 10-membered fused ring system having ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen and sulfur, wherein one ring is aromatic and the other is non-aromatic. In some embodiments, at least one heteroatom is present in either the aromatic or non-aromatic ring, while in other embodiments, at least one heteroatom is present in both rings. In heterocyclyl groups that contain one or more optionally substituted nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Examples of such heterocyclyl groups include indolinyl (e.g., indolin-1-yl, indolin-4-yl, and the like), isoindolinyl (e.g., isoindolin-1-yl, isoindolin-4-yl, and the like), 4,5,6,7-tetrahydro-lH-indolyl (e.g., tetrahydro-lH-indol-2-yl, 4,5,6,7-tetrahydro-lH-indol-4-yl, and the like), dihydrobenzofuranyl (e.g., dihydrobenzofuran-3-yl, dihydrobenzofuran-5-yl, and the like), 4,5,6,7-tetrahydrobenzofuranyl (e.g., 4,5,6, 7-tetrahydrobenzofuran-2-yl, 4,5,6,7- tetrahydrobenzofuran-5-yl, and trhe like), dihydrobenzothienyl (e.g., dihydrobenzothien-2-yl, dihydrobenzothien-4-yl, and the like), 4,5,6,7-tetrahydrobenzothiophenyl (e.g., 4,5,6,7-tetra- hydrobenzothiophen-2-yl, 4,5,6,7-tetrahydrobenzothiophen-7-yl, and the like), 1,2,3,4- tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydroquinolin-l-yl, l,2,3,4-tetrahydroquinolin-7-yl, and the like), chromanyl (e.g., chroman-2-yl, chroman-5-yl, and the like), chromenyl (chromen-4-yl, chromen-8-yl, and the like), thiochromanyl (e.g., thiochroman-3-yl, isochroman-7-yl, and the like), lH-benzo[e][l,4]diazepinyl (e.g., lH-benzo[e][l,4]diazepin-2- yl, lH-benzo[e][l,4]diazepin-6-yl, and the like), 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl (e.g., 2,3-dihydro-lH-pyrrolo[2,3-b]pyridin-l-yl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridin-4-yl, and the like), 4,5,6,7-tetrahydro-lH-pyrrolo[2,3-b]pyridinyl (e.g., 4,5,6,7-tetrahydro-lH-pyrrolo- [2,3-b]pyridin-2-yl, 4,5,6,7-tetrahydro-lH-pyrrolo[2,3-b]pyridin-4-yl, and the like), 1,4,5,7- tetrahydropyrano[3,4-b]pyrrolyl (e.g., l,4,5,7-tetrahydropyrano[3,4-b]pyrrol-2-yl, 1,4,5,7- tetrahydropyrano[3,4-b]pyrrol-4-yl, and the like), 2,3-dihydrofuro[2,3-b]pyridinyl (e.g., 2,3- dihydrofuro[2,3-b]pyridin-3-yl, 2,3-dihydrofuro[2,3-b]pyridin-5-yl, and the like), 4,5,6,7- tetrahydrofuro[3,2-c]pyridinyl (e.g., 4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl, 4,5,6,7- tetrahydrofuro[3,2-c]pyridin-5-yl, and the like), 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl (e.g., 4,5,6,7-tetrahydrothieno[3,2-b]pyridin-2-yl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridin-7-yl, and the like), 5,6-dihydro-4H-furo[3,2-b]pyrrolyl (e.g., 5,6-dihydro-4H-furo[3,2-b]pyrrol-6-yl, 5,6-dihydro-4H-furo[3,2-b]pyrrol-2-yl, and the like), 6,7-dihydro-5H-furo[3,2-b]pyranyl (e.g., 6,7-dihydro-5H-flιro[3,2-b]pyran-2-yl, 6,7-dihydro-5H-furo[3,2-b]pyran-6-yl, and the like), 5,7-dihydro-4H-thieno[2,3-c]pyranyl (e.g., 5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl, 5,7-dihydro-4H-thieno[2,3-c]pyran-4-yl, and the like), l,2,3,4-tetrahydro-l,6-naphthyridinyl (e.g., l,2,3,4-tetrahydro-l,6-naphthyridin-3-yl, l,2,3,4-tetrahydro-l,6-naphthyridin-8-yl, and the like), and the like. Unless otherwise specified, each instance of an "optionally substituted" heterocyclyl group is independently unsubstituted or substituted with 1-5 groups as described below. As used herein, alone or as part of another group, "aryl" refers to a radical of an aromatic monocyclic or bicyclic ring system having 6 or 10 ring carbon atoms. Examples of such aryl groups include phenyl, 1-naphthyl and 2-naphthyl. Unless otherwise specified, each instance of an "optionally substituted" aryl group is independently unsubstituted or substituted with 1-5 groups as described below.
The term "aralkyl" refers to an alkyl group substituted by an aryl group, wherein the alkyl and aryl portions independently are optionally substituted as described below.
As used herein, alone or as part of another group, "heteroaryl" refers to a radical of a 5- to 10-membered aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, each heteroatom independently selected from optionally substituted nitrogen, oxygen and sulfur. Examples of such heteroaryl groups include pyrrolyl, furanyl (furyl), thiophenyl (thienyl), pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl (pyridyl), pyridazinyl, pyrimdinyl, pyrazinyl, triazinyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl), indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl and the like. As the foregoing examples illustrate, in some embodiments a heteroaryl group can be monocyclic ("monocyclic heteroaryl"), and in some embodiments a heteroaryl group can be bicyclic ("bicyclic heteroaryl"). For bicyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, and the like) the point of attachment may be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2- indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). Unless otherwise specified, each instance of an "optionally substituted" heteroaryl group is independently unsubstituted or substituted with 1-5 groups as described below.
The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl group, wherein the alkyl and heteroaryl portions independently are optionally substituted as described below.
As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined. As described herein, compounds of the invention may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
Suitable monovalent substituents on a carbon atom of an "optionally substituted" group are independently halogen; -(CH2V4R0; -(CH2V4OR0; -0-(CH2ViC(O)OR0; -(CH2V 4CH(OR°)2; -(CH2V4SR0; -(CH2)0^Ph, which may be substituted with one or more R°; - (CH2V4O(CH2ViPh which may be substituted with R°; -CH=CHPh, which may be substituted with one or more R°; -NO2; -CN; -N3; -(CH2)0^N(R°)2; -(CH2)0 4N(R°)C(0)R°; - N(R°)C(S)R°; -(CH2)O 4N(R°)C(O)NR°2; -N(R°)C(S)NR°2; -(CH2)0 4N(R°)C(0)0R°; - N(R°)N(R°)C(0)R°; -N(R°)N(R°)C(0)NR°2; -N(R°)N(R°)C(0)0R°; -(CH2)0^C(O)R°; - C(S)R0; -(CH2)O 4C(O)OR°; -(CH2)0 4C(O)SR°; -(CH2)0 4C(O)OSiR°3; -(CH2)0 4OC(O)R°; - OC(O)(CH2)O 4SR, SC(S)SR0; -(CH2)0^SC(O)R°; -(CH2)0 4C(O)NR°2; -C(S)NR°2; -C(S)SR0; -SC(S)SR0, -(CH2)o 4OC(O)NR°2; -C(O)N(OR°)R°; -C(O)C(O)R0; -C(O)CH2C(O)R0; - C(N0R°)R°; -(CH2)O^SSR0; -(CH2)0 4S(O)2R°; -(CH2)0 4S(O)2OR°; -(CH2)0^OS(O)2R°; - S(O)2NR°2;
Figure imgf000018_0001
-N(R°)S(O)2NR°2; -N(R°)S(O)2R°; -N(0R°)R°; -C(NH)NR°2; - P(O)2R0; -P(O)R°2; -OP(O)R°2; -OP(O)(OR0V SiR°3; -(C1-4 alkylene)O-N(R°)2; or -(C1-4 alkylene)C(O)O-N(R°)2, wherein each R0 may be substituted as defined below and is independently hydrogen, Ci_g alkyl, C2_g alkenyl, C2_g alkynyl, Ci_g heteroalkyl, C2_ 8 heteroalkenyl, C2_8 heteroalkynyl, -CH2Ph, -O(CH2)0 iPh, or a 5- or 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the definition above, two independent occurrences of R0, taken together with the atom(s) to which they are bound, form a 3- to 12- membered saturated, partially unsaturated, or aromatic mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below. Suitable monovalent substituents on R0 (or the ring formed by two independent occurrences of R0 together with the atoms to which they are bound), are independently halogen, -(CH2)O 2R*, -(CH2)O 2OH, -(CH2)O 2OR*, -(CH2)0 2CH(OR*)2, -CN, -N3, -(CH2)0 2C(O)R*, - (CH2)o 2C(O)OH, -(CH2)O 2C(O)OR*, -(CH2)0 2SR*, -(CH2)0 2SH, -(CH2)0 2NH2, -(CH2)0 2NHR*, -(CH2)o 2NR*2, -NO2, -SiR*3, -OSiR*3, -C(O)SR*, -(Ci 4 alkylene)C(O)OR*, or - SSR* wherein each R* is unsubstituted or substituted with one or more halogens, and is independently selected from Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, -CH2Ph, -O(CH2)0 iPh, or a 5- or 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R0 include =0 and =S. Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR* 2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR , =NOR , -O(C(R 2))2 3O-, or -S(C(R 2))2_3S-, wherein each independent occurrence of R is selected from hydrogen; Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, each of which may be substituted as defined below; or an unsubstituted 5- or 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted" group include: -O(CR* 2)2 3O-, wherein each independent occurrence of R* is selected from hydrogen;-, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, each of which may be substituted as defined below; or an unsubstituted 5- or 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on a Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl R group include halogen, -R*, -(haloR*), -OH, -OR*, -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or - NO2, wherein each R* is unsubstituted or substituted with one or more halogens, and is independently Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, -CH2Ph, -O(CH2)0 iPh, or a 5- or 6- membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include
Figure imgf000020_0001
- S(O)2NR^, -C(S)NR^, -C(NH)NR^, or -N(Rt)S(0)2Rt; wherein each Rf is independently hydrogen; Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, each of which may be substituted as defined below; unsubstituted -OPh; or an unsubstituted 5- or 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the definition above, two independent occurrences of
Figure imgf000020_0002
taken together with the atom(s) to which they are bound form an unsubstituted 3- to 12- membered saturated, partially unsaturated, or aromatic mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on a Ci_6 alkyl, C2_6 alkenyl, or C2_6 alkynyl R1^ group are independently halogen, -R*, -OH, -OR*, -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or substituted with one or more halogens, and is independently Ci_4 alkyl, C2_4 alkenyl, C2_4 alkynyl, -CH2Ph, -O(CH2)0 iPh, or a 5- or 6- membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and
Figure imgf000021_0001
salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
As used herein, the term "prodrug" refers to a derivative of a parent compound that requires transformation within the body in order to release the parent compound. In certain cases, a prodrug has improved physical and/or delivery properties over the parent compound. Prodrugs are typically designed to enhance pharmaceutically and/or pharmacokinetically based properties associated with the parent compound. The advantage of a prodrug can lie in its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it enhances absorption from the digestive tract, or it may enhance drug stability for long-term storage. The compounds of the invention readily undergo dehydration to form oligomeric anhydrides by dehydration of the boronic acid moiety to form dimers, trimers, and tetramers, and mixtures thereof. These oligomeric species hydrolyze under physiological conditions to reform the boronic acid. As such, the oligomeric anhydrides are contemplated as a "prodrug" of the compounds described herein, and may be used in the treatment of disorder and/or conditions a wherein the inhibition of FAAH provides a therapeutic effect.
Exemplary prodrugs of the compounds described herein include, but are not limited to, compounds wherein Z1 and Z2 taken together form a 5- to 8-membered ring having at least one heteroatom atom selected from optionally substituted nitrogen, oxygen and sulfur directly attached to boron (B), wherein the ring is comprised of carbon atoms and optionally one or more additional heteroatoms independently selected from optionally substituted nitrogen, oxygen and sulfur.
Other examples of prodrugs of the compounds described herein are trifluoroborate prodrugs which hydrolyze to the boronic acid (i.e., -BF3 hydrolyzing to -B(OH)2) at acidic pH. Salt forms of the boronic acid (e.g., Na+, Li+, Mg2+, Ca2+, and the like) are also considered prodrugs. Amino acids can be used to form prodrugs, such as, for example, serine and cysteine protected boronic acids. 1,2 and 1,3 hydroxy sugars can be used to form prodrugs, such as, for example, glycerol, erythritol, threitol, ribitol, arabinitol, xylitol, allitol, altritol, galactitol, sorbitol, mannitol, and iditol protected boronic acids. Other sugars which are useful in the formation of prodrugs include, but are not limited to, maltitol, lactitol, and isomalt; other monosaccharides which include hexoses (e.g., allose, altrose, glucose, mannose, gulose, idose, galactose, talose) and pentoses (e.g., ribose, arabinaose, xylose, lyxose); pentaerythritols and structural derivatives thereof, such as methylated, ethylated, acetate, ethoxylate, and propoxylate derivatives; and phenolic polyols such as 1,2,4 benzenetriol, 5-methyl benzene 1, 2, 3-triol, 2,3,4- trihydroxybenzaldehyde, and 3,4,5-trihydroxybenzamide. Prodrugs also include NMIDA- derivatives.
As used herein, the term "tautomer" includes two or more interconvertable compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol; amide-to-imide; lactam-to-lactim; enamine- to-imine; and enamine-to-(a different) enamine tautomerizations.
As used herein, the term "isomers" includes any and all geometric isomers and stereoisomers. For example, "isomers" include cis- and trans-isomcrs, E- and Z- isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. For instance, an isomer/enantiomer may, in some embodiments, be provided substantially free of the corresponding enantiomer, and may also be referred to as "optically enriched." "Optically- enriched," as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound of the present invention is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer.
Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New
York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, EX. Stereochemistry of
Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S. H. Tables of Resolving Agents and
Optical Resolutions p. 268 (EX. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
3. Description of Exemplary Compounds
(i) Z1 and Z2
As defined generally above, in certain embodiments, Z1 is -OH or -OR3 and Z2 is -OH, -
OR4, optionally substituted Ci_g alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl group.
In certain embodiments, Z1 is -OH and Z2 is -OH. In certain embodiments, Z1 is -OH and Z2 is -OR4.
In certain embodiments, Z1 is -OR3 and Z2 is -OR4. In certain embodiments, Z1 is -OH or -OR3, and Z2 is optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl or an optionally substituted C3-10 carbocyclyl. In other embodiments, Z1 is -OH or -OR3, and Z2 is optionally substituted Ci_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, or an optionally substituted 3-10 membered heterocyclyl.
In yet other embodiments, Z1 is -OH or -OR3, and Z2 is an optionally substituted Cβ-io aryl. In yet other embodiments, Z1 is -OH or -OR3, and Z2 is an optionally substituted 5-10 membered heteroaryl. Alternatively, in certain embodiments, Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly attached to the boron atom, wherein R5 is hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(O)N(R1 %, optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2_ 8 alkynyl, optionally substituted Ci_s heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl, and each instance of R11 is, independently, optionally substituted Ci_g alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl. In certain embodiments, Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly attached to the boron atom, wherein the 5- to 8-membered ring is optionally substituted with one or more hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), optionally substituted Ci 8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl groups, or two groups present on the ring are joined to form a 5- to 8-membered monocylic or bicyclic ring optionally containing one or more heteroatoms selected from O, S, N or NR5, wherein each instance of R18 is independently, optionally substituted Ci_s alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl. In certain embodiments, the 5- to 8-membered ring is optionally substituted with with one or more -C(=O)R18, -C(=O)OR18, -C(=O)NH(R18), -C(=O)N(R18)2 and optionally substituted Ci_8 alkyl groups.
For example, in certain embodiments, Z1 and Z2, taken together with the boron atom to which they are bound, form a 5-membered ring having at least one O, S, N or NR5 atom directly attached to the boron atom. Exemplary 5-membered rings include, but are not limited to:
Figure imgf000025_0001
s and wherein each R5 is as defined above and herein.
In other embodiments, Z1 and Z2, taken together with the boron atom to which they are bound, form a 6-membered ring having at least one O, S, N or NR5 atom directly attached to the boron atom. Exemplary 6-membered rings include, but are not limited to:
Figure imgf000025_0002
In yet other embodiments, Z1 and Z2 form an 8-membered ring having at least one O, S, N or NR5 atom directly attached to the boron atom. Exemplary 8-membered ring structures include, but are not limited to:
Figure imgf000026_0001
wherein each R5 is as defined above and herein.
Furthermore, as generally defined above, in certain embodiments, Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring.
For example, in certain embodiments, Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 6-membered ring. Exemplary ring structures include, but are not limited to:
Figure imgf000026_0002
wherein Ring A is as defined above and herein.
(U) ϋ_
As defined generally above, in certain embodiments, L1 is a covalent bond, an optionally substituted straight or branched Ci_6 alkylene or an optionally substituted straight or branched C2-6 alkenylene moiety.
In certain embodiments L1 is a covalent bond.
In some embodiments, L1 is an optionally substituted Ci_6 alkylene moiety. In some embodiments, L1 is an optionally substituted Ci_3 alkylene moiety. In other embodiments, L1 is an optionally substituted Ci_2 alkylene moiety. In certain embodiments, L1 is a -CH2- group. In other embodiments, L1 is a -CH2CH2- group. In yet other embodiments, L1 is a -CH=CH- group.
(Ui) RinsA
As defined generally above, Ring A is an optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl. Ring A is monocyclic or bicyclic. In certain embodiments, Ring A is aromatic. In certain embodiments, Ring A is saturated or partially unsaturated.
In certain embodiments, Ring A is an optionally substituted C6 or Cs monocyclic aryl group. Such monocyclic ring systems include, but are not limited to:
Figure imgf000027_0001
wherein each of X, RA, R1 and n is as defined above and herein.
In certain embodiments, Ring A is an optionally substituted phenyl ring system of formula:
Figure imgf000027_0002
. wherein each of X, RA, R1 and n is as defined above and herein.
In certain embodiments, Ring A is phenyl and has at least one fluorine substituent (i.e., n is at least one and R1 is F). In certain embodiments, Ring A has at least two fluorine substituents (i.e., n is at least 2 and each R1 is F). In certain embodiments, Ring A has at least three fluorine substituents (i.e., n is at least 3 and each R1 is F). In certain embodiments, at least one R1 group is fluoro in the ortho position relative to the boron atom. However, in certain embodiments, compounds containing fluorine substituents on Ring A are specifically excluded (i.e., when R1 is F). In certain embodiments, compounds containing fluorine substituents ortho to the boron atom on Ring A are specifically excluded (i.e., when R1 is F at the ortho position of Ring A with respect to the boron atom).
In certain embodiments, Ring A is an optionally substituted phenyl ring system of any one of formulae:
Figure imgf000028_0001
wherein each of X, RA, R1 and n is as defined above and herein.
In other embodiments, Ring A is an optionally substituted phenyl ring system having an XRA group para to the boron atom, i.e., a phenyl ring of any one of formulae:
Figure imgf000028_0002
wherein each of X, RA, and R1 is as defined above and herein.
In yet other embodiments, Ring A is an optionally substituted phenyl ring system having an -XRA group meta to the boron atom, i.e., a phenyl ring of any one of formulae:
Figure imgf000029_0001
wherein each of X, RA, and R1 is as defined above and herein.
In yet other embodiments, Ring A is an optionally substituted phenyl ring system having an -XRA group ortho to the boron atom, i.e., a phenyl ring of any one of formulae:
Figure imgf000029_0002
Figure imgf000030_0001
wherein each of X, RA, and R1 is as defined above and herein.
In certain embodiments, Ring A is phenyl, X is a covalent bond and RA is hydogen, i.e., Ring A is an optionally substituted phenyl ring system of formula:
Figure imgf000030_0002
wherein each of R1 and n is as defined above and herein. Examples of such ring systems include:
Figure imgf000030_0003
wherein each R1 is as defined above and herein.
In other embodiments, Ring A is an optionally substituted saturated or partially unsaturated C3-Io or C3-S monocyclic ring system. Such monocyclic ring systems include, but are not limited to:
Figure imgf000031_0001
; wherein each of X, RA, R1 and n is as defined above and herein.
In certain embodiments, Ring A is an optionally substituted 5-8 membered or 5-6 membered monocyclic heteroaryl group. Such aromatic monocyclic ring systems include, but are not limited to, 5-membered rings of any of following formulae:
Figure imgf000031_0002
Figure imgf000032_0001
and 6-membered rings of the formulae:
Figure imgf000032_0002
wherein each of X, RA, R and n is as defined above and herein,
R14 is hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(O)N(R . I1 hO2, -C(O)NH(R I I1h1), - C(O)NH2, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl, and each instance of R11 is, independently, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl. In certain embodiments, Ring A is an optionally substituted furanyl group. In certain embodiments, Ring A is a furanyl group of the formula:
Figure imgf000033_0001
wherein each of X, RA, R1 and n is as defined above and herein.
In certain embodiments, Ring A is an optionally substituted thiophenyl group. In certain embodiments, Ring A is a thiophenyl group of the formula:
Figure imgf000033_0002
wherein each of X, RA, R1 and n is as defined above and herein.
In certain embodiments, Ring A is an optionally substituted pyridinyl group. In certain embodiments, Ring A is pyridinyl group of the formula:
Figure imgf000033_0003
wherein each of X, RA, R1 and n is as defined above and herein.
In other embodiments, Ring A is an optionally substituted saturated or partially unsaturated 3-8 membered or 5-8-membered monocyclic heterocyclyl group. Examples of such saturated or partially unsaturated monocyclic ring systems include, but are not limited to:
Figure imgf000033_0004
Figure imgf000034_0001
wherein each of X, RA, R1, R14 and n is as defined above and herein.
In certain embodiments, Ring A is an optionally substituted bicyclic aryl group. Such bicyclic ring systems include, but are not limited to:
Figure imgf000034_0002
wherein each of X, RA, R1 and n is as defined above and herein. For example, in certain embodiments, Ring A is a bicyclic group of any of formulae:
Figure imgf000035_0001
wherein each of X, RA, R1 and n is as defined above and herein.
In other embodiments, Ring A is an optionally substituted bicyclic Cs-io carbocyclyl group. In some embodiments, both rings of the bicyclic Cg-io carbocyclyl group are saturated or partially saturated. In other embodiments, one ring of the bicyclic Cg-io carbocyclyl group is saturated or partially saturated and the other ring is aromatic. Such bicyclic Cg-io carbocyclyl ring systems include, but are not limited to:
Figure imgf000035_0002
wherein each of X, RA, R1 and n is as defined above and herein.
In certain embodiments, Ring A is an optionally substituted 6-10 membered bicyclic heteroaryl group. In certain embodiments, Ring A is an optionally substituted 9-10 membered bicyclic heteroaryl group. In certain embodiments, Ring A is an optionally substituted 9 membered bicyclic heteroaryl group. In certain embodiments, the optionally substituted 9- membered bicyclic heteroaryl is a 6,5-fused heteroaryl ring. In certain embodiments, the optionally substituted 10-membered bicyclic heteroaryl is a 6,6-fused heteroaryl ring.
For example, in certain embodiments, Ring A is a 6,5-fused heteroaryl ring of any of formulae:
Figure imgf000036_0001
Figure imgf000037_0001
wherein each of X, RA, R1, R14 and n is as defined above and herein.
In certain embodiments, Ring A is a 6,6-fused heteroaryl ring of any of formulae:
.
Figure imgf000037_0002
wherein each of X, R >A , r R, l and n is as defined above and herein.
In other embodiments, Ring A is an optionally substituted bicyclic 6-10 membered heterocyclyl group. In some embodiuments, both rings of the bicyclic 6-10 membered heterocyclyl group are saturated or partially saturated. In other embodiments, one ring of the bicyclic 6-10 membered heterocyclyl group is saturated or partially saturated and the other ring is aromatic. Such bicyclic heterocyclyl ring systems include, but are not limited to:
Figure imgf000037_0003
Figure imgf000038_0001
and
Figure imgf000038_0002
each of X, RA, R1, R14 and n is as defined above and herein.
It will be appreciated that in any of the above drawings of bicyclic Ring A having one or more floating substituents (e.g., -R1 and/or -X-RA) that the floating substituent may be present on any substitutable carbon atom on either ring of the fused ring system.
(iv) X
As is also defined generally above, X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, - C(NR6)-, -S-, -C(O)-, -S(O)-, -S(O)2-, optionally substituted Ci_6 alkylene, or optionally substituted C2_6 alkenylene, wherein one, two or three methylene units of the Ci_6 alkylene or C2-
6 alkenylene are optionally and independently replaced with one or more -O-, -N=N-, -C=N-, -
NR6-, -C(NR )-, -S-, -C(O)-, -S(O)-, or -S(O)2-.
In certain embodiments, X is a covalent bond. In certain embodiments, X is -0-.
In certain embodiments, X is -NR6-. In certain embodiments, X is -S-.
In certain embodiments, X is an optionally substituted Ci_6 alkylene. In other embodiments, X is an optionally substituted Ci_4 alkylene. In yet other embodiments, X is an optionally substituted Ci_2 alkylene. In certain embodiments, X is -(CH2)4-. In certain embodiments, X is -(CH2)3-. In certain embodiments, X is -(CH2)2-. In certain embodiments,
X is -CH2-. In certain embodiments, X is an optionally substituted C2-6 alkenylene. In other embodiments, X is an optionally substituted C 2-4 alkenylene. In yet other embodiments, X is an optionally substituted C2 alkenylene. In certain embodiments, X is -CH=CH-.
In certain embodiments, X is an optionally substituted Ci_6 alkylene, wherein one methylene unit is replaced with -O-. In certain embodiments, X is -CH2O- or -OCH2-.
In certain embodiments, X is an optionally substituted Ci_6 alkylene, wherein one methylene unit is replaced with -NR6-. In certain embodiments, X is -CH2NR6- or -NR6CH2-.
In certain embodiments, X is a covalent bond, C(O), -0-, -CH2O-, -OCH2-, -NR6-, or -CH2NR6-, or -NR6CH2-. In certain embodiments, X is a covalent bond, -0-, or optionally substituted Ci_6 alkylene.
(V) gL
As is defined generally above, RA is hydrogen, halogen, -OR7, -CF3, -CN, -NO2, - SO2R7, -SOR7, -C(O)R7, -CO2R7, -C(O)N(R7)2, -CHO, -N3, -N2R7, -N(R7)2, or Ring B having formula:
Figure imgf000039_0001
wherein Ring B is optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl, and R2, R7 and m are as defined herein. In certain embodiments, RA is hydrogen. In certain embodiments, RA is Ring B, as defined above and herein.
(vi) RinsB
As described herein, Ring B is optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl. Ring B is monocyclic or bicyclic. In certain embodiments, Ring B is aromatic.
In some embodiments, Ring B is an optionally substituted C6 or Cg monocyclic aryl group. Such monocyclic aryl ring systems include, but are not limited to:
Figure imgf000040_0001
wherein each of R and m is as defined above and herein.
In certain embodiments, Ring B is an optionally substituted phenyl ring of formula:
Figure imgf000040_0002
wherein each of R2 and m is as defined above and herein.
In certain embodiments, Ring B is an optionally substituted phenyl ring of any one of formulae:
Figure imgf000040_0003
Figure imgf000041_0001
wherein R2 is as defined above and herein.
In certain embodiments, both of Ring B and Ring A are phenyl.
In other embodiments, Ring B is an optionally substituted saturated or partially unsaturated C3_io or Cs_8 monocyclic carbocyclyl group. Such monocyclic ring systems include, but are not limited to:
Figure imgf000041_0002
wherein each of R and m is as defined above and herein. In certain embodiments, Ring B is an optionally substituted 5-8 membered or 5-6 membered monocyclic heteroaryl group.
In certain embodiments, Ring B is an optionally substituted 5-membered heteroaryl group. Such monocyclic heteroaryl systems include, but are not limited to, any of formulae:
Figure imgf000041_0003
Figure imgf000042_0001
wherein each of R2 and m is as defined above and herein,
R16 is hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(O)NH2 , -C(O)NH(R11), - C(O)N(R1 %, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl, and each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl.
In certain embodiments, Ring B is an optionally substituted 6-membered monocyclic heteroaryl group. Such monocyclic heteroaryl systems include, but are not limited to, 6- membered rings of any of formulae:
Figure imgf000043_0001
wherein each o R2 and m is as defined above and herein.
In other embodiments, Ring B is an optionally substituted saturated or partially unsaturated monocyclic 3 to 10 membered heterocyclyl group. Such saturated or partially unsaturated monocyclic heterocyclyl systems include, but are not limited to:
Figure imgf000043_0002
Figure imgf000044_0001
wherein each of R , R , 16 and m is as defined above and herein.
In certain embodiments, Ring B is an optionally substituted C10 bicyclic aryl group (i.e., naphthyl) having the formula:
Figure imgf000044_0002
wherein each of R2 and m is as defined above and herein.
In other embodiments, Ring B is a bicyclic Cg-io carbocyclyl group. In some embodiments, both rings of the bicyclic C8-io carbocyclyl group are saturated or partially saturated. In other embodiments, one ring of the bicyclic Cs-io carbocyclyl group is saturated or partially saturated and the other ring is aromatic. Such bicyclic ring systems include, but are not limited to:
Figure imgf000045_0001
wherein each of R and m is as defined above and above and described herein.
In certain embodiments, Ring B is an optionally substituted 6-10 membered bicyclic heteroaryl group. In certain embodiments, Ring B is an optionally substituted 9-10 membered bicyclic heteroaryl group. In certain embodiments, an optionally substituted 9-membered bicyclic heteroaryl group is a 6,5-fused bicyclic heteroaryl group. In certain embodiments, an optionally substituted 10-membered bicyclic heteroaryl group is a 6,6-fused bicyclic heteroaryl group.
Exemplary heteroaryl systems include, but are not limited to, 6,5-fused ring systems of any of formulae:
Figure imgf000045_0002
Figure imgf000046_0001
and 6,6-fused ring systems of any of formulae:
Figure imgf000046_0002
wherein each of R ,2 , r R,16 and m is as defined above and herein. In certain embodiments, Ring B is an optionally substituted saturated or partially saturated 9-10 membered bicyclic heterocyclyl group. Such bicyclic heterocyclyl systems include, but are not limited to:
Figure imgf000047_0001
wherein each of R , R , 16 and m is as defined above and herein.
It will be appreciated that in any of the above drawings of bicyclic Ring B having one or more floating substituents (e.g., -R2) that the floating substituent may be present on any substitutable carbon atom on either ring of the fused bicyclic ring system.
(vii) R1 and n
As defined generally above, each instance of R1 is, independently, halogen, -OR8, -CF3,
-CN, -NO2, -SO2R8, -SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2,-N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_
8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or an optionally substituted 5-10 membered heteroaryl group; and wherein R8 is as described herein.
In certain embodiments, each instance of R1 is, independently, halogen, -OR8, -CF3, - CN, -NO2, -SO2R8, -SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -N3, -N2R8, or - N(R8)2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, or optionally substituted C2_ 8 alkynyl.
In certain embodiments, each instance of R1 is, independently, halogen, -OR8 or optionally substituted Ci_8 alkyl. In some embodiments, R1 is halogen. In other embodiments, R1 is -F or -Cl. In certain embodiments, R1 is -Cl. In other embodiments, R1 is -F. In certain embodiments, at least one R1 is ortho to the boron atom. In other embodiments, at least one R1 is meta to the boron atom. In yet other embodiments, at least one R1 is para to the boron atom.
In certain embodiments, at least one R1 is alpha to the boron atom. In other embodiments, at least one R1 is beta to the boron atom. In yet other embodiments, at least one R1 is gamma to the boron atom.
In certain embodiments, n is 0, 1, 2 or 3. In some embodiments, n is 0, 1 or 2. In other embodiments, n is 1 or 2. In yet other embodiments, n is 3. In yet other embodiments, n is 2. In still yet other embodiments, n is 1. In still yet other embodiments, n is 0.
It is understood that when n is 0 then Ring A is not substituted with an R1 group, but instead is substituted with hydrogen. It is also understood that when n is 0, X is a covalent bond and RA is hydrogen, then Ring A is unsubstituted.
(viii) R2 and m
As defined generally above, each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, -SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-
10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl group; and wherein R9 is as described herein. In certain embodiments, each instance of R2 is, independently, halogen, -OR9, -CF3, - CN, -NO2, -SO2R9, -SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, or optionally substituted C2_8 alkynyl.
In certain embodiments, each instance of R2 is, independently, halogen or -OR9. In some embodiments, R2 is halogen. In other embodiments, R2 is -F or -Cl. In certain embodiments, R2 is -Cl. In yet other embodiments, R2 is -F.
In certain embodiments, at least one R2 is ortho to X. In other embodiments, at least one R2 is meta to X. In yet other embodiments, at least one R2 is para to X.
In certain embodiments, at least one R2 is alpha to X. In other embodiments, at least one R2 is beta to X. In yet other embodiments, at least one R2 is gamma to X.
In certain embodiments, m is O, 1, 2, 3, 4 or 5. In some embodiments, m is O, 1, 2 or 3. In some embodiments, m is 0, 1 or 2. In other embodiments, m is 1 or 2. In yet other embodiments, m is 3. In still other embodiments, m is 2. In still yet other embodiments, m is 1. In still other embodiments, m is 0. It is understood that when m is 0, then Ring B is not substituted with an R2 group, but instead is substituted with hydrogen.
(ix) Compounds of Formula (II) wherein Ring A is Bicyclic
In certain embodiments, the present invention provides compounds of formula (I):
Figure imgf000049_0001
(I) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, L1, X, R1, RA, and n are as defined above and herein, and wherein Ring A is an optionally substituted Cio bicyclic aryl or an optionally substituted 9-10 membered bicyclic heteroaryl. In certain embodiments, Ring A is an optionally substituted Cio bicyclic aryl group. In certain embodiments, Ring A is an optionally substituted naphthyl group.
In certain embodiments, Ring A is an optionally substituted 9-10 membered bicyclic heteroaryl group. In certain embodiments, Ring A is an optionally substituted 10- membered bicyclic heteroaryl group. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl containing 1 to 2 N atoms. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl containing 1 N atom. In certain embodiments, Ring A is a 6,6-fused bicyclic heteroaryl containing 2 N atoms.
In certain embodiments, Ring A is an optionally substituted isoquinoline group. In certain embodiments, Ring A is an optionally substituted quinolinyl group. In certain embodiments, Ring A is an optionally substituted quinoxalinyl group.
In certain embodiments, the present invention provides 6,6-fused bicyclic compounds of formula (III):
Figure imgf000050_0001
(III) or a pharmaceutically acceptable salt or prodrug thereof, wherein: (i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; (ii) Z1 and Z2 taken together form a 5- to 8-membered ring having at least one O, S, N or
NR5 directly bonded to the boron atom; or
(iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring;
W1 and W2 are independently selected from CR12, C and N; X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, -
S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-; RA is hydrogen, halogen, -OR7, -CF3, -CN, -NO2, -SO2R7, -SOR7, -C(O)R7, -CO2R7, - C(O)N(R7)2, -N3, -N2R7, -N(R7)2, or Ring B having formula:
Figure imgf000051_0001
wherein Ring B is optionally substituted C3-Io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2 -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted C i_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted
Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, and R10 is, independently, hydrogen, -C(O)R11, - SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R12 is, independently, hydrogen, halogen, -CF3, optionally substituted Ci_8 alkyl, optionally substituted C 2-8 alkenyl, or optionally substituted C2-s alkynyl; n is, independently, 0, 1, 2 or 3 and m is 0, 1, 2, 3, 4 or 5.
In certain embodiments, the present invention provides 6,6-fused bicyclic compounds of the formula (III-a), (III-b), (III-c), (III-d) or (III-e):
Figure imgf000052_0001
(III-a)
Figure imgf000052_0002
(III-b)
Figure imgf000052_0003
(III-c)
Figure imgf000053_0001
(III-e) or a pharmaceutically acceptable salt or prodrug thereof, wherein W1, W2, Z1, Z2, X, R1, RA, and n are as defined above and herein.
In certain embodiments, n is 0. In certain embodiments, n is 1 or 2. In certain embodiments, n is 1.
In certain embodiments, R1 is optionally substituted Ci_8 alkyl. In certain embodiments, R1 Is -CH3.
In certain embodiments, X is a covalent bond, -(C=O)-, -O-, -CH2O-, -OCH2-, -NH-, -N(R9)-, -N(R9)CH2-, -CH2N(R9)- or an optionally substituted Ci_6 alkylene. In certain embodiments, X is is a covalent bond, -(C=O)-, -O-, -CH2O-, -OCH2-, -NH-, -N(R9)-, - N(R9)CH2- -CH2N(R9)-, -CH2-, -(CH2),- -(CH2),- -(CH2)4- or -(CH2)5-. In certain embodiments, RA is hydrogen.
In certain embodiments, RA is Ring B. In certain embodiments, Ring B is an optionally substituted aryl, optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, optionally substituted 1,2,3,4-tetrahydroquinolinyl, optionally substituted cyclopentyl or optionally substituted cyclohexyl. In certain embodiments, m is 0. In certain embodiments, m is 1 or 2. In certain embodiments, m is 1.
In certain embodiments, R2 is halogen, -OR9, -CN, -NO2, or -N(R9)2. In certain embodiments, R2 is -Cl, -CN, -NO2, -OH, -OCH3, -OC4H9, or -N(CH3)2. In certain embodiments, at least one of W1 and W2 is N.
In certain embodiments, W1 is N and W2 is C or CR12. In certain embodiments, W2 is N and W1 is C or CR12. In some embodiments, W1 is N and W2 is CH. In some embodiments, W2 is N and W1 is CH. In certain embodiments, wherein W1 is N and W2 is C, CH or CR12, or wherein W2 is N and W1 is C, CH or CR12, the following compounds are specifically excluded: (i) compounds wherein n is 0, X is a covalent bond and RA is hydrogen; (ii) compounds wherein n is 1, R1 is fluoro, X is -CH2-, and RA is hydrogen; and/or (iii) compounds wherein n is 1, R1 is chloro, X is a covalent bond, and RA is hydrogen. In certain embodiments, both W1 and W2 are N. In certain embodiments, wherein both W1 and W2 are N, the following compounds are specifically excluded:
(i) compounds wherein n is 0, X is a covalent bond and RA is hydrogen. In certain embodiments, both W1 and W2 are, independently, C or CR12. In certain embodiments, both W1 and W2 are CH. In certain embodiments, wherein both W1 and W2 are C, CH or CR12, the following compounds are specifically excluded: (i) compounds wherein n is 0, X is a covalent bond and RA is hydrogen, -OH, -
OCH3, -OCH2CH3 or -OCH2C6H5; (ii) compounds wherein n is 1, R1 is -CHO or -CH2N(R9)CδH5, X is a covalent bond, and RA is hydrogen;
(iii) compounds wherein n is 0, X is a covalent bond, and RA is an optionally substituted phenyl or napthyl ring (Ring B); and/or
(iv) compounds wherein n is 0 and X is -C=N-NH-(C=S)- or-C=N-NH-(C=O)-. In certain embodiments, the following compounds are specifically excluded:
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000055_0002
Figure imgf000056_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In certain embodiments, W1 is C or CH and W2 is N, providing 6,6-fused bicyclic compounds of the formula (III-e):
Figure imgf000056_0002
(III-e) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, L1, X, R1, RA, and n are as defined above and herein. Examples of such compounds include compounds of any of formulae (III-el), (IH-e2), (III-e3), (III-e4) and (III-e5):
Figure imgf000056_0003
(III-el)
Figure imgf000056_0004
(III-e2)
Figure imgf000057_0001
(III-e3)
Figure imgf000057_0002
(III-e4)
Figure imgf000057_0003
(III-e5) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, X, R1, RA, and n are as defined above and herein.
In certain embodiments, both W1 and W2 are N, providing 6,6-fused bicyclic compounds of the formula (III-f):
Figure imgf000057_0004
(III-f) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, L1, X, R1, RA, and n are as defined above and herein. Examples of such compounds include compounds of any of formulae (III-fl), (IH-f2), (HI-O) or (IH-f4):
Figure imgf000058_0001
(III-fl)
Figure imgf000058_0002
(III-f4) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, L1, X, R1, RA, and n are as defined above and herein.
In certain embodiments, both W1 and W2 are C or CH, providing 6,6-fused bicyclic compounds of formula (III-g):
Figure imgf000058_0003
(iii-g) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, L1, X, R1, RA, and n are as defined above and herein. Examples of such compounds include compounds of any of formulae (III-gl), (IH-g2), (HI-g3), (HI-g4), (IH-g5), (III-g6) or (IH-g7):
Figure imgf000059_0001
(III-gl)
Figure imgf000059_0002
(in-g2)
Figure imgf000059_0003
(in-g3)
Figure imgf000059_0004
(in-g4)
Figure imgf000059_0005
(in-g5)
Figure imgf000060_0001
(in-g7) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, X, R1, RA, and n are as defined above and herein.
Exemplary 6,6-fused bicyclic compounds encompassed by formulae (I), (III), and subgenera thereof, are provided below in Tables 1-3.
Table 1
Figure imgf000060_0002
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000062_0002
Figure imgf000063_0001
In certain embodiments, Ring A is an optionally substituted 9-membered bicyclic heteroaryl group. In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl group. In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl group containing 2-3 heteroatoms selected from O, S, N and NR14, wherein:
R14 is, independently, hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, - C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; and each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl.
In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl group containing 2 heteroatoms selected from O, S, N and NR14. In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl group containing 3 heteroatoms selected from O, S, N and NR14. In certain embodiments, Ring A is an optionally substituted benzoxazolyl, optionally substituted benzthiazolyl, optionally substituted benzimidazolyl, an optionally substituted indazolyl or an optionally substituted imidazopyridinyl group.
In certain embodiments, the present invention provides compounds of formula (IV):
Figure imgf000064_0001
(IV) or pharmaceutically acceptable salt or prodrug thereof, wherein: (i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C1- 8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; (ii) Z1 and Z2 taken together form a 5- to 8-membered ring having at least one O, S, N or
NR5 atom directly bonded to the boron atom; or
(iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring; each of Y3, Y4 and Y5 is independently selected from C, CR13, N, NR14, O and S, with the proviso that at least one of Y3, Y4 or Y5 is a heteroatom selected from N, NR14, O or S; Y6 is C or N;
X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-;
RA is hydrogen, halogen, -OR7, -CF3, -CN, -NO2, -SO2R7, -SOR7, -C(O)R7, -CO2R7, - C(O)N(R7)2, -N3, -N2R7, -N(R7)2, or Ring B having formula:
Figure imgf000064_0002
wherein Ring B is optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, R10, and R14 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(O)N(R1 %, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R13 is, independently, hydrogen, halogen, -CF3, optionally substituted C i_8 alkyl, optionally substituted C2-8 alkenyl, or optionally substituted C2-8 alkynyl; n is 0, 1, 2 or 3; and m is O, 1, 2, 3, 4 or 5.
In certain embodiments, the present invention provides compounds of any of formulae (IV-a), (IV-b), (IV-c), (IV-d) or (IV-e):
Figure imgf000066_0001
(IV-a)
Figure imgf000066_0002
(IV-b)
Figure imgf000066_0003
(IV-c)
Figure imgf000067_0001
(IV-e) or pharmaceutically acceptable salts or prodrugs thereof, wherein Y3, Y4, Y5, Y6, Z1, Z2, R1, X, n and RA are as defined above and herein.
In certain embodiments, n is 0. In certain embodiments, n is 1 or 2. In certain embodiments, n is 1.
In certain embodiments, R1 is halogen. In certain embodiments, R1 is -F. In certain embodiments, R1 is -Br.
In certain embodiments, X is a covalent bond or an optionally substituted Ci_6 alkylene. In certain embodiments, X is a covalent bond. In certain embodiments, X is -CH2-, -(CH2)2-, - (CH2)S-, -(CH2)4- -(CH2)S- or -(CH2)5(C=O)-.
In certain embodiments, RA is hydrogen. In certain embodiments, RA is -CF3.
In certain embodiments, RA is Ring B. In certain embodiments, Ring B is an optionally substituted phenyl, optionally substituted pyrrolidinone or an optionally substituted piperidinyl.
In certain embodiments, m is 0. In certain embodiments, m is 1 or 2. In certain embodiments, m is 1.
In certain embodiments, R2 is optionally substituted Ci_g alkyl, optionally substituted C6_
10 aryl, -SO2R9, -SOR9, -C(O)R9, or -CO2R9. In certain embodiments, R2 is -C3H7, -
CH2CH(CHs)2, -CO2tBu, -C(O)(CH2)2C6H5, -C6H5, -CH2C6H5, or -SO2C6H5.
In certain embodiments, two of Y3, Y4 and Y5 are, independently, heteroatoms selected from N, NR14, O or S, and Y6 is C. In certain embodiments, one of Y3, Y4, Y5 is a heteroatom selected from N, NR14, O or S, and Y6 is C or N.
In certain embodiments, one of Y3, Y4, Y5 is a heteroatom selected from N, NR14, O or S, and Y6 is N. In certain embodiments, Y3 is O or S. In certain embodiments, Y3 is O. In certain embodiments, Y is S.
In certain embodiments, Y6 is C.
In certain embodiments, Y3 is O or S, Y4 is C, Y5 is N and Y6 is C. In certain embodiments, wherein Y3 is O or S; Y4 is C; Y5 is N and Y6 is C, the following compounds are specifically excluded:
(i) compounds wherein n is 0, X is a covalent bond, and RA is hydrogen; and/or (ii) compounds wherein n is 0, X is -CH2-, and RA is hydrogen. In certain embodiments, Y3 is O or S, Y4 and Y5 are, independently, C or CR13 and Y6 is C. In certain embodiments, wherein Y3 is O or S, Y4 and Y5 are, independently, C or CR13 and Y6 is C, the following compounds are specifically excluded:
(i) compounds wherein n is 0, X is a covalent bond or -CH2-, and RA is hydrogen or chloro;
(ii) compounds wherein n is 0, X is -CH2O- or -OCH2- and RA is -C6H5; and/or (iii) compounds wherein n or is 0, X is -(C=O)-, and RA is -C6H5. In certain embodiments, Y3 and Y4 are, independently, N or NR14, Y5 is C or CR13 and Y6 is C. In certain embodiments, wherein Y3 and Y4 are, independently, N or NR14, Y5 is C or CR13 and Y6 is C, the following compounds are specifically excluded:
(i) compounds wherein n is 0, X is a covalent bond, and RA is hydrogen. In certain embodiments, Y3 and Y5 are, independently, N or NR14, Y4 is C or CR13, and Y6 is C. In certain embodiments, wherein Y3 and Y5 are, independently, N or NR14, Y4 is C or CR13, and Y6 is C, the following compounds are specifically excluded:
(i) compounds wherein n is 0, X is a covalent bond, and RA is hydrogen. In certain embodiments, Y3 and Y6 are, independently, N and Y4 and Y5 are, independently, C or CR13. In certain embodiments, wherein Y3 and Y6 are, independently, N and Y4 and Y5 are, independently, C or CR13, the following compounds are specifically excluded: (i) compounds wherein n is 0, X is a covalent bond, and RA is hydrogen. In certain embodiments, Y3 is N or NR14, and Y4, Y5 and Y6 are, independently, C or CR13. In certain embodiments, wherein Y3 is N or NR14, and Y4, Y5 and Y6 are, independently,
C or CR , 13 , the following compounds are specifically excluded:
(i) compounds wherein n is 0, X is a covalent bond, and R A is hydrogen;
(ii) compounds wherein n is 0, X is -OCH2- or -CH2O-, and RA is -C6Hs; and/or (iii) compounds wherein n is 0, 1 or 2, R1 is -OH or -OCH3, X is -(C=O)- and RA is -
OR7. In certain embodiments, the following compounds are specifically excluded:
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000070_0002
Figure imgf000071_0001
Figure imgf000071_0002
or pharmaceutically acceptable salts or prodrugs thereof.
In certain embodiments, the present invention provides compounds of the formula (IV-f):
Figure imgf000072_0001
(IV-f) or pharmaceutically acceptable salts or prodrugs thereof, wherein Y3, Z1, Z2, R1, X, n and RA are as defined above and herein. Examples of such compounds include compounds of the formulae (IV-fl) and (IV-O):
Figure imgf000072_0002
(IV-fl)
Figure imgf000072_0003
(IV-f2) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y3, Z1, Z2, R1, X, n and RA are as defined above and herein.
In certain embodiments, the present invention provides compounds of the formula (IV- g):
Figure imgf000072_0004
(iv-g) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y3, Z1, Z2, R1, X, n and RA are as defined above and herein. Examples of such compounds include compounds of either of formulae (IV-gl) and (IV-g2):
Figure imgf000073_0001
(IV-gl)
Figure imgf000073_0002
(IV-g2) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y3, Z1, Z2, R1, X, n and RA are as defined above and herein.
In certain embodiments, the present invention provides compounds of formula (IV-h):
Figure imgf000073_0003
(IV-h) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, R1, X, n and RA are as defined above and herein. Examples of such compounds include compounds of the formulae (IV-hl) and (IV-h2):
Figure imgf000074_0001
(IV-hl)
Figure imgf000074_0002
(IV-h2)
In certain embodiments, the present invention provides compounds of either of formulae (IV-i) or (IV-k):
Figure imgf000074_0003
(IV-i) (IV-k) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, R1, X, n and RA are as defined above and herein. Examples of such compounds include compounds of any of formulae (IV-il), (IV-i2), (IV-kl) and (IV-k2):
Figure imgf000074_0004
(IV-il)
Figure imgf000075_0001
(TV-H)
Figure imgf000075_0002
(IV-k2) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, R1, X, n and RA are as defined above and herein.
In certain embodiments, the present invention provides compounds of the formulae (IV- m) or (IV-n):
Figure imgf000075_0003
(IV-m) (IV-m) or a pharmaceutically acceptable salt or prodrug thereof, wherein R14, Z1, Z2, R1, X, n and RA are as defined above and herein. Exemplary 6,5-fused bicyclic compounds encompassed by formulae (I), (IV), and subgenera thereof, are provided below in Tables 4-8.
Figure imgf000076_0001
Table 4
Figure imgf000077_0001
303 304
Figure imgf000077_0002
Figure imgf000077_0003
Figure imgf000078_0001
(x) Compounds of Formula II, wherein Ring B is Het-B
In certain embodiments, the present invention provides compounds of formula (II):
Figure imgf000078_0002
(H) or a pharmaceutically acceptable salt or prodrug thereof, wherein Z1, Z2, L1, X, Ring A, Ring B,
R . 1 , r R> 2 , n and m are as defined above and herein.
In certain embodiments, Ring B is optionally substituted 3-10 membered heterocyclyl or optionally substituted 5-10 membered heteroaryl {i.e., referred to as "Het-B"). Such ring systems are depicted and described in detail above and herein.
For example, in certain embodiments, the present invention provides compounds of formula (V):
Figure imgf000078_0003
(V) or a pharmaceutically acceptable salt or prodrug thereof; wherein:
(i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_
8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl;
(ii) Z1 and Z2 taken together form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom; or
(iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring;
W3 is C, CR15, or N;
X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-;
Het-B is an optionally substituted 3-10 membered heterocyclyl or an optionally substituted 5-10 membered heteroaryl ring; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, -
SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2,-N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted C i_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_s heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, -
SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C i_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-w aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, and R10 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-s alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, hydrogen, optionally substituted Ci_s alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C1- 8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; R15 is hydrogen, halogen, -CF3, optionally substituted Ci_8 alkyl, optionally substituted
C2-8 alkenyl, or optionally substituted C2-8 alkynyl; n is 0, 1, 2 or 3; and m is O, 1, 2, 3, 4, or 5.
In certain embodiments, each n is 0. In certain embodiments, each n is independently 1 or 2. In certain embodiments, each n is 1.
In certain embodiments, R1 is halogen, -OR8, -CF3, optionally substituted Ci_8 alkyl or optionally substituted 5-membered heteroaryl. In certain embodiments, R1 is -Cl, -F, -OCH3, - OCH2CH2C6H5, -O(CH2)3CH3, -CH2C(CH3)2, or an optionally substituted oxadiazolyl.
In certain embodiments, X is a covalent bond or an optionally substituted Ci_6 alkylene. In certain embodiments, X is a covalent bond. In certain embodiments, X is -CH2- or - CH=CH-. In certain embodiments, each m is O. In certain embodiments, each m is independently 1 or 2. In certain embodiments, each m is 1.
In certain embodiments, R2 is selected from -OR9, -N(R9)2, optionally substituted C1-
8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C6_io aryl, or optionally substituted 5-10 membered heteroaryl. In certain embodiments, R2 is selected from optionally substituted Ci_s alkyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl.
In certain embodiments, R2 is selected from -CH3, -CH2CH3, -CH2C(CH3)2, -
(CH2)2CH3, -C(CH3)3, -(CH2)3CH3, -CH2C(CH3),, -(CH2)4CH3, -(CH2)5CH3, -(CH2)3C(CH3)2, -(CH2)6CH3, -(CH2)4CH3, -CH2CH2CF3, -CH(CH3)(CH2)3CH3, -CH=CH(CH2)2CH3, -
(CHj)2CH(CH3)CH2CH3, -CH2CH2CH2CF3, -CH2CH2CF2CF3, -C(OH)(CH3)2, -
CH2CH2CH2(C=O)-(oxadiazole), optionally substituted pyridinyl, -C6Hs1 optionally substituted phenyl, optionally substitututed benzyl, -CH2CH2Ph1 optionally substituted furanyl, optionally substituted imidazolyl, optionally substituted thiazolyl, -OCH3, -OCH2CH35-CH2OCH3, - CH2OCH2CH3, -CH2CH2CH2OCH3, -CH2NHBoC, -CH2CH2NHBoC, -CH2CH2NHAc, -
CH2CH2NH(C=O)OCH3, -N(CH3)2, -CH2CH2N(-C=OCH2CH2CH2-), -CH2CH2(C=O)N(-
CH2CH2CH2CH2CH2-), -CH2CsHg, -CH2C6Hn, -CH2CH2CsHg, -CH2CH2C6Hn, —
CH2(furanyl), -CH2(thiophenyl), and -CH2(indanyl). In certain embodiments, R2 is selected from -(CH2)4CH3, -CH2CH2CF2CF3, optionally substituted pyridinyl and optionally substituted phenyl. In certain embodiments, R2 is selected from -(CH2)4CH3, -CH2CH2CF2CF3, -pyridinyl
Or -C6H5.
In certain embodiments, W3 is C or CR15. In certain embodiments, W3 is C or CH. In certain embodiments, W3 is CH. In certain embodiments, W3 is N.
In certain embodiments, the present invention provides compounds of formula (V-a):
Figure imgf000081_0001
(V-a) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, Het-B, R1, R2, m and n are as defined above and herein. Examples of such compounds, wherein Ring A is substituted ortho, meta, ox para to the boron atom with the group X-HetB, are provided in compounds of any of formulae (V-b), (V-c) or (V-d):
Figure imgf000082_0001
(V-b) (V-c)
Figure imgf000082_0002
(V-d) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, Het-B, R1, R2, m and n are as defined above and herein.
Exemplary Het-B rings include, but are not limited to,
Figure imgf000082_0003
wherein Y1, Y2, Y7, Y8, W4, W5, W6, W7 and p are as defined below, and R2 and m are as defined above and herein.
For example, in certain embodiments, the present invention provides compounds of formula (V-e):
Figure imgf000083_0001
(V-e) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, Het-B, R1, R2, m and n are as defined above and herein, and Y1 is O, S or NR16.
In certain embodiments, Y1 is O or S. In certain embodiments, Y1 is O. In certain embodiments, Y1 is S. For example, in certain embodiments, the present invention provides compounds of any of formulae (V-el), (V-e2), (V-e3), (V-e4), (V-e5), (V-e6), or (V-e7):
Figure imgf000083_0002
(V-e2)
Figure imgf000083_0003
(V-e3)
Figure imgf000084_0001
(V-e6)
Figure imgf000084_0002
(V-e7) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, Het-B, R1, R2, m and n are as defined above and herein.
In certain embodiments, the present invention provides compounds of formula (V-f):
Figure imgf000085_0001
(V-f) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, R1, R2, m and n are as defined above and herein. For example, in certain embodiments, the present invention provides compounds of any of formulae (V-fl), (V-f2), (V-f3) or (V-f4):
Figure imgf000085_0002
(V-fl)
Figure imgf000085_0003
(V-O)
Figure imgf000086_0001
(V-f4) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, Het-B, R1, R2, m and n are as defined above and herein.
In certain embodiments, the present invention provides compounds of formula (V-g):
Figure imgf000086_0002
(V-g) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, R1, R2, and m and n are as defined above and herein. For example, in certain embodiments, the present invention provides compounds of either of formulae (V-gl) and (V-g2):
Figure imgf000086_0003
(V-g2) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, R16, Z1, Z2, X, R1, R2, m and n are as defined above and herein.
In certain embodiments, the present invention provides compounds of formula (V-h):
Figure imgf000087_0001
(V-h) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, R1, R2, m and n are as defined above and herein, and Y2 is O, S or NR16.
In certain embodiments, the present invention provides compounds of formulae (V-hl) or (V-h2):
Figure imgf000087_0002
(V-hl)
Figure imgf000087_0003
(V-h2) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y2, W3, Z1, Z2, X, R1, R2, m and n are as defined above and herein.
In certain embodiments, Y2 is O or S. In certain embodiments, Y2 is O. In certain embodiments, Y2 is S. For example, in certain embodiments, the present invention provides compounds of any of formulae (V-h3), (V-h4), (V-h5), (V-h6), (V-h7), (V-h8), (V-h9) or (V-hlO):
Figure imgf000088_0001
(V-h3)
Figure imgf000088_0002
(V-h5)
Figure imgf000088_0003
(V-h7)
Figure imgf000089_0001
(V-h9)
Figure imgf000089_0002
(V-hlO) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, R16, Z1, Z2, X, R1, R2, m and n are as defined above and herein.
In certain embodiments, the present invention provides compounds of formula (V-i):
Figure imgf000089_0003
(V-i) or pharmaceutically acceptable salts or prodrugs thereof, wherein W3, Z1, Z2, X, R1, R2, m and n are as defined above and herein, Y7 and Y8 are independently selected from N, NR16, O and S, and
W4 is C, CR17 or N, wherein R17 is hydrogen, halogen, -CF3, optionally substituted C1. 8 alkyl, optionally substituted C2-8 alkenyl, or optionally substituted C2-8 alkynyl.
In certain embodiments, Y7 is O or S and Y8 is N. In certain embodiments, Y7 is O and Y8 is N. In certain embodiments, Y7 is S and Y8 is N.
In certain embodiments, W4 is N.
In certain embodiments, W4 is C or CR17. In certain embodiments, W4 is C or CH.
In certain embodiments, the present invention provides compounds of formulae (V-il):
Figure imgf000090_0001
(V-il) or pharmaceutically acceptable salts or prodrugs thereof, wherein W3, Z1, Z2, X, R1, R2, m, n, W4, Y7 and Y8, are as defined above and herein.
In certain embodiments, the present invention provides compounds of the formula (V-j):
Figure imgf000090_0002
(V-j) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, R1, R2, m and n are as defined above and herein, W5 is N or N16, and the dashed line represents a single or double bond. In certain embodiments, the dashed line is a single bond. In certain embodiments, the dashed line is a double bond. For example, in certain embodiments, the present invention provides compounds of formulae (V-jl), (V-J2), (V-J3), (V-J4), (V-J5) or (V-J6):
Figure imgf000091_0001
(V-jl)
Figure imgf000091_0002
(V-J2)
Figure imgf000091_0003
(V-J3)
Figure imgf000091_0004
(V-J4)
Figure imgf000091_0005
(V-J5)
Figure imgf000092_0001
(V-J6) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, R1, R2,
R16, m and n are as defined above and herein.
In certain embodiments, the present invention provides compounds of formula (V-k):
Figure imgf000092_0002
(V-k) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, R1, R2, m and n are as defined above and herein, and p is 1 or 2. For example, in certain embodiments, the present invention provides compounds of either of formulae (V-kl) or (V-k2):
Figure imgf000092_0003
(V-kl)
Figure imgf000092_0004
(V-k2) or a pharmaceutically acceptable salt or prodrug thereof, wherein W3, Z1, Z2, X, R1, R2, m and n are as defined above and herein.
In certain embodiments, the present invention provides compounds of formula (V-m):
Figure imgf000093_0001
(V-m) or pharmaceutically acceptable salts or prodrugs thereof, wherein W3, Z1, Z2, X, R1, R2, R16, m, and n, are as defined above and herein, and W6 and W7 are selected from N or CH, with the proviso that one or both of W6 and W7 is N. For example, in certain embodiments, the present invention provides compounds of either of formulae (V-ml), (V-m2) or (V-m3):
Figure imgf000093_0002
(V-m2)
Figure imgf000093_0003
(V-m3) or pharmaceutically acceptable salts or prodrugs thereof, wherein W3, W6, W7, Z1, Z2, X, R1, R2, R16, m, and n, are as defined above and herein. Additional embodiments wherein Het-B is an optionally substituted 3-10 membered heterocvclyl ring
As generally defined above, in certain embodiments, Het-B is an optionally substituted 3-10 membered heterocyclyl ring. In certain embodiments, Het-B is an optionally substituted 3-10 membered heterocyclyl ring, wherein said heterocyclyl ring has 1 to 3 heteroatoms selected from N, NR16, O and S, and R16 is, independently, hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, - C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl.
In certain embodiments, Het-B is an optionally substituted 5-6 membered monocyclic heterocyclyl ring. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5- membered monocyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an an optionally substituted 5-membered monocyclic heterocyclyl ring selected from the group consisting of optionally substituted 1 ,3-dioxolanyl, optionally substituted 4,5-dihydroisoxazolyl, optionally substituted isoxazolidinyl, optionally substituted oxazolidinyl, optionally substituted tetrahydrofuranyl, optionally substituted pyrrolidinyl and optionally substituted pyrrolyl-2,5-dione.
In certain embodiments, wherein Het-B is an optionally substituted pyrrolidinyl {i.e., containing 1 heteroatom selected from N or NR16), the following compounds are specifically excluded: (i) compounds wherein W3 is CH, n is 0, m is 0 and X is a covalent bond or -
CH2OCH2-;
(ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a 5-membered ring containing 1 O atom.
In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 6- membered monocyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heterocyclyl ring selected from the group consisting of optionally substituted 1,3-dioxanyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted morpholinyl, and optionally substituted tetrahydropyranyl.
In certain embodiments, wherein Het-B is an optionally substituted piperidinyl (i.e., containing 1 heteroatom selected from N or NR16), the following compounds are specifically excluded: (i) compounds wherein W3 is CH, n is 0, m is 0 and X is -(C=O)- or a covalent bond; (ii) compounds wherin W3 is CH, n is 1, R1 is fluoro, and X is -OCH2CH2- or -
CH2CH2O-;
(iii) compounds wherein W3 is CH, n is 0 and X is -(C=O)-; (iv) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(v) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted piperazinyl (i.e., containing 2 heteroatoms selected from N or NR16), the following compounds are specifically excluded: (i) compounds wherein W3 is CH, n is 1, and X is a covalent bond, -OCH2(C=O)- or
-(C=O)CH2O-;
(ii) compounds wherein W3 is N, n is 1 , R1 is -CH3 and X is a covalent bond; (iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted morpholynyl (i.e., containing 1 heteroatom selected from O and 1 heteroatom selected from N or NR16), the following compounds are specifically excluded: (i) compounds wherein W3 is CH, n is O or 1, m is O and X is -(C=O)- or a covalent bond;
(ii) compounds wherein W3 is N, n is 1 , R1 is -CH3 and X is a covalent bond; (iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a 5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted tetrahydropyranyl (i.e., containing 2 O heteroatoms), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is O, m is O and X is -O- or -CH2OCH2-; (ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, Het-B is an optionally substituted 9-10 membered bicyclic heterocyclyl ring.
In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring selected from the group consisting of optionally substituted indolinyl, optionally substituted isoindolinyl-l,3-dione, and optionally substituted benzo[d][l,3]dioxolyl.
In certain embodiments, wherein Het-B is an optionally substituted indolinyl (i.e., containing 1 heteroatom selected from N or NR16), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is 0, m is 0, and X is -CH2-; (ii) compounds wherein W3 is CH, n is 1, R1 is fluoro, m is 0, and X is -CH2-; (iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a 5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted isoindolinyl-1,3- dione (i.e., containing 1 heteroatom selected from N or NR16), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is 0, m is 0 and X is -CH2-; (ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted benzo[d][l,3]dioxolyl (i.e., containing 2 O heteroatoms), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is 0, m is 0 and X is -O-;
(ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heterocyclyl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heterocyclyl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heterocyclyl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 10- membered bicyclic heterocyclyl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heterocyclyl ring selected from the group consisting of optionally substituted 1,2,3,4-tetrahydroquinolinyl.
In certain embodiments, wherein Het-B is an optionally substituted 1,2,3,4- tetrahydroquinolinyl (i.e., containing 1 heteroatom selected from N or NR16), the following compounds are specifically excluded:
(iv) compounds wherein W3 is CH, n is 0, m is 0 and X is -CH2-;
(v) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(vi) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
Additional embodiments wherein Het-B is an optionally substituted 5-10 membered heteroaryl ring
As generally defined above, in certain embodiments, Het-B is an optionally substituted 5-10 membered heteroaryl ring. In certain embodiments, Het-B is an optionally substituted 5-10 membered heteroaryl ring, wherein said heteroaryl ring has 1 to 3 heteroatoms selected from N, NR16, O and S, and R16 is, independently, hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(O)N(Rπ)2, - C(O)NH(R11), -C(O)NH2, optionally substituted C1-* alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl.
In certain embodiments, Het-B is an optionally substituted 5-6 membered monocyclic heteroaryl ring. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5- membered monocyclic heteroaryl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring selected from the group consisting of optionally substituted triazolyl, optionally substituted oxadiazolyl, optionally substituted thiadiazolyl, optionally substituted imidazolyl, optionally substituted pyrazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiophenyl, optionally substituted furanyl and optionally substituted pyrrolyl.
In certain embodiments, wherein Het-B is an optionally substituted oxadiazolyl group (i.e., containing one O and two N atoms), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0; (ii) compounds wherein W3 is CH, X is a covalent bond, n is 0, m is 1 and R2 is an unsubstituted furanyl group; (iii) compounds wherein W3 is CH, X is a covalent bond, n is 0, m is 1 and R2 is -
CH3;
(iv) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (v) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted thiadiazolyl group (i.e., containing one S and two N atoms), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0; (ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted triazolyl group (i.e., containing three heteroatoms selected from N and NR16), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0;
(ii) compounds wherein W3 is CH, X is -OCH2- or -CH2O-, n is 1, R1 is fluoro, m is
1 and R2 is a cyclohexyl group;
(iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom. In certain embodiments, wherein Het-B is an optionally substituted oxazolyl group (i.e., containing one N atom and one O atom), the following compounds are specifically excluded: (i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0; (ii) compounds wherein W3 is CH, n is 1, R1 is fluoro, X is -OCH2- or -CH2O-, and m is 0;
(iii) compounds wherein W3 is CH, X is a covalent bond, n is 0, m is 2 and each R2 is independently -CH3, an optionally substituted Ci_g alkyl or Ci_g heteroalkyl group;
(iv) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (v) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted thiazolyl group (i.e., containing one S atom and one N atom), the following compounds are specifically excluded:
(i) compounds wherein W is CH, n is 0, X is a covalent bond, m is 1 and R2 is -CH3; (ii) compounds wherein W is CH, n is 1, R1 is fluoro, X is -OCH2- or -CH2O- and m is O;
(iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom. In certain embodiments, wherein Het-B is an optionally substituted pyrazolyl group (i.e., containing two heteroatoms selected from N or NR16), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is 1, R1 is fluoro, X is -OCH2- or -CH2O-,and m is 0; (ii) compounds wherein W3 is CH, n is 0, X is -OCH2CH2- or -CH2CH2O- and m is
0;
(iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a 5-membered ring containing 1 O atom. In certain embodiments, wherein Het-B is an optionally substituted imidazolyl group (i.e., containing two heteroatoms selected from N or NR16), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is 1, R1 is fluoro, X is -OCH2- or -CH2O-,and m is 0;
(ii) compounds wherein W is CH, n is 0, X is -OCH2CH2- or -CH2CH2O- and m is
0;
(iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a 5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted thiophenyl group (i.e., containing one S atom), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is 0, m is 0 and X is a covalent bond; (ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted furanyl group (i.e., containing one O atom), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, n is 0, X is -(C=O)NHCH2- or -CH2NH(C=O)- and m is 0;
(ii) compounds wherein W3 is CH, n is 0, m is 0 and X is a covalent bond;
(iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom. In certain embodiments, wherein Het-B is an optionally substituted pyrrolyl group (i.e., containing one heteroatom selected from N or NR16), the following compounds are specifically excluded:
(i) compounds wherein W τ-3 is CH, n is 0 and X is a covalent bond;
(ii) compounds wherein W τ-3 is CH, n is 0 and X is -SO2-; (iii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iv) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heteroaryl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 6-membered monocyclic heteroaryl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 6- membered monocyclic heteroaryl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted pyridinyl group (e.g., 2-pyridinyl, 3- pyridinyl, 4-pyridinyl).
However, in certain embodiments, Het-B is not an optionally substituted 6-membered monocyclic heteroaryl ring. In certain embodiments, Het-B is not an optionally substituted pyridinyl. Alternatively, in certain embodiments, wherein Het-B is an optionally substituted pyridinyl group, the following compounds are specifically excluded:
(i) 3-pyridinyl compounds wherein W3 is CH, n is 1 , R1 is a fluoro group ortho to the boron atom, X is a covalent bond, -O-, -CH2O-, -OCH2-, -OCH2CH2- or - CH2CH2O-, and m is O;
(ii) 3-pyridinyl compounds wherein W3 is CH, n is 0, X is a covalent bond and m is 0;
(iii) 2-pyridinyl compounds wherein W3 is CH, n is 1 , R1 is fluoro ortho to the boron atom, X is -OCH2CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2- or -CH2CH2O-, and m is 0;
(iv) 2-pyridinyl compounds wherein W3 is CH, n is 0, X is -(C=O)NH- or - NH(C=O) - and m is 0;
(v) 4-pyridinyl compounds wherein W3 is CH, n is 1 , R1 is fluoro ortho to the boron atom, X is -CH2O- or -OCH2-, and m is 0; (vi) 4-pyridinyl compounds wherein W is CH, n is 0, X is a covalent bond and m is
0; (vii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (viii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, Het-B is an optionally substituted 9-10 membered bicyclic heteroaryl ring. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S (e.g., a 6-5 fused heteroaryl ring). In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 9-membered bicyclic heteroaryl ring selected from the group consisting of optionally substituted benzthiazolyl, optionally substituted benzoxazolyl, optionally substituted benzisoxazolyl, optionally substituted benzimidazolyl, optionally substituted indazolyl, optionally substituted benzofuranyl, optionally substituted benzothiophenyl and optionally substituted indolyl.
In certain embodiments, wherein Het-B is an optionally substituted benzoxazolyl group (i.e., containing one N atom and one O atom), the following compounds are specifically excluded: (i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0;
(ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted benzisoxazolyl group (i.e., containing one N atom and one O atom), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0; (ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a 5-membered ring containing 1 O atom. In certain embodiments, wherein Het-B is an optionally substituted benzthiazolyl group (i.e., containing one N atom and one S atom), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0; (ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted benzimidazolyl group (i.e., containing two heteroatoms selected from from N or NR16), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0;
(ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom. In certain embodiments, wherein Het-B is an optionally substituted indazolyl group (i.e., containing two heteroatoms selected from from N or NR16), the following compounds are specifically excluded:
(i) compounds wherein W3 is CH, X is a covalent bond, n is 0 and m is 0; (ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, wherein Het-B is an optionally substituted indolyl group (i.e., containing one heteroatom selected from from N or NR16), the following compounds are specifically excluded: (i) compounds wherein W3 is CH, X is -CH2-, n is 0 and m is 0;
(ii) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or (iii) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a
5-membered ring containing 1 O atom.
In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N, NR16, O and S (e.g., a 6,6-fused heteroaryl ring). In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 1 heteroatom selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 2 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 10-membered bicyclic heteroaryl ring containing 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 10- membered bicyclic heteroaryl ring selected from the group consisting of optionally substituted quinolinyl, optionally substituted isoquinolinyl or optionally substituted quinoxalinyl.
In certain embodiments, wherein Het-B is an optionally substituted quinolinyl group (i.e., containing one heteroatom selected from from N), the following compounds are specifically excluded:
(iv) compounds wherein W3 is CH, X is a covalent bond, n is 0, m is 1 and R2 is - CO2H;
(v) compounds wherein W3 is CH, n is 1 and R1 is CH2OH; and/or
(vi) compounds wherein Z1 is -OH or -OR3, and Z2 and Ring A taken together form a 5-membered ring containing 1 O atom.
In certain embodiments, the following compounds are specifically excluded:
Figure imgf000105_0001
Figure imgf000105_0002
Figure imgf000106_0001
Figure imgf000106_0002
Figure imgf000106_0003
Figure imgf000106_0004
Figure imgf000107_0001
Figure imgf000107_0002
Figure imgf000107_0003
Figure imgf000107_0004
Figure imgf000108_0001
Figure imgf000108_0002
Figure imgf000109_0001
Figure imgf000109_0002
Figure imgf000109_0003
Figure imgf000110_0001
Figure imgf000110_0002
Figure imgf000111_0001
Figure imgf000111_0002
Figure imgf000111_0003
10
Figure imgf000112_0001
Figure imgf000112_0002
and pharmaceutically acceptable salts or prodrugs thereof.
Exemplary compounds encompassed by formulae (II), (V), and subgenera thereof, are provided below in Tables 9-20.
Figure imgf000112_0003
Figure imgf000113_0001
Figure imgf000113_0002
Figure imgf000113_0003
Figure imgf000114_0001
Table 11
Figure imgf000115_0001
282 283
Figure imgf000115_0002
260 261
Figure imgf000115_0003
262 263
Figure imgf000115_0004
264 265
Figure imgf000115_0005
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Table 12
Figure imgf000120_0002
266
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000122_0002
Figure imgf000123_0001
Table 16
Figure imgf000124_0001
Figure imgf000124_0002
Figure imgf000125_0001
Figure imgf000125_0002
Table 19
Figure imgf000126_0001
Figure imgf000126_0002
Additionally, in certain embodiments, the present invention provides compounds of formula (VI):
Figure imgf000127_0001
(VI) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
(i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C i_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl;
(ii) Z1 and Z2 taken together form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom; or (iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted
5- to 7-membered ring; Y9 is an S or O;
X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-;
Het-B is an optionally substituted 3-10 membered heterocyclyl or an optionally substituted 5-10 membered heteroaryl ring; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted
C i_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2-s heteroalkenyl, optionally substituted C2-s heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl ; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted
C i_8 heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, and R10 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; n is 0, 1, 2 or 3 and m is 0, 1, 2, 3, 4, or 5.
In certain embodiments, the present invention provides compounds of any of formulae (VI-a), (VI-b), (VI-c), (VI-d) or (VI-e):
Figure imgf000129_0001
(VI-a) (VI-b)
Figure imgf000129_0002
(VI-C) (VI-d) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y9, Z1, Z2, Het-B, X, R1, R2, m and n are as defined above and herein.
Exemplary Het-B rings include, but are not limited to,
Figure imgf000129_0003
wherein Y1, Y2, Y7, Y8, W4, W5, W6, W7, p, R2 and m are as defined above and herein. In certain embodiments, Het-B of formula (VI), and subgenera thereof, is selected from
Figure imgf000129_0004
In certain embodiments, Het-B of formula (Vl), and subgenera thereof, is selected from
Figure imgf000130_0001
For example, in certain embodiments, the present invention provides compounds of formula (VI-e):
Figure imgf000130_0002
(VI-e) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y9, Z1, Z2, X, R1, R2, m and n are as defined above and herein. For example, in certain embodiments, the present invention provides compounds of any of formulae (VI-el), (VI-e2), (VI-e3), (VI-e4) or (VI-e5):
Figure imgf000130_0003
(VI-el)
Figure imgf000130_0004
(VI-e2)
Figure imgf000130_0005
(VI-e3)
Figure imgf000131_0001
(VI-e5) or a pharmaceutically acceptable salt or prodrug thereof, wherein Y9, Z1, Z2, X, R1, R2, m and n are as defined above and herein.
In certain embodiments, n is 0. In certain embodiments, X is a covalent bond. In certain embodiments, m is 1. In certain embodiments, R2 is selected from optionally substituted Ci_8 alkyl or optionally substituted Cβ-io aryl. In certain embodiments, R2 is selected from -CH3, -CH2CH3, -(CH2)2CH3, -(CH2)3CH3, -(CH2)4CH3, optionally substituted phenyl, optionally substituted benzyl, and -(CH2)2CeH5.
In certain embodiments, Y9 is a S atom. In certain embodiments, Y9 is an O atom. In certain embodiments, Het-B is an optionally substituted 3-10 membered heterocyclyl ring having 2 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5-10 membered heteroaryl ring having 2 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5- membered heteroaryl ring having 2 to 3 heteroatoms selected from N, NR16, O and S. In certain embodiments, Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring selected from the group consisting of an optionally substituted triazolyl, optionally substituted oxadiazolyl, optionally substituted thiadiazolyl, optionally substituted imidazolyl, optionally substituted pyrazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl and optionally substituted isoxazolyl.
In certain embodiments, compounds of formula (VI) or subgenera thereof, wherein Y9 is S, X is a covalent bond, n is 0, m is 0 and Het-B is C6Hs or unsubstituted thiophenyl, are specifically excluded.
In certain embodiments, the following compounds are specifically excluded:
Figure imgf000132_0001
or a pharmaceutically acceptable salt or prodrug thereof.
Exemplary compounds encompassed by formulae (II), (VI), and subgenera thereof, are provided below in Table 21.
Figure imgf000132_0002
Figure imgf000133_0001
4. Pharmaceutically Acceptable Compositions and Formulations
In certain embodiments, the present invention provides a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient, medium, or carrier.
In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in any of Tables 1 through 20, and a pharmaceutically acceptable excipient, medium, or carrier.
In some embodiments, the present invention provides a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (Vl), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples, and a pharmaceutically acceptable excipient, medium, or carrier. In other embodiments, the present invention provides a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples having a K1 of less than or equal to 0.01 microM or having a K1 of between 0.01 microM and 0.1 microM {i.e., compounds with activities designated "A" and "B"), and a pharmaceutically acceptable excipient, medium, or carrier.
In yet other embodiments, the present invention provides a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples having a K1 of less than or equal to 0.01 microM (i.e., compounds with activities designated "A") and a pharmaceutically acceptable excipient, medium, or carrier.
In still yet other embodiments, the present invention provides a pharmaceutically acceptable composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient, medium, or carrier, wherein said compound is selected from the any compound depicted in the Examples.
As described above, pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
Provided formulations of pharmaceutically acceptable compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
A pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a "unit dose" is discrete amount of the pharmaceutically acceptable composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one- third of such a dosage.
Relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and/or any additional ingredients in a pharmaceutically acceptable composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.
In some embodiments, the pharmaceutically acceptable excipient is at least 95%, 96%, 97%, 98%, 99%, or 100% pure. In some embodiments, the excipient is approved for use in humans and for veterinary use. In some embodiments, the excipient is approved by United States Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia. Pharmaceutically acceptable excipients used in the manufacture of provided pharmaceutically acceptable compositions include, but are not limited to, inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Such excipients may optionally be included in the inventive formulations. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents can be present in the composition, according to the judgment of the formulator.
Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
Exemplary granulating and/or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers {e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays {e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols {e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers {e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives {e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters {e.g. polyoxy ethylene sorbitan monolaurate [Tween 20], polyoxy ethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myrj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
Exemplary binding agents include, but are not limited to, starch (e.g. cornstarch and starch paste); gelatin; sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.); natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; etc.; and combinations thereof. Exemplary preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfϊte, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and trisodium edetate. Exemplary antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl. In certain embodiments, the preservative is an anti-oxidant. In other embodiments, the preservative is a chelating agent.
Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D- gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and combinations thereof. Exemplary lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
Exemplary oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof. Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifϊers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In certain embodiments for parenteral administration, the conjugates of the invention are mixed with solubilizing agents such as Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.
Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
The active ingredients can be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active ingredient may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
Dosage forms for topical and/or transdermal administration of a compound of this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. Generally, the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier and/or any needed preservatives and/or buffers as may be required. Additionally, the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body. Such dosage forms may be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium. Alternatively or additionally, the rate may be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel. Suitable devices for use in delivering intradermal pharmaceutically acceptable compositions described herein include short needle devices such as those described in U.S. Patents 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662. Intradermal compositions may be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof. Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Patents 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT publications WO 97/37705 and WO 97/13537. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes may be used in the classical mantoux method of intradermal administration. Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions. Topically-administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
A pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers or from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low- boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form. Low boiling propellants generally include liquid propellants having a boiling point of below 65 0F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non- ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
Pharmaceutically acceptable compositions of the invention formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension. Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers.
The formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutically acceptable composition of the invention. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nares. Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
A pharmaceutically acceptable composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier. Such drops may further comprise buffering agents, salts, and/or one or more other of the additional ingredients described herein. Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this invention.
General considerations in the formulation and/or manufacture of pharmaceutical agents may be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005. Although the descriptions of pharmaceutically acceptable compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutically acceptable compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation.
5. Kits Still further encompassed by the invention are kits comprising one or more compounds of the invention (or pharmaceutically acceptable salts or prodrugs thereof), and/or one or more pharmaceutically acceptable compositions as described herein. Kits are typically provided in a suitable container (e.g., for example, a foil, plastic, or cardboard package).
In certain embodiments, an inventive kit may include one or more pharmaceutical excipients, pharmaceutical additives, therapeutically active agents, and the like, as described herein. In certain embodiments, an inventive kit may include means for proper administration, such as, for example, graduated cups, syringes, needles, cleaning aids, and the like. In certain embodiments, an inventive kit may include instructions for proper administration and/or preparation for proper administration.
6. Methods of Treatment
The present invention also provides methods for treating an FAAH-mediated disease, disorder or condition by administering a therapeutically effective amount of a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable composition thereof, to a patient in need thereof.
Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable composition thereof, to a patient in need thereof. A patient to which administration is contemplated includes, but is not limited to, humans
{e.g., male, female, infant, child, adolescant, adult, elderly, etc.) and/or other primates; mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys. "Treating," as used herein, refers to partially or completely inhibiting or reducing the condition from which the patient is suffering. "Therapeutically effective amount," as used herein, refers to the minimal amount or concentration of an inventive compound, or pharmaceutically acceptable composition thereof, that, when administered, is sufficient in treating the patient. Treating may be via prophylactic or therapeutic therapy. In other embodiments, the present invention provides a method for inhibiting FAAH in a biological sample comprising the step of contacting said sample with a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or with a compound set forth in the Examples.
FAAH-mediated diseases, disorders or conditions include, but are not limited to, painful conditions, inflammatory disorders, immune disorders, depression, anxiety, anxiety-related disorders, sleep disorders, feeding behaviors, movement disorders, glaucoma, neuroprotection and cardiovascular disease.
In certain embodiments, the FAAH-mediated disease, disorder or condition is a painful condition, disease or disorder. As used herein, a "painful condition, disease or disorder" includes, but is not limited to, neuropathic pain (e.g., peripheral neuropathic pain), central pain, deafferentiation pain, chronic pain (e.g., chronic nociceptive pain, and other forms of chronic pain such as post-operative pain), stimulus of nociceptive receptors, acute pain (e.g., phantom and transient acute pain), non-inflammatory pain, inflammatory pain, pain associated with cancer, wound pain, burn pain, post-operative pain, pain associated with medical procedures, arthritic pain (e.g., pain associated with rheumatoid arthritis, osteoarthritis), lumbosacral pain, musculoskeletal pain, headache, migraine, muscle ache, lower back and neck pain, toothache and the like. In certain embodiments, the painful condition, disease or disorder is neuropathic pain. The term "neuropathic pain" refers to pain resulting from injury to a nerve. Neuropathic pain is distinguished from nociceptive pain, which is the pain caused by acute tissue injury involving small cutaneous nerves or small nerves in muscle or connective tissue. Neuropathic pain typically is long-lasting or chronic and often develops days or months following an initial acute tissue injury. Neuropathic pain can involve persistent, spontaneous pain as well as allodynia, which is a painful response to a stimulus that normally is not painful. Neuropathic pain also can be characterized by hyperalgesia, in which there is an accentuated response to a painful stimulus that usually is trivial, such as a pin prick. Neuropathic pain conditions can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain conditions include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; neuralgia, such as post-herpetic neuralgia and trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, chemotherapy-induced pain, chemotherapy, surgery, invasive medical procedures, toxins burns, infection, or chronic inflammatory conditions. Neuropathic pain can result from a peripheral nerve disorder such as neuroma; nerve compression; nerve crush, nerve stretch or incomplete nerve transsection; mononeuropathy or polyneuropathy. Neuropathic pain can also result from a disorder such as dorsal root ganglion compression; inflammation of the spinal cord; contusion, tumor or hemisection of the spinal cord; tumors of the brainstem, thalamus or cortex; or trauma to the brainstem, thalamus or cortex.
The symptoms of neuropathic pain are heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia). In certain embodiments, the painful condition, disease or disorder is non-inflammatory pain and/or inflammatory pain. The types of non-inflammatory pain include, without limitation, peripheral neuropathic pain (e.g., pain caused by a lesion or dysfunction in the peripheral nervous system), central pain (e.g., pain caused by a lesion or dysfunction of the central nervous system), deafferentation pain (e.g., pain due to loss of sensory input to the central nervous system), chronic nociceptive pain (e.g., certain types of cancer pain), noxious stimulus of nociceptive receptors (e.g., pain felt in response to tissue damage or impending tissue damage), phantom pain (e.g., pain felt in a part of the body that no longer exists, such as a limb that has been amputated), pain felt by psychiatric patients (e.g., pain where no physical cause may exist), and wandering pain (e.g., wherein the pain repeatedly changes location in the body). In certain embodiments, non-inflammatory pain and/or inflammatory pain are associated with disorders such as inflammatory diseases (e.g., autoimmune disease). In certain embodiments, the FAAH-mediated disease, disorder or condition is an inflammatory disorder. The term "inflammatory disorders" refers to those diseases or conditions that are characterized by signs of pain (dolor, from the generation of noxious substances and the stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of fluid), and/or loss of function (functio laesa, which may be partial or complete, temporary or permanent). Inflammatory disorders include, without limitation, those affecting the blood vessels (e.g., polyarteritis, temporal arteritis); joints (e.g, arthritis: crystalline, osteo-, psoriatic, reactive, rheumatoid, Reiter's syndrome); gastrointestinal tract (e.g, Crohn's disease, ulcerative colitis); skin (e.g, dermatitis); or multiple organs and tissues (e.g, systemic lupus erythematosus). Inflammatory disorders include, but are not limited to, inflammation associated with vascular diseases, migraine headaches, tension headaches, arteritis, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, multiple sclerosis, and ischemia (e.g., myocardial ischemia), and the like. The compounds and compositions may be useful for treating neuroinflammation associated with brain disorders (e.g., Parkinson's disease and Alzheimer's disease) and chronic inflammation associated with cranial radiation injury. The compounds may be useful for treating acute inflammatory conditions (e.g., conditions resulting from infection) and chronic inflammatory conditions (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease). The compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia. Inflammation takes on many forms and includes, but is not limited to, acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative, fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial, metastatic, necrotic, obliterative, parenchymatous, plastic, productive, proliferous, pseudomembranous, purulent, sclerosing, seroplastic, serous, simple, specific, subacute, suppurative, toxic, traumatic, and/or ulcerative inflammation.
In certain embodiments, the FAAH-mediated disease, disorder or condition is an immune disorder. Immune disorders, such as auto-immune disorders, include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, haemolytic autoimmune anaemias, multiple sclerosis, amyotrophic lateral sclerosis, amylosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin inflammation disorders (e.g., psoriasis, eczema, burns, dermatitis), enuresis, eosinophilic disease, gastrointestinal disorders (e.g., inflammatory bowel disease (IBD), peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, Crohn's disease, gastritis, diarrhoea, irritable bowel syndrome and ulcerative colitis), and disorders ameliorated by a gastroprokinetic agent (e.g., ileus, postoperative ileus and ileus during sepsis; gastroesophageal reflux disease (GORD, or its synonym GERD); eosinophilic esophagitis, gastroparesis such as diabetic gastroparesis; food intolerances and food allergies and other functional bowel disorders, such as non-ulcerative dyspepsia (NUD) and non-cardiac chest pain (NCCP, including costo-chondritis)).
In certain embodiments, the immune disorder is a gastrointestinal disorder. In some embodiments, the immune disorder is inflammatory bowel disease (e.g., Crohn's disease and/or ulcerative colitis), peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, Crohn's disease, gastritis, diarrhea, irritable bowel syndrome and ulcerative colitis. In other embodiments, the immune disorder is inflammatory bowel disease (IBD).
In certain embodiments, the FAAH-mediated disease, disorder or condition is a skin disorder. In some embodiments, the skin disorder is pruritus (itch), psoriasis, eczema, burns or dermatitis. In certain embodiments, the the skin disorder is psoriasis. In certain embodiments, the the skin disorder is pruritis.
In certain embodiments, the FAAH-mediated disease, disorder or condition is anxiety. "Anxiety," as used herein, includes, but is not limited to anxiety and anxiety disorders or conditions, such as, for example, clinical anxiety, panic disorder, agoraphobia, generalized anxiety disorder, specific phobia, social phobia, obsessive-compulsive disorder, acute stress disorder, and post-traumatic stress disorder; and adjustment disorders with anxious features, anxiety disorders associated with depression, anxiety disorders due to general medical conditions, and substance-induced anxiety disorders. This treatment may also be to induce or promote sleep in a patient (e.g., for example, a patient with anxiety).
In certain embodiments, the FAAH-mediated disease, disorder or condition is a sleep disorder. "Sleep disorders" include, but are not limited to, insomia, sleep apnea, restless legs syndrome (RLS), delayed sleep phase syndrome (DSPS), periodic limb movement disorder (PLMD), hypopnea syndrome, rapid eye movement behavior disorder (RBD), shift work sleep disorder (SWSD), and sleep problems (e.g., parasomnias) such as nightmares, night terrors, sleep talking, head banging, snoring, and clenched jaw and/or grinding of teeth (bruxism).
In certain embodiments, the FAAH-mediated disease, disorder or condition is depression. "Depression," as used herein, includes, but is not limited to, depressive disorders or conditions, such as, for example, major depressive disorders (unipolar depression), dysthymic disorders (chronic, mild depression) and bipolar disorders (manic-depression). The depression may be clinical or subclinical depression.
In certain embodiments, the FAAH-mediated disease, disorder or condition is feeding behavior. "Feeding behavior," as used herein, includes but is not limited to, eating disorders (e.g., anorexias and cachexias of various natures, over-eating leading to obesity), weight loss associated with cancer, weight loss associated with other general medical conditions, weight loss associated with failure to thrive, and other wasting conditions. The compounds disclosed herein can also be used to reduce body fat and for treating or preventing obesity in a mammal. The compounds disclosed herein can also be used for preventing or treating the diseases associated with these health conditions.
In certain embodiments, the FAAH-mediated disease, disorder or condition is a movement disorder. In other embodiments, the FAAH-mediated disease, disorder or condition is glaucoma. In yet other embodiments, the FAAH-mediated disease, disorder or condition is neuroprotection. In still yet other embodiments, the FAAH-mediated disease, disorder or condition is cardiovascular disease.
In certain embodiments, the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, to a patient in need thereof. In some embodiments, the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, as provided in the Examples.
In other embodiments, the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, having a K1 of less than or equal to 0.01 microM or having a K1 of between 0.01 microM and 0.1 microM (i.e., compounds with activities designated "A" or "B").
In yet other embodiments, the above methods provide administering a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, or a pharmaceutically acceptable salt or prodrug thereof, having a K1 of less than or equal to 0.01 microM (i.e., compounds with activities designated "A").
7. Administration
Provided compounds may be administered using any amount and any route of administration effective for treatment. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular composition, its mode of administration, its mode of activity, and the like.
Compounds of the present invention are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease, disorder, or condition being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts. Provided compounds and compositions of the present invention may be administered by any route. In some embodiments, provided compounds and compositions are administered via a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. Specifically contemplated routes are systemic intravenous injection, regional administration via blood and/or lymph supply, and/or direct administration to an affected site. In general the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration), etc. At present the oral and/or nasal spray and/or aerosol route is most commonly used to deliver therapeutic agents directly to the lungs and/or respiratory system. However, the invention encompasses the delivery of a provided pharmaceutically acceptable composition by any appropriate route taking into consideration likely advances in the sciences of drug delivery. The exact amount of a compound required to achieve a therapeutically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
In certain embodiments of the present invention, a therapeutically effective amount of an inventive compound for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 1000 mg of an inventive compound per unit dosage form. It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutically acceptable compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
It will be also appreciated that an inventive compound or composition, as described above and herein, can be administered in combination with one or more additional therapeutically active agents.
By "in combination with," it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are certainly within the scope of the invention. The compositions can be administered concurrently with, prior to, or subsequent to, one or more other additional therapeutically active agents. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In will further be appreciated that the additional therapeutically active agent utilized in this combination may be administered together in a single composition or administered separately in different compositions. The particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved.
In general, it is expected that additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
By a "therapeutically active agent" or "active agent" refers to any substance that is useful for therapy, including prophylactic and therapeutic treatment.
The invention encompasses the delivery of provided pharmaceutically acceptable compositions in combination with agents that may improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. It will also be appreciated that therapy employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered in combination with an antiinflammatory, anti-anxiety and/or anti-depressive agent, etc.), and/or they may achieve different effects (e.g., control of any adverse side-effects).
Exemplary active agents include, but are not limited to, anti-cancer agents, antibiotics, anti-viral agents, anesthetics, anti-coagulants, inhibitors of an enzyme, steroidal agents, steroidal or non-steroidal anti-inflammatory agents, antihistamine, immunosuppressant agents, antineoplastic agents, antigens, vaccines, antibodies, decongestants sedatives, opioids, pain- relieving agents, analgesics, anti-pyretics, hormones, prostaglandins, progestational agents, anti- glaucoma agents, ophthalmic agents, anti-cholinergics, anti-depressants, anti-psychotics, hypnotics, tranquilizers, anti-convulsants, muscle relaxants, anti-spasmodics, muscle contractants, channel blockers, miotic agents, anti-secretory agents, anti-thrombotic agents, anticoagulants, anti-cholinergics, β-adrenergic blocking agents, diuretics, cardiovascular active agents, vasoactive agents, vasodilating agents, anti-hypertensive agents, angiogenic agents, modulators of cell-extracellular matrix interactions (e.g. cell growth inhibitors and anti-adhesion molecules), or inhibitors/intercalators of DNA, RNA, protein-protein interactions, protein- receptor interactions, etc. Active agents include small organic molecules such as drug compounds {e.g. , compounds approved by the Food and Drugs Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins and cells.
In certain embodiments, the additional therapeutically active agent is a pain-relieving agent. In other embodiments, the additional therapeutically active agent is an anti-inflammatory agent.
8. Methods of Determining Biological Activity
Methods of determining the activity of compounds of the present invention for various therapeutic uses are well known in the art. These include, but are not limited to, high throughput screening to identify compounds that bind to and/or modulate the activity of isolated FAAH, as well as animal and cellular models of therapies.
Assays for compounds described herein are amenable to high throughput screening. Assays useful for screening the compounds of the present invention may detect the binding of the inhibitor to FAAH or the release of a reaction product (e.g., fatty acid amide or ethanolamine) produced by the hydrolysis of a substrate such as oleoylethanolamide or ananadamide. The substrate may be labeled to facilitate detection of the released reaction products. U.S. Pat. No. 5,559,410 discloses high throughput screening methods for proteins, and U.S. Pat. Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.
Methods for screening FAAH inhibitors for an antinociceptive effect are well known to one of ordinary skill in the art. For instance, the test compounds can be administered to the subject animals in the mouse hot-plate test and the mouse formalin test and the nociceptive reactions to thermal or chemical tissue damage measured (for example, see U.S. Pat. No. 6,326,156 which teaches methods of screening for antinociceptive activity; see also Cravatt et al. Proc. Natl. Acad. Sci. U.S.A. (2001) 98:9371-9376). Two pharmacologically validated animal models of anxiety are the elevated zero maze test, and the isolation-induced ultrasonic emission test. The zero maze consists of an elevated annular platform with two open and two closed quadrants and is based on the conflict between an animal's instinct to explore its environment and its fear of open spaces, where it may be attacked by predators (see, for example, Bickerdike, M. J. et al., Eur. J. Pharmacol, (994) 271, 403-411; Shepherd, J. K. et al., Psychopharmacology, (1994) 116, 56-64). Clinically used anxiolytic drugs, such as the benzodiazepines, increase the proportion of time spent in, and the number of entries made into, the open compartments.
A second test for an anti-anxiety compound is the ultrasonic vocalization emission model, which measures the number of stress-induced vocalizations emitted by rat pups removed from their nest (see, for example, Insel, T. R. et al., Pharmacol. Biochem. Behav., 24, 1263-1267 (1986); Miczek, K. A. et al., Psychopharmacology, 121, 38-56 (1995); Winslow, J. T. et al., Biol. Psychiatry, 15, 745-757 (1991).
The effect of the compound of the invention in the treatment of depression can be tested in the model of chronic mild stress induced anhedonia in rats. This model is based on the observation that chronic mild stress causes a gradual decrease in sensitivity to rewards, for example consumption of sucrose, and that this decrease is dose-dependently reversed by chronic treatment with antidepressants. The method has previously been described and more information with respect to the test appears from Willner, Paul, Psychopharmacology, 1997, 134, 319-329. Another test for antidepressant activity is the forced swimming test (Nature 266, 730-
732, 1977). In this test, animals are administered an agent, preferably by the intraperitoneal route or by the oral route, 30 or 60 minutes before the test. The animals are placed in a crystallizing dish filled with water and the time during which they remain immobile is clocked. The immobility time is then compared with that of the control group treated with distilled water. Imipramine 25 mg/kg. can be used as the positive control. The antidepressant compounds decrease the immobility time of the mice thus immersed.
Another test for antidepressant activity is the caudal suspension test on the mouse (Psychopharmacology, 85, 367-370, 1985). In this test, animals are preferably treated with the study compound by the intraperitoneal route or by the oral route 30 or 60 minutes before the test. The animals are then suspended by the tail and their immobility time is automatically recorded by a computer system. The immobility times are then compared with those of a control group treated with distilled water. Imipramine 25 mg/kg can be used as the positive control. Antidepressant compounds decrease the immobility time of the mice.
Animal models are available to one of ordinary skill in the art for studying anticonvulsant activity of test compounds. See for instance, U.S. Pat. No. 6,309,406 and U.S. Pat. No. 6,326,156 which describe methods for performing such tests.
Inhibition of FAAH has been reported to induce sleep in test animals (U.S. Pat. No. 6,096,784). Methods for studying sleep inducing compounds are well known to one of ordinary skill in the art. In particular, methods for testing the ability of a FAAH inhibitory compound to induce sleep or treat insomnia are disclosed in U.S. Pat. No. 6,096,784 and U.S. Pat. No. 6,271,015. Most obviously, the compounds can be administered to a test animal (e.g., rat or mouse) or a human and the subsequent time (e.g., onset, duration) spent sleeping (e.g., eyes closed, motor quiescence) can be monitored. See also WO 98/24396.
Methods for screening FAAH inhibitors which induce catalepsy are also well known to one of ordinary skill in the art. See Quistand et al. in Toxicology and Applied Pharmacology 173: 48-55 (2001). See Cravatt et al. Proc. Natl. Acad. Sci. U.S.A. 98:9371-9376 (2001).
Methods of assessing appetitive behavior are known to one of ordinary skill in the art.
For instance, Maruani et al. (U.S. Pat. No. 6,344,474) teach two such assays. One method of assessing the effect on appetite behavior is to administer a FAAH inhibitor to a rat and assess its effect on the intake of a sucrose solution. This method is taught in W. C. Lynch et al., Physiol. Behav., 1993, 54, 877-880.
9. Covalent Complex Formation between Serine-241 of FAAH and Boronic Acid Inhibitors
Compounds provided herein can form reversible covalent complexes with the nucleophilic side chain of Ser-241 FAAH.
Thus, compounds of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, as described above and herein, associated with {e.g., complexed with) a serine residue of a protein are also provided.
For example, in certain embodiments, compounds of any offormulae (III), (IV), (V), or (VI), or subgenera thereof, as described above and herein, are associated with a serine residue of a protein:
Figure imgf000157_0001
(IΙI)-complex
Figure imgf000157_0002
(IV)-complex
Figure imgf000157_0003
(V)-complex
Figure imgf000157_0004
(VΙ)-complex wherein Resi — Ser — ReS2 is a protein having a length between about 400 to about 600 residues. By "Ser" is meant a serine residue. In certain embodiments, Ser is Ser24i of FAAH protein. In some embodiments, the protein is rat FAAH. In other embodiments, the protein is human FAAH (SEQ ID NO. 1). In certain embodiments, the active site of the protein has a Lys at 142; a Ser at 217; and a Ser at 241. In certain embodiments, the compound binds at Ser24i.
By Resi is meant the residue(s) closer to the N-terminus than Ser. By Res2 is meant the residue(s) closer to the C-terminus than Ser. In certain embodiments, Resi has a serine residue that is 24 amino acids closer to the N terminus than (Ser) and a lysine residue that is 99 amino acids closer to the N terminus than (Ser).
In certain embodiments, Z1 and Z2 are both -OH. Thus, in certain embodiments, the compound is a boronic acid compound.
10. Methods of Synthesis
A number of methods are known in the art to synthesize the compounds provided herein. A recognized method of synthesizing boronate esters is the reaction of an organometallic species with an organic borate, such as trimethyl borate. Suitable organometallic species include, but are not limited to, alkyl lithium and Grignard reagents. Other methods for the synthesis of boronates are employed when the boronate contains sensitive functionality that may not tolerate alkyl lithium reagents or Grignard reagents. These methods include palladium coupling reactions of aryl or akenyl halides and diboronates or dialkoxy boranes and hydroboration of alkenes or alkynes. Using these methods a diverse collection of boronates can be synthesized. Boronates can be readily transformed in to boronic acids by hydro lyzing the boronate under aqueous acidic conditions using a suitable acid. Suitable acids include, but are not limited to HCl, H2SO4, and HBr. Another method of hydrolyzing boronates is an oxidative hydrolysis employing an oxidizing agent, such as NaIO4, as exemplified in Example 5. The boronic acid compounds of the present invention readily form boronic esters when exposed to alcohols. The resulting boronic esters may also be used in the methods provided herein. Cyclic boronates are formed when certain diols (e.g., 1,2- and 1,3-diols) are used. Boronic acid compounds provided herein readily form oligomeric anhydrides by dehydration of the boronic acid moiety to form dimers, trimers, and tetramers, and mixtures thereof. These species in the presence of water and under physiological conditions convert back to the boronic acid by hydrolysis.
EXEMPLIFICATION
The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
Exemplary compounds are set forth in the Examples provided below. Compounds were assayed as inhibitors of human FAAH using the method described in detail in Example 286. Activity of exemplified compounds are provided in the Examples, wherein activity designated as "A" refers to compounds having a K1 of less than or equal to 0.01 microM, "B" refers to compounds having a K1 of between 0.01 microM and 0.1 microM, "C" refers to compounds having a K1 of between 0.1 microM and 1 microM, and "D" refers to compounds having a K1 of greater than 1 microM.
GENERAL SYNTHETIC METHODS Preparation of boronic acids:
Figure imgf000159_0001
Method 1
General conditions for the preparation of boronic acids: under an argon atmosphere, 0.1 M aryl bromide (1.0 equiv) dissolved in 4:1 toluene/tetrahydrofuran was cooled to -78 0C. Triisopropylborate (1.3 equiv) was added, and the mixture was treated dropwise with nBuLi in hexanes (1.2 equiv). After stirring for 30 min, the mixture was warmed to 0 0C and stirred for an additional 30 min. The mixture was quenched with 2N aqueous HCl (10 equiv) and stirred for Ih at 23 0C. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine and then dried over sodium sulfate. The residue upon concentration was purified either by recrystallization/trituration (heptanes, acetonitrile, or other) or by flash silica gel chromatography (l-> 10% methanol/dichloromethane) to generally produce a white solid.
Method 2 General conditions for the preparation of boronic acids: under an argon atmosphere, 0.1
M aryl bromide (1.0 equiv) dissolved in 4:1 toluene/tetrahydrofuran was cooled to -78 0C. nBuLi in hexanes (2.5M, 1.2 equiv) was added dropwise, and the mixture was stirred for 60 min.
Triisopropylborate (1.3 equiv) was then added dropwise to the clear stirring solution. After 15 min, the mixture was warmed to 0 0C and stirred for an additional 30 min. The mixture was quenched with 2N aqueous HCl (10 equiv) and stirred for Ih at 23 0C. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine and then dried over sodium sulfate. The residue upon concentration was purified either by recrystallization/trituration (heptanes, acetonitrile, or other) or by flash silica gel chromatography ( 1 -M 0% methanol/dichloromethane) to generally produce a white solid.
Preparation of boronic acid pinacol esters:
Figure imgf000160_0001
Method 3
General conditions for the preparation of boronic acid pinacol esters: a dry flask under argon atmosphere was charged with aryl bromide (1.0 equiv), l,l"-Bis(diphenylphosphino)- ferrocenedichloropalladium(II) (0.05 equiv), potassium acetate (1.0 equiv), cesium carbonate (3 equiv), and bis(pinacolato)diboron (2.0 equiv). The mixture was suspended with dimethylsulfoxide (0.1 M with respect to aryl bromide) and heated at 80 0C for 2-8 h. Upon completion as judged by thin layer chromatography analysis, the reaction was split between water and ethyl acetate, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The concentrated reaction mixture was purified by flash silica gel chromatography (ethyl acetate / hexanes) to provide boronic acid pinacol ester. Method 4
General conditions for the preparation of boronic acid pinacol esters: a dry flask under argon atmosphere was charged with aryl bromide (1.0 equiv), bis(triphenylphosphine)palladium(II) dichloride (0.05 equiv), potassium acetate (2.0 equiv), and bis(pinacolato)diboron (1.5 equiv). The mixture was suspended with 1,4-dioxane (0.1 M with respect to aryl bromide) and heated at 80 0C for 2-8 h. Upon completion as judged by thin layer chromatography analysis, the reaction was split between water and ethyl acetate, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The concentrated reaction mixture was purified by flash silica gel chromatography (ethyl acetate / hexanes) to provide boronic acid pinacol ester.
Conversion of boronate esters to boronic acids:
Figure imgf000161_0001
Method 5
General conditions for the conversion of boronate esters to boronic acids: the boronate ester (1.0 eq), sodium periodate (5.0 eq) and ammonium acetate (5.0 eq) were dissolved in acetone/water 2:1 (0.05 M boronate ester) and stirred for 12 h at 23 0C until TLC or LCMS indicated conversion to the boronic acid was complete. One option for isolation is to precipitate the product by dilution of the mixture with IN aqueous HCl and collection by filtration of the solid boronic acid. Alternately, the mixture was split between water and ethyl acetate, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified either by recrystallization and trituration (heptane, acetonitrile, or other solvents) or by flash silica gel chromatography (0.5% -> 10% methanol/dichloromethane) to afford pure boronic acid. Method 6
General conditions for the conversion of boronate esters to boronic acids: the boronate ester was treated with concentrated sulfuric acid (0.2 M final ester concentration) and stirred until the mixture became a clear solution, about 10 min, at 23 0C. The solution was diluted with water 15 fold, and the precipitated boronic acid collected by filtration and washed with water.
Preparation of oxadiazoles:
Figure imgf000162_0001
Method 7
General conditions for the preparation of oxadiazoles: in a microwave reactor tube, (hydrazinocarbonyl)arylboronic acid pinacol ester (1.0 equiv) and carboxylic acid (1.0 equiv) were dissolved in dry acetonitrile (0.1 M each). Polystyrene-supported triphenylphosphine (3.0 equiv) and trichloro acetonitrile (2.0 equiv) were added, and the mixture was sealed and heated in a microwave reactor at 130 0C for 2 hours. The concentrated reaction mixture was purified by flash silica gel chromatography (hexanes/ethyl acetate) to provide oxadiazole-aryl boronic acid pinacol ester.
Method 8
General conditions for the preparation of oxadiazoles: the oxadiazole was formed as in Method 7, except that the reactants are a carboxyarylboronic acid pinacol ester and either an alkyl or aryl hydrazide.
Preparation of thiadiazoles:
Figure imgf000162_0002
Method 9
General conditions for the preparation of thiadiazoles: (hydrazinocarbonyl)arylboronic acid pinacol ester (1.0 equiv) and carboxylic acid (1 equiv) were dissolved in dry DCM (0.1 M each) and treated with EDC (1.05 equiv) and DMAP (0.10 equiv). The mixture was stirred for 6 h at 23 0C, and then diluted into a separatory funnel with DCM and washed twice each with 0.5 M aqueous citric acid and saturated aqueous sodium bicarbonate. The organic layer was dried over magnesium sulfate and concentrated to a clear oil.
This oil was dissolved in dry THF and 1.2 equiv Lawesson's reagent added. The mixture was sealed in a tube and heated in a microwave reactor at 115 0C for 30 min. The concentrated reaction mixture was purified by flash silica gel chromatography (hexanes/ethyl acetate) to provide thiadiazole-aryl boronic acid pinacol ester.
Method 10
General conditions for the preparation of thiadiazoles: the thiadiazole was formed as in Method 9, except that the reactants are a carboxyarylboronic acid pinacol ester and either an alkyl or aryl hydrazide.
Preparation of quinoline-2-ethers:
Figure imgf000163_0001
Method 11
Conditions for the preparation of quinoline-2-ethers: substituted 2-chloroquinoline (1.0 eq.), alcohol (3.0 eq.), and crushed NaOH (2.0 eq.) were suspended in NMP (0.3 M quinoline) and subjected to microwave heating at a temperature of ca. 160 0C during 15 min. When done by lc/ms, the reaction mixture was diluted into 0.1M NaOH and MTBE and separated. The organic phase was washed with brine, dried on Na2SO4, and treated with silica gel. After removal of the solvent, the residue was chromatographed (2→10% EtOAc/hexanes) to give clean ether product. Preparation of isoxazolines and isoxazoles:
OO N-O
J it //
R1^ ^R2 R1-^N^"R2
Method 12
General conditions for the preparation of isoxazolines and isoxazoles: Aldehyde (1.0 equiv.) was added to the solution of hydroxylamine hydrochloride (1.0 equiv.) in 1 :1 J-BuOH:
H2O (0.1 M aldehyde). To this was added NaOH to pH 5, and after being stirred for 30 min at ambient temperature, TLC analysis indicated that oxime formation was complete. Chloramine-T trihydrate (1.0 equiv.) was added in small portions over 5 min, followed by CuSO4 (0.045 equiv.) and copper turnings (ca. 0.01 equiv.). Alkene or alkyne (1.0 equiv.) was added, and the pH was adjusted to ca. 6 by addition of a few drops of 1 M NaOH, and stirring was continued for another
6 h. The reaction mixture was poured into ice/water, and dilute NH4OH was added to remove all copper salts. The desired product was collected by filtration and purified by flash silica gel chromatography.
Preparation of benzoxazoles:
Figure imgf000164_0001
Method 13
General conditions for the preparation of benzoxazoles: in a microwave reactor tube, aminophenol (1.0 equiv) and carboxylic acid (1.0 equiv) were dissolved in dry acetonitrile (0.1 M each). Polystyrene-supported triphenylphosphine (3.0 equiv) and trichloroacetonitrile (2.0 equiv) were added, and the mixture was sealed and heated in a microwave reactor at 150 0C for 2 hours. The concentrated reaction mixture was purified by flash silica gel chromatography (hexanes/ethyl acetate) to provide the desired benzoxazole.
Method 14
General conditions for the preparation of benzoxazoles: in a sealed tube, aminophenol (1.0 equiv) and carboxylic acid (1.0 equiv) were dissolved in dry acetonitrile (0.1 M each). Polystyrene-supported triphenylphosphine (4.0 equiv) and trichloroacetonitrile (2.0 equiv) were added, and the mixture was sealed and heated at 100 0C for 20-36h. The concentrated reaction mixture was purified by flash silica gel chromatography (hexanes/ethyl acetate) to provide the desired benzoxazole.
Preparation of boronic acid pinacol esters from aryl chlorides:
Figure imgf000165_0001
Method 15
General conditions for the preparation of boronic acid pinacol esters from aryl chlorides: a dry flask under argon atmosphere was charged with aryl chloride (1.0 equiv) and dissolved in tetrahydrofuran (0.1 M with respect to aryl chloride). Bis(pinacolato)diboron (2.5 equiv) was added followed by potassium acetate (2.5 equiv), palladium diacetate (0.2 equiv) and 1,3- bis(2,6-di-iso-propylphenyl)imidazolium chloride (0.4 equiv). The reaction was heated to 95 0C in a sealed tube for 14-36 h. Upon completion as judged by thin layer chromatography analysis the mixture was then filtered through a plug of celite with some silica gel on top. The celite was washed with ethyl acetate. The combined solution was concentrated in vacuo and purified by flash silica gelchromatography (ethyl acetate / hexanes) to provide the desired boronic acid pinacol ester.
Synthesis of Exemplary Compounds:
Example 1
Figure imgf000165_0002
3-Fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid (470 mg, 1.77 mmol) and 2-aminoacetophenone hydrochloride (318 mg, 1.89 mmol) were dissolved in 10 mL anhydrous dichloromethane. HOBt (286 mg, 2.12mmol) and EDC (406 mg, 2.12 mmol) were added followed by triethylamine (741 uL, 5.30 mmol). The reaction was allowed to stir for 12h at room temperature after which point it was transferred to a separatory funnel with excess dichloromethane and washed with 0.5 M citric acid (2 x 75 mL) and saturated NaHCO3 (2 x 75 mL). The organic layer was then dried over MgSO4, filtered and concentrated to provide the desired ketoamide as a yellow solid in quantitative yield (680 mg) which was used directly to form the oxazole the in the following step. The crude ketoamide (100 mg, 0.261 mmol) was dissolved in 2 mL concentrated H2SO4.
The reaction solution first turns bright orange, then a brown solid forms. The reaction was allowed to stir at room temperature for 10 minutes after which it was poured into 75 mL water at which point a white solid forms that was isolated using vacuum filtration. The solid was washed with excess water and dried under vacuum for 12h to provide 45 mg of oxazole 1 in 61% yield. [M-Hf = 282.1 m/z. Activity: B
Example 2
Figure imgf000166_0001
Oxazole 2 was prepared using conditions described for example 1. [M-H]" = 264.1 m/z. Activity: B Example 3
Figure imgf000166_0002
The ketoamide that was used to prepare 2 (223 mg, 0.58 mmol) was dissolved in 5 mL anhydrous tetrahydrofuran and Lawesson's reagent (282 mg, 0.70 mmol) was then added. The reaction was heated to 70 0C for 14h after which point it was loaded directly onto silica gel and purified using silica gel chromatography using a gradient of 20-70% ethyl acetate/hexanes to provide 200 mg of the desired thiazole in 90% yield. The resulting pinacol ester (2-(3-fluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl)-5-phenylthiazole) was then converted to thiazole 3 using Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 298.1 m/z. Activity: D
Example 4
Figure imgf000167_0001
6-Bromo-2-tetralone (4) was converted to its corresponding pincol ester boronate (5) using Method 3. This ketone (6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4- dihydronaphthalen-2(lH)-one) (600 mg, 2.21 mmol) was dissolved in 10 mL 1 :1 v/v methanol/tetrahydrofuran and cooled to 0 0C in an ice bath. Sodium borohydride (250 mg, 6.63 mmol) was added portion wise and the reaction was allowed to stir for 2h after which point there was no more starting material as indicated by TLC analysis. Saturated NaCl (100 mL) was added to reaction and the mixture was transferred to a separatory funnel with excess water and methylene chloride. The water layer was washed with methylene chloride (2 x 75 mL). The organic layers were combined, washed with saturated NaCl (1 x 75 mL), dried over Na2SO4 and concentrated under reduced pressure to provide the corresponding secondary alcohol in quantitative yield (600 mg).
This secondary alcohol (110 mg, 0.40 mmol) was dissolved in 2 mL anhydrous N, N- dimethylforamide and cooled to 0 0C in an ice bath. Sodium hydride (48 mg, 1.20 mmol, 60% in dispersion oil) was added with some fizzing. After 10 min, benzyl bromide (95 μL, 0.80 mmol) was added and the reaction was allowed to stir at room temperature for 2h. A large amount of starting material was still remaining at this point so sodium hydride and benzyl bromide was added in 3 additional portions and the reaction was allowed to stir for an additional 48h. After this point, the reaction was quenched with saturated NH4Cl (75 mL) and transferred to a separatory funnel with excess water and ethyl acetate. The water layer was washed with ethyl acetate (2 x 75mL). The combined organic layers were washed with saturated NaCl (2 x 75 mL), dried over MgSO4, concentrated directly onto silica gel and purified by silica gel chromatography using a gradient of 5-10% ethyl acetate/hexanes to provide the desired ether as an oil (57 mg) in 39% yield.
The resulting pinacol ester (2-(6-(benzyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl)- 4,4,5, 5-tetramethyl-l,3,2-dioxaborolane) was then converted to tetrahydronaphthalene 6 using Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 281.1 m/z. Activity: A
Example 5
Figure imgf000168_0001
The ketoamide used to prepare 2 (100 mg, 0.26 mmol) and ammonium acetate (1.0Og, 13.0 mmol) was added to a 5 mL microwave reaction vial. Acetic acid (2 mL) is added and the reaction is heated for 30 min at 175 0C in a microwave reactor. Water (100 mL) is added to the crude reaction mixture at which point a small amount of solid crashes out which is isolated using vacuum filtration and dried under vacuum overnight to provide 6 mg of imidazole 7 in 8% yield. [M-H]" = 281.1 m/z. Activity: D
Example 6
Figure imgf000168_0002
4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid (160 mg, 0.645 mmol) and 2-amino-l,4-diphenylbutan-l-one hydrochloride (178 mg, 0.645 mmol) were dissolved in 10 mL anhydrous dichloromethane. HOBt (105 mg, 0.774 mmol) and EDC (148 mg, 0.774 mmol) were added followed by triethylamine (270 uL, 1.94 mmol). The reaction was allowed to stir for 12h at room temperature after which point it was transferred to a separatory funnel with excess dichloromethane and washed with 0.5 M citric acid (2 x 75 mL) and saturated NaHCO3 (2 x 75 mL). The organic layer was then dried over MgSO4, filtered and concentrated to provide the desired ketoamide as a white solid in 93% yield (281 mg) which was used directly to form the thiazole in the following step.
The ketoamide (140 mg, 0.298 mmol) was dissolved in 4 mL anhydrous tetrahydrofuran and followed by the addition of Lawesson's reagent (145 mg, 0.358 mmol). The reaction was heated to 115 0C in a microwave reactor for 90 min after which point the crude mixture was loaded directly onto silica gel and purified using a gradient of 25-50% ethyl acetate/hexanes to isolate 90 mg of the desired compound in 65% yield. The resulting pinacol ester (4-phenethyl- 5-phenyl-2-(4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl)thiazole) was then converted to thiazole 8 by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 384.1 m/z. Activity: D Example 7
Figure imgf000169_0001
Oxadiazole 9 was prepared in 2 steps starting with oxadiazole formation between 5- bromopicolic acid and hexanoic hydrazide using Method 7 followed by the lithiation conditions of Method 1. [M-H]" = 260.1 m/z. Activity: A
Figure imgf000169_0002
10
Oxadiazole 10 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzohydrazide and 3-(2-oxo-pyrrolidin-l-yl)-propionic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 300.1 m/z. Activity: C
Example 9
Figure imgf000170_0001
11
Oxadiazole 11 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-5-(trifluoromethyl)benzoic acid and acetic hydrazide using Method 7 followed by lithiation using Method 1. [M-H]" = 271.0 m/z. Activity: C
Example 10
Figure imgf000170_0002
Oxadiazole 12 was prepared in 2 steps starting with oxadiazole formation between 5- bromopicolic acid and benzoic hydrazide using Method 7 followed by lithiation using Method 1. [M-H]" = 266.1 m/z. Activity: B
Example 11
Figure imgf000170_0003
Oxadiazole 13 was prepared by Method 8 followed by Method 5. [M-H]- = 231.1 m/z. Activity: D
Example 12
Figure imgf000170_0004
Part A
Figure imgf000171_0001
14 15
2-Bromo-5-hydroxybenzaldehyde 14 (1.0 g, 5 mmol. 1.0 equiv), phenethyl bromide (2.76g, 15 mmol, 3.0 equiv), and potassium carbonate (2.75g, 20 mmol, 4.0 equiv) were suspended in dimethylformamide (15 ml) and heated at 80 0C for 14 h. The mixture was cooled and split between water (150 ml) and ethyl acetate (150 ml), and the organic layer was washed with brine and dried over sodium sulfate. The oil from concentration in vacuo was purified by flash silica gel chromatography (l->30% ethyl acetate / hexanes) to give phenethyl ether 15 as a clear oil (550 mg). Part B
Figure imgf000171_0002
15 16 17
Bromobenzaldehyde 15 (3.0 g, 9.83 mmol, 1.0 equiv) dissolved in 2:1 tetrahydrofuran /water (75 ml) was treated with 2-methyl-2-butene (6.9 g, 98 mmol, 10 equiv), sodium phosphate monobasic, dihydrate, (4.6 g, 29.5 mmol, 3.0 equiv), and sodium chlorite (2.1 g, 24 mmol, 2.4 equiv). The mixture was stirred at 23 0C for 6h and was then split between ethyl acetate (200 ml) and IN aqueous HCl (100 ml). The organic layer was washed with brine (100 ml) and concentrated in vacuo. The resulting oil was purified by flash silica gel chromatography (1-^30% ethyl acetate / hexanes) to give the carboxylic acid 16 (56% yield).
The acid 16 was converted to the oxadiazole-arylboronic acid 17 by Method 8 followed by Method 1. [M-H]" = 351.1 m/z. Activity: A Example 13
Figure imgf000172_0001
Oxadiazole 18 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-5-phenethoxybenzoic acid 16 and furoic hydrazide using Method 7 followed by lithiation using Method 1. [M-H]" = 375.1 m/z. Activity: A
Figure imgf000172_0002
Oxadiazole 19 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-5-phenethoxybenzoic acid 16 and acetic hydrazide using Method 7 followed by lithiation using Method 1. [M-H]" = 323.1 m/z. Activity: A
Example 15
Figure imgf000172_0003
20
Oxadiazole 20 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 4,4,5,5,5-pentafluoropentanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 335.1 m/z. Activity: A Example 16
Figure imgf000173_0001
Oxadiazole 21 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and nicotinic hydrazide using Method 8 followed by Method 6. [M-H]" = 266.1 m/z. Activity: A
Example 17
Figure imgf000173_0002
Oxadiazole 22 was prepared in 2 steps by first forming the oxadiazole from 4-fluoro-2- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and butyric hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture followed by purification using flash silica gel chromatography. [M-H]" = 249.1 m/z. Activity: D
Example 18
Figure imgf000173_0003
Oxadiazole 23 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and (2-methyl-thiazol-4-yl)acetic acid hydrazide using Method 8 followed by Method 6. [M-H]" = 300.1 m/z. Activity: B
Figure imgf000173_0004
Oxadiazole 24 was prepared in 2 steps from the corresponding aryl bromide using Method 3 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 231.1 m/z. Activity: A
Figure imgf000174_0001
Oxadiazole 25 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 2-hexenoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 257.1 m/z. Activity: A Example 21
Figure imgf000174_0002
Oxadiazole 26 was prepared in 2 steps by first forming the oxadiazole from 3-fluoro-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and hexanoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 279.1 m/z. Activity: A
Example 22
Figure imgf000174_0003
Oxadiazole 27 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)thiophene-2-carboxylic acid and hexanoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 265.1 m/z. Activity: A Example 23
Figure imgf000175_0001
Oxadiazole 28 was prepared in 2 steps by first forming the oxadiazole from (E)-3-(2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)acrylic acid and acetic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 229.1 m/z. Activity: C
Example 24
Figure imgf000175_0002
Oxadiazole 29 was prepared in 2 steps by first forming the oxadiazole from 3-chloro-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and hexanoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 293.1 m/z. Activity: A
Example 25
Figure imgf000175_0003
Oxadiazole 30 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and hexanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 259.1 m/z. Activity: A
Figure imgf000176_0001
Oxadiazole 31 was prepared in 2 steps by first forming the oxadiazole from 2-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture followed by purification using flash silica gel chromatography. [M-H]" = 265.1 m/z. Activity: D
Example 27
Figure imgf000176_0002
Oxadiazole 32 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 4-methylhexanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 273.1 m/z. Activity: A
Example 28
Figure imgf000176_0003
Oxadiazole 33 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 3-cyclopentylpropionic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 285.1 m/z. Activity: A Example 29
Figure imgf000177_0001
34
Oxadiazole 34 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 2-methylhexanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 273.1 m/z. Activity: A
Example 30
Figure imgf000177_0002
35
Oxadiazole 35 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and cyclopentylacetic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 271.1 m/z. Activity: A
Example 31
Figure imgf000177_0003
Oxadiazole 36 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 3-cyclohexylpropionic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 299.1 m/z. Activity: A
Example 32
Figure imgf000177_0004
37 Oxadiazole 37 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and heptanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 273.1 m/z. Activity: A
Example 33
Figure imgf000178_0001
38
Oxadiazole 38 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 5-methylhexanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 273.1 m/z. Activity: A
Example 34
Figure imgf000178_0002
39
Oxadiazole 39 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and butyric hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 231.1 m/z. Activity: A
Figure imgf000178_0003
40
Oxadiazole 40 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 5,5,5-trifluoropentanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 299.1 m/z. Activity: A Example 36
Figure imgf000179_0001
Oxadiazole 41 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 5-fluoronicotinic acid using Method 7 followed by Method 6. [M-H]" = 284.1 m/z. Activity: B
Example 37
Figure imgf000179_0002
Oxadiazole 42 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and valeric hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 245.1 m/z. Activity: A
Example 38
Figure imgf000179_0003
43
Oxadiazole 43 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 1 ,4-benzodioxan-5-carboxylic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 323.1 m/z. Activity: A Example 39
Figure imgf000180_0001
44
Oxadiazole 44 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 2,3-dimethoxybenzoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 325.1 m/z. Activity: A
Example 40
Figure imgf000180_0002
Oxadiazole 45 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and piperonylic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 309.0 m/z. Activity: A
Example 41
Figure imgf000180_0003
Oxadiazole 46 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzohydrazide and 2,3-dihydro-l-benzofuran-7- carboxylic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 307.1 m/z. Activity: A Example 42
Figure imgf000181_0001
Oxadiazole 47 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 3-trifluoromethylbenzoic acid using Method 7 followed by Method 6. [M-H]" = 333.0 m/z. Activity: A
Example 43
Figure imgf000181_0002
Thiadiazole 48 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 3-trifluoromethylbenzoic acid using Method 9 followed by Method 6. [M-H]" = 349.1 m/z. Activity: A
Example 44
Figure imgf000181_0003
Thiadiazole 49 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and nicotinic hydrazide using Method 9 followed by Method 6. [M-H]" = 282.1 m/z. Activity: A
Example 45
Figure imgf000181_0004
Thiadiazole 50 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and 3-trifluoromethylbenzoic acid using Method 9 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 325.1 m/z. Activity: A Example 46
Figure imgf000182_0001
Oxadiazole 51 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzohydrazide and 1 -methyl- lH-indole-4-carboxylic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 318.1 m/z. Activity: A
Example 47
Figure imgf000182_0002
Oxadiazole 52 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzohydrazide and 2,2-difluoro-l ,3-benzodioxole-4- carboxylic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 345.1 m/z. Activity: A
Example 48
Figure imgf000182_0003
53
Oxadiazole 53 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and l,3-benzodioxole-4-carboxylic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 309.1 m/z. Activity: A Example 49
Figure imgf000183_0001
54
Oxadiazole 54 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and 1 -methyl- lH-imidazole-5- carbohydrazide using Method 8 followed by Method 6. [M-H]" = 269.1 m/z. Activity: B
Example 50
Figure imgf000183_0002
Oxadiazole 55 was prepared in 2 steps by first forming the oxadiazole from 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)thiophene-2-carboxylic acid and phenylacetic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 285.1 m/z. Activity: B
Example 51
Figure imgf000183_0003
Oxadiazole 56 was prepared in 2 steps by first forming the oxadiazole from 5-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)thiophene-2-carboxylic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 271.1 m/z. Activity: B Example 52
Figure imgf000184_0001
Oxadiazole 57 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and 3-phenylpropionic acid hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 293.1 m/z. Activity: A
Example 53
H
Figure imgf000184_0002
Oxadiazole 58 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)thiophene-2-carboxylic acid and 3- phenylpropionic acid hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 299.1 m/z. Activity: A
Example 54
Figure imgf000184_0003
Oxadiazole 59 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and 2-(3-thienyl)ethanohydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 285.1 m/z. Activity: A
Figure imgf000185_0001
60
Oxadiazole 60 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetra-methyl-l,3,2-dioxaborolan-2-yl)thiophene-2-carboxylic acid and phenylacetic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 285.1 m/z. Activity: A
Example 56
Figure imgf000185_0002
Oxadiazole 61 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetra-methyl-l,3,2-dioxaborolan-2-yl)thiophene-2-carboxylic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 271.1 m/z. Activity: B
Figure imgf000185_0003
Thiadiazole 62 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetra-methyl-l,3,2-dioxaborolan-2-yl)benzohydrazide and benzoic acid using Method 9 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H] = 281.1 m/z. Activity: A
Example 58
Figure imgf000186_0001
63
Oxadiazole 63 was prepared in 2 steps by first forming the oxadiazole from 3-(4,4,5,5- tetra-methyl-l,3,2-dioxaborolan-2-yl)benzoic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 265.1 m/z. Activity: C
Example 59
Figure imgf000186_0002
Oxadiazole 64 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolane)phenylacetic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 279.1 m/z. Activity: B
Example 60
Figure imgf000186_0003
Oxadiazole 65 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and 2-picolinyl hydrazide using Method 8 followed by Method 6. [M-H]" = 266.1 m/z. Activity: B Example 61
Figure imgf000187_0001
Oxadiazole 66 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and 3-methoxybenzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 295.1 m/z. Activity: A
Example 62
Figure imgf000187_0002
Oxadiazole 67 was prepared in 2 steps by first forming the oxadiazole from 2-fluoro-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 283.1 m/z. Activity: B
Example 63
Figure imgf000187_0003
Oxadiazole 68 was prepared in 2 steps by first forming the oxadiazole from 2-chloro-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. ESI-MS [M+H]+ = 301.2 m/z. Activity: A Example 64
Figure imgf000188_0001
Oxadiazole 69 was prepared in 2 steps by first forming the oxadiazole from 3-fluoro-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and phenylacetic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 297.1 m/z. Activity: B
Figure imgf000188_0002
Oxadiazole 70 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and phenylacetic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 279.0 m/z. Activity: A
Example 66
Figure imgf000188_0003
Oxadiazole 71 was prepared in 2 steps by from the corresponding aryl bromide using Method 1 followed by Method 6. [M-H]" = 265.1 m/z. Activity: A Example 67
Figure imgf000189_0001
72
Oxadiazole 72 was prepared in 2 steps by first forming the oxadiazole from 2-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)thiophene-3-carboxylic acid and butyric hydrazide using Method 8 followed by Method 5. [M-H]" = 237.1 m/z. Activity: D
Figure imgf000189_0002
73
Oxadiazole 73 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and 2-hydroxyisobutryic hydrazide using Method 8 followed by Method 5. [M-H]" = 247.1 m/z. Activity: B
Example 69
Figure imgf000189_0003
74
Oxadiazole 74 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic hydrazide and ethoxyacetic acid using Method 7 followed by Method 5. [M-H]" = 247.1 m/z. Activity: B
Example 70
Figure imgf000189_0004
Oxadiazole 75 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic hydrazide and methoxyacetic acid using Method 7 followed by Method 5. [M-H]" = 233.1 m/z. Activity: A
Example 71
Figure imgf000190_0001
76
Oxadiazole 76 was prepared in 2 steps by first forming the bis-oxadiazole from bromobenzene-2,4-dicarboxylic acid and butryic hydrazide using Method 8 followed by Method 1. [M-H]" = 341.1 m/z. Activity: A
Example 72
Figure imgf000190_0002
Oxadiazole 77 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and pivaloic hydrazide using Method 8 followed by Method 5. [M-H]" = 245.1 m/z. Activity: A
Figure imgf000190_0003
Oxadiazole 78 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic hydrazide and 5-hexenoic acid using Method 7 followed by Method 5. [M-H]" = 257.1 m/z. Activity: A Example 74
Figure imgf000191_0001
Oxadiazole 79 was prepared in 2 steps by first forming the oxadiazole from 3-fluoro— 4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and benzoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 283.1 m/z. Activity: B
Example 75
Figure imgf000191_0002
80
Oxadiazole 80 was prepared in 2 steps by first forming the oxadiazole from 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and furoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 255.0 m/z. Activity: A
Example 76
Figure imgf000191_0003
81 In a microwave reactor tube, 4-chloro-2-(trifluoromethyl)benzoic acid (300 mg, 1.34 mmol) and benzoic hydrazide (182 mg, 1.34 mmol) were dissolved in dry acetonitrile (6 mL). Polystyrene-supported triphenylphosphine (3.0 equiv, 1.80 g, 2.23 mmol/g loading) and trichloroacetonitrile (270 uL, 2.68 mmol) were added, and the mixture was sealed and heated in a microwave reactor at 130 0C for 2 hours. The reaction was then filtered and the resin was washed with excess tetrahydrofuran and methylene chloride. The filtrate was concentrated onto silica gel and purified by column chromatography using a gradient of 25-50% ethyl acetate/hexanes to provide the 300 mg of the desired oxadiazole in 70% yield. 2-(4-Chloro-2-(trifluoromethyl)phenyl)-5-phenyl-l,3,4-oxadiazole (296 mg, 0.921 mmol) was dissolved in 6 niL anhydrous tetrahydrofuran in a microwave reaction tube. Bis(pinacolato)diboron (278 mg, 1.09 mmol) was added followed by potassium acetate (206 mg, 2.10 mmol), palladium(II) acetate (12 mg, 0.055 mmol) and l,3-bis(2,6-di- isopropylphenyl)imidazolium chloride (46 mg, 0.11 mmol). The reaction was heated in a microwave reactor was heated to 110 0C for 20 min. A slurry of palladium(II) acetate and the imidazolum catalyst in 1 mL tetrahydrofuran was then added and the reaction was reheated under the same conditions. This was repeated a third time after which point the reaction was filtered through a plug of slica gel using 1 : 1 ethyl acetate/hexanes (v/v) as eluent. The filtrate was then concentrated onto silica gel and purified by column chromatography using a gradient of 25-50% ethyl acetate/hexanes to provide the 300 mg of the desired oxadiazole in 79% yield.
The resulting pinacol ester (2-phenyl-5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-2-(trifluoromethyl)phenyl)-l,3,4-oxadiazole) was then converted to boronic acid 81 using Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 333.1 m/z. Activity: C
Example 77
Figure imgf000192_0001
82
4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)benzohydrazide (300 mg, 1.15 mmol) and JV-Boc-β-alanine (227 mg, 1.20 mmol) were dissolved in 10 mL anhydrous dichloromethane. HOBt (187 mg, 1.37 mmol) and EDC (263 mg, 1.37 mmol) were added followed by triethylamine (480 uL, 3.43 mmol). The reaction was allowed to stir for 12h at room temperature after which point it was transferred to a separatory funnel with excess dichloromethane and washed with 0.5 M citric acid (2 x 75 mL) and saturated NaHCO3 (2 x 75 mL). The organic layer was then dried over MgSO4, filtered and concentrated to provide the desired diacyl hydrazone as a while foamy solid in 93% yield (461 mg) which was used directly to form the oxadiazole in the following step.
The diacyl hydrazone (461 mg, 1.06 mmol) was dissolved in anhydrous tetrahydrofuran. Burgess' reagent (355 mg, 1.60 mmol) was added and the reaction was heated to 60 0C in a sealed tube for 2Oh. After this point, the reaction was allowed to cool and transferred to a separatory funnel with excess saturated NaHCO3 (50 mL) and ethyl acetate (50 rnL). The organic layer is washed with saturated NaCl (50 mL), dried over MgSO4, and concentrated under vacuum to provide a crude oil that is purified using silica gel chromatography with a gradient of 20-70% ethyl/hexanes to provide the 187 mg of the desired oxadiazole in 43% yield.
The resulting pinacol ester (tert-butyi 2-(5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)phenyl)-l,3,4-oxadiazol-2-yl)ethylcarbamate) was then converted to boronic acid 82 using Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 332.1 m/z. Activity: B
Figure imgf000193_0001
83
Carbamate 83 was prepared using the analogous procedure as Example 77 except that N-
Boc glycine was used in place of JV-Boc-β-alanine. [M-H]" = 318.1 m/z. Activity: B
Figure imgf000193_0002
84
Carbamate 82 (20 mg, 0.060 mmol) was dissolved in 5 mL methylene chloride. Excess trifluoroacetic acid (5 mL) was added and the reaction was allowed to stir at room temperature for 10 min. The reaction was then diluted with toluene (40 mL) and azeotroped under vacuum to remove the excess acid. This was repeated 2 times and the resultant solid was dried under vacuum overnight to provide the desired amine 84 in quantitative yield (14 mg). [M-H]" = 232.1 m/z. Activity: D
Figure imgf000193_0003
85 Amine 84 (17 mg, 0.050 mmol) was suspended in 5 mL methylene chloride. Acetic anhydride (49 μL, 0.49 mmol) was added followed by NaHCO3 (29 mg, 0.25 mmol) and allowed to stir at room temperature for 10 min. An additional 49 uL of acetic anhydride and 29 mg of NaHCO3 were then added and the reaction was allowed to stir for an additional hour at which point the reaction was determined to be complete by LC/MS. Methanol (1 mL) was added and the mixture was allowed to stir at room temperature for 20 min. The reaction mixture was then filtered and concentrated to provide 6 mg of amide 85 in 45% yield. [M-H]" = 274.1 m/z. Activity: C
Example 81
Figure imgf000194_0001
86
Tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl)-l ,3,4- oxadiazol-2-yl)ethylcarbamate (187 mg, 0.450 mmol) was dissolved in 10 mL 2N HCl in dioxane and allowed to stir at room temperature for 2h. After this point the solvent was removed under vacuum to provide the desired free amine in quantitative yield as the HCl salt. A portion of this free amine (63 mg, 0.18 mmol) was dissolved in 3 mL anhydrous THF. Methyl chloroformate (18 μL, 0.23 mmol) was added followed by diisopropylethylamine (83 μL, 0.47 mmol) and the reaction was allowed to stir at room temperature for 2h at which point there is no more starting material visible by LC/MS. Water (30 mL) was added and the mixture is acidified to pH <4 with 0.5 M citric acid. The solid that remains was collected via vacuum filtration and washed with excess water to provide the desired pinacol ester in 12% yield (8.0 mg).
The resulting pinacol ester (methyl 2-(5-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl)-l,3,4-oxadiazol-2-yl)ethylcarbamate) was then converted to amide 86 using Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 290.1 m/z. Activity: B
Example 82
Figure imgf000194_0002
Benzothiazole 87 was prepared in two steps from the corresponding aryl bromide using Method 3 followed by Method 5 and purified using flash silica gel chromatography. [M-H]" = 254.1 m/z. Activity: D
Example 83
Figure imgf000195_0001
88
Benzothiazole 88 was prepared in two steps from the corresponding aryl bromide using Method 3 followed by Method 5 and purified using flash silica gel chromatography. [M-H]" = 192.0 m/z. Activity: C
Example 84
Figure imgf000195_0002
89
Thiazole 89 was prepared in two steps from the corresponding aryl bromide using
Method 3 followed by Method 5 and purified using flash silica gel chromatography. [M-H]" = 218.1 m/z. Activity D
Example 85
Figure imgf000195_0003
90
Oxazole 90 was prepared in two steps from the corresponding aryl bromide using Method
3 followed by Method 5 and purified using flash silica gel chromatography. [M-H]" = 188.1 m/z. Activity: B
Example 86
Figure imgf000195_0004
Figure imgf000196_0001
Pyrazole 92 was prepared in 5 steps from 3-(4-bromophenyl)-l-phenylpyrazole-4- propionic acid (1.00 g, 2,69 mmol) starting with the methylation of the free acid using trimethylsilyl-diazomethane (4.0 equiv in hexanes) in 1 :1 toluene/methanol (0.05 M) for Ih after which point the reaction was concentrated and dried under vacuum. The crude mixture was then redissolved in THF (0.15 M) and cooled to 0 0C in an ice bath under N2. DIBAL (3.5 equiv, 1.0 M in toluene) was added drop wise and the reaction was allowed to warm to room temperature and allowed to stir for 2h. The reaction was then quenched methanol (20 mL) followed by the addition of a saturated solution of Rochelle's salt (100 mL) After Ih, the reaction was transferred to a separatory funnel with excess ethyl acetate and water after which the water layer was washed with ethyl acetate (2 x 75 mL). The organic layers were combined and washed with brine (2 x 75 mL), dried over MgSO4, and concentrated to provide the desired product as a crude oil in quantitative yield. The crude alcohol (340 mg, 0.95 mmol) was then redissolved in anhydrous N, N- dimethylforamide (0.20 M) and cooled to 0 0C in an ice bath. Sodium hydride (3.0 equiv) was added portion wise and allowed to stir for 10 min after which point iodomethane (2.0 equiv) was added and the reaction was allowed to stir for 2h at room temperature. The reaction was then quenched with saturated NH4Cl and was transferred to a separatory funnel with excess ethyl acetate and water after which the water layer was washed with ethyl acetate (2 x 75 mL). The organic layers were combined and washed with brine (2 x 75 mL), dried over MgSO4, and concentrated to provide the desired ether as a crude oil in quantitative yield.
The resulting methyl ether was then converted to the desired pyrazole 92 using Method 3 followed by Method 5 and purified using flash silica gel chromatography. [M-H]" = 335.1 m/z. Activity: D Example 87
Figure imgf000197_0001
95
Part A
Figure imgf000197_0002
93 94
At 0 0C, aldehyde 93 (15) (1.8 mmol, 1.0 equiv) was dissolved in 1 :1 tetrahydrofuran/methanol (14 ml) and treated with sodium borohydride (136 mg, 3.6 mmol, 2.0 equiv). After stirring for 2h, the mixture was diluted with water (100 ml) and extracted with ethyl acetate (100 ml). The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The resulting oil was purified by flash silica gel chromatography (5-^30% ethyl acetate / hexanes) to give a colorless oil (500 mg). Part B
Figure imgf000197_0003
94 95
Benzylic alcohol 94 (185 mg, 0.6 mmol, 1.0 equiv) and iodomethane (128 mg, 0.9 mmol, 1.5 equiv) were dissolved in dimethylformamide (3 ml) and, at 0 0C, were treated with sodium hydride (36 mg, 0.9 mmol, 1.5 equiv of a 60% dispersion in mineral oil). The mixture was stirred for 2 h and then quenched by addition of saturated aqueous ammonium chloride (1 ml). The mixture was split between water (100 ml) and extracted with ethyl acetate (100 ml). The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. Purification by flash silica gel chromatography (l->5% ethyl acetate / hexanes) to give a colorless oil (143 mg). The resulting aryl bromide was converted to the boronic acid 95 by Method 1. [M-H] = 285.1 m/z. Activity: B
Example 88
Figure imgf000198_0001
96
Benzyl alcohol 96 was prepared by reduction of the benzaldehyde-boronic acid as described for 94 and purified by flash silica gel chromatography (l->5% methanol / dichloromethane). [M-H]" = 257.1 m/z. Activity: D
Example 89
Figure imgf000198_0002
The benzyl ether 97 was made according to the procedures described for 95. [M-H] =
361.2 m/z. Activity: D
Example 90
Figure imgf000198_0003
93 98 The bromobenzaldehyde 93 (15) (500 mg, 1.6 mmol, 1.0 equiv) and ethylene glycol (712 mg, 11.5 mmol, 7.0 equiv) with toluenesulfonic acid (9 mg, 3 mol%) were dissolved in toluene (35 ml) and heated at reflux 24 h with azeotropic removal of water with a Dean-Stark apparatus. After cooling, the mixture was split between 5% aqueous sodium bicarbonate (100 ml), and the organic layer was then washed with water (100 ml) and then brine (50 ml), dried over sodium sulfate, and concentrated in vacuo. The resultant clear oil was purified by flash silica gel chromatography (l->5% ethyl acetate / hexanes) to give a colorless oil (534 mg).
This pure acetal was then converted to the boronic acid 98 by Method 1. It was important to stir the mixture after the quench with 2N aqueous HCl for 1 h to ensure full hydrolysis of the acetal. [M-H]" = 269.1 m/z. Activity: A
Example 91
H
Figure imgf000199_0001
98 100
Benzaldehyde-boronic acid 98 (500 mg, 1.85 mmol, 1 equiv) and pinacol (263 mg, 2.2 mmol, 1.2 equiv) were heated at reflux in benzene (12 ml) for 5 h, with azeotropic removal of water using a Dean-Stark apparatus. The solution was concentrated and purification by flash silica gel chromatography (l-> 10% ethyl acetate / hexanes) gave pinacol ester (436 mg).
The product ester and methyl (triphenylphosphoranylidene)acetate (540 mg, 1.6 mmol, 1.3 equiv) were heated at 90 0C in dry toluene for 18h. The mixture was cooled and split split between water (150 ml) and ethyl acetate (150 ml), and the organic layer was washed with brine and dried over sodium sulfate. The oil from concentration in vacuo was purified by flash silica gel chromatography (l->30% ethyl acetate / hexanes) to give a clear oil (70% yield). The pinacol ester was cleaved by Method 5 to produce boronic acid 100. [M-H]" = 325.1 m/z. Activity: A
Figure imgf000200_0001
101
The thienyl-unsaturated ester boronic acid 101 was prepared by condition similar to those for compound 100. [M-H]" = 211.0 m/z. Activity: C
Example 93
Figure imgf000200_0002
93 102 Bromobenzaldehyde 93 (15) (420 mg, 1.4 mmol, 1.0 equiv) and methyl (triphenylphos- phoranylidene)acetate (690 mg, 2.1 mmol, 1.5 equiv) were heated at 90 0C in dry toluene for 18h. The mixture was cooled and split split between water (150 ml) and ethyl acetate (150 ml), and the organic layer was washed with brine and dried over sodium sulfate. The oil from concentration in vacuo was purified by flash silica gel chromatography (l-> 10% ethyl acetate / hexanes) to give a clear oil (55% yield).
The unsaturated ester (276 mg, 0.764, 1.0 equiv) in dry methanol (10 ml) was stirred under nitrogen atmosphere with magnesium turnings (279 mg, 11.5 mmol, 15 equiv) for 6 h at 23 0C. The mixture was filtered, diluted with ethyl acetate (100 ml) and then washed with IN aqueous HCl (100 ml) and brine (100 ml). The residue from concentration in vacuo was purified by flash silica gel chromatography (l-> 10% ethyl acetate / hexanes) to give the saturated ester (70% yield). The resulting aryl bromide was converted to the boronic acid pinacol ester 102 by Method 3 and the resultant pinacol ester cleaved by method 5. [M-H]" = 327.1 m/z. Activity: B
Example 94
Figure imgf000201_0001
103
The pinacol ester of compound 100 (442 mg, 1.1 mmol, 1.0 equiv) was dissolved in 3:1 tetrahydrofuran/water (8 ml) and stirred with lithium hydroxide (78 mg, 3.25 mmol, 3.0 equiv) at 50 0C for 3 h. The mixture was diluted with ethyl acetate (50 ml), washed with IN aqueous HCl (50 ml) and then brine (25 ml) and concentrated in vacuo. Purification by flash silica gel chromatography (l->20% ethyl acetate / hexanes) gave product (60% yield) which was used directly in the next step. Carboxylic acid (133 mg, 0.34 mmol, 1.0 equiv) was dissolved in dry dichloromethane (5 ml) and treated with EDC-HCl (78 mg, 0.41 mmol, 1.2 equiv), HOBt (55 mg, 0.41 mmol, 1.2 equiv), 1Pr2EtN (130 mg, 1.02 mmol, 3.0 equiv), dimethylamine (0.4 ml of a 2 M solution in tetrahydrofuran, 0.56 mmol, 2.2 equiv), and DMAP (2 mg, 0.02 mmol, 0.05 equiv). The mixture was stirred at 23 0C for 16 h and then split between 5% aqueous sodium bicarbonate and ethyl acetate (100 ml each). The organic layer was washed with brine (50 ml) and concentrated in vacuo. Purification by flash silica gel chromatography (l-> 10% methanol / dichloromethane) gave the desired amide (84% yield) which was cleaved by Method 5 to produce the arylboronic acid 103. [M-H]" = 338.2 m/z. Activity: B
Example 95
Figure imgf000202_0001
98 104
Benzaldehydeboronic acid 98 (240 mg, 0.89 mmol, 1.0 equiv) was suspended in water (10 ml) with hydroxylamine hydrochloride (195 mg, 2.80 mmol, 3.0 equiv) and sodium acetate (230 mg, 2.80 mmol, 3.0 equiv). The mixture was heated at 60 0C for 16 h and then cooled to room temperature. Addition of IN HCl to achieve pH 1 produced (104) as a white precipitate that was collected and washed with water (64% yield). [M-H]" = 266.1 m/z. Activity: B
Example 96
Figure imgf000202_0002
4-(Benzyloxy)-2-formylphenylboronic acid (72 mg, 0.28 mmol) was suspended in water (10 mL) followed by the addition of hydroxylamine hydrochloride (62 mg, 0.89 mmol). The pH was adjusted to 4 with IN NaOH and the reaction was heated to 60 0C for 16h after which point LC/MS analysis showed only the desired product. Additional water is added (50 mL) and the pH is adjusted to <2 with 6N HCl. The resultant solid is isolated using vacuum filtration, washed with excess water and dried under vacuum to provide 55 mg of benzoazaborine 105 in 77% yield. [M-H]" = 252.1 m/z. Activity: B Example 97
H
Figure imgf000203_0001
4-(Benzyloxy)-2-formylphenylboronic acid (100 mg, 0.391 mmol) was dissolved in 20 niL water/ethanol (1 :1 v/v) followed by the addition of JV-benzylhydroxylamine hydrochloride (62 mg, 0.391 mmol). The reaction was basified to pH = 7 with IN NaOH and stirred at room temperature for 6h after which point there was no more starting material remaining by LC/MS analysis. The ethanol was removed under a stream of N2 and 100 mL IN HCl was added. The white solid that precipitated was collected using vacuum filtration, washed with excess water and dried under vacuum to provide 55 mg of nitrone 106 in 39% yield. [M-H]" = 360.2 m/z. Activity: C
Example 98
Figure imgf000203_0002
107
2-Formyl-4-phenethoxyphenylboronic acid (111 mg, 0.411 mmol) and 2-hydroxy ethyl hydrazine (33 mL, 0.43 mmol) are dissolved in 10 mL ethanol and heated to 50 0C for 12h. The reaction is allowed to cool and the solvent is removed under a stream of N2 until there is only 2 mL of ethanol left. IN HCl (50 mL) is then added until a solid crashes out which is isolated using vacuum filtration and washed with excess water. The resultant solid is dried under vacuum overnight to provide 10 mg of benzodiazoborine 107 in 8% yield. [M-H]" = 309.1 m/z. Activity: D Example 99
Figure imgf000204_0001
Benzodiazoborine 108 was prepared using the analogous procedure as example 98 except that JV-methyhydrazine was used in place of 2-hydroxyethyl hydrazine. [M-H]" = 279.1 m/z. Activity: D
Example 100
Figure imgf000204_0002
Benzodiazoborine 109 was prepared using the analogous procedure as example 98 except that JV-benzylhydrazine was used in place of 2-hydroxyethyl hydrazine. [M-H]" = 341.2 m/z. Activity: B
Example 101
H
Figure imgf000204_0003
4-(Benzyloxy)-2-formylphenylboronic acid (78 mg, 0.31 mmol) is dissolved in 5 mL methylene chloride. ΛMVlethyl-/V-benzylamine (41 μL, 0.32 mmol) is added and the mixture is allowed to stir at room temperature for 20 min. Sodium triacetoxyborohydride (68 mg, 0.32 mmol) is then added and the reaction is allowed to stir at room temperature for 30 min after which point there is no starting material visible by LC/MS. The solvent is evaporated under a stream of N2. The resultant solid is resuspended in a solution of 2% acetic acid in water (50 mL). The solid that forms is isolated using vacuum filtration, washed with excess water, and dried under vacuum to provide 93 mg of amine 110 in 85% yield. [M-H] = 360.2 m/z. Activity: C
Example 102
H
Figure imgf000205_0001
Amine 111 was prepared using the analogous procedure as example 101 except that benzylamine was used in place of Λf-methyl-JV-benzylamine. [M-H]" = 364.2 m/z. Activity: C.
Example 103
Figure imgf000205_0002
112
(E)-3-(2-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)acrylic acid (80 mg, 0.29 mmol) was dissolved in 10 mL anhydrous dichloromethane and benzylamine (33 μL, 0.31 mmol) was added. HOBt (47 mg, 0.35 mmol) and EDC (67 mg, 0.35 mmol) were then added followed by triethylamine (59 uL, 58 mmol). The reaction was allowed to stir for 12h at room temperature after which point it was transferred to a separatory funnel with excess dichloromethane and washed with 0.5 M citric acid (2 x 75 mL) and saturated NaHCO3 (2 x 75 mL). The organic layer was then dried over MgSO4, filtered and concentrated to provide the desired ketoamide as a white solid in 94% yield (100 mg) which was used directly in the following step.
The resulting pinacol ester ((£)-N-benzyl-3-(2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)acrylamide) was then converted to amide 112 using Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 280.1 m/z. Activity: C Example 104 oc
Figure imgf000206_0001
1 13
Amide 113 was prepared using the analogous procedure as example 103 except that N- Boc-m-phenylenediamine was used in place of benzylamine. [M-H]" = 381.2 m/z. Activity: D
Figure imgf000206_0002
Amide 114 was prepared using the analogous procedure as example 103 except that N- methyl-JV-benzylamine was used in place of benzylamine. [M-H]" = 294.1 m/z. Activity: C
Example 106
Figure imgf000206_0003
4-(Benzyloxy)-2-formylphenylboronic acid (100 mg, 0.39 mmol) and O- benzylhydroxylamine hydrochloride (62 mg, 0.39 mmol) were dissolved in 5 mL ethanol. The reaction was allowed to stir at room temperature for 14h. The reaction was then added to IN HCl (75 mL) and a solid crashed out which was collected via vacuum filtration and washed with excess water to provide 92 mg of the benzyloxyimine 115 after drying under vacuum overnight. [M-H]" = 360.1 m/z. Activity: B Example 107
Figure imgf000207_0001
1 16
2-Formylphenylboronic acid (150 mg, 1.0 mmol) and 3-phenylpropionic hydrazide (164 mg, 1.0 mmol) were dissolved in 5 mL ethanol. The reaction was heated to 50 0C for 14h after which point there was more starting material by LC/MS analysis. The reaction was allowed to cool after which point 100 mL IN HCl was added to the reaction and the solid which crashes out is collected by vacuum filtration and washed with excess water. The solid is dried under vacuum overnight to provide 200 mg of acyl hydrazone 116 as a white solid in 68% yield. [M-H]" = 295.1 m/z. Activity: D
Example 108
Figure imgf000207_0002
Acyl hydrazone 117 was prepared using the analogous procedure as example 107 except that N-Boc glycine hydrazide was used in place of 3-phenylpropionic hydrazide and 2-formyl- 4-benzyloxyphenylboronic acid was used in place of 2-formylphenylboronic acid. [M-H]" = 426.1 m/z. Activity: B
Example 109
Figure imgf000207_0003
Acyl hydrazone 117 (58 mg, 0.14 mmol) is suspended in 10 mL ethyl acetate saturated with HCl. The reaction is allowed to stir for 30 min. The solvent is then removed under a stream of N2 over the course of 1.5h. The resulting oil is triturated with tert-butyi methylether until a solid forms, which is filtered and washed with excess tert-butyi methylether to provide 35 mg of acyl hydrazone 118 as the hydrochloride salt in 70% yield. [M-H]" = 326.1 m/z. Activity: D
Example 110
Figure imgf000208_0001
Acyl hydrazone 119 was prepared using the analogous procedure as example 107 except that 3-maleimidopropionic hydrazide was used in place of 3-phenylpropionic hydrazide and 2- formyl-4-phenethoxyphenylboronic acid was used in place of 2-formylphenylboronic acid. [M- H]" = 434.1 m/z. Activity: A
Example 111
Figure imgf000208_0002
Acyl hydrazone 120 was prepared using the analogous procedure as example 107 except that acetic hydrazide was used in place of 3-phenylpropionic hydrazide and 2-formyl-4- benzyloxyphenylboronic acid was used in place of 2-formylphenylboronic acid. [M-H]" = 325.1 m/z. Activity: A Example 112
Figure imgf000209_0001
Acyl hydrazone 121 was prepared using the analogous procedure as example 107 except that pheylacetic hydrazide was used in place of 3-phenylpropionic hydrazide. [M-H]" = 281.1 m/z. Activity: D
Example 113
Figure imgf000209_0002
Acyl hydrazone 122 was prepared using the analogous procedure as example 107 except that indole-3-acetic acid hydrazide was used in place of 3-phenylpropionic hydrazide. [M-H]" = 320.1 m/z. Activity: D
Example 114
Figure imgf000209_0003
Acyl hydrazone 123 was prepared using the analogous procedure as example 107 except that (2-methyl-thiazol-4-yl)acetic acid hydrazide was used in place of 3-phenylpropionic hydrazide. [M-H]" = 302.1 m/z. Activity: D Example 115
Figure imgf000210_0001
Acyl hydrazone 124 was prepared using the analogous procedure as example 107 except that pheylacetic hydrazide was used in place of 3-phenylpropionic hydrazide and 2-formyl— 4- benzyloxyphenylboronic acid was used in place of 2-formylphenylboronic acid. [M-H]" = 387.2 m/z. Activity: B
Example 116
Figure imgf000210_0002
Acyl hydrazone 125 was prepared using the analogous procedure as example 107 except 2-picolinyl hydrazide was used in place of 3-phenylpropionic hydrazide and 2-formyl— 4- benzyloxyphenylboronic acid was used in place of 2-formylphenylboronic acid. [M-H]" = 374.1 m/z. Activity: B
Example 117
Figure imgf000210_0003
A mixture of 4-ethynylbenzeneboronic acid (42 mg, 0.289 mmol, 1.0 equiv), benzyl azide (38.5 mg, 0.289 mmol, 1.0 equiv), copper sulfate (0.5 mg, 0.003 mmol, 1 mol%), and sodium ascorbate (5 mg, 0.03 mmol, 0.1 equiv) were stirred in 2:1 te/t-butanol/water (3 ml) for 14 h at 23 0C. The mixture was split between ethyl acetate (25 ml) and water (25 ml), and the organic layer was washed with brine (20 ml) and dried over sodium sulfate. The residue upon concentration was purified by flash silica gel chromatography (l->30% methanol/dichloromethane) to give a white solid (70% yield). [2M-H2O]" = 539.1 m/z. Activity: A
Example 118
Figure imgf000211_0001
127
Compound 127 was prepared by methods described for Example 117. [M-U] = 346.1.1 m/z. Activity: C
Example 119
Figure imgf000211_0002
Compound 128 was prepared by methods described for Example 117. [M-H]" = 308.1 m/z. Activity: B
Example 120
Figure imgf000211_0003
129
Compound 129 was prepared by methods described for Example 117. [M-H]" = 292.1 m/z. Activity: A Example 121
Figure imgf000212_0001
A mixture of 4-ethynylbenzeneboronic acid (180 mg, 1.23 mmol, 1.45 equiv), phenyl azide (100 mg, 0.84 mmol, 1.0 equiv), copper powder (0.5 mg, 0.003 mmol, 1 mol%), and sodium ascorbate (16 mg, 0.08 mmol, 0.1 equiv) were stirred in 1 :1 terJ-butanol/water (6 ml) for 14 h at 23 0C. The mixture was split between ethyl acetate (25 ml) and water (25 ml), and the organic layer was washed with brine (20 ml) and dried over sodium sulfate. The residue upon concentration was purified by flash silica gel chromatography (l-> 10% methanol/dichloromethane) to give 130 as a white solid (30% yield). [M-H]" = 264.1 m/z. Activity: B
Example 122
Figure imgf000212_0002
A 6 ml DMF solution of 4-bromomethylphenylboronic acid pinacol ester (150 mg, 0.5 mmol, 1.0 equiv) was heated with sodium azide (164 mg, 2.5 mmol, 5 equiv) at 60 0C for 24 h. The mixture was diluted with water (50 ml) and extracted with ethyl acetate (50 ml). The organic layer was washed with water (50 ml), then brine (30 ml) and then dried over sodium sulfate. The clear oil produced upon concentration was then stirred with phenylacetylene (62 mg, 0.6 mmol, 1.0 equiv), copper sulfate (1 mg, 1 mol%), and sodium ascorbate (12 mg, 0.06 mmol, 0.1 equiv) in 2:1 tert-butano I/water (6 ml) for 16h at 23 0C. The mixture was diluted with water (50 ml) and extracted with ethyl acetate (50 ml). The organic layer was washed with water (50 ml), then brine (30 ml) and then dried over sodium sulfate. The residue from concentration in vacuo was purified by flash silica gel chromatography (5-^60% ethyl acetate / hexanes) to give the pinacol ester as a clear oil. This resultant pinacol ester was cleaved by Method 5. [M-H]" = 278.1 m/z. Activity: B
Example 123
Figure imgf000213_0001
134
Part A
Figure imgf000213_0002
132
A flame-dried flask equipped with a rubber septum was charged with 4-bromo-3- fluoroiodobenzene (1.0 g, 3.3 mmol, 1.0 equiv), copper(I) iodide (63 mg, 0.33 mmol. 0.1 equiv), and bis(triphenylphosphine)palladium(II) dichloride (117 mg, 0.17 mmol, 0.05 equiv). Under argon atmosphere, the solids were suspended in dry THF (8 ml), and triethylamine (1.15 ml, 8.3 mmol, 2.5 equiv) and trimethylsilylacetylene (490 mg, 5 mmol, 1.5 equiv) were added. The mixture was stirred at 23 0C for 4 h, turning from orange to black, and was then split between ethyl acetate (50 ml) and water (50 ml). The organic layer was washed with brine (25 ml) and dried over sodium sulfate. The residue from concentration in vacuo was restored in methanol (15 ml) and stirred with potassium carbonate (1.4 g, 10 mmol, 3.0 equiv) for 1 h. The mixture was split between ethyl acetate (50 ml) and water (50 ml) and the organic layer was washed with brine (25 ml) and then dried over sodium sulfate and concentrated in vacuo. Purification by flash silica gel chromatography (hexanes) gave acetylene 132 as a pale yellow solid (60% yield). Part B
Figure imgf000214_0001
4-Bromo-3-fluorophenylacetylene (132) (400 mg, 2.0 mmol, 1.0 equiv), copper powder (126 mg, 2.0 mmol, 1.0 equiv), copper sulfate (6 mg, 0.1 mmol, 0.05 equiv), and sodium ascorbate (40 mg, 0.2 mmol, 0.1 equiv) in 2:1 terJ-butanol/water (6 ml) were stirred for 16h at 23 0C. The mixture was diluted with water (50 ml) and extracted with ethyl acetate (50 ml). The organic layer was washed with water (50 ml), then brine (30 ml) and then dried over sodium sulfate. The residue from concentration in vacuo was purified by flash silica gel chromatography (5-^60% ethyl acetate / hexanes) to give the triazole 133 as a white solid (35 mg). Part C
Figure imgf000214_0002
The aryl bromide 133 was converted to arylboronic acid 134 by Method 1. [M-H] = 282.1 m/z. Activity: B
Example 124
Figure imgf000214_0003
Part A
Figure imgf000214_0004
4-Bromo-3-fluorophenylacetylene (900 mg, 4.5 mmol, 1.0 equiv) and benzyl azide (600 mg, 4.5 mmol, 1.0 equiv) were suspended in water (15 ml) and heated in a sealed tube at 120 0C for 24 h. The mixture was cooled and extracted with ethyl acetate (50 ml), and the organic layer was washed with brine and dried over sodium sulfate. The 1,5-triazole 135 (10% yield) was precipitated from 40% ethyl acetate/hexanes, and the 1,4-triazole 136 (25% yield) was isolated after purification of the mother liquor by flash silica gel chromatography (5-^60% ethyl acetate / hexanes). Part B
The 1,4 isomer 136 was converted to boronic acid 137 by Method 4 and Method 5. [M- H]" = 296.1 m/z. Activity: B
Example 125
Figure imgf000215_0001
The 1,5-triazole-arylbromide 135 was converted to the arylboronic acid 138 by Method 1. [M-H]" = 296.1 m/z. Activity: C
Example 126
Figure imgf000215_0002
141 Part A
Figure imgf000215_0003
139 140
4-Bromo-3-fluoroaniline (1.0 g, 5.26 mmol, 1.0 equiv) was dissolved in 25ml of CH3- CN and cooled to 0 0C. With stirring, tøt-BuONO (1.04 ml, 7.9 mmol, 1.5 equiv) was added portionwise over 5 minutes, followed by dropwise addition of trimethylsilylazide (0.67 g, 5.8 mmol, 1.2 equiv). The resulting pale-yellow solution was stirred at 23 0C for 1.5h. The mixture was then diluted with water (50 ml) and extracted with ethyl acetate (50 ml). The organic layer was washed with water (50 ml), then brine (30 ml) and then dried over sodium sulfate. Concentration in vacuo gave a yellow oil used without purification.
Crude azide (490 mg, 2.25 mmol, 1.0 equiv) and phenylacetylene (231 mg, 2.25 mmol, 1.0 equiv) were suspended in water (15 ml) and heated in a sealed tube at 120 0C for 24 h. The mixture was cooled and extracted with ethyl acetate (50 ml), and the organic layer was washed with brine and dried over sodium sulfate. The 1,5-triazole 140 (25% yield) was precipitated from 40% ethyl acetate/hexanes, and the 1,4-triazole 139 (45% yield) was isolated after purification of the mother liquor by flash silica gel chromatography (5-^60% ethyl acetate / hexanes). Part B
The 1 ,4-regioisomer 141 was converted to the arylboronic acid by Method 4. [M-H]" = 282.1 m/z. Activity: B
Example 127
Figure imgf000216_0001
142 The 1 ,5-triazole-arylbromide 142 was converted to the arylboronic acid by Method 1.
[M-H]" = 282.1 m/z. Activity: C
Figure imgf000216_0002
143
1,4-Triazole 143 was prepared according to the procedure described in example 126. [M-H]" = 264.1 m/z. Activity: A Example 129
Figure imgf000217_0001
144
1,5-Triazole 144 was prepared according to the procedure described in example 127. [M-H]" = 264.1 m/z. Activity: B
Example 130
Figure imgf000217_0002
Part A
Figure imgf000217_0003
145
A flask is charged with 4-bromo-3-fluorobenzylaldehyde (1.5 g, 7.5 mmol, 1.0 equiv) in MeOH-THF (3:1, 20 rnL) was added an aqueous solution of hydroxylamine (0.67 g, 1.3 equiv. in 2 rnL water) in one portion. The ph was adjusted to 9 with 6N KOH, and stirred at rt for 2 h.
After the disappearance of the aldehyde by TLC analysis, sodium cyanoborohydride (0.93 g, 2 equiv.) was added and the solution was acidified to pH 2-3 using concentrated HCl. The solution was allowed to stir over night. The solution was basified with 2N KOH to a pH of 11, extracted with DCM (3 x 50 mL), dried, concentrated in vacuo to afford a off white solid hydroxylamine 145 (1.4g). Part B
1) refluxing DCE
2) Methods 3, 5
Figure imgf000218_0002
Figure imgf000218_0001
The mixture of 145 (500 mg, 1.0 equiv.), 146 (820 mg, 3 equiv.), 147 (400 mg, 1.5 equiv.) and 1 g of 4A molecular sieves in 5mL of 1 ,2-dichloroethane was heated at reflux for 14 h. TLC analysis showed no more starting material remaining. The mixture was cooled to rt and filtered to remove sieves and wash solid with ethyl acetate. The organic mixtures were washed with brine, dried and concentrated. Purification on silica gel (0-30% ethyl acetate in hexanes) gave isoxazolidine as a yellow oil (470 mg). Conversion to the boronic acid 148 was achieved by Methods 3 and 5. [M-H]" = 372.1 m/z. Activity: B
Example 131
Figure imgf000218_0003
(8-Bromo-l-naphthyl)methanol 149 (210 mg, 1.0 equiv.), phenol 150 (130 mg, 1.3 equiv.), triphenylphosphine (465 mg, 2.0 equiv.), triethylamine (0.25 mL, 2.0 equiv.) were dissolved in 2 mL THF and cooled to 0 0C under nitrogen. Diisopropyl azodicarboxylate (0.34 mL, 2.0 equiv.) was added dropwise and the mixture was warmed to rt and stirred overnight. The mixture was concentrated and purified using flash silica gel chromatography (12 g, 0-10% EtOAc in hexanes) to provide coupled product 100 mg. Conversion to boronic acid 151 was achieved by Method 1. [M-H]" = 295.1 m/z. Activity: D
Example 132
Figure imgf000219_0001
Compound 152 was synthesized via Method 12 from 152 and 153. [M-H] = 266.1 m/z. Activity: A
Example 133
Figure imgf000219_0002
156
Figure imgf000219_0003
Compound 156 was synthesized via Method 12 from 152 and 155. [M-H] = 264.1 m/z. Activity: A Example 134
Figure imgf000220_0001
Compound 159 was synthesized via Method 12 from 157 and 158. [M-H]" = 266.1 m/z. Activity: A
Example 135
Figure imgf000220_0002
Compound 160 was synthesized via Method 12 from phenylacetylene and 157. [M-H]" 264.1 m/z. Activity: A Example 136
Figure imgf000221_0001
Compound 161 was synthesized via Method 12 from 1-heptene and 157. [M-H] = 260.2 m/z. Activity: A
Example 137
Figure imgf000221_0002
162
Figure imgf000221_0003
Compound 162 was synthesized via Method 12 from 2-methyl- 1-heptene and 157. [M- H] = 274.2 m/z. Activity: A Example 138
Figure imgf000222_0001
163
Figure imgf000222_0002
Compound 163 was synthesized via Method 12 from β-propylstyrene and 157. [M-H] 308.2 m/z. Activity: C
Example 139
Figure imgf000222_0003
Compound 164 was synthesized via Method 12 from 2-pentyl-l-hexene and 157. [M- H]" = 330.2 m/z. Activity: C
Example 140
Figure imgf000223_0001
Compound 165 was synthesized via Method 12 from 3-vinylpyridine and 157. [M-H]" 267.1 m/z. Activity: B
Example 141
Figure imgf000223_0002
Compound 166 was synthesized via Method 12 from 3-pyridylacetylene and 157. [M- H]" = 265.1 m/z. Activity: A Example 142
Figure imgf000224_0001
1 ) Method 12
Figure imgf000224_0003
2) Method 5,3
Figure imgf000224_0002
Compound 167 was synthesized via Method 12 from 2-bromobenzaldehdye and 1- pentene, followed by methods 5 and 3. [M-H]" = 232.1 m/z. Activity: B
Example 143
Figure imgf000224_0004
1 ) Method 12
2) Method 5,3
Figure imgf000224_0006
Figure imgf000224_0005
Compound 168 was synthesized via Method 12 from 2-bromobenzaldehdye and 1- pentyne, followed by methods 5 and 3. [M-H]" = 230.1 m/z. Activity: D
Figure imgf000225_0001
A mixture of 1 ,3-dihydroxypropane 170 (340 mg, 2 mmol, 1.0 equiv.), 4-bromo-3- fluorobenzaldehyde 169 (450 mg, 2 mmol, 1.0 equiv.), and /?-toluenesulfonic acid (0.1 g, 0.25 equiv.) in toluene (30 mL) was refluxed for 24 h with a Dean-Stark trap attached for removal of water. The mixture was diluted with EtOAc, washed with sat. sodium bicarbonate and brine, dried and concentrated. The crude mixture was purified on a silica gel column (5-20% EtOAc in hexane) to give major isomer 171 (210 mg) and minor isomer 172 (70 mg). Compound 173 was synthesized from 171 according to Method 1. [M-H]" = 301.1 m/z. Activity: A
Figure imgf000225_0002
Compound 174 was synthesized from 172 according to Method 1. [M-H] = 301.1 m/z. Activity: A Example 146
Figure imgf000226_0001
Compound 175 was synthesized from 4-bromobenzaldehyde by methods described for example 145. [M-H]" = 283.1 m/z. Activity: A
Example 147
Figure imgf000226_0002
Step A
Figure imgf000226_0003
To a mixture of diol 176 (540 mg, 3.9 mmol, 1.0 equiv.), 4-bromobenzaldehyde (795 mg, 4.3mmol, 1.1 equiv.), and /?-toluenesulfonic acid (1 g, 5.3mmol, 1.3 equiv) in toluene (6 mL) was added crushed molecular sieves 1.2 g. The mixture was stirred at rt for 3.5 h, then 10 ml of sat. NaHCO3 was added. The mixture was filtered through celite, washed with EtOAc. The combined organic layers were washed with water, brine, dried and concentrated. The crude was purified on a silica gel column (hexane to 5-20% EtOAc in hexane) to give trans product 177 590 mg and cis product 178 540 mg. Step B
Compound 179 was synthesized from 177 by Method 1. [M-H]" = 269.1 m/z. Activity: A Example 148
Figure imgf000227_0001
Compound 180 was synthesized from 178 by Method 1. [M-H]" = 269.1 m/z. Activity: A
Example 149
Figure imgf000227_0002
Boronic acid 181 was prepared by methods described for example 147. [M-H]" = 269.1 m/z. Activity: A
Example 150
Figure imgf000227_0003
Boronic acid 182 was prepared by methods described for example 148. [M-H]" = 269.1 m/z. Activity: A Example 151
Figure imgf000228_0001
To the suspension of propyltriphenylphosphonium bromide (140 mg, 1.1 equiv.) in 3 mL of THF is added drop wise 0.16 mL of a 2.5 M solution of BuLi in hexanes under nitrogen at 0 C. After 15 min, the red solution is cooled at -78 0C and treated with benzaldehyde 93 (100 mg, 1 equiv.) in 1 mL THF. After an additional 15 min, the solution was slowly warmed to rt for Ih, then water (2 ml) and brine (10 ml) are added followed by an extractive workup using ethyl acetate (100 ml). The organic extract is dried (MgSO4), filtered, concentrated, and purified to give desired product olefin as 1 :3 trans to cis mixture. The mixture was dissolved in 2 ml toluene, AIBN (5 mg) and PhSH (5 μl) were added. The solution was heated to 80 0C for 2 h, cooled to rt and filtered through short silica gel column. Hexanes was used to wash the product out and the combined solution was concentrated to give the aryl bromide as a single trans isomer. The aryl bromide was converted by Method 1 to boronic acid 183. [M-H]" = 295.1 m/z. Activity: B Example 152
Figure imgf000229_0001
Compound 184 was by methods described for example 151, using 3-phenylpropyl triphenylphosphonium bromide in place of propyltriphenylphosphonium bromide. [M-H]" = 371.2 m/z. Activity: C
Example 153
Figure imgf000229_0002
185
6-Bromo-2-naphthol (2.8g, 12.5 mmol), 2-chloropyridine (1.7g, 15 mmol, 1.2 eq.), and NaOH (750 mg, 19 mmol, 1.5 eq.) were combined in NMP (15 mL) and heated in the microwave at 2200C during 15 min. The reaction mixture was diluted with water and extracted into MTBE; the organic phase was dried on Na2SO4 and concentrated. Chromatography on silica (l→10% EtOAc/hexanes) gave 6-bromonaphthalene-2-(2-pyridyl)ether as a white solid, 3.3 Ig. This material was converted to the 6-pinacolboronate via Method 3 and the free boronate via Method 5, giving compound 185 as a white solid (1.1 Ig, 38%). [M-H]" = 264.1 m/z. Activity: A
Example 154
Figure imgf000229_0003
186 6-Hydroxynaphthalene-2-boronic acid (1.5g, 8 mmol) was dissolved in MTBE (75 mL) and stirred with pinacol (943 mg, 8 mmol) for Ih, then dried on Na2SO4 and concentrated to crude pinacol ester which was used without further purification.
This crude ester (220 mg, 0.81 mmol), NaOH (150 mg, 3.7 mmol, 4.5 eq.), and chloropyrazine (215 uL, 2.4 mmol, 3 eq.) were dissolved in DMF (3 mL) and heated via microwave at 1600C for 15 min. Dilution with water and extraction into EtOAc, followed by purification via chromatography on silica gel (4→20% EtOAc/hexanes) gave the pinacol ester as a yellow oil. This was deprotected to the free boronic acid via Method 5 to give 186 as a yellowish solid (172 mg, 79%), approx. 90% pure by rp-hplc. [M-H]" = 265.1 m/z. Activity: A
Example 155
Figure imgf000230_0001
187
6-Bromo-2-chloroquinoline (2.5g, 10.3 mmol) was converted, via Methods 11, 3, and 5, to compound 187 (1.3 Ig, 47%) as a white solid. [M-H]" = 264.1 m/z. Activity: A
Example 156
Figure imgf000230_0002
7-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) was converted, via Methods 11, 3, and 5, to compound 188 (113 g, 41%) as a white solid. [M-H]" = 264.1 m/z. Activity: A
Example 157
Figure imgf000230_0003
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-methoxyphenol (330 uL, 3. eq.) were converted, via Methods 11, 3, and 5, to compound 189 (141 mg, 46%) as a white solid. [M- H]" = 294.1 m/z. Activity: A
Example 158
Figure imgf000231_0001
190
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and potassium te/t-butoxide (230 mg,
2.0 eq.) were dissolved in cyclopentanol (3 mL) and heated by microwave at 1500C for 30 min.
Extraction from water into MTBE and drying on Na2SO4 gave the crude ether. This was converted, via Methods 3 and 5, to compound 190 (66 mg, 25%) as a yellow waxy solid. [M-H]"
= 256.1 m/z. Activity: A
Example 159
Figure imgf000231_0002
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and potassium te/t-butoxide (230 mg, 2.0 eq.) were dissolved in n-butanol (3 mL) and heated by microwave at 1500C for 30 min.
Extraction from water into MTBE and drying on Na2SO4 gave the crude ether. This was converted, via Methods 3 and 5, to compound 191 (74 mg, 29%). [M-H]" = 244.1 m/z. Activity:
A
Example 160
Figure imgf000231_0003
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and potassium tert-butoxidc (230 mg, 2.0 eq.) were dissolved in cyclohexanol (3 mL) and heated at 1200C for 16 hours. Extraction from water into MTBE and drying on Na2SO4 gave the crude ether. This was converted, via Methods 3 and 5, to compound 192 (156 mg, 57%).[M-H]~ = 270.1 m/z. Activity: B
Example 161
Figure imgf000232_0001
6-Bromo-2-chloroquinoline (200 mg, 0.8 mmol) and NaH (40 mg, 2.0 eq.) were dissolved in BnOH (2 mL) and heated at 1200C for 16 hours. Extraction from water into MTBE and drying on Na2SO4 gave the crude ether. This was converted, via Methods 3 and 5, to compound 193 (40 mg, 18%). [M-H]" = 278.1 m/z. Activity: A
Example 162
Figure imgf000232_0002
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-(dimethylamino)phenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 194 (140 mg, 44%). [M- H]" = 307.1 m/z. Activity: A
Example 163
Figure imgf000232_0003
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-nitrophenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 195 (83 mg, 26%). [M-H]" = 309.1 m/z. Activity: A
Example 164
Figure imgf000233_0001
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 2-chlorophenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 196 (132 mg, 43%). [M-H]" = 298.1 m/z. Activity: A
Example 165
Figure imgf000233_0002
197
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-chlorophenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 197 (93 mg, 30%). [M-H]" = 298.1 m/z. Activity: A
Example 166
Figure imgf000233_0003
198
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-cyanophenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 198 (46 mg, 15%). [M-H]" = 289.1 m/z. Activity: A Example 167
Figure imgf000234_0001
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and catechol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 199 (78 mg, 28%). [M-H]" = 280.2 m/z. Activity: A
Example 168
Figure imgf000234_0002
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and guaiacol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 200 (159 mg, 61%). [M-Hf = 294.1 m/z. Activity: A
Example 169
Figure imgf000234_0003
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 4-chlorophenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 201 (63 mg, 21%). [M-H]" = 298.1 m/z. Activity: A
Example 170
Figure imgf000234_0004
202
6-Bromo-2-chloroquinoline (200 mg, 0.8 mmol) and 25% methanolic NaOMe (2 mL) were heated at 500C for 16 hours. Extraction from water into EtOAc and drying on Na2SO4 gave the crude ether. This was converted, via Methods 3 and 5, to compound 202 (110 mg, 66%). [M-H]" = 202.1 m/z. Activity: B
Figure imgf000235_0001
203 Ethoxyquinoline 203 was prepared by methods used for example 170. (110 mg, 66%).
[M-H]" = 215.1 m/z. Activity: B
Example 172
Figure imgf000235_0002
6-Bromo-2-chloroquinoline (200 mg, 0.8 mmol) and N-methylbenzylamine (2 mL) were heated at 1200C for 16 hours. Extraction from 2M NaOH into DCM and drying on Na2SO4 gave the crude 2-aminoquinoline. This was converted, via Methods 3 and 5, to compound 204 (110 mg, 46%). [M-H]" = 291.1 m/z. Activity: A
Example 173
Figure imgf000235_0003
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and N-methylaniline (2 mL) were heated at 1200C for 16 hours. Extraction from 2M NaOH into DCM and drying on Na2SO4 gave the crude 2-aminoquinoline. This was converted, via Methods 3 and 5, to compound 205 (88 mg, 31 %). [M-H]" = 277.0 m/z. Activity: B Example 174
Figure imgf000236_0001
206
6-Bromo-2-chloroquinoline (1 g, 4.1 mmol) and aniline (8 mL) were heated at 10O0C for 16 hours. Some dark color was removed by pushing through a plug of silica gel with MTBE. The eluent was taken up in hexanes, washed with water, and concentrated; the residue was shaken with water (100 mL) and hexanes (20 mL), giving a beige solid which was collected by filtration and washed with water. This material was converted, via Methods 3 and 5, to compound 206 (647 mg, 60%). [M-H]" = 263.1 m/z. Activity: A
Example 175
Figure imgf000236_0002
6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and tetrahydroquinoline (2 mL) were heated at 1200C for 16 hours. The material was taken up in DCM (20 mL) and treated with NEt3
(6 mL) and Ac2O (3 mL) for 2h, then extracted from 0.1 M NaOH into DCM. Drying on Na2SO4 and concentration gave a crude residue which was converted, via Methods 3 and 5, to compound 207 (151 mg, 48%). [M-H]" = 303.1 m/z. Activity: B
Example 176
Figure imgf000236_0003
208 6-hydroxynaphthalene-2-boronic acid (1.5g, 8 mmol) was dissolved in MTBE (75 mL) and stirred with pinacol (943 mg, 8 mmol) for Ih, then dried on Na2SO4 and concentrated to crude pinacol ester which was used without further purification. This crude ester (220 mg, 0.81 mmol), NaOH (150 mg, 3.7 mmol, 4.5 eq.), and 2- bromo-pyrimidine (390 mg, 2.4 mmol, 3.0 eq.) were dissolved in DMF (3 mL) and heated via microwave at 1600C for 15 min. Dilution with water and extraction into EtOAc, followed by purification via chromatography on silica gel (4→20% EtOAc/hexanes) gave the pinacol ester as a yellow oil. This was deprotected to the free boronic acid via Method 5 to give 208 (54 mg, 25%). [M-H]" = 265.1 m/z. Activity: A
Example 177
Figure imgf000237_0001
209 6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-hydroxypyridine (3 mmol, 3. eq.) were converted, via Methods 11, 3, and 5, to compound 209 (69 mg, 26%). [M-H]" = 265.1 m/z. Activity: A
Figure imgf000237_0002
210 A solution of 4-bromoaniline (9.Og, 52.3 mmol) in PhMe (100 mL) and pyridine (8.5 mL, 110 mmol, 2.0 eq.) was cooled in an ice bath and slowly treated with propionyl chloride (5.5 mL, 63 mmol, 1.2 eq.). After 2h, the reaction mixture was added to 0.1 M HCl and extracted into EtOAc. Concentration followed by recrystallization of the residue from EtOH/water gave N-propionyl-4-bromoaniline (10.64g, 89%). [M-H]" = 278.1 m/z. Phosphorous oxychloride (3 mL, excess) was treated with DMF (650 uL, 8.7 mmol, 1.5 eq.) and the solution allowed to return to ambient temperature. N-propionyl-4-bromoaniline (1.32 g, 5.8 mmol, 1 eq.) was added and the mixture heated at 85 0C for 4h. The hot mixture was poured onto ice (100 g), stirred until melted, and the solids were collected by filtration. Washing with water and drying in vacuo gave clean 6-bromo-2-chloro-3-methylquinoline (914 mg, 61 %). This intermediate (250 mg, 1.0 mmol) and phenol (3 mmol, 3. eq.) were converted, via Methods 11, 3, and 5, to compound 210 (118 mg, 42%). [M-H]" = 278.1 m/z. Activity: A
Example 179
Figure imgf000238_0001
21 1
2-Quinoxalinol (2.9g, 20 mmol) and silver sulfate (3.1g, 10 mmol, 0.5 eq.) in sulfuric acid (20 mL) were treated with bromine (1.03 mL, 20 mmol, 1.0 eq.). After stirring at ambient temperature for 18h, the reaction mixture was diluted with carbon tetrachloride (50 mL), heated to 500C, and filtered. The filtrate was poured onto ice and the solids collected by filtration and recrystallized from HOAc, giving 6-bromo-2-quinoxalinol (1.8g, 40%).
6-Bromo-2-quinoxalinol (631 mg) in POCI3 (6.3 mL) was refluxed for 2h, then poured onto ice. The solution was neutralized to pH 7 by addition OfNH4OH, and the resulting solid collected by filtration. Washing with water and drying in vacuo gave 6-bromo-2- chloroquinoxaline (627 mg, 92%). This intermediate (250 mg, 1.0 mmol) and phenol (3 mmol, 3.0 eq.) were converted, via
Methods 11, 3, and 5, to compound 211 (4.4 mg, 2%). [M-H]" = 265.1 m/z. Activity: B
Example 180
Figure imgf000238_0002
212 4-Bromo-2-methylaniline (1.8g, 10 mmol) in PhMe (25 mL) was treated with ethyl acetoacetate (1.3 mL, 11 mmol, 1.1 eq.) and refluxed during 18h. Upon cooling a precipitate of N-acetoacetyl-4-bromo-2-methylaniline (1.59g, 60%) formed, which was collected by filtration and used without further purification.
This acetoacetamide (Ig, 3.7 mmol) was dissolved in sulfuric acid (5 mL) and heated at 1200C during 2h. The hot solution was poured onto ice (100 g), giving a white solid which was collected by filtration, washed with water, and dried in vacuo to give 6-bromo-4,8-dimethyl-2- quinolone (418 mg, 45%).
This quinolone (410 mg, 1.6 mmol) in POCI3 (5 rnL) was refluxed for 2h, then poured onto ice. The solution was neutralized to pH 7 by addition of NH4OH, and the resulting solid collected by filtration. Washing with water and drying in vacuo gave 6-bromo-2-chloro-4,8- dimethyl-quinoline (407 mg, 93%).
This intermediate (200 mg, 0.74 mmol) and phenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 212 (141 mg, 65%). [M-H]" = 292.1 m/z. Activity: B
Example 181
Figure imgf000239_0001
213
Compound 213 was produced in a manner analogous to compound 212, using 4- bromoaniline in place of 4-bromo-2-methylaniline. Yield 131 mg. [M-H]" = 278.1 m/z. Activity: A
Figure imgf000239_0002
A solution of 6-bromobenzothiazolin-2-one (500 mg, 2.2 mmol) in POCI3 (5 mL) was refluxed during 18h, then poured onto ice. The solution was neutralized to pH 9 by addition of NH4OH, and the resulting solid collected by filtration. Washing with water and drying in vacuo gave 6-bromo-2-chlorobenzothiazole (450 mg, 83%).
This intermediate (200 mg, 0.8 mmol) and phenol (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 214 (25 mg, 12%). [M-H]" = 270.1 m/z. Activity: A Example 183
Figure imgf000240_0001
6-Bromo-2-chloroquinoline (500 mg, 2.0 mmol) and 2-hydroxypyridine (3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 215 (35 mg, 7%). [M-H]" = 265.1 m/z. Activity: A
Figure imgf000240_0002
216
6-Hydroxynaphthalene-2-boronic acid (1.5g, 8 mmol) was dissolved in MTBE (75 mL) and stirred with pinacol (943 mg, 8 mmol) for Ih, then dried on Na2SO4 and concentrated to crude pinacol ester which was used without further purification.
Phenylboronic acid (140 mg, 1.1 mmol, 2.0 eq.) was coevaporated with PhMe twice to produce the anhydride. This was treated with crude 6-hydroxynaphthalene-2-boronic acid pinacol ester (150 mg, 0.56 mmol), DCM (5 mL), NEt3 (400 uL, 3 mmol, 5 eq.), and cupric acetate (100 mg, 0.53 mmol, 0.95 eq.) and stirred at ambient temperature during 16h. The mixture was extracted from 0.1M NaOH into DCM, dried on Na2SO4, concentrated, and chromatographed on silica gel (0→2% EtOAc/hexanes) to give 6-phenoxynaphthalene-2- boronic acid pinacol ester, which was deprotected via Method 5 to provide compound 216 (54 mg, 37%). [M-H]" = 263.1 m/z. Activity: A
Example 185
Figure imgf000240_0003
217 The corresponding pinacol ester (22 mg, 0.066 mmol) was cleaved according to Method 5 to give compound 217 (17 mg, quant.). [M-H]" = 251.1 m/z. Activity: A
Example 186
Figure imgf000241_0001
The corresponding bromide (256 mg, 1.0 mmol) was reacted according to Method 2 to give compound 218 (37 mg, 17%). [M-H]" = 214.1 m/z. Activity: D
Example 187
Figure imgf000241_0002
21 9
The corresponding bromide (336 mg, 1.1 mmol) was converted via Methods 3 and 5 to compound 219 (77 mg, 26%). [M-H]" = 273.1 m/z. Activity: B
Example 188
Figure imgf000241_0003
220
The corresponding pinacol ester (200 mg, 0.8 mmol) was cleaved according to Method 5 to give compound 220 (89 mg, 66%). [M-H]" = 181.1 m/z. Activity: C Example 189
Figure imgf000242_0001
6-Bromoquinaldine (Ig, 4.5 mmol) in CCl4 (6 niL) was treated with NBS (750 mg, 4.2 mmol, 0.95 eq.) and a few crystals of benzoyl peroxide and refluxed during 2h. The hot solution was filtered, the filtrated cooled, and the resulting crystals collected by filtration and used without further purification.
A solution of phenol (60 mg, 0.63 mmol, 2.0 eq.) in NMP was treated with 60% NaH dispersion (25 mg, 0.63 mmol, 2.0 eq.) and the dibromoquinaldine produced in the previous step
(150 mg, 0.31 mmol). After stirring at ambient temperature for 18h, the reaction was extracted from 0.1M NaOH into MTBE, dried on Na2SO4, concentrated, and chromatographed on silica gel (0→10% EtOAc/hexanes) to give a-phenoxy-6-bromoquinaldine (93 mg, 94%).
This bromide was converted via Methods 3 and 5 to compound 221 (48 mg, 58%). [M- H]" = 278.1 m/z. Activity: B
Example 190
Figure imgf000242_0002
4-Bromoiodobenzene (460 mg, 1.6 mmol, 1.5 eq.), l-isoamylpyrazole-4-boronic acid
(200 mg, 1.1 mmol), potassium acetate (100 mg, 1.0 eq.), Pd(dppf)Cl2 (100 mg, 0.1 eq.), and CS2CO3 (Ig, 3.0 eq.) in DMSO (5 mL) were heated under argon at 8O0C during Ih. The reaction mixture was extracted from water into ether, dried Na2SO4, concentrated, and chromatographed on silica gel (0→10% EtOAc/hexanes) to give l-isoamyl-4-(4-bromophenyl)pyrazole (263 mg, 82%).
This bromide was converted via Methods 3 and 5 to compound 222 (147 mg, 64%). [M- H]" = 257.2 m/z. Activity: A Example 191
Figure imgf000243_0001
The corresponding iodide (125 mg, 0.4 mmol) was converted via Methods 3 and 5 to compound 223 (9 mg, 10%). [M-H]" = 237.1 m/z. Activity: D
Example 192
Figure imgf000243_0002
2-(4-Iodophenyl)benzimidazole (200 mg, 0.6 mmol) was methylated with iodomethane (180 mg, 1.2 mmol, 2.0 eq.) and NaH (45 mg, 1.8 mmol, 3 eq.) in DMF (3 mL) for 18h. Dilution with diethyl ether, washing with water, drying over Na2SO4, and chromatography (10→25% EtOAc/hexanes) gave l-methyl-2-(4-iodophenyl)benzimidazole (124 mg, 59%).
This iodide was converted via Method 2 to compound 224 (9 mg, 10%). Activity: D
Example 193
Figure imgf000243_0003
225
4-Bromo-3-fluoroiodobenzene (250 mg, 0.7 mmol, 1.2 eq.), 4-methyl-2- phenylthiazole-5-boronic acid pinacol ester (170 mg, 0.6 mmol), potassium acetate (70 mg, 1.0 eq.), Pd(dppf)Cl2 (70 mg, 0.1 eq.), and Cs2CO3 (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 800C during Ih. The reaction mixture was extracted from water into diethyl ether, dried over Na2SO4, concentrated, and chromatographed on silica gel (5→10% EtOAc/hexanes) to give the corresponding bromide to 225 (169 mg, 85%).
This bromide was converted via Methods 3 and 5 to compound 225 (15 mg, 10%). Activity: B
Example 194
Figure imgf000244_0001
226
4-Bromo-3-fluoroiodobenzene (250 mg, 0.8 mmol, 1.2 eq.), l-benzylpyrazole-4- boronic acid pinacol ester (200 mg, 0.7 mmol), potassium acetate (70 mg, 1 eq.), Pd(dppf)Cl2 (70 mg, 0.1 eq.), and Cs2CO3 (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 800C during Ih. The reaction mixture was extracted from water into diethyl ether, dried over Na2SO4, concentrated, and chromatographed on silica gel (5→10% EtOAc/hexanes) to give the corresponding bromide to 226 (193 mg, 83%).
This bromide was converted via Methods 3 and 5 to compound 226 (13 mg, 8%). [M-H]" = 295.1 m/z. Activity: A
Figure imgf000244_0002
227
4-Bromo-iodobenzene (240 mg, 0.8 mmol, 1.2 eq.), l-benzylpyrazole-4-boronic acid pinacol ester (200 mg, 0.7 mmol), potassium acetate (70 mg, 1 eq.), Pd(dppf)Cl2 (70 mg, 0.1 eq.), and Cs2CO3 (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 800C during Ih. The reaction mixture was extracted from water into diethyl ether, dried over Na2SO4, concentrated, and chromatographed on silica gel (5→10% EtOAc/hexanes) to give 1 -benzyl— 4- (4-bromophenyl)pyrazole (218 mg, 99%).
This bromide was converted via Methods 3 and 5 to compound 227 (142 mg, 73%). [M- H]" = 277.1 m/z. Activity: A Example 196
Figure imgf000245_0001
228
4-Bromo-iodobenzene (250 mg, 0.9 mmol, 1.2 eq.), 2-methoxynaphthalene-6-boronic acid (150 mg, 0.7 mmol), potassium acetate (70 mg, 1.0 eq.), Pd(dppf)Cl2 (70 mg, 0.1 eq.), and Cs2CO3 (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 800C during Ih. The reaction mixture was extracted from water into diethyl ether, dried over Na2SO4, concentrated, and chromatographed on silica gel (5→20% EtOAc/hexanes) to 2-methoxy-6-(4- bromophenyl)naphthalene (131 mg, 56%).
This bromide was converted via Methods 3 and 5 to compound 228 (47 mg, 41%). [M- H]" = 277.1 m/z. Activity: B
Example 197
Figure imgf000245_0002
229
4-Bromo-3-fluoroiodobenzene (250 mg, 0.8 mmol, 1.2 eq.), quinoline-5-boronic acid (120 mg, 0.7 mmol), potassium acetate (70 mg, 1 eq.), Pd(dppf)Cl2 (70 mg, 0.1 eq.), and Cs2CO3 (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 800C during Ih. The reaction mixture was extracted from water into ether, dried over Na2SO4, concentrated, and chromatographed on silica gel (5→20% EtOAc/hexanes) to give 5-(4-bromo-3- fluorophenyl)quinoline (220 mg, quant.). This bromide was converted via Methods 3 and 5 to compound 229 (39 mg, 20%). [M-
H]" = 266.1 m/z. Activity: B Example 198
Figure imgf000246_0001
230
4-Bromo-3-fluoroiodobenzene (250 mg, 0.8 mmol, 1.2 eq.), indole-4-boronic acid (110 mg, 0.7 mmol), potassium acetate (70 mg, 1 eq.), Pd(dppf)Cl2 (70 mg, 0.1 eq.), and Cs2CO3 (700 mg, 3 eq.) in DMSO (5 mL) were heated under argon at 800C during Ih. The reaction mixture was extracted from water into ether, dried Na2SO4, concentrated, and chromatographed on silica gel (5→15% EtOAc/hexanes) to give 4-(4-bromo-3-fluorophenyl)indole (164 mg, 83%).
This bromide was converted via Methods 3 and 5 to compound 230 (77 mg, 53%). [M- H]" = 254.1 m/z. Activity: B
Example 199
Figure imgf000246_0002
231
2-Phelylmalondialdehyde (200 mg, 1.4 mmol) in EtOH (10 mL) was treated with 4- bromophenylhydrazine HCl (300 mg, 1.4 mmol) and NEt3 (200 uL, 1.4 mmol) and refluxed for Ih. The solution was diluted slightly with water, chilled, and the resulting precipitate of l-(4- bromophenyl)-4-phenylpyrazole collected by filtration (179 mg, 44%).
This bromide was converted via Methods 3 and 5 to compound 231 (35 mg, 23%). [M- H]" = 263.1 m/z. Activity: A
Example 200
Figure imgf000247_0001
232
2-(4-Bromophenyl)malondialdehyde (250 mg, 1.1 mmol) in EtOH (10 niL) was treated with phenylhydrazine (110 uL, 1.1 mmol) and refluxed for Ih. The solution was diluted slightly with water, chilled, and the resulting precipitate of 4-(4-bromophenyl)-l-phenylpyrazole collected by filtration (270 mg, 82%).
This bromide was converted via Methods 3 and 5 to compound 232 (155 mg, 68%). [M- H]" = 263.0 m/z. Activity: A
Example 201
Figure imgf000247_0002
4-(4-Bromophenyl)piperidine HCl (Ig, 3.7 mmol) in DCM (6 mL) was treated with K2CO3 (1.3g, 9 mmol, 2.5 eq.) and Boc2O (1.35 g, 6 mmol, 1.6 eq). The mixture was diluted with water, extracted with MTBE, washed with brine, dried on Na2SO4, and concentrated. Chromatography on silica gel (2→8% EtOAc/hexanes) gave 1-Boc— 4-(4- bromophenyl)piperidine (944 mg, 76%)._This bromide was converted via Method 3 to 1-Boc- 4-(4-boronophenyl)piperidine pinacol ester (1.16g, quant.).
A portion of this ester (270 mg) was deprotected via Method 5 to give compound 233 (144 mg, 68%). [M-H]" = 304.2 m/z. Activity: A Example 202
Figure imgf000248_0001
234
4-Bromophenethylamine (2 niL, 13 mmol) in DCM (12 mL) was treated with K2CO3 (2.7g, 20 mmol, 1.5 eq.) and Boc2O (3.1g, 14 mmol, 1.1 eq.). The mixture was diluted with water, extracted with MTBE, washed with brine, dried on Na2SO4, and concentrated to give clean N-Boc-4-bromophenethylamine (4 g, quant.).
This carbamate was dissolved in DMF (40 mL) and treated with 60% NaH dispersion (1.7g, 42 mmol, 3.0 eq.) and MeI (1.7 mL, 28 mmol, 2.0 eq.). After stirring at ambient temperature 18h, the reaction mixture is extracted from 0.1M NaOH into MTBE, dried on Na2SO4, and concentrated to clean N-Boc-N-methyl-4-bromophenethylamine (4.67g, quant.). Ig of this bromide (3.2 mmol) was converted via Method 3 to N-Boc-N-methyl-4- boronophenethylamine pinacol ester (981 mg, 85%).
A portion of this ester (150 mg) was deprotected via Method 5 to give compound 234 (95 mg, 82%). [M-H]" = 278.1 m/z. Activity: A Example 203
Figure imgf000248_0002
A solution of 4-bromodihydrocinnamic acid (1.5 g, 6.6 mmol) in THF (10 mL) and DMF
(10 mL) was treated with 2.0M methylamine in THF (10 mL, 3.0 eq.) and HBTU (2.75 g, 7.2 mmol, 1.1 eq.) The mixture was diluted with water, extracted with MTBE, washed with brine, dried on Na2SO4, and pushed through a pad of silica gel using 50% EtOAc/hexanes, giving N- methyl-4-bromodihydrocinnamide.
This amide was dissolved in THF (20 mL) and treated with borane-dimethylsulfide complex (1.25 mL, 13 mmol, 2.0 eq.) and refluxed for 3h. The reaction was quenched with MeOH, thentreated with 6M HCl to a pH of 1 and concentrated in vacuo. The residue was extracted from IM NaOH into DCM, dried Na2SO4, and concentrated to N-methyl-3-(4- bromophenyl)propylamine (562 mg, 38%) which is used without further purification.
This amine in DCM (5 mL) was treated with K2CO3 (500 mg, 3.7 mmol, 1.5 eq.) and Boc2O (900 mg, 4 mmol, 1.6 eq.). The mixture was diluted with water, extracted with MTBE, washed with brine, dried on Na2SO4, concentrated, and chromatographed to give clean N-Boc- N-methyl-3-(4-bromophenyl)propylamine (546 mg, 68%). This bromide was converted via Method 3 to N-Boc-N-methyl-3-(4-boronophenyl)propylamine pinacol ester (594 mg, 95%).
A portion of this ester (100 mg) was deprotected via Method 5 to give compound 235 (59 mg, 76%). [M-H]" = 292.2 m/z. Activity: A
Example 204
Figure imgf000249_0001
l-Boc-4-(4-boronophenyl)piperidine pinacol ester (887 mg, 2.3 mmol), prepared in the synthesis of compound 233, was dissolved in TFA (10 mL), stirred for Ih, and coevaporated with twice with PhMe to give deprotected salt with pinacol ester intact (by NMR and LC). 190 mg of this salt (0.47 mmol) in DCM (5 mL) was treated with NEt3 (250 uL, 1.8 mmol, 3.8 eq.) and benzenesulfonyl chloride (75 uL, 0.57 mmol, 1.2 eq.). After stirring at ambient temperature 16h, the reaction mixture was diluted with DCM and concentrated onto silica gel. Chromatography (3 — »-15% EtOAc/hexanes) gave l-benzenesulfonyl-4-(4- boronophenyl)piperidine pinacol ester. Deprotection of this ester via Method 5 gave compound 236 (80 mg, 49%). [M-H]" = 344.1 m/z. Activity: B
Example 205
Figure imgf000249_0002
237 N-Boc-N-methyl-4-boronophenethylamine pinacol ester (430 mg), prepared in the synthesis of compound 234, was dissolved in TFA (5 mL), stirred for Ih, and coevaporated with twice with PhMe to give deprotected salt with pinacol ester intact (by NMR and LC). 208 mg of this salt (0.55 mmol) in DCM (5 mL) was treated with NEt3 (250 uL, 1.8 mmol, 3.3 eq.) and benzenesulfonyl chloride (85 uL, 0.67 mmol, 1.2 eq.). After stirring at ambient temperature 16h, the reaction mixture was diluted with DCM and concentrated onto silica gel. Chromatography (2→15% EtOAc/hexanes) gave N-benzenesulfonyl-N-methyl-4- boronophenethylamine pinacol ester. Deprotection of this ester via Method 5 gave compound 237 (117 mg, 66%). [M-H]" = 318.1 m/z. Activity: A
Example 206
Figure imgf000250_0001
N-Boc-N-methyl-3-(4-boronophenyl)propylamine pinacol ester (494 mg), prepared in the synthesis of compound 235, was dissolved in TFA (5 mL), stirred for Ih, and coevaporated with twice with PhMe to give deprotected salt with pinacol ester intact (by NMR and LC).
256 mg of this salt (0.66 mmol) in DCM (5 mL) was treated with NEt3 (300 uL, 2.2 mmol, 3.3 eq.) and benzenesulfonyl chloride (100 uL, 0.79 mmol, 1.2 eq.). After stirring at ambient temperature 16h, the reaction mixture was diluted with DCM and concentrated onto silica gel. Chromatography (2→15% EtOAc/hexanes) gave N-benzenesulfonyl-N-methyl-3-(4- boronophenyl)propylamine pinacol ester. Deprotection of this ester via Method 5 gave compound 238 (135 mg, 62%). [M-H]" = 332.1 m/z. Activity: A Example 207
Figure imgf000251_0001
239
Oxadiazole 239 was prepared in 2 steps by first forming the oxadiazole from 4-(4 ,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzohydrazide and 4-oxo-4-(l-piperidinyl)butanoic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 328.1 m/z. Activity: B
Example 208
Figure imgf000251_0002
24°
Oxadiazole 60 was prepared in 2 steps by first forming the oxadiazole from 5-(4,4,5,5- tetra-methyl-l,3,2-dioxaborolan-2-yl)furan-3-carboxylic acid and hexanoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [2M-H2O]" = 481.0 m/z. Activity: B
Figure imgf000251_0003
241
Benzoxazole 241 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chlorophenol and phenyl acetic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 252.0 m/z. Activity: A Example 210
Figure imgf000252_0001
Benzoxazole 242 was prepared in 3 steps by first forming the benzoxazole from 2- amino-4-bromophenol and 3-phenylpropionic acid using Method 13 followed by conversion to the boronate ester using Method 3 followed by Method 5. [M-H]" = 266.1 m/z. Activity: A
Figure imgf000252_0002
Benzoxazole 243 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chlorophenol and 3-phenylpropionic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 266.1 m/z. Activity: A
Figure imgf000252_0003
Benzoxazole 244 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chlorophenol and butyric acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 204.1 m/z. Activity: A
Figure imgf000253_0001
245
Benzoxazole 245 was prepared in 3 steps by first forming the benzoxazole from 2-amino-5-chlorophenol and hexanoic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 233.9 m/z. Activity: A
Figure imgf000253_0002
Benzoxazole 246 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chlorophenol and 5,5,5-trifluoropentanoic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 272.1 m/z. Activity: A
Figure imgf000253_0003
Benzoxazole 247 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chlorophenol and 4-oxo-4-(l-piperidinyl)butanoic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 301.1 m/z. Activity: B
Figure imgf000254_0001
248
Benzoxazole 248 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chlorophenol and S-oxo-l-phenyl-pyrrolidine-S-carboxylic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 321.1 m/z. Activity: B
Example 217
Figure imgf000254_0002
249 Benzoxazole 249 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chlorophenol and 5-oxo-l-phenyl-pyrrolidine-3-carboxylic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 335.1 m/z. Activity: B
Example 218
Figure imgf000254_0003
Part A
Figure imgf000255_0001
250 251 252
5-Fluoro-2(3H)-benzoxazolone 250 (0.50 g, 1.0 equiv) and phosphorus pentachloride (1.36 g, 2.0 equiv) were placed in a microwave reactor vial. The reaction was sealed and heated to 175 0C in a microwave reactor for 45 min. The reaction was then quenched with excess saturated sodium bicarbonate (100 mL) which resulted in significant fuming. The reaction mixture was then transferred to a separatory funnel with excess water and ethyl acetate at which point the water layer was washed with ethyl acetate (2 x 50 mL). The organic layers were combined, dried over MgSO4 and concentrated under vacuum to provide 500 mg of the desired product 251 that was taken on directly to the next step.
Compound 251 (0.50 g, 1.0 equiv) was suspended in 10 mL of water in a microwave reactor vial. Sodium hydroxide (1.60 g, 15.0 equiv) was added and the mixture was stirred at room temperature until all the sodium hydroxide dissolved. The reaction was then heated to 150 0C in a microwave reactor for 20 min after which IN HCl was added until a solid crashes out (pH ~ 7). The solid is isolated via vacuum filtration, washed with excess water and dried on the high vac to provide 300 mg of the desired aminophenol 252 (70% yield). Part B
Figure imgf000255_0002
Benzoxazole 253 was prepared in 3 steps by first forming the benzoxazole from 2- amino-5-chloro-4-fluorophenol 252 and 3-phenylpropionic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]" = 284.1 m/z. Activity: A Example 219
Figure imgf000256_0001
254
Benzodiazoborine 254 was prepared using the analogous procedure as example 98 except that JV-benzylhydrazine was used in place of 2-hydroxyethyl hydrazine and (2-formyl— 4,5- methylenedioxy)phenylboronic acid was used in place of benzene boronic acid 98. [M-H]" = 279.1 m/z. Activity: D
Example 220
Figure imgf000256_0002
255 Benzodiazoborine 255 was prepared using the analogous procedure as example 98 except that JV-benzylhydrazine was used in place of 2-hydroxyethyl hydrazine and 5-methoxy-2- formylphenylboronic acid was used in place of benzene boronic acid 98. [M-H]" = 265.1 m/z. Activity: D
Example 221
Figure imgf000256_0003
256
Benzodiazoborine 256 was prepared using the analogous procedure as example 98 except that JV-benzylhydrazine was used in place of 2-hydroxyethyl hydrazine and 3-formylthiophene- 2-boronic acid was used in place of benzene boronic acid 98. [M-H]" = 241.1 m/z. Activity: D Example 222
Figure imgf000257_0001
257
Benzodiazoborine 257 was prepared using the analogous procedure as example 98 except that JV-benzylhydrazine was used in place of 2-hydroxy ethyl hydrazine and 4-formylthiophene- 3-boronic acid was used in place of benzene boronic acid 98. [M-H]" = 241.1 m/z. Activity: D
Figure imgf000257_0002
258
Benzodiazoborine 258 was prepared using the analogous procedure as example 98 except that hydrazine was used in place of 2-hydroxyethyl hydrazine and 4-(benzyloxy)-2- formylphenylboronic acid was used in place of benzene boronic acid 98. [M-H]" = 251.1 m/z. Activity: D
Example 224
Figure imgf000257_0003
259 Benzoxazole 259 was prepared in 2 steps by first forming the benzoxazole from 2- amino-3-hydroxypyridine and 2-bromo benzoic acid using Method 13 followed by conversion to the boronic acid using Method 1. [M-H]" = 239.0 m/z. Activity: D Example 225
Figure imgf000258_0001
260
Oxadiazole 260 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-5-methoxybenzoic acid and butyric hydrazide using Method 8 followed by lithiation using Method 1. [M-H]" = 261.1 m/z. Activity: D
Example 226
Figure imgf000258_0002
Oxadiazole 261 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-5-fluorobenzoic acid and butyric hydrazide using Method 8 followed by lithiation using Method 1. [M-H]" = 249.0 m/z. Activity: D
Example 227
Figure imgf000258_0003
262 Oxadiazole 262 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-6-fluorobenzoic acid and butyric hydrazide using Method 8 followed by lithiation using Method 1. [M-H]" = 249.2 m/z. Activity: D Example 228
Figure imgf000259_0001
263
Oxadiazole 263 was prepared in 2 steps by first forming the oxadiazole from 2-(4 ,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzohydrazide and 3-(2-oxo-pyrrolidin-l-yl)-propionic acid using Method 7 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 300.1 m/z. Activity: D
Example 229
Figure imgf000259_0002
Oxadiazole 264 was prepared in 2 steps by first forming the oxadiazole from 2-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and furoic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 455.1 m/z. Activity: D.
Example 230
Figure imgf000259_0003
265
Oxadiazole 265 was prepared in 2 steps by first forming the oxadiazole from 2-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and 3-phenylpropionic hydrazide using Method 8 followed by Method 5 and was isolated after precipitation from the reaction mixture. [M-H]" = 293.1 m/z. Activity: D Example 231
Figure imgf000260_0001
266
Thiadiazole 266 was prepared in 2 steps by first forming the thiadiazole from 2- bromobenzoic acid and butyric hydrazide using Method 9 followed by lithiation using Method 1. [M-H]" = 247.1 m/z. Activity: D.
Example 232
Figure imgf000260_0002
267
Thiadiazole 267 was prepared in 2 steps starting with thaidiazole formation between 2- bromo-5-phenethoxybenzoic acid 16 and propionic hydrazide using Method 9 followed by lithiation using Method 1. [M-H]" = 267.1 m/z. Activity: A
Example 233
Figure imgf000260_0003
268 Oxadiazole 268 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-5-phenethoxybenzoic acid 16 and 1 -methyl- lH-imidazole-5-carbohydrazide using Method 7 followed by lithiation using Method 1. [M-H]" = 389.0 m/z. Activity: B. Example 234
Figure imgf000261_0001
269
Oxadiazole 269 was prepared in 2 steps starting with oxadiazole formation between 2- bromo-5-phenethoxybenzoic acid 16 and 2-methyl-l,3-thiazole-4-carbohydrazide using Method 7 followed by lithiation using Method 1. [M+H]+ = 408.3 m/z. Activity: C.
Example 235
Figure imgf000261_0002
271
Figure imgf000261_0003
271
Oxadiazole 271 was prepared in analogous fashion to the oxadiazole 17 in example 12 except that 1-bromobutane was used in the place of phenethylbromide in part A to synthesize 2- bromo-5-butoxybenzaldehyde 270. Aldehyde 270 was then converted to the desired oxadiazole using the oxidation, cyclization and lithiation steps in part B. [M-H]" = 303.2 m/z. Activity: B
Example 236
Figure imgf000262_0001
272
Oxadiazole 272 was prepared in analogous fashion to the oxadiazole 17 in example 12 except that 1-bromobutane was used in the place of phenethylbromide in part A to synthesize 2- bromo-5-butoxybenzaldehyde 270 and that acetic hydrazide was used in place of butyric hydrazide during the cyclization step in part B. [M-H]" = 275.1 m/z. Activity: B
Figure imgf000262_0002
272
In a microwave reactor tube, 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid (300 mg, 1.0 equiv), polystyrene-supported triphenylphosphine (3.0 equiv) and trichloroacetonitrile (0.18 mL, 2.0 equiv) were added, and the mixture was sealed and heated in a microwave reactor at 100 0C for 30 min. JV-Hydroxy-butyramidine (0.14 mL, 1.1 equiv) was then added followed by /V,/V-diisopropyl ethylamine (0.43 mL, 2.0 equiv) and the reaction was reaheated in a microwave reactor to 150 0C for Ih. The concentrated reaction mixture was purified by flash silica gel chromatography (hexanes/ethyl acetate) to provide oxadiazole-aryl boronic acid pinacol ester in 32% yield. The boronate was then converted the boronic acid 272 using Method 5. [M-H]" = 231.1 m/z. Activity: A. Example 238
Figure imgf000263_0001
273
Oxadiazole 273 was prepared in two steps first using the analogous procedure as example 238 except that 2-bromo-5-phenethoxybenzoic acid 16 was used in place of 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid. The resultant oxadiazole was then converted to the corresponding boronic acid using the lithiation conditions in Method 1. [M-H]" = 351.2 m/z. Activity: B
Example 239
Figure imgf000263_0002
Figure imgf000263_0003
274 275
Thiazole 276 was prepared in 3 steps from 2-bromo-5-phenethoxybenzoic acid 16. Acid 16 (700 mg, 1.0 equiv) and l-aminopentan-2-one hydrochloride (390 mg, 1.3 equiv) were dissolved in 20 mL anhydrous dichloromethane. HOBt (353 mg, 1.2 equiv) and EDC (501 mg, 1.2 equiv) were added followed by triethylamine (940 uL, 3.0 equiv). The reaction was allowed to stir for 12h at room temperature after which point it was transferred to a separatory funnel with excess dichloromethane and washed with 0.5 M citric acid (2 x 75 mL) and saturated NaHCO3 (2 x 75mL). The organic layer was then dried over MgSO4, filtered and concentrated to provide the desired ketoamide 274 as a yellow solid in quantitative yield (880 mg) which was used directly to form the thiazole the in the following step.
Ketoamide 274 (308 mg, 1.0 equiv) was added to a microwave reactor vial and dissolved in 5 mL anhydrous tetrahydrofuran after which Lawesson's reagent (462 mg, 1.5 equiv) was then added. The reaction was heated to 115 0C for 90 min in a microwave reactor after which point it was loaded directly onto silica gel and purified using flash silica gel chromatography using a gradient of 20-70% ethyl acetate/hexanes to provide 230 mg of the desired thiazole 275 in 50% yield.
The resultant thiazole 275 was then converted to the corresponding boronic acid using the lithiation conditions in Method 1. [M+H]+ = 368.2 m/z. Activity: B
Example 240
Figure imgf000264_0001
277
Benzodiazoborine 277 was prepared in 3 steps by first preparing the corresponding boronic acid aldehyde in analogous fashion to example 90 except that aldehyde 270 used in place of aldehyde 93. Benzodiazoborine 277 was then prepared using the analogous procedure as example 96 except that 4-butoxy-2-formylphenylboronic acid was used in the place of 98. [M-
H]" = 218.1 m/z. Activity: C.
Figure imgf000264_0002
Benzothiazole 278 was prepared in 3 steps by first forming the benzothiazole from 2- amino-5-chlorothiophenol and 3-phenylpropionic acid using Method 13 followed by conversion to the boronate ester using Method 15 followed by Method 5. [M-H]~=282.2 m/z. Activity: A.
Example 242
Figure imgf000265_0001
279
Piperidine 279 was prepared in 3 steps starting from l-Boc-4(4- boronophenyl)piperidine pinacol ester 233 which was first deprotected as described in Example 204. This salt (150 mg, 0.374 mmol) was dissolved in tetrahydrofuran (5 mL) and treated with triethylamine (41.6mg, 0.411 mmol, 1.1 eq.) and benzaldehyde (43.6 mg, 0.411 mmol, 1.1 eq.) and stirred for 30 minutes while being cooled in an ice bath. To this solution sodium triacetoxyborohydride (87mg, 0.411 mmol, 1.1 eq.) was added in portions and the reaction was allowed to warm to ambient temperature and stir for 16h. The reaction was diluted with ethyl acetate (50 mL) and washed with water (2 X 15mL). The organic layer was dried over magnesium sulfate , filtered and evaporated onto silica gel. Purification using silica gel chromatography (gradient of 0 to 20% ethyl acetate/hexanes) gave 1 -benzyl— 4-(4- boronophenyl)piperidine pinacol ester. Deprotection of this ester via Method 5 gave compound 279 (30mg, 30%). [M-H]~=294.2 m/z. Activity: C.
Example 243
Figure imgf000265_0002
Piperidine 280 was prepared using the analogous procedure as example 242 except that 4-isopropylbenzaldehyde was used in place of benzaldehyde. [M-H]~=336.3 m/z. Activity: B. Example 244
Figure imgf000266_0001
281
Oxadiazole 281 was prepared in 2 steps by first forming the oxadiazole from 2-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzoic acid and hexanoic hydrazide using Method 8 followed by Method 5 and was isolated and purified by using flash silica gel chromatography. [M-H]" = 259.1 m/z. Activity: D
Example 245
Figure imgf000266_0002
282 2-Bromobenzhydrazide (1.03 g, 4.8 mmol, 1.0 equiv) and l,l '-carbonyldiimidazole
(1.01 g, 6.23 mmol, 1.3 equiv) were heated in 1,4-dioxane (20 mL) for 4 h at 80 0C. The mixture was concentrated in vacuo, and the resulting residue split between ethyl acetate and water (100 mL each). The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to afford a white solid (1.1 g, 95% yield). A portion of this intermediate oxadiazolidinone (820 mg, 3.4 mmol, 1.0 equiv) was suspended in a solution of dimethylamine (2.0 M in THF, 20 mL) and stirred at 23 0C overnight. The resulting solution was concentrated in vacuo; the residue was re-suspended in dry dichloromethane (30 mL) and concentrated in vacuo. This residue was again re-suspended in dry dichloromethane (5 mL) and treated with p- toluenesulfonyl chloride (681 mg, 3.57 mmol, 1.05 equiv) and triethylamine (1.2 ml, 8.5 mmol, 2.5 equiv). After stirring at 23 0C for 16h, the mixture was split between ethyl acetate and water (50 mL each), and the organic layer was washed with brined and dried over sodium sulfate. Concentration in vacuo gave a residue which, upon purification by silica gel chromatography (3 O-M 00% ethyl acetate / hexanes) gave dimethylamino-oxadiazole as a white solid. This bromide was converted to the boronic acid by Method 1 , and was isolated and purified by using flash silica gel chromatography to provide 282 as a white solid. [2M-H2O]" = 447.1 m/z. Activity: D
Example 246
Figure imgf000267_0001
283
2-Bromobenzhydrazide (500 mg, 2.32 mmol, 1.0 equiv) and isobutyryl chloride (372 mg, 3.49 mmol, 1.5 equiv) were stirred with sodium bicarbonate (590 mg, 7.0 mmol, 3.0 equiv) in water and 1,4-dioxane (10 mL each), at 0 0C for Ih. The mixture was split between ethyl acetate and water (50 mL each), and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to a white solid. This solid was dissolved in dry dichloromethane (5 mL), and the solution was concentrated to 2.5 mL in vacuo. This solution was treated with p- toluenesulfonyl chloride (465 mg, 2.44 mmol, 1.05 equiv) and triethylamine (0.8 ml, 5.8 mmol, 2.5 equiv) and stirred at 23 0C for 16 h. The mixture was split between ethyl acetate and water (50 mL each), and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to give oxadiazole as a clear oil. This bromide was converted to the boronic acid by Method 1, and was isolated and purified by using flash silica gel chromatography to provide 283 as a white solid. [M-H]" = 231.1 m/z. Activity: D
Example 247
Figure imgf000267_0002
284 Oxadiazole 284 was prepared using the analogous procedure as example 246 except that isovaleryl chloride was used in place of isobutyryl chloride. [M-H]" = 245.1 m/z. Activity: D.
Example 248
Figure imgf000268_0001
285
Oxadiazole 285 was prepared in 2 steps by first forming the oxadiazole from 2-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)benzhydrazide and 3,3,3-trifluorobutanoic acid using Method 7 followed by Method 5 and was isolated and purified by using flash silica gel chromatography. [M-H]" = 285.0 m/z. Activity: D
Example 249
Figure imgf000268_0002
286
2-Bromobenzhydrazide (500 mg, 2.32 mmol, 1.0 equiv) and ethyl chloroformate (359 mg, 2.88 mmol, 1.2 equiv) were stirred with sodium bicarbonate (605 mg, 7.2 mmol, 3.0 equiv) in water and 1,4-dioxane (10 mL each), at 0 0C for Ih. The mixture was split between ethyl acetate and water (50 mL each), and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to a white solid. This solid was dissolved in dry dichloromethane (5 mL), and the solution was concentrated to 2.5 mL in vacuo. This solution was treated with /?-toluenesulfonyl chloride (480 mg, 2.52 mmol, 1.05 equiv) and triethylamine (0.84 ml, 6.0 mmol, 2.5 equiv) and stirred at 23 0C for 16 h. The mixture was split between ethyl acetate and water (50 mL each), and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to give oxadiazole as a clear oil. This bromide was converted to the boronic acid by Method 3 followed by method 5, and purification using silica gel chromatography gave the 286 as a white solid. [2M-H2O]" = 488.8 m/z. Activity: D
Example 250
Figure imgf000269_0001
287
Figure imgf000269_0002
The pinacol ester of compound 100 (18 mg, 0.04 mmol, 1.0 equiv) was dissolved in 3:1 tetrahydrofuran/water (1.2 mL) and stirred with lithium hydroxide (6 mg, 0.26 mmol, 6.0 equiv) at 50 0C for 2 h. The mixture was diluted with ethyl acetate (50 mL), washed with IN aqueous HCl (100 mL) and then brine (15 mL) and concentrated in vacuo to yield 17 mg of crude carboxylic acid, which was used in the next step without purification.
Carboxylic acid (8 mg, 0.02 mmol, 1.0 equiv) was dissolved in dry dichloromethane (1 mL) and treated with 3-aminomethyl pyridine (4 mg, 0.04 mmol, 2.0 equiv), HBTU (8 mg, 0.03 mmol, 1.5 equiv) and 1Pr2EtN (8 mg, 0.06 mmol, 3.0 equiv). The mixture was stirred at 23 0C for 16 h and then split between 5% aqueous sodium bicarbonate and ethyl acetate (20 mL each). The organic layer was concentrated in vacuo to yield 10 mg crude product. The crude product was cleaved by Method 5 to produce the arylboronic acid 287 after HPLC purification. [M-H]" = 401.2 m/z. Activity: D Example 251
Figure imgf000270_0001
288
Boronic acid 288 was prepared using the analogous procedure as example 250 except 2- furylmethylamine was used in place of isobutyryl chloride. [M-H]" = 390.2 m/z. Activity: D.
Example 252
H
Figure imgf000270_0002
289
A mixture of l-bromo-2-fluoro-4-iodobenzene (460 mg, 1.5 mmol, 1.0 equiv), 3- isopropylphenyl-boronic acid (250 mg, 1.5 mmol, 1.0 equiv), Pd(PPh ) Cl (35 mg, 0.05 mmol, 0.03 equiv) and NaHCO (640 mg, in 4 mL water) were added to a flask and dioxane (4 mL) was added. The mixture was purged with argon for 5 min, and then stirred at 80 0C under an argon atmosphere for 6 h. The reaction was diluted with ethyl acetate (200 mL), washed with 60 mL water, then 40 mL brine, dried and concentrated. Purification via silica gel column chromatography with (gradient of 0-2.5% ethyl acetate/hexanes) gave desired the biphenyl bromide as yellow oil 340 mg. The biphenyl bromide was converted to 289 by Method 1. [M- H]" = 357.1 m/z. Activity: A Example 253
Figure imgf000271_0001
Part A
To a solution of 2-amino-4-bromophenol (2 g, 8.9 mmol, 1.0 equiv) in HCl (5 M, 12.5 niL, 7.0 equiv) was added drop-wise a solution of sodium nitrite (0.62 g, 8.9 mmol, 1.0 equiv) in water (5 mL) at 0 0C. The mixture was stirred at this temperature for 30 min after which a cooled solution of KI (1.5 g, 8.9 mmol, 1.0 equiv) in H2O (14 mL) was slowly added at 0 0C. The mixture was then allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with ethyl acetate (200 mL) and the separated aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic fraction was washed with Na2S2O3 (10%, 40 mL), water (100 mL x 2) and brine (40 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by flash silica gel chromatography (ethyl acetate/hexanes) to afford 1.1 g 4-bromo-2-iodo-pheno as a yellow solid.
Part B
Cu2O
Pyridine
Figure imgf000271_0002
Figure imgf000271_0003
290 291
4-Phenyl-l-pentyne (131 mg, 1.0 mmol, 1.0 equiv) was added to a suspension of 4- bromo-2-iodophenol (300 mg, 1.0 mmol, 1.0 equiv) and Cu2O (85 mg, 0.6 mmol) in dry pyridine (4 mL). The mixture was refluxed under nitrogen for 4 h. The mixture was filtered through celite and washed with ethyl acetate. The pyridine was evaporated under reduced pressure, and the residue was purified by chromatography (combiflash, hexane) gave partially pure desired product 290 (276 mg). The benzofuran bromide 290 was converted to desired boronic acid 291 by Method 3 followed by Method 5. [M-H]" = 265.0 m/z. Activity: A.
Example 254
Figure imgf000272_0001
293
Part A
6-Chloro-2-phenethylbenzofuran 292 was prepared using the analogous procedure as example 253 except 2-amino-5-chlorophenol hydrochloride was used in place of 2-amino-4- bromophenol.
Figure imgf000272_0002
292 293
Part B
Benzofuran 293 was synthesized from 292 according to the following procedure: 292 (160 mg, 0.6 mmol, 1.0 equiv), tetramethyl dioxaborolane (160 mg, 1.2 mmol, 2.0 equiv), phospine ligand and palladium diacetate were added together in to 8 mL toluene. The mixture was purged with Ar for 5 min, and then was heated to 80 0C for 5 h. The reaction was cooled to room temperature and water (20 mL) was added after which diethyl ether (3 x 50 mL) was used to extract the product. The organic layer was washed with brine, dried (Na2SO4), and concentrated. Purification on combiflash (10-15-20% ethyl acetate in hexanes) gave 50 mg of the desired pinacol ester. This was converted to compound 293 by Method 5. [M-H]" = 265.2 m/z. Activity: A. Example 255
Figure imgf000273_0001
296
Part A
I ) Cs2CO3, CuI
Figure imgf000273_0002
Figure imgf000273_0003
294
A mixture of 3-iodopyridine (980 mg, 4.8 mmol, 1.0 equiv), 2-bromo-5- hydroxybenzaldehyde (960 mg, 4.8 mmol, 1.0 equiv), cesium carbonate (3.11 g, 9.6 mmol, 2.0 equiv), copper iodide (182 mg, 0.96 mmol, 0.2 equiv), and JV,JV-dimethylglycine HCl salt (533 mg, 3.8 mmol, 0.8 equiv) are suspended in 10 mL of dioxane in a sealed tube and heated to 90 C under a nitrogen atmosphere. After 16h, the cooled mixture was filtered through a bed of celite with small amount of silica gel on top of it. Ethyl acetate (3 x 20 mL) was used to wash the celite. The filtrate was concentrated in vacuo. The residual oil was loaded on a silica gel column and eluted with ethyl acetate/hexanes (15-20%) to afford 0.4 g of the corresponding aldehyde. A solution of the aldehyde (160 mg, 0.58 mmol, 1.0 equiv) in tetrahydrofuran (10 mL) is placed in a flask with stir bar and isoprene (404 mg, 5.8 mmol, 10 equiv), 2.7M phosphate buffer (1.7 mL, 4.6 mmol, 8.0 equiv), and NaClO2 (208 mg, 2.3 mmol, 4.0 equiv) are added. The reaction is stirred at room temperature for 2h and stopped by the addition of water (30 mL), acidificaiton to pH 1 with 6M HCl, and extraction (3 x 50 mL methylene chloride). The organic layers are dried on Na2SO4 and concentrated to give 294 as a white foam (182 mg), which is used without further purification.
Part B
Figure imgf000274_0001
A solution of the acid 294 (140 mg, 0.48 mmol, 1.0 equiv) in methylene chloride (5 mL) is treated with oxalyl chloride (91 mg, 0.71 mmol, 1.5 equiv) followed by a drop of N, N- dimethylforamide and stirred 23 0C for 3h. The mixture was concentrated in vacuo and resuspended in methylene chloride (6 mL). To this mixture were treated with triethylamine (96 mg, 0.96 mmol, 2.0 equiv) followed by butyric hydrazide (73 mg, 0.71 mmol, 1.5 equiv) and catalytic DMAP. After 20 min at 23 0C, the reaction mixture was split between water and methylene chloride. The aqueous layer was back extracted again with methylene chloride. The combined organics were washed with 5% NaHCO3 and then brine, dried over sodium sulfate and concentrated in vacuo to yield 150 mg crude material. The crude material was suspended in POCl3 (6 mL) and heated at 90 0C for 2h after which point the mixture was poured into ice water. Methylene chloride was used to extract the aqueous layer and the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. HPLC purification (FA 10-80) gave oxadiazole 295 (8 mg), which was converted to compound 296 by Method 1. [M+H]+ = 326.0 m/z. Activity: B. Example 256 H
Figure imgf000275_0001
297
4-Bromo-3-fluorophenol (200 mg, 1.0 mmol, 1.0 equiv), 5-fluoropyridin-3-ylboronic acid (221 mg, 1.5 mmol, 1.5 equiv), copper (II) acetate (190 mg, 0.481 mmol, 1.0 equiv) and 4A MS were suspended in 10 mL methylene chloride. Triethylamine (530 mg, 5.0 mmol, 5.0 equiv) was then added after which point the reaction turned from blue to brown and was stirred at room temperature for 16h under ambient atmosphere after which poin the reaction turned back blue.
The slurry was filtered through a small pad of celite and washed with 30% ethyl acetate in hexanes. The combined filtrate was concentrated in vacuo. Purification using flash silica gel chromatography gave the desired biaryl bromide (45 mg) which was converted to boronic acid
297 by Method 1. [M-H]" = 250.1 m/z. Activity: A.
Example 257
Figure imgf000275_0002
Biaryl boronic acid 298 was prepared using the analogous procedure as example 256 except that 4-fluoropyridin-3-ylboronic acid was used in place of 5-fluoropyridin-3-ylboronic acid. [M-H]" = 250.1 m/z. Activity: A.
Figure imgf000276_0001
299 l-Boc-piperidin-4-ylacetic acid (1.7 g, 7.0 mmol, 1.0 equiv) and 4-chloro aminophenol
(1.0 g, 7.0 mmol, 1.0 equiv) were added to a sealed flask. Acetonitrile (20 mL) was added followed by triphenylphosphine resin (11.1 g, 1.88 mmol/g, 4.0 equiv) and trichloroacetonitrile
(2.0 g, 14 mmol, 2.0 equiv). The flask was sealed and heated at 100 0C for 20 h and cooled to room temperature. The resin was rinsed with excess tetrahydrofuran /methylene chloride (1 :1). The resulting filtrate was then concentrated to yield the corresponding Boc-deprotected benzoxazole chloride. The solid was washed with 30% ethyl acetate in hexanes to get rid of the non polar impurities and used directly in next step.
To a solution of the amine (1.2 g, 4.8 mmol, 1.0 equiv) and triethylamine (1.5 g, 14.4 mmol, 4.0 equiv) in 70 mL of methanol was added di-tert-buty{ dicarbonate (1.3 g, 5.7 mmol, 1.2 equiv) and the mixture stirred at room temperature for 24 h. The solvent was evaporated and the residue was suspended in 100 mL of ethyl acetate. The mixture was washed with a saturated sodium bicarbonate solution (50 mL) and subsequently with water (2x100 mL). The organic layer was dried with anhydrous sodium sulfate and concentrated. The Boc-protected benzoxazole chloride 1.2 g was obtained as yellow oil and was used directly in the conversion to the boronate ester using Method 15 to provide pinacol ester 300 followed by Method 5 to provide 299. [M-H]" = 359.1 m/z. Activity: A.
Example 259
Figure imgf000276_0002
301
Figure imgf000277_0001
Boc protected benzoxazole pinacol ester 300 (600 mg, 1.4 mmol, 1.0 equiv) is stirred in trifluoroacetic acid (6 mL) for Ih, after which point the solution was evaporated under reduced pressure. The crude material was azeotroped twice with toluene (75 mL) after which point the piperidine salt was used directly in the next step.
The crude amine TFA salt (200 mg, 0.45 mmol, 1.0 equiv) is dissolved in 4 mL dry methylene chloride. Triethylamine (181 mg, 1.82 mmol, 4.0 equiv) and 4- isopropylbenzaldehyde (135 mg, 0.9 mmol, 2.0 equiv) were added followed by the addition of sodium triacetoxyborohydride (386 mg, 1.82 mmol, 4.0 equiv). The reaction was stirred at room temperature for 20 h then concentrated. Methanol was added to the residue to quench the unreacted borohydride after which point the crude material was directly purified with HPLC (FA 10-80) to give 50 mg of pure pinacol ester, which was converted to compound 301 by Method 5. [M-H]" = 391.2 m/z. Activity: B
Example 260
Figure imgf000277_0002
302
Benzoxazole 302 was prepared using the analogous procedure as example 259 except that benzaldehyde was used in place of 4-isopropylbenzaldehyde. [M-H]" = 349.2 m/z. Activity: B. Example 261
Figure imgf000278_0001
303
Benzoxazole 303 was prepared using the analogous procedure as example 259 except that propionaldehyde was used in place of 4-isopropylbenzaldehyde. [M-H]" = 301.2 m/z. Activity: C.
Example 262
Figure imgf000278_0002
304
Benzoxazole 304 was prepared using the analogous procedure as example 259 except that isobutyraldehyde was used in place of 4-isopropylbenzaldehyde. [M-H]" = 315.2 m/z. Activity: D.
Example 263
Figure imgf000278_0003
305 Boc-protected benzoxazole pinacol ester 300 is deprotected as in example 259 and the crude amine TFA salt (190 mg, 0.43 mmol, 1.0 equiv) is dissolved in 5 mL dry methylene chloride. Triethylamine (175 mg, 1.73 mmol, 4.0 equiv) followed by benzenesulfonyl chloride (153 mg, 0.86 mmol, 2.0 equiv) were added. The reaction was stirred at room temperature for 20 h and then concentrated under reduced pressure. Methanol was added to the residue and the crude material was directly purified with HPLC (FA 10-80) to give 70 mg pure sulfonamide pinacol ester product, which was converted to compound 305 by Method 5. [M-H]" = 399.0 m/z. Activity: B.
Figure imgf000279_0001
306
Boc-protected benzoxazole pinacol ester 300 is deprotected as in example 259 and the crude amine TFA salt (200 mg, 0.45 mmol, 1.0 equiv) is dissolved in 5 mL dry methylene chloride. Triethylamine (181 mg, 1.8 mmol, 4.0 equiv) and hydrocinnamoyl chloride (154 mg,
0.9 mmol, 2.0 equiv) were added. The reaction was stirred at room temperature for 20 h and then concentrated. Methanol was added to the residue and the crude material was directly purified with HPLC (FA 10-80) to give 60 mg pure amide pinacol ester product, which was converted to compound 306 by Method 5. [M-H]" = 391.1 m/z. Activity: A.
Example 265
Figure imgf000279_0002
307
5-Bromophthalic anhydride (1.0 g, 4.4 mmol) in ethanol (10 mL) was treated with n- amylamine (562 uL, 4.9 mmol, 1.1 eq.) and heated at reflux overnight. The mixture was diluted into 0.1M HCl (100 mL) and the resulting white solid collected by filtration, washed with water, and dried in vacuo to give 136 mg of the corresponding phthalimide as a white solid. The filtrate was diluted with brine and chilled at -20 0C for 2d. A second crop of precipitate was collected, washed with water, and dried in vacuo to give another 116 mg phthalimide as a white solid. The crops are identical by NMR and combined to give a total yield of 252 mg (0.85 mmol, 19%).
This material was used without further purification.
This precipitated phthalimide (250 mg, 0.84 mmol) was converted using methods 3 followed by method 5, to form boronic acid 307 (22 mg, 10 %) as a white solid. [M-H]" = 260.1 m/z. Activity: A. Example 266
Figure imgf000280_0001
308
5-Bromo-2-benzylphthalimide was produced from 5-bromophthalic anhydride (1.0 g, 4.4 mmol) using the analogous procedure as example 265 except that benzylamine was used in the place of n-amylamine, to provide 421 mg (30%) of product as a white crystals.
This precipitated phthalimide (200 mg, 0.63 mmol) was converted using methods 3 followed by method 5, to form boronic acid 308 (67 mg, 38 %) as an off-white solid. Activity: A.
Example 267
Figure imgf000280_0002
309
5-Bromo-2-phenethylphthalimide was produced from 5-bromophthalic anhydride (1.0 g, 4.4 mmol) using the analogous procedure as example 265 except that phenethylamine was used in the place of n-amylamine, to provide 521 mg (36%) of product as a white crystals.
This precipitated phthalimide (270 mg, 0.82 mmol) was converted using methods 3 followed by method 5, to form boronic acid 309 (106 mg, 44%) as a brownish powder. [M-H]" = 294.0 m/z. Activity: A.
Example 269
Figure imgf000280_0003
311
3-Fluoro-4-bromotoluene (5.0 g, 27 mmol) in carbon tetrachloride (50 mL) was treated with N-bromosuccinimide (7.0 g, 40 mmol, 1.5 eq) and heated to 80 0C. Benzoyl peroxide (65 mg, 0.27 mmol, 0.01 eq.) was added and heating was continued for Ih. The reaction was then cooled to ambient temperature and filtered, and the filtercake was washed sparingly with chloroform. The filtrate was washed with water and brine, dried over Na2SO4, and concentrated to give crude 3-fluoro-4-bromobenzyl bromide as a clear oil which was used without further purification.
This crude benzyl bromide (27 mmol) and sodium cyanide (2.38g, 54 mmol, 2.0 eq.) were combined in ethanol (100 mL) and heated at 80 0C for 2h. The reaction mixture was concentrated to dryness in vacuo, suspended in water, and extracted with ethyl acetate. Washing with brine and drying over Na2SO4 gave, after removal of the solvent, a red oil which was purified using silica gel chromatography (gradient of 2->12% ethyl acetate/hexanes) to provide 3-fluoro-4-bromophenylacetonitrile as white needles (1.96g, 35% over 2 steps). A solution of lithium aluminum hydride (IM in THF, 14 mL, 14 mmol, 3.0 eq.) was chilled in an ice bath and slowly treated with sulfuric acid (390 uL, 7.0 mmol, 1.5 eq.). After the visible reaction was complete, a solution of the nitrile produced above (1.0 g, 4.7 mmol) in tetrahydrofuran (10 mL) was dripped in to the mixture slowly. The mixture was stirred at 0 0C for 20 min, then refluxed for 30 min. After cooling to room temperature, the excess reagents were quenched with 2-propanol, followed by 4M NaOH. After stirring to assure complete reaction, the resulting suspension was filtered through celite and the fϊltercake was washed well with 2-propanol. The filtrate was concentrated to give crude 3-fluoro-4-bromophenethylamine as a clear oil which was used without further purification.
This crude material (4.7 mmol) was dissolved in methylene chloride (10 mL) and treated with potassium carbonate (1.0 g, 7.0 mmol, 1.5 eq.) and di-tert-butyldicarbonate (1.15g, 5.2 mmol, 1.1 eq). The mixture was stirred at ambient temperature for 2 days, then diluted with water, extracted into MTBE, washed with brine, dried over Na2SO4, and concentrated to a white solid which contains excess dicarbonate reagent. The material was taken up in ethanol (20 mL) and treated with imidazole (200 mg). After stirring for a few minutes, the solvent was removed under vacuum and the residue dissolved in methylene chloride, washed several times with 1% HCl, and concentrated to give crude N-Boc-3-fluoro-4-bromophenethylamine as a yellow solid which was used without further purification.
This crude material (4.7 mmol) was dissolved in N,7V-dimethylforamide (10 mL) and chilled in an ice bath. Sodium hydride dispersion (60% in mineral oil, 560 mg, 14 mmol, 3.0 eq.) was added and stirring continued until gas evolution ceased, then iodomethane (580 uL, 9.4 mmol, 2.0 eq,) was added and the mixture allowed to warm to room temperature. After stirring overnight, the mixture is diluted with MTBE, washed with water and brine, dried over Na2SO4, and concentrated to give crude Λf-methyl-ΛM3oc-3-fluoro-4-bromophenethylamine (916 mg, 59% over 3 steps).
This material (916 mg, 2.76 mmol) was converted to the pinacolatoboronate (351 mg, 34%) using Method 3. This boronate ester (70 mg) was converted, via Method 5, to provide boronic acid 311 (52 mg) as a colorless oil. [M-H]" = 296.2 m/z. Activity: A.
Figure imgf000282_0001
312 N-Methyl-N-Boc-3-fluoro-4-bromophenethylamine from Example 269 was converted to the corresponding boronate ester using method 3. This compound (280 mg, 0.74 mmol) was dissolved in trifluoroacetic acid (4 mL) and stirred for Ih. The acid was removed under vacuum, and was then azeotroped twice with toluene, to give the crude trifluoroacetate salt of N-methyl- 3-fluoro-4-pinacolboronato-phenethylamine as a clear viscous oil. This crude salt (100 mg, 0.25 mmol) was taken up in methylene chloride (5 mL) and treated with triethylamine (150 uL, 1.0 mmol, 4.0 eq.). Benzenesulfonyl chloride (40 uL, 0.31 mmol, 1.2 eq.) was added and the solution stirred at ambient temperature overnight. The mixture was diluted with methylene chloride and treated with silica gel. Concentration and purification using silica gel chromatography (gradient of 2->18% ethyl acetate/hexanes) provided the benzenesulfonamide derivative as a clear oil.
This material was converted, via Method 5, to provide boronic acid 312 (29 mg, 34%) as a white solid. [M-H]" = 336.3 m/z. Activity: A.
Figure imgf000282_0002
313 A solution of 2-fluoro-4-bromobenzaldehyde (5.09 g, 25 mmol) was dissolved in glyme (25 mL) and slowly treated over 10 minutes with anhydrous hydrazine (25 mL, 0.8 mol, 32 eq.). The resulting biphasic mixture was then held at reflux overnight. The reflux condenser was replaced with a short-path distillation head and about half the solvent distilled, at which time the reaction flask showed one phase and two phases were evident in the distillate. The undistilled residue was cooled and treated with water (25 mL), forming a white precipitate. This solid was collected by filtration, washed thoroughly with water, and dried in vacuo to give 6- bromoindazole (4.21 g, 85%) as white crystals.
6-Bromoindazole (3.63g, 18 mmol) was suspended in dioxane (15 mL) and benzyl bromide (2.65 mL, 22 mmol, 1.2 eq.) was added. The reaction was heated to reflux overnight, then allowed to cool to 80 0C after which point ethyl acetate (50 mL) added. The cake was broken up with a spatula and after stirring for 20 min, the solids were filtered off and washed with ethyl acetate, giving glossy white crystals of the hydrobromide salt of 2-benzyl-6- bromoindazole. These were suspended in ethyl acetate (100 mL) and shaken with saturated NaHCO3 (150 mL) until dissolution. The layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL). The combined organic layers were concentrated to an off- white powder which was recrystallized from 66% ethanol (40 mL). Washing with water and drying in vacuo gave 2-benzyl-6-bromoindazole (3.30g, 62%) as shiny white plates.
This material (3.0 g, 10.3 mmol) was converted to boronic acid 313 (1.8 g, 69%) as a white powder using method 3 followed by method 5. [M-H]" = 251.1 m/z. Activity: A.
Figure imgf000283_0001
6-Bromoindazole, produced in example 271 (300 mg, 1.5 mmol) and sodium hydroxide (90 mg, 2.3 mmol, 1.5 eq.) were suspended in dioxane (3 mL) and phenethyl bromide (500 uL,
3.6 mmol, 2.4 eq). was added. The reaction was heated to 80 0C for 4h. The product was extracted from water into MTBE, washed with brine, and dried with Na2SO4. Silica gel was added and the solvent removed after which purification using silica gel chromatography (gradient of 0— >12% ethyl acetate/hexanes) separated two products, l-phenethyl-6- bromoindazole (122 mg) and 2-phenethyl-6-bromoindazole (273 mg, 60%).
2-Phenethyl-6-bromoindazole (273 mg, 0.9 mmol) was converted to boronic acid 314 (152 mg, 63%) as an off-white foam using method 3 followed by method 5. [2M-H2O]" = 513.0 m/z. Activity: A.
Example 273
Figure imgf000284_0001
5-Bromoindazole, (300 mg, 1.5 mmol) and sodium hydroxide (90 mg, 2.3 mmol, 1.5 eq.) were suspended in dioxane (2 mL) and phenethyl bromide (500 uL, 3.6 mmol, 2.4 eq). was added. The reaction was heated to 80 0C for 4h. The product was extracted from water into MTBE, washed with brine, and dried with Na2SO4. Silica gel was added and the solvent removed after which purification using silica gel chromatography (gradient of 0->15% ethyl acetate/hexanes) separated two products, l-phenethyl-5-bromoindazole (134 mg) and 2- phenethyl-5-bromoindazole (228 mg, 50%). 2-Phenethyl-5-bromoindazole (228 mg, 0.76 mmol) was converted to boronic acid 315
(131 mg, 65%) as a tan foam using method 3 followed by method 5. [2M-H2O]" = 513.1 m/z. Activity: A.
Example 274
Figure imgf000284_0002
316 5-Bromoindazole, (500 mg, 2.5 mmol), tetrabutylammonium iodide (100 mg, 0.25 mmol, 0.1 eq.) and sodium hydroxide (150 mg, 3.8 mmol, 1.5 eq.) were suspended in para- xylene (10 mL) and benzyl bromide (360 uL, 3 mmol, 1.2 eq) was added. The reaction was heated to 130 0C overnight. The mixture was diluted with MTBE, washed with water and brine, and dried with Na2SO4. After partial concentration in vacuo to a xylene solution purification using silica gel chromatography (gradient of 0— > 10% ethyl acetate/hexanes) separated two products, l-benzyl-5-bromoindazole (364 mg) and 2-benzyl-5-bromoindazole (302 mg). l-Benzyl-5-bromoindazole (364 mg, 1.3 mmol) was converted to boronic acid 316 (126 mg, 40%) as a white solid using method 3 followed by method 5. [M-H]" = 251.1 m/z. Activity: A.
Example 275
Figure imgf000285_0001
317
5-Borono-2-aminopyridine pinacol ester (250 mg, 1.1 mmol) and 94%-pure 2- bromoacetophenone containing 2,2,-dibromoacetophenone (250 mg, 1.25 mmol, 1.1 eq.) were combined in ethanol (2.5 mL) and subjected to microwave heating at a temperature of 130 0C for 30 min. The solvent was removed in vacuo and the pinacol ester cleaved using method 5. Purification using silica gel chromatography of the product (gradient of 0->30% methanol/methylene chloride) afforded only one compound, brominated imidazopyridine boronic acid 317 (84 mg) as a yellow crystalline solid. [M-H]" = 317.0 m/z. Activity: A.
Example 276
Figure imgf000285_0002
318 l-Boc-4-(4-boronophenyl)piperazine pinacol ester (200 mg, 0.52 mmol) was converted, via method 5, to boronic acid 318 (121 mg, 77%) as a white solid. [M-H]" = 305.1 m/z. Activity: B.
Example 277
Figure imgf000285_0003
A solution of 2-chloro-6-bromoquinoline (250 mg, 1.0 mmol) and benzylnitrile (148 mg, 1.2 mmol, 1.2 eq.) in tetrahydrofuran (20 mL) was treated with 1.0M NaHMDS in THF (2.6 mL, 2.6 mmol, 2.5 eq.) and stirred at ambient temperature overnight. LC/MS showed complete conversion to the diarylacetonitrile intermediate. Saturated aqueous ammonium acetate (5 mL) and sodium peroxide (320 mg, 4.1 mmol, 4.0 eq.) were added and the solution stirred at room temperature for 24h. LC/MS indicated incomplete conversion, about 40%. The reaction mixture was diluted with MTBE, washed with water and brine, dried over Na2SO4, treated with silica gel, concentrated, and purified using silica gel chromatography (gradient of 0->8% ethyl acetate/hexanes), giving two products, 2-(6-bromoquinoline-2-yl)-2-phenylacetonitrile (185 mg) and 2-benzoyl-6-bromoquinoline (97 mg, 30%).
2-Benzoyl-6-bromoquinoline (97 mg, 0.31 mmol) was converted to boronic acid 319 (42 mg, 50%) as a brownish solid using method 3 followed by method 5. [M-H]" = 276.1 m/z. Activity: A.
Example 278
Figure imgf000286_0001
321
Tert-butyl 3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl) propionate (0.313 g) was dissolved in 5 mL of methylene chloride. Trifluoroacetic acid was added (0.5 mL) and the reaction was allowed to stir overnight at room temperature. The solvent and acid were then removed under vacuum and the crude mixture was azeotroped using toluene (2 x 50 mL) to provide crude deprotected acid 320 which was used directly. A portion of acid 320 (72 mg, 1.0 equiv) was dissolved in 1 rnL JV,Λf-dimethyl foramide, followed by the addition of PyBOP (190 mg, 1.0 equiv) and phenethylamine (50 μL, 1.11 equiv). Triethylamine (150 μL, 3.0 equiv) was then slowly added and the reaction was allowed to stir at room temperature for 30 min. After this point the reaction was transferred to a separatory funnel with excess water and ethyl acetate. The water layer was extracted with ethyl acetate (3 x 50 mL) and dried over Na2SO4 and concentrated. This residue was used directly to form the desired boronic acid 321 using method 5 and was purified using semi-preparatory reverse phase liquid chromatography. [M-H]" = 220.1m/z. Activity: C.
Example 279
Figure imgf000287_0001
Boronic acid 322 was prepared using the analogous procedure as example 278 except that l-(benzyloxycarbonyl)piperazine was used in place of phenethylamine. [M-H]" = 319.2 m/z. Activity: B.
Example 280
Figure imgf000287_0002
323
Boronic acid 323 was prepared using the analogous procedure as example 278 except that
1-Boc-piperazine was used in place of phenethylamine. [M-H]" = 285.2 m/z. Activity: C. Example 281
Figure imgf000288_0001
324
3-(4-Boronophenyl)propanoic acid (102 mg, 1.0 equiv) was dissolved in 2 niL N, N- dimethylforamide after which BOP (293 mg, 1.0 equiv), DIPEA (300 μL, 3.2 equiv) and benzylamine (100 uL, 1.78 equiv) were added and the reaction was allowed to stir for 16h at room temperature. After this point, 25 mL of water was added and the mixture was transferred to a separatory funnel. The water layer was extracted with ethyl acetate (2 x 50 mL). The organics were combined, dried over MgSO4, and concentrated to provide crude material that was purified by silica gel chromatography (gradient 50% ethyl acetate/hexanes to 1% methanol/ethyl acetate to provide 88 mg of boronic acid 324. [M-H]" = 282.2 m/z. Activity: C
Figure imgf000288_0002
325
4-Hydroxyphenylboronic acid (63 mg, 1.0 equiv) was suspended in 2 mL 5% sodium bicarbonate solution and a 12 mL of tetrahydrofuran/water solution is added (1 :1 v/v). 4-
(Bromomethyl)phenylboronic acid (116 mg, 1.2 equiv) was then added and the reaction was allowed to stir for 16h at room temperature. After this point, the tetrahydrofuran was removed under vacuum and the reaction was acidified to pH <2 with IN HCl. The mixture was transferred to a separatory funnel and the water layer was extracted with methylene chloride (2x75 mL). The organics were combined, dried over MgSO4 and concentrated to provide crude material that was purified by silica gel chromatography (gradient 50% ethyl acetate/hexanes to
5% methanol/ethyl acetate to provide boronic acid 325. [M-H]" = 271.1 m/z. Activity: C Example 283
Figure imgf000289_0001
326
3-Hydroxyphenylboronic acid (40 mg, 1.05 equiv) and 4-(bromomethyl)phenylboronic acid (65 mg, 1.0 equiv) were dissolved in 6 rnL solution of tetrahydrofuran/JV,jV- dimethylforamide (1 :1 v/v). Sodium hydride (36 mg, 5.0 equiv) is added and the reaction is allowed to stir at room temperature overnight. Water (25 mL) is then added and the reaction is acidified to pH < 2 with IN HCl and transferred to a separatory funnel. The water layer is washed with ethyl acetate (1 x 75 mL) and diethyl ether (1 x 75 mL). The water layer is then concentrated under vacuum to provide crude oil which is triturated with tetrahydrofuran and methanol to provide the desired boronic acid 326. [2M-SH2O]" = 488.0 m/z. Activity: A
Example 284
Figure imgf000289_0002
329
Part A
Figure imgf000289_0003
4-(l-Boc-piperidin-4-yl)-butanoic acid (6.45 g, 1.0 equiv) was dissolved in 40 mL methylene chloride and cooled to 0 0C in an ice bath. Ethyl chloroformate (2.9 mL, 1.28 equiv) was added followed, by Λ^Λ^-dimethylhydroxylamine hydrochloride (2.6 g, 1.1 equiv) and triethylamine (10 mL, 3.0 equiv). The reaction was allowed to warm to room temperature overnight during which time the was the formation of significant amounts of white precipitate. The reaction was then diluted with water (50 mL) and extracted with methylene chloride (2 x 75 niL). The combined organics were combined, dried over MgSO4, and concentrated to provide crude 327 which was used directly in the next step.
Oxazole (710 mg, 1.3 equiv) was dissolved in 5 mL of tetra hydro furan and cooled to -78 0C in a dry ice/acetone bath. Isopropyl magnesium chloride (5.0 mL, 2.0 M in diethyl ether, 1.23 equiv) was added over 5 minutes and the reaction was allowed to stir for 20 min at -20 0C during which time the solution turned orange. Weinreb amide 327 (2.56 g, 1.0 equiv) dissolved in 5 mL tetrahydrofuran was then added and the reaction was allowed to warm to room temp overnight. After this point, 40 mL of saturated ammonium chloride was added after which the reaction was transferred to a separatory funnel. The water layer was washed with diethyl ether (2x 100 mL). The organic layers were dried over MgSO4, filtered and concentrated to provide crude material which was purified using silica gel chromatography (gradient of 20-70 % ethyl acetate/hexanes) to provide 500 mg of ketooxazole 328. Part B
Figure imgf000290_0001
Ketooxazole 328 was dissolved in 15 mL diethyl ether. Anhydrous HCl was bubbled through the solution for a few seconds and allowed to stir for 20 min after which point TLC analysis indicated that there was no more starting material. The rxn was then concentrated and used directly.
4-(Bromomethyl)phenylboronic acid (125 mg, 1.03 equiv) and the HCl salt of 328 (146 mg, 1.0 equiv) were dissolved in 4 mL of methylene chloride. Hunig's base (300 μL) was added and the reaction was allowed to stir overnight with the formation of a significant amount of solid in the flask. The reaction is quenched with water and acidified to pH < 2 with IN HCl. However in this case the product stayed in the water layer. The organic layer was removed and a 5% solution of sodium carbonate was added which caused the desired product to crash out the water layer to provide boronic acid 329. [M-H]" = 355.1 m/z. Activity: C. Example 285
Figure imgf000291_0001
BIOLOGICAL PROTOCOLS
Example 286 Inhibition of Rat and Human FAAH The following assays may be used to determine the inhibition of FAAH by the compounds of the present invention: (1) a fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening as described in Manjunath et al., Analytical Biochemistry (2005) 343:143-151; and (2) a high-throughput screening for the discovery of inhibitors of fatty acid amide hydrolase using a microsome-based fluorescent assay. Wang et al., Biomolecular Screening (2006) 1-9.
Rat FAAH Preparation: Five rat livers were homogenized in five fold volume with ice cold Tris (20 mM pH 8.0) and 0.32 M Sucrose solution via an Ultra Turrax T25 homogenizer. All subsequent preparation steps were carried out at 4 0C. The homogenate was centrifuged at 6000 g, for 20 minutes and the pellet, containing nuclear debris and mitochondria was discarded. The supernatant was centrifuged at 40,000 g for 30 minutes. The supernatant was discarded and the pellet solubilized via a dounce homogenizer in resuspension buffer (20 mM Hepes pH 7.8, 10% v/v glycerol, 1 mM EDTA, 1% triton X-100) overnight at 40C to resolubilize membrane bound FAAH. The solution was centrifuged at 40,000 g for 30 minutes and the pellet discarded. The supernatant containing rat FAAH was aliquoted and flash frozen with liquid nitrogen and stored for long term usage at -80 0C.
Human FAAH Preparation: COS-7 cells were split the day before, 1 :5 into 150 mm x 25 mm cell culture dishes (Corning Inc., Cat. No. 430599). Transient transfection took place at 30- 40% confluency according to FuGENE 6 Transfection Reagent (Roche, Cat. No. 11814 443 001). Transfection Procedure: The FuGENE transfection 6 reagent (45uL) was added to 1410 μL of media (DMEM, serum free without pen/strep) in a 15 mL conical tube and incubated at room temp for 5 minutes, followed by the addition of FAAH plasmid DNA (15 μg) (OriGene Cat. No. TCl 19221, Genbank Accession No. NM 001441.1, 0.67 ug/uL) and a further incubation of 15 minutes at room temperature. The resulting solution was added into one dish of 30-40% confluent COS-7 cells in a drop-wise manner. The COS-7 cell dish was subsequently incubated for 48 hours. The cells are then harvested. Harvest procedure: Media was aspirated from the dishes and the cells rinsed with 1OmL
PBS. The PBS was removed and 3 mL of PBS added to the dish. The dish was scraped to resuspend the cells, and the subsequent cell suspension collected into a 15 mL conical tube. The cells were pelleted by centrifugation at 1200 rpm for 5 minutes in a bench top centrifuge. PBS was removed and the cell pellet snap frozen in liquid nitrogen and stored at -80 0C.
COS-7 cells - FAAH purification:
(1) Fractionation: Frozen cell pellets from transient transfections were thawed on ice and resuspended in 12.5mM Hepes pH 8.0, 10OmM NaCl, ImM EDTA (10 mL/0.2 g cell pellet). The pellets were dounce homogenized and then sonicated to produce cell extract. The cell extract was subsequently centrifuged at 1000 g to remove cellular debris. The pellet was discarded and the supernatant centrifuged at 13,000 g for 20 minutes. The pellet contained membrane bound FAAH. The supernatant was discarded and the pellet resolubilized.
(2) Re-so lubilization: The fraction of interest, (13,000g, membrane fraction) was re- suspended in 2.3 mL re-suspension buffer (2OmM Hepes pH 7.8, 10%v/v Glycerol, 1 mM EDTA, 1% Triton X-100) and the sample incubated on ice for 1 hour and then centrifuged to remove any particulate matter. The supernatant containing solubilized human FAAH was aliquoted and snap frozen in liquid nitrogen and stored at -80 0C until use. (3) Characterization: Protein Concentration determined by Bradford assay.
SDS gel and Western blot to confirm presence of FAAH FAAH activity assay Km determination - 96-well assay Linear dependence - 96-well assay Standard compound Ki determination - 384-well assay
Rat FAAH Biochemical Inhibition Assay; Materials and methods: Rat FAAH biochemical assays were carried out in a 96 well flat bottom black non-treated polystyrene plates (Corning Costar Catalogue # 3915). FAAH reaction buffer: 50 mM Hepes (pH 7.5), 1 mM EDTA, 0.2% Triton X-100. FAAH substrate- AMC Arachidonoyl Amide (Cayman Chemicals Company, Catalog # 10005098). The reaction was read in an Envision microtiter plate reader [Excitation filter 355 nm (40 nm bandpass); Emmision filter 460 nm (25 nm bandpass)]. The raw fluorescence was plotted on the y axis and the inhibitor concentration on the x axis to give a dose response inhibition curve. The data was fitted to a single site competitive inhibition equation, fixing the Km for the rat and human enzyme to 12 μM and 9 μM respectively.
Rat FAAH Biochemical Inhibition Assay; Experimental Protocol: The principle of this assay was the hydrolysis of AMC-Arichodonoyl, a fluorescent analogue of Anandamide, which results in the formation of Arachidonic acid and AMC. The formation of AMC results in an increase in fluorescence (see, for example, Manjunath et al., Analytical Biochemistry (2005) 343:143-151; and Wang et al., Biomolecular Screening (2006) 1-9). The inhibition of product formation and hence fluorescence as a function of inhibitor concentration enables the determination of Ki for the compounds .
A 0.49 mg/ml Rat liver FAAH solution was made up in FAAH reaction buffer, and 78 ul pipetted into a 96 well plate. To this was added 2 uL of a 3 fold serially diluted inhibitor from a DMSO stock solution. The FAAH solution and inhibitor were incubated for 30 minutes at room temperature. The FAAH reaction was initiated by the addition of 80 μL of 40 μM AMC Arachidonoyl Amide in FAAH reaction buffer, yielding a final reaction FAAH rat liver preparation concentration of 0.25 mg/mL and AM C- Arachidonoyl substrate concentration of 20 μM, reaction volume 160 μL. The reaction was allowed to proceed for 4 hours at room temperature. The reaction was stopped by the addition of 80 μL 12 uM a-ketoheterocycle (Cayman Chemicals, catalogue # 10435). The microtiter plate was read in the envision plate reader.
Human FAAH assay; Experimental Protocol: A 0.1 mg/mL Human FAAH solution was made up in FAAH reaction buffer, and 24 ul pipeted into a 384 well plate. To this was added 1 μL of a 3 fold serially diluted inhibitor from a DMSO stock solution. The FAAH solution and inhibitor were incubated for 30 minutes at room temperature. The FAAH reaction was initiated by the addition of 25 μL of 40 μM AMC Arachidonoyl Amide in FAAH reaction buffer, yielding a final reaction human FAAH preparation concentration of 0.05 mg/ml and AMC- Arachidonoyl substrate concentration of 20 μM, reaction volume 50 μL. The reaction was allowed to proceed for 4 hours at room temperature. The reaction was stopped by the addition of 25 μL 12 μM a-ketoheterocycle (Cayman Chemicals, catalogue # 10435). The microtiter plate was read in the envision plate reader. The raw fluorescence was plotted on the y axis and the inhibitor concentration on the x axis to give a dose response inhibition curve. The data was fitted to a single site competitive inhibition equation, fixing the Km for the rat and human enzyme to 12 μM and 9 μM respectively. Example 287
Inhibition of FAAH in its native cellular environment
Cellular FAAH inhibition assay: This assay measures the activity of FAAH in its native cellular environment. Radiolabeled anandamide, tritiated on its ethanolamine component was added to a cell suspension. Anadamide diffuses into the cell, whereby the native cellular FAAH hydro lyses anandamide into arachdonic acid and ethanolamine. The cellular reaction was quenched in a methanol/chloroform mixture. Ethanolamine partitions into the aqueous phase and was counted via a scintillation counter giving a measure of cellular FAAH activity. Inhibition studies were performed by pre-incubating the cells with serially diluted inhibitor, followed by the addition of radiolabeled anandamide. Cell preparation: RBL-2H3 and T-47D adherent cells were cultured via the standard protocols. Cells were trypsinized and washed 3 times in RPMI buffer plus 0.1% BSA. The cells were resuspended, counted and diluted to a final cell density of 1 x 106 cells/mL. Human PBMC were isolated from whole blood and used at a final cell density of 4.5 x 106 cells/mL in RPMI plus 0.1% BSA buffer. Anandamide substrate solution: A lO nM H anandamide substrate solution was prepared by diluting from a 16.7 μM (lμCi / μL) stock in RPMI buffer plus 0.1% BSA, and incubated at room temperature for 90 minutes. A substrate-inhibitor solution was made by adding serially diluted inhibitor from a DMSO stock solution to the desired concentration into the substrate solution. Assay: A 350 μL cell suspensions was incubated with serially diluted inhibitor added from a
DMSO stock and incubated for 30 minutes with constant agitation. Cells were pelleted and the supernatant removed. The cells were resuspended in 300 μL of 10 nM substrate + serially diluted inhibitor, to maintain a constant free inhibitor concentration during the time-course of the reaction. The RBL-2H3 and T-47D cells were incubated with the substrate - inhibitor for 5 minutes and PBMC for 15 minutes. The reaction was quenched by the addition of 700 μL of methanol : chloroform (1 :1 v/v), which lyses the cells and inactivates FAAH. Sampled were vortexed and centrifuged to separate the aqueous and organic solutions. 3H ethanolamine, the polar product of anandamide hydrolysis partitions into the aqueous phase and was counted via a scintillation counter.
Data Analysis: The radioactivity in the aqueous phase was plotted with respect to inhibitor concentration to generate dose response inhibition curves, and the data fitted to determine the IC50.
Example 288 FAAH Cell-Based Assay Protocol for Human and Rat Whole Blood
This assay measures the cellular activity of FAAH in whole blood via the hydrolysis of radiolabeled anandamide by the same methodology and principle used in the cell based assay described in Example 172. FAAH is found to be expressed in the cells of the immune system.
Substrate Solution: H Anandamide (1 μC/μL, 16.7 μM stock) was added to a final concentration of 40 nM (4x) for the human whole blood assays and 20 nM (2x) for rat whole blood assays to the RMPI buffer plus 0.1% BSA. The H anandamide stock solutions were incubated for 90 minutes at room temperature prior to use in the whole blood assay.
Human whole Blood Cellular FAAH assay: Human blood (262.5 μL) was pre- incubated with serially diluted inhibitor added from DMSO stock solution for 30 minutes. The assay was initiated by the addition of 40 nM 3H anandamide ( 87.5 μL) yielding a final assay volume of 350 μL and 3H anandamide substrate concentration of 10 nM. The reaction mixture was incubated for 30 minutes at room temperature, and the reaction stopped by the addition of 700 μL of methanol: chloroform (1 :1 v/v). This lyses the cells and inactivates the FAAH. The solution was vortexed and 3H ethanolamine, the radiolabeled product of 3H anandamide hydrolysis partitioning into the aqueous phase, and was counted via a scintillation counter.
Rat whole Blood Cellular FAAH assay: Rat blood (175 μL) was pre-incubated with serially diluted inhibitor added from DMSO stock solution for 30 minutes. The assay was initiated by the addition of 20 nM 3H anandamide (175 μL) yielding a final assay volume of 350 ul and 3H anandamide substrate concentration of 10 nM. The reaction mixture was incubated for
30 minutes at room temperature, and the reaction stopped by the addition of 700 μL of methanol: chloroform (1 :1 v/v). This lyses the cells and inactivates the FAAH. The solution was vortexed and 3H ethanolamine, the radiolabeled product of 3H anandamide hydrolysis partitioning into the aqueous phase, and was counted via a scintillation counter. Data Analysis: The radioactivity in the aqueous phase was plotted with respect to inhibitor concentration to generate dose response inhibition curves, and the data fitted to determine the IC50.
Example 289 In Vivo Analysis of Boronic Acid and Boronic Ester Derivatives in a Pain Model
This assay may be used to evaluate the effect of the compounds of the present invention on the reflexive withdrawal of the rat from an acute noxious stimulus (hot surface).
(1) Heat plate to testing temperature (Hot plate analgesia meter; Harvard Apparatus) - takes about 10-15 min (the actual surface temperature is not reflected in the LED read out. The actual surface temperature is 10 0C less than the read out indicates). Read-out Surface temp 57 0C 47 0C
62 0C 52 0C
65 0C 55 0C (2) Place plexi-glass cylinder on hot plate. Place rat within cylinder and start timer.
When the rat either licks its hind paw or jumps, stop the timer and remove from hot plate. Record the response latency (in sec), usually 6-7 sec at 52 0C. Measure baseline latencies for all rats.
(3) Inject drug or vehicle. (4) Measure response 5, 15, 30, 60, 90, 120 min, etc. after drug injection. Cut-off time for 52 0C is 30 sec. A rat that does not respond by 30 sec. is assigned a latency of 30 sec.
(5) Clean hot plate surface in between time points with water, dry with kimwipe and wait until temperature read out has returned to 57 0C.
Data may be expressed as either latency or percent maximum possible effect [% MPE = (drug latency - baseline latency )/(cut-off- baseline latency) x 100].
Other temperatures may be used (e.g., 47 0C, 55 0C). Cut-off time should be adjusted accordingly (e.g., 40 sec at 47 0C; 20 sec at 55 0C). Increased temperatures recruit myelinated afferents (Aδ-fibers) whereas lower temperatures involve unmyelinated afferents (c-fibers). Sensitivity to drug effects may be altered with different plate temperatures. Example 290
Evidence for Covalent Complex Formation between Serine-241 of FAAH and Boronic Acid Inhibitors
Treatment of rat FAAH protein with the active site-directed irreversible inhibitor methoxy arachidonyl fluorophosphonate results in a crystal structure wherein methoxy arachidonyl phosphonate is covalently bound to the side chain of Ser-241 (Bracey et al., Science (2002) 298:1793-1796).
Based on this data, it is hypothesized that the boronic acid compounds provided by the present invention form reversible covalent complexes with the nucleophilic side chain of Ser- 241. This hypothesis is consistent with the kinetic data. Molecular modeling studies of aryl boronic acid compounds provided herein indicates that the aryl ring can be directed to bind either in the narrow hydrophobic channel of the enzyme near Ser241, which is confluent with the membrane portion and the acyl chain binding pocket, or alternatively bind toward the cytosolic portion. To distinguish between these two binding modes, a mutant protein was cloned and expressed which was identical to the rat FAAH protein sequence, except at four positions in the sequence: I491V, V495M, L192F, and F194Y. These four residues line the narrow hydrophobic channel near Ser-241 in the rat x-ray structure. Starting from the published X-ray crystal structure of rat FAAH, a 3-D homology model was built of human FAAH using the program Deep View (Nicolas Guex, Manuel Peitsch, Torsten Schwede Alexandre Diemand "Deep View / Swiss-Pdbviewer" (1995-2001)). Based on this 3-D homology model of the human protein, mutation of these four residues to the corresponding amino acids in the human sequence was predicted to significantly influence the binding of the aryl boronic acid compounds if the aryl ring is in close proximity to these residues. The inhibition constant (K1) was measured for a panel of eleven boronic acid-containing compounds differing in their ability to inhibit rat and human FAAH. Table B below summarizes the statistical analysis for the panel of eleven compounds, comparing the ratio of inhibition constants for the wild-type rat and human enzymes (R/H) to ratio of inhibition constants for the mutant rat and human enzymes (M/H). The data indicates that the compounds bind at Serine- 241 with the aryl ring directed toward the narrow hydrophobic channel.
Figure imgf000299_0001
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

CLAIMS We claim:
1. A pharmaceutically acceptable composition comprising a compound of formula (III):
Figure imgf000300_0001
(III) or a pharmaceutically acceptable salt or prodrug thereof; wherein:
(i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C1-
8 heteroalkyl, optionally substituted C2-s heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl;
(ii) Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom; or
(iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring;
W1 and W2 are independently selected from CR12, C and N;
X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-;
RA is hydrogen, halogen, -OR7, -CF3, -CN, -NO2, -SO2R7, -SOR7, -C(O)R7, -CO2R7, - C(O)N(R7)2, -N3, -N2R7, -N(R7)2, or Ring B having formula:
Figure imgf000300_0002
wherein Ring B is optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2,-N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl ; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_g alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, and R10 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R12 is, independently, hydrogen, halogen, -CF3, optionally substituted C i_8 alkyl, optionally substituted C2-8 alkenyl, or optionally substituted C2-8 alkynyl; n is, independently, 0, 1, 2 or 3 and m is 0, 1, 2, 3, 4 or 5.
2. The composition of claim 1 , wherein the compound is of formula (III-a):
Figure imgf000302_0001
3. The composition of claim 2, wherein the compound is of formula (III-c) or (III— d):
Figure imgf000302_0002
(III-c)
Figure imgf000302_0003
(III-d)
4. The composition of claim 1 , wherein the compound is of formula (III-e):
Figure imgf000303_0001
(III-e)
5. The composition of any one of claims 1, 2, 3 or 4, wherein W1 is CR12 or C and W2 is N.
6. Thecomposition of any one of claims 1 , 2, 3 or 4, wherein both W1 and W2 are N.
7. The composition of any one of claims 1, 2, 3 or 4, wherein both W1 and W2 are, independently, CR12 or C.
8. The composition of any one of claims 1, 2, 3 or 4, wherein RA is Ring B.
9. The composition of claim 8, wherein Ring B is an optionally substituted Cβ-io aryl.
10. Thecomposition of claim 8, wherein Ring B is an optionally substituted 5-10 membered heteroaryl.
11. The composition of claim 8, wherein Ring B is an optionally substituted C3_io carbocyclyl.
12. The composition of claim 8, wherein Ring B is an optionally substituted 3-10 membered heterocyclyl.
13. The composition of any one of claims 1, 2, 3 or 4, wherein X is a covalent bond,
C(O), -O-, -CH2O-, -OCH2-, -NR6-, - NR6CH2- or -CH2NR6-.
14. The composition of claim 13, wherein X is -O-, -CH2O-, or -OCH2-.
15. The composition of claim 1, wherein the compound is selected from any compound provided in Table 1.
16. Thecomposition of claim 1, wherein the compound is selected from any compound provided in Table 2.
17. Thecomposition of claim 1, wherein the compound is selected from the compound provided in Table 3.
18. A pharmaceutically acceptable composition comprising a compound of formula
(IV):
Figure imgf000304_0001
(IV) or pharmaceutically acceptable salt or prodrug thereof, wherein:
(i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_
8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl;
(ii) Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom; or (iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring; Y3, Y4 and Y5 each is independently selected from C, CR13, N, NR14, O and S, with the proviso that at least one of Y3, Y4 or Y5 is a heteroatom selected from N, NR14, O or S; Y6 is C or N; X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - 0-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-; RA is hydrogen, halogen, -OR7, -CF3, -CN, -NO2, -SO2R7, -SOR7, -C(O)R7, -CO2R7, -
C(O)N(R7)2, -CHO, -N3, -N2R7, -N(R7)2, or Ring B having formula:
(R2)m
wherein Ring B is optionally substituted C3_10 c.arbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -CHO, -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, R10 and R14 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R13 is, independently, hydrogen, halogen, -CF3, optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, or optionally substituted C2_g alkynyl; n is 0, 1, 2 or 3; and m is O, 1, 2, 3, 4 or 5.
19. The composition of claim 18, wherein the compound is of formula (IV-c):
Figure imgf000306_0001
(IV-c) or a pharmaceutically acceptable salt or prodrug thereof.
20. The composition of claim 18, wherein the compound is of either of formula (IV- a) or (IV-b):
Figure imgf000307_0001
(IV-a)
Figure imgf000307_0002
(IV-b) or a pharmaceutically acceptable salt or prodrug thereof.
21. The composition of claim 18, wherein the compound is of either of formula (IV-d) or (IV-e):
Figure imgf000307_0003
(IV-d)
Figure imgf000307_0004
(IV-e) or a pharmaceutically acceptable salt or prodrug thereof.
22. The composition of any one of claims 18 to 21, wherein Y is C.
23. The composition of claim 22, wherein Y3 is O or S; Y4 is C; and Y5 is N.
24. The composition of claim 22, wherein Y3 is O or S; and Y4 and Y5 are C or CR13.
25. The composition of claim 22, wherein Y3 and Y4 are N or NR14; and Y5 is C or
CR 13
26. The composition of claim 22, wherein Y3 and Y5 are N or NR14; and Y4 is C or CR 13
27. The composition of any one of claims 18 to 21 , wherein Y3 and Y6 are N; and Y4 and Y5 are C or CR13.
28. The composition of claim 18, wherein X is a covalent bond, -O-, or optionally substituted Ci_6 alkylene.
29. The composition of claim 18, wherein RA is Ring B.
30. The composition of claim 29, wherein Ring B is optionally substituted 3-10 membered heterocyclyl.
31. The composition of claim 29, wherein Ring B is optionally substituted C6-Io aryl.
32. The composition of claim 18, wherein the compound is selected from any of the compounds provided in Table 4.
33. The composition of claim 18, wherein the compound is selected from any of the compounds provided in Table 5.
34. The composition of claim 18, wherein the compound is selected from any of the compounds provided in Table 6.
35. The composition of claim 18, wherein the compound is selected from any of the compounds provided in Table 7.
36. The composition of claim 18, wherein the compound is selected from any of the compounds provided in Table 8.
37. A pharmaceutically acceptable composition comprising a compound of compound of formula (V):
Figure imgf000309_0001
(V) or a pharmaceutically acceptable salt or prodrug thereof; wherein:
(i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C1-
8 heteroalkyl, optionally substituted C2-s heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl;
(ii) Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom; or (iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring; W3 is C, CR15 Or N; X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - 0-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-; Het-B is an optionally substituted 3-10 membered heterocyclyl or an optionally substituted 5-10 membered heteroaryl ring; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -CHO, -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3-Io carbocyclyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted C i_8 heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_s heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9 and R10 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-w aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3-Io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl;
R15 is hydrogen, halogen, -CF3, optionally substituted Ci_s alkyl, optionally substituted C2-8 alkenyl, or optionally substituted C2-8 alkynyl; n is O, 1, 2 or 3 and m is O, 1, 2, 3, 4, or 5.
38. The composition of claim 37, wherein the compound is any of formula (V-b), (V-c) or (V-d):
Figure imgf000311_0001
Figure imgf000311_0002
(V-d) or a pharmaceutically acceptable salt or prodrug thereof.
39. The composition of claim 37, wherein W3 is C or CR15.
40. The composition of claim 37, wherein W is N.
41. The composition of claim 37, wherein:
Het-B is an optionally substituted 5-membered monocyclic heteroaryl ring having 2 to 3 heteroatoms selected from N, NR16, O and S, or an optionally substituted 9-membered bicyclic heteroaryl ring having 2 to 3 heteroatoms selected from N, NR16, O and S; and
R16 is hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl.
42. The composition of claim 37, wherein Het-B is an optionally substituted triazolyl, optionally substituted oxadiazolyl, optionally substituted thiadiazolyl, optionally substituted imidazolyl, optionally substituted pyrazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted benzthiazolyl, optionally substituted benzisothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzisoxazolyl, optionally substituted benzimidazolyl, or an optionally substituted indazolyl.
43. The composition of claim 37, wherein the compound is of formula:
Figure imgf000312_0001
(V-e) or a pharmaceutically acceptable salt or prodrug thereof; wherein Y1 is O, S or NR16, and R16 is hydrogen, -SO2R11, -SOR11, -C(O)R11, -CO2R11,
-C(O)N(R1 %, optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-s heteroalkynyl, optionally substituted C3_i0 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl.
44. The composition of claim 37, wherein X is a covalent bond, -O-, - (CH=CH) - Or -(CH2)-.
45. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 9.
46. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 10.
47. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 11.
48. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 12.
49. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 13.
50. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 14.
51. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 15.
52. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 16.
53. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 17.
54. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 18.
55. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 19.
56. The composition of claim 37, wherein the compound is selected from any of the compounds provided in Table 20.
57. A pharmaceutically acceptable composition comprising a compound of formula
(VI):
Figure imgf000314_0001
(VI) or a pharmaceutically acceptable salt or prodrug thereof, wherein:
(i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted C i_8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; (ii) Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom; or
(iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted 5- to 7-membered ring; Y9 is an S or O;
X is a covalent bond, -0-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the C i_6 alkylene are optionally and independently replaced with one or more groups selected from - 0-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-; Het-B is an optionally substituted 3-10 membered heterocyclyl or an optionally substituted 5-10 membered heteroaryl ring; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -CHO, -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl ; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted
C i_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, and R10 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; n is 0, 1, 2 or 3 and m is 0, 1, 2, 3, 4, or 5.
58. The composition of claim 54, wherein the compound is of formula (VI-e):
Figure imgf000316_0001
(VI-e)
59. The composition of claim 57, wherein the compound is selected from any of the compounds provided in Table 21.
60. A method of treating a painful condition, disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of the composition of any one of claims 1, 18, 37 or 57.
61. The method according to claim 59, wherein the painful syndrome, disease and/or disorder selected from neuropathic pain, central pain, deafferentiation pain, chronic pain, stimulus of nociceptive receptors, acute pain, non-inflammatory pain, inflammatory pain, pain associated with cancer, preoperative pain, arthritic pain, lumbosacral pain, musculo-skeletal pain, headache, migraine, muscle ache, lower back and neck pain, and toothache.
62. The method according to claim 61, wherein the painful syndrome, disease and/or disorder is neuropathic pain.
63. The method according to claim 61, wherein the painful syndrome, disease and/or disorder is arthritic pain.
64. The method according to claim 62, wherein the arthritic pain is osteoarthritic pain.
65. The method according to claim 63, wherein the arthritic pain is rheumatoid arthritic pain.
66. A method of treating an inflammatory disorder comprising administering to a patient in need thereof a therapeutically effective amount of the composition of any one of claims 1, 18, 37 or 57.
67. The method according to claim 66, wherein the inflammatory disorder is irritable bowel disease.
68. A compound of formula (V-e2):
Figure imgf000317_0001
(V-e2) or a pharmaceutically acceptable salt or prodrug thereof; wherein:
(i) Z1 is -OH or -OR3 and Z2 is -OH, -OR4, an optionally substituted Ci_8 alkyl, optionally substituted C2-8 alkenyl, optionally substituted C2-8 alkynyl, optionally substituted Ci_ 8 heteroalkyl, optionally substituted C2-8 heteroalkenyl, optionally substituted C2-8 heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-io aryl, or optionally substituted 5-10 membered heteroaryl;
(ii) Z1 and Z2 taken together with the boron atom to which they are bound, form a 5- to 8-membered ring having at least one O, S, N or NR5 atom directly bonded to the boron atom; or (iii) Z1 is -OH or -OR3, and Z2 and Ring A taken together form an optionally substituted
5- to 7-membered ring;
W3 is C, CR15, or N;
X is a covalent bond, -O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, - S(O)2-, or optionally substituted Ci_6 alkylene, wherein one, two or three methylene units of the Ci_6 alkylene are optionally and independently replaced with one or more groups selected from - O-, -N=N-, -C=N-, -NR6-, -C(NR6)-, -S-, -C(O)-, -S(O)-, and -S(O)2-; each instance of R1 is, independently, halogen, -OR8, -CF3, -CN, -NO2, -SO2R8, - SOR8, -C(O)R8, -CO2R8, -C(O)N(R8)2, -CHO, -N3, -N2R8, -N(R8)2, -B(OH2), optionally substituted Ci_g alkyl, optionally substituted C2_g alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_g heteroalkenyl, optionally substituted C2_g heteroalkynyl, optionally substituted C3_10 carbocyclyl, optionally substituted 3- 10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl ; each instance of R2 is, independently, halogen, -OR9, -CF3, -CN, -NO2, -SO2R9, - SOR9, -C(O)R9, -CO2R9, -C(O)N(R9)2, -N3, -N2R9, -N(R9)2, optionally substituted C1-* alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted
C i_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R3 and R4 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted Cβ-io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R5, R6, R7, R8, R9, and R10 is, independently, hydrogen, -SO2R11, - SOR11, -C(O)R11, -CO2R11, -C(0)N(Rπ)2, -C(O)NH(R11), -C(O)NH2, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, optionally substituted C2_8 alkynyl, optionally substituted Ci_8 heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl; each instance of R11 is, independently, optionally substituted Ci_8 alkyl, optionally substituted C2_s alkenyl, optionally substituted C2_g alkynyl, optionally substituted Ci_g heteroalkyl, optionally substituted C2_8 heteroalkenyl, optionally substituted C2_8 heteroalkynyl, optionally substituted C3_io carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-Io aryl, or optionally substituted 5-10 membered heteroaryl;
R15 is hydrogen, halogen, -CF3, optionally substituted Ci_8 alkyl, optionally substituted C2_8 alkenyl, or optionally substituted C2_g alkynyl; n is 0, 1, 2 or 3 and m is 0, 1, 2, 3, 4, or 5; with the proviso that the following compounds are specifically excluded:
Figure imgf000319_0001
69. The compound of claim 68, wherein the compound is of any of formula (V-e3), (V-e4) or (V-e5):
Figure imgf000319_0002
Figure imgf000320_0001
(V-e5) or a pharmaceutically acceptable salt or prodrug thereof.
70. The compound of claim 68, wherein W is C or CH.
71. The compound of claim 68, wherein W is N.
72. The compound of claim 68, wherein X is a covalent bond.
73. The compound of claim 68, wherein the compound is selected from any one of the compounds provided in Table 11.
PCT/US2009/039872 2008-04-09 2009-04-08 Inhibitors of fatty acid amide hydrolase WO2009126691A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2009233711A AU2009233711B2 (en) 2008-04-09 2009-04-08 Inhibitors of fatty acid amide hydrolase
CA2721060A CA2721060A1 (en) 2008-04-09 2009-04-08 Inhibitors of fatty acid amide hydrolase
JP2011504146A JP5637982B2 (en) 2008-04-09 2009-04-08 Inhibitors of fatty acid amide hydrolase
CN200980119527.3A CN102046179B (en) 2008-04-09 2009-04-08 Inhibitors of fatty acid amide hydrolase
EP09729529A EP2282742A1 (en) 2008-04-09 2009-04-08 Inhibitors of fatty acid amide hydrolase
IL208536A IL208536A0 (en) 2008-04-09 2010-10-07 Inhibitors of fatty acid amide hydrolase
US12/901,421 US8957049B2 (en) 2008-04-09 2010-10-08 Inhibitors of fatty acid amide hydrolase
US14/599,192 US20150368278A1 (en) 2008-04-09 2015-01-16 Inhibitors of fatty acid amide hydrolase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4368608P 2008-04-09 2008-04-09
US61/043,686 2008-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/901,421 Continuation US8957049B2 (en) 2008-04-09 2010-10-08 Inhibitors of fatty acid amide hydrolase

Publications (1)

Publication Number Publication Date
WO2009126691A1 true WO2009126691A1 (en) 2009-10-15

Family

ID=40912141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039872 WO2009126691A1 (en) 2008-04-09 2009-04-08 Inhibitors of fatty acid amide hydrolase

Country Status (12)

Country Link
US (2) US8957049B2 (en)
EP (1) EP2282742A1 (en)
JP (1) JP5637982B2 (en)
CN (1) CN102046179B (en)
AR (1) AR072249A1 (en)
AU (1) AU2009233711B2 (en)
CA (1) CA2721060A1 (en)
CL (1) CL2009000870A1 (en)
IL (1) IL208536A0 (en)
PE (1) PE20091838A1 (en)
TW (1) TW201000107A (en)
WO (1) WO2009126691A1 (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947663B2 (en) 2006-10-10 2011-05-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
EP2416660A1 (en) * 2009-04-07 2012-02-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US20120184768A1 (en) * 2009-09-25 2012-07-19 Peking University Preparation method of aromatic boronate compounds
JP2012232924A (en) * 2011-04-28 2012-11-29 Tosoh Corp Novel naphthyl boronic acid compound, and manufacturing method of the same
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
WO2014086664A1 (en) * 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole boronic acid compounds
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8859543B2 (en) 2010-03-09 2014-10-14 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8946238B2 (en) 2011-12-22 2015-02-03 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
US8957049B2 (en) 2008-04-09 2015-02-17 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8980878B2 (en) 2012-04-17 2015-03-17 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US9034849B2 (en) 2010-02-03 2015-05-19 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2015164213A1 (en) * 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
WO2015196258A1 (en) * 2014-06-26 2015-12-30 Monash University Enzyme interacting agents
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
JP2017522375A (en) * 2014-07-02 2017-08-10 ザビエル・ユニバーシティ・オブ・ルイジアナＸａｖｉｅｒ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｌｏｕｉｓｉａｎａ Boron-based prodrug strategy for increased bioavailability and lower required dose for drug molecules containing at least one phenol (or aromatic hydroxyl) group
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US10011594B2 (en) 2015-06-03 2018-07-03 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
US10172840B2 (en) 2014-12-01 2019-01-08 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10328053B2 (en) 2016-08-26 2019-06-25 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2021222637A1 (en) * 2020-04-30 2021-11-04 United States Government As Represented By The Department Of Veterans Affairs Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11492365B2 (en) 2020-02-07 2022-11-08 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
KR20220165359A (en) * 2021-06-08 2022-12-15 한국원자력의학원 Novel benzothiazole derivatives and use thereof in boron neutron capture therapy
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer
US12091407B2 (en) 2010-02-18 2024-09-17 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290504B2 (en) * 2011-07-19 2016-03-22 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (en) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Therapeutic compounds and their uses
MX355330B (en) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106800569B (en) * 2016-12-12 2019-04-16 上海中医药大学附属龙华医院 ATG analog and its preparation method and application
JP2019533641A (en) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018090717A1 (en) * 2016-11-16 2018-05-24 上海中医药大学附属龙华医院 Atg analogue, preparation method therefor and use thereof
CN109180712B (en) * 2018-08-08 2020-12-25 南京医科大学 2-arrowhead alcohol arylboronic acid ester derivatives and application thereof
CN109096043B (en) * 2018-08-24 2021-03-12 盐城师范学院 Synthesis method of 2, 5-dibromoiodobenzene
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN112147273B (en) * 2020-11-02 2022-08-16 北京市理化分析测试中心 Method for detecting trace acid in oil product
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4430042A1 (en) 2021-11-09 2024-09-18 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
KR102668048B1 (en) * 2022-08-02 2024-05-22 한국원자력의학원 Novel benzocyazole derivatives and uses thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2344817A (en) * 1998-12-15 2000-06-21 Clariant Gmbh Preparation of para-oxadiazolylphenylboronic acids
WO2000042213A1 (en) * 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
WO2002057273A1 (en) * 2001-01-20 2002-07-25 Trigen Limited Serine protease inhibitors comprising a hydrogen-bond acceptor
EP1236726A1 (en) * 1999-12-03 2002-09-04 Ono Pharmaceutical Co., Ltd. Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
EP1444981A1 (en) * 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
WO2004081008A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
WO2005080403A2 (en) * 2004-02-20 2005-09-01 Astrazeneca Ab Chemical process
US20050250825A1 (en) * 2000-08-23 2005-11-10 Brooks Dawn A Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
WO2007028104A2 (en) * 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US20070129544A1 (en) * 2005-12-01 2007-06-07 Jean Ackermann Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors
WO2007078340A2 (en) * 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007088148A1 (en) * 2006-02-01 2007-08-09 Smithkline Beecham Corporation Derivatives of thiophene carboxilic acid as antiviral agent
WO2007095638A2 (en) * 2006-02-16 2007-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
WO2007146965A2 (en) * 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Compounds for the treatment of periodontal disease
WO2008002674A2 (en) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
WO2008020920A1 (en) * 2006-08-15 2008-02-21 Duke University Ros-sensitive iron chelators and methods of using the same
WO2008063300A2 (en) * 2006-10-10 2008-05-29 Infinity Pharmaceuticals, Inc. Boronic acids and esters as inhibitors of fatty acid amide hydrolase

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1268808A (en) * 1985-07-23 1990-05-08 Alan G. Macdiarmid High capacity polyaniline electrodes
GB2201150B (en) * 1986-12-17 1991-04-24 Nii Prikladnych 2-(4,3-disubstituted phenyl)-5-alkyl-1,3,2-dioxaborinane derivatives and liquid crystal material
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) * 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3807862A1 (en) * 1988-03-10 1989-09-21 Merck Patent Gmbh SMEQUATIC LIQUID CRYSTAL PHASE
US5273680A (en) 1988-03-10 1993-12-28 Merck Patent Gesellschaft Mit Beschrankter Haftung Fluorinated oligophenyls and their use in liquid crystal materials
US5339163A (en) * 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (en) * 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP0440082B1 (en) 1990-02-01 1998-04-15 MERCK PATENT GmbH Method for the conversion of fluorinated aromatic compounds using electrophiles
DE4014488A1 (en) 1990-05-07 1991-11-14 Merck Patent Gmbh Novel dioxa:borinane(s) - for use in liq. crystal media for optical displays
US5190521A (en) * 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) * 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
DE59206518D1 (en) * 1991-02-25 1996-07-18 Hoffmann La Roche Liquid-crystalline compounds with a terminal 1-alkynyl radical
CA2109526C (en) 1991-04-30 1998-01-20 Dwight M. Peterson Liquid detergents with an aryl boroic acid
GB2258232B (en) 1991-07-31 1995-03-15 Merck Patent Gmbh Alkoxymethylene fluoroterphenyls and liquid crystalline medium
GB9118204D0 (en) * 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
CH683522A5 (en) 1992-03-13 1994-03-31 Hoffmann La Roche Process for the preparation of diaryls.
FR2688783A1 (en) 1992-03-23 1993-09-24 Rhone Poulenc Chimie NOVEL BORONES OF ONIUM OR ORGANOMETALLIC COMPLEX CATIONIC PRIMERS FOR POLYMERIZATION.
FR2688790B1 (en) * 1992-03-23 1994-05-13 Rhone Poulenc Chimie COMPOSITIONS BASED ON POLYORGANOSILOXANES WITH CROSSLINKABLE FUNCTIONAL GROUPS AND THEIR USE FOR THE PRODUCTION OF ANTI-ADHESIVE COATINGS.
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
PL167141B1 (en) 1992-05-12 1995-07-31 Wojskowa Akad Tech Method of obtaining liquid crystalline compounds containing a 1,3-dioxaborate ring
JP3255965B2 (en) 1992-05-26 2002-02-12 昭和シェル石油株式会社 Antiferroelectric liquid crystal compound
DE4220065A1 (en) 1992-06-19 1993-12-23 Merck Patent Gmbh Linear poly:cyclic pyrimidine and 2-phenyl-5-bromo-pyrimidine cpds. - aare useful in liquid crystal medium and as intermediates
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9220189D0 (en) * 1992-09-24 1992-11-04 Central Research Lab Ltd Dioxane derivatives
US5569189A (en) * 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
GB9220750D0 (en) * 1992-10-02 1992-11-18 Merck Patent Gmbh Liquid crystalline material forming ananisotropic
DE4236103A1 (en) * 1992-10-26 1994-04-28 Hoechst Ag Process for the cross-coupling of aromatic boronic acids with aromatic halogen compounds or perfluoroalkyl sulfonates
US5334144A (en) * 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW240217B (en) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5576220A (en) * 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
FR2702485B1 (en) 1993-03-10 1995-04-14 Rhone Poulenc Chimie Compositions based on cationically crosslinkable polyorganosiloxanes and their use in the field of paper anti-adhesion, protection of optical fibers and printed circuits.
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5417885A (en) * 1993-08-03 1995-05-23 Showa Shell Sekiyu Kabushiki Kaisha Antiferroelectric liquid crystal compound
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
JPH07145174A (en) 1993-11-22 1995-06-06 Takeda Chem Ind Ltd Dioxaborinane compound, its production, liquid crystal composition containing the compound and liquid crystal light-modulator produced by using the composition
JPH07165717A (en) 1993-12-16 1995-06-27 Sumitomo Chem Co Ltd Heterocyclic compound and its production
JPH07206715A (en) 1994-01-21 1995-08-08 Sumitomo Chem Co Ltd Production of heterocyclic compound
DE19502178A1 (en) 1994-01-27 1995-08-03 Hoechst Ag Novel 1,3,4-thiadiazole(s) useful as liq. crystal intermediates
WO1995024176A1 (en) * 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) * 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
JP3702426B2 (en) 1994-08-03 2005-10-05 関東化学株式会社 Trifluoromethylbenzene derivative and liquid crystal composition
FR2724660B1 (en) 1994-09-16 1997-01-31 Rhone Poulenc Chimie CATIONIC CROSSLINKING INITIATORS OF POLYMERS WITH ORGANOFUNCTIONAL GROUPS, COMPOSITIONS BASED ON CROSSLINKABLE POLYORGANOSILOXANE AND CONTAINING THESE INITIATORS AND APPLICATION OF THE SAID COMPOSITIONS IN ANTI-ADHERENCE
JPH0892137A (en) 1994-09-26 1996-04-09 Sumitomo Chem Co Ltd Aromatic esters, production and use thereof
FR2727416A1 (en) 1994-11-24 1996-05-31 Rhone Poulenc Chimie Heat activated cationic polymerisation and crosslinking initiators
DE4445224B4 (en) 1994-12-17 2014-03-27 Merck Patent Gmbh benzene derivatives
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
JP3783246B2 (en) 1995-07-18 2006-06-07 大日本インキ化学工業株式会社 p-terphenyl derivatives
DE59605843D1 (en) * 1995-07-28 2000-10-12 Rolic Ag Zug Photocrosslinkable liquid crystalline 1,2-phenylene derivatives
EP0846670A4 (en) 1995-08-09 1999-01-13 Chisso Corp Cyclohexane derivatives and liquid-crystal compositions
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
FR2745288B1 (en) 1996-02-27 1998-04-17 Adir NOVEL BORONIC ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9605334D0 (en) 1996-03-13 1996-05-15 British Nuclear Fuels Plc Biodecontamination reactor
JP3555325B2 (en) 1996-04-12 2004-08-18 チッソ株式会社 Method for producing biaryl derivative
US5892131A (en) * 1997-05-29 1999-04-06 American Cyanamid Company Process for the preparation of pesticidal fluoroolefin compounds
US5998673A (en) 1996-06-03 1999-12-07 American Cyanamid Company 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
US5849958A (en) 1997-03-17 1998-12-15 American Cyanamid Company 1,4,diaryl-2-fluoro-2-butene insecticidal and acaricidal agents
BG63255B1 (en) 1996-06-03 2001-07-31 American Cyanamid Company 1,4-diaryl-2-fluoro-2-butene insecticide and acaricidal formulations
ZA974582B (en) 1996-06-03 1998-11-26 American Cyanamid Co Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH1025261A (en) 1996-07-09 1998-01-27 Chisso Corp Production of phenol derivative
CN1232443A (en) * 1996-07-31 1999-10-20 盐野义制药株式会社 Novel p-terphenyl compounds
JP3899557B2 (en) 1996-08-21 2007-03-28 大日本インキ化学工業株式会社 Fluorobibiphenyl derivatives
FR2752582B1 (en) * 1996-08-21 2003-06-13 Rhone Poulenc Chimie POLYORGANOSILOXANE COMPOSITIONS HAVING CROSS-LINKED FUNCTIONAL GROUPS AND THEIR USE FOR MAKING ANTI-ADHERENT COATINGS
JP4526605B2 (en) * 1996-08-28 2010-08-18 チッソ株式会社 Tetracyclic compound having lateral halogen substituent and liquid crystal composition
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
FR2757530A1 (en) 1996-12-24 1998-06-26 Rhodia Chimie Sa USE FOR STEREOPHOTOLITHOGRAPHY - A CATIONIC PHOTORETICULABLE LIQUID COMPOSITION COMPRISING A PHOTOAMORER OF THE ONIUM SALTS OR ORGANOMETALLIC COMPLEX TYPE
FR2757870B1 (en) * 1996-12-30 1999-03-26 Rhodia Chimie Sa USE OF CATIONICALLY CROSSLINKABLE SILICONE COMPOSITIONS AND AN ONIUM BORATE PHOTO-PRIMER FOR COATING FLAT JOINTS, PARTICULARLY CYLINDER JOINTS
FR2758329B1 (en) 1997-01-16 1999-02-12 Synthelabo BORONIC IMIDAZOLE-4-BUTANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2758560B1 (en) 1997-01-20 2000-02-04 Adir NEW DERIVATIVES OF AMINOPHENYLBORONIC ACIDS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2758723B1 (en) * 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
WO1998035924A1 (en) 1997-02-13 1998-08-20 Chisso Corporation Liquid-crystalline compounds having bicyclo[1.1.1]pentane structure, liquid-crystal composition, and liquid-crystal display element
DE19710614A1 (en) 1997-03-14 1998-09-17 Hoechst Ag Di:substituted 1,2,4-thiadiazole derivative preparation
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JP2002504122A (en) * 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー Beta-lactamase inhibitors and methods of use
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
DZ2769A1 (en) 1998-04-17 2003-12-01 Lilly Co Eli Substituted tricyclics.
DE19909761A1 (en) 1998-04-17 1999-10-21 Merck Patent Gmbh New optically inactive benzo(b)furan, benzo(1,2-b:4,5-b')difuran and benzo(1,2-b:5,4-b')difuran derivatives, used in liquid crystal media
JP2000001463A (en) 1998-06-12 2000-01-07 Dainippon Ink & Chem Inc Production of 4-cynobenzene derivative
GB9814450D0 (en) 1998-07-04 1998-09-02 Sharp Kk Novel compounds
GB2339778A (en) 1998-07-17 2000-02-09 Secr Defence Terphenyl Liquid Crystals
WO2000020466A1 (en) 1998-10-01 2000-04-13 Targor Gmbh Catalyst system
DE19858594A1 (en) 1998-12-18 2000-06-21 Merck Patent Gmbh Cyanobenzene-boronic acid or ester preparation in high yield comprises treating halo-benzonitrile and trialkyl borate with alkyl lithium, used as intermediate e.g. for liquid crystals, pesticides or drugs
DE59904576D1 (en) * 1998-12-19 2003-04-17 Basell Polyolefine Gmbh METHOD FOR PRODUCING MONO OR DI ORGANO BORANES
JP4507294B2 (en) 1999-05-27 2010-07-21 チッソ株式会社 Method for producing biaryl derivative
JP2003509507A (en) 1999-09-21 2003-03-11 キネティック リミテッド Liquid crystal compound
US6309406B1 (en) * 1999-11-24 2001-10-30 Hamit-Darwin-Fresh, Inc. Apparatus and method for inducing epileptic seizures in test animals for anticonvulsant drug screening
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
FR2805273B1 (en) * 2000-02-18 2006-08-11 Rhodia Chimie Sa SURFACE TREATMENT OF PLASTIC MATERIAL WITH A POLYMERIZABLE AND / OR CROSS-REACTIVE REACTIVE FUNCTION COMPOSITION
DE10009714A1 (en) 2000-03-01 2001-09-06 Targor Gmbh Preparation of main group III element mono- or di-organo-compound, e.g. halogenated diorgano-hydroxyborane used as precursor for cocatalyst in olefin polymerization with metallocene, uses two-stage, preferably one-pot reaction
GB2362882A (en) 2000-06-02 2001-12-05 Sharp Kk Liquid crystalline optionally laterally fluorinated terphenyl with chiral 3,4-di[(un)saturated-alkoxy]butoxy or 1,4-di[(un)saturated-alkoxy]but-2-oxy terminus
AU2001287399A1 (en) 2000-08-16 2002-02-25 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
US6927216B2 (en) * 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
ES2335478T3 (en) * 2000-10-05 2010-03-29 Millennium Pharmaceuticals, Inc. 32144, A HUMAN HYDROLASE OF AMIDAS OF FATTY ACIDS AND ITS USES.
GB0100110D0 (en) 2001-01-04 2001-02-14 Univ Leeds Modulation of calcium channel activity
JP4721027B2 (en) 2001-03-29 2011-07-13 Ｄｉｃ株式会社 Method for producing phenylpyrimidine derivative
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
US6858592B2 (en) * 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US6617125B2 (en) * 2001-06-29 2003-09-09 Perkinelmer Life Sciences, Inc. Compositions for enhanced catalyzed reporter deposition
DE60205824T2 (en) * 2001-07-09 2006-05-18 Merck Patent Gmbh Thienothiophenderivate
BR0213639A (en) * 2001-10-12 2004-09-14 Dow Global Technologies Inc Metal complex compositions and their use as catalysts to produce polydienes
DE60219569T2 (en) * 2001-11-07 2007-12-27 Merck Patent Gmbh Liquid crystalline compound, liquid crystalline medium and liquid crystal display
GB0126844D0 (en) * 2001-11-08 2002-01-02 Qinetiq Ltd Novel compounds
CA2466870A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
KR20040077660A (en) * 2001-12-12 2004-09-06 가부시끼가이샤 도꾸야마 Organic electroluminescent materials
DE10201764A1 (en) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituted 4-aminopyridine derivatives
WO2003064484A1 (en) 2002-01-28 2003-08-07 Dow Global Technologies Inc. Metal complex compositions based on cobalt and their use as polymerization catalyst for olefins and dienes
DE10206759A1 (en) * 2002-02-19 2003-08-28 Dragoco Gerberding Co Ag Use of 1,2-alkanediol mixture as an antimicrobial agent, e.g. for treating body odor, acne or mycoses or preserving perishable products
DE10211597A1 (en) * 2002-03-15 2003-10-02 Merck Patent Gmbh Process for the production of ring connections
EP1546086A2 (en) * 2002-06-27 2005-06-29 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
EP1388538B1 (en) 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
US20040115475A1 (en) * 2002-08-14 2004-06-17 Matsushita Electric Industrial Co., Ltd. Aromatic methylidene compound, methylstyrul compound for producing the same, production electroluminescent element
AU2003290780B2 (en) 2002-11-14 2009-05-07 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (FAAH)
EP1565450B1 (en) * 2002-11-27 2007-07-04 MERCK PATENT GmbH Tetrahydropyran derivatives
US6924269B2 (en) * 2002-12-04 2005-08-02 Vdf Futureceuticals, Inc. Enzyme inhibitors and methods therefor
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
US7456169B2 (en) * 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
EP1599475A2 (en) * 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
WO2004080989A1 (en) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited Process for production of furan compounds
JP2004292766A (en) * 2003-03-28 2004-10-21 Tokuyama Corp Organic electroluminescent element material
DE10325438A1 (en) * 2003-05-21 2004-12-09 Bayer Cropscience Ag Difluormethylbenzanilide
EP2492264A3 (en) 2003-06-03 2012-12-19 Rib-X Pharmaceuticals, Inc. Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same
US7183267B2 (en) 2003-06-10 2007-02-27 The Johns Hopkins University β-lactamase inhibitors and methods of use thereof
US7465836B2 (en) 2003-06-16 2008-12-16 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
DE10337497A1 (en) * 2003-08-14 2005-03-10 Bayer Cropscience Ag 4-biphenyl-pyrazolidine-3,5-dione derivatives
WO2005037227A2 (en) 2003-10-16 2005-04-28 Microbia, Inc. Selective cox-2 inhibitors
JP2007512244A (en) 2003-10-31 2007-05-17 フルクラム・ファーマシューティカルズ・インコーポレーテッド Coronavirus protease inhibitors and methods of use thereof
DK1682499T3 (en) * 2003-11-10 2008-01-02 Microbia Inc 4-biarylyl-1-phenylazetidin-2-ones
US20070010559A1 (en) * 2003-11-25 2007-01-11 Novo Nordisk A/S Indole derivatives for use as chemical uncoupler
JP4491666B2 (en) 2003-12-02 2010-06-30 東ソー株式会社 Method for producing arylamine derivative having fluorene skeleton and synthetic intermediate thereof
GB2410745B (en) 2004-02-06 2007-07-25 Merck Patent Gmbh Cholestanyl derivatives
EP1717230B1 (en) * 2004-02-13 2014-08-06 Msd K.K. Fused-ring 4-oxopyrimidine derivative
DE102004041530A1 (en) * 2004-08-27 2006-03-02 Bayer Cropscience Ag biphenyl thiazole carboxamides
DE102004041532A1 (en) 2004-08-27 2006-03-02 Bayer Cropscience Ag biphenyl thiazole carboxamides
US20100286211A1 (en) * 2004-10-08 2010-11-11 Biswajit Das Oxazolidinone derivatives as antimicrobials
JP2008518923A (en) 2004-11-01 2008-06-05 ヌアダ，リミテッド・ライアビリティ・カンパニー Compounds and methods of use thereof
WO2006050236A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050054A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
KR20070086076A (en) 2004-11-12 2007-08-27 트러스티즈 오브 터프츠 칼리지 Lipase inhibitors
DE102005023834A1 (en) * 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituted [(phenylethanoyl) amino] benzamide
WO2006060625A2 (en) * 2004-12-02 2006-06-08 Displaytech, Inc. Liquid crystal compositions comprising an organogermanium compound and methods for using the same
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
US20060211698A1 (en) 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
US20090005321A1 (en) * 2005-02-09 2009-01-01 Microbia, Inc. Phenylazetidinone Derivatives
EP2987796B1 (en) * 2005-02-16 2018-08-08 Anacor Pharmaceuticals, Inc. Halogen-substituted boronophthalides for the treatment of infections
JP5308676B2 (en) 2005-02-22 2013-10-09 住友化学株式会社 High band gap arylene polymer
US7589066B2 (en) 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
GB2424881B (en) 2005-04-07 2010-11-24 Merck Patent Gmbh Halophenyl derivatives of bisalkylfluorene
JP4792796B2 (en) 2005-04-08 2011-10-12 東ソー株式会社 2,3-Dihalobiphenylene derivative, precursor compound thereof and production method thereof
EP1879860A2 (en) 2005-05-10 2008-01-23 Microbia Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006124713A2 (en) 2005-05-13 2006-11-23 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
EP1726581A1 (en) 2005-05-25 2006-11-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthesis of novel monomers containing the Trifluorovinylidene-group and the Cyanato-group and polymers thereof
CA2610659A1 (en) 2005-06-14 2006-12-21 Merck Frosst Canada Ltd. Reversible inhibitors of monoamine oxidase a and b
KR100659088B1 (en) * 2005-07-15 2006-12-21 삼성에스디아이 주식회사 Difluoropyridine-based compound and organic light-emitting device employing the same
TW200740823A (en) * 2005-08-01 2007-11-01 Ihara Chemical Ind Co Oxadiazole-substituted Sym-triindole derivative and organic el element employing the same
DE102005037925A1 (en) 2005-08-11 2007-02-15 Merck Patent Gmbh New hydro-cyclopentanaphthalene compound, useful as a component for a liquid crystalline medium, which is used as a component for an electrooptical display element
EP1926706B1 (en) * 2005-09-13 2012-03-21 Bayer CropScience AG Pesticide bi-phenyl-amidine derivatives
CN101336124B (en) 2005-12-02 2012-06-13 塞克姆公司 Anion-exchange displacement chromatography process and anionic organic compounds for use as displacer compounds in anion-exchange displacement chromatography
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
DE102007009944B4 (en) 2006-03-15 2016-04-28 Merck Patent Gmbh Liquid-crystalline medium and its use
BRPI0710133A2 (en) 2006-04-13 2012-10-30 Aegera Therapeutics Inc use of imidazo [2,1-b] -1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain
JP5145753B2 (en) 2006-04-20 2013-02-20 Ｊｎｃ株式会社 Compound having fluoroisopropyl group as side chain and liquid crystal composition using the same
CA2653056A1 (en) 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
US8034940B2 (en) * 2006-08-09 2011-10-11 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
ATE515553T1 (en) 2006-08-16 2011-07-15 Merck Patent Gmbh CYCLOHEXENE COMPOUNDS FOR LIQUID CRYSTALLINE MIXTURES
DE502007004625D1 (en) * 2006-09-13 2010-09-16 Merck Patent Gmbh Fluorophenyl compounds for liquid crystalline mixtures
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
KR101181194B1 (en) 2006-10-18 2012-09-18 화이자 프로덕츠 인코포레이티드 Biaryl ether urea compounds
KR101435236B1 (en) 2007-01-24 2014-08-28 제이엔씨 석유 화학 주식회사 Liquid crystalline compound, liquid crystal composition, liquid crystal display element
JP5299265B2 (en) 2007-02-28 2013-09-25 Ｊｎｃ石油化学株式会社 Pentacyclic liquid crystal compound having CF2O bond group, liquid crystal composition, and liquid crystal display device
JP2010520873A (en) * 2007-03-07 2010-06-17 ドン・ア・ファーム・カンパニー・リミテッド Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, methods thereof and pharmaceutical compositions containing the same
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009011904A1 (en) 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
US8237002B2 (en) 2008-05-08 2012-08-07 Sumitomo Chemical Company, Limited Method for producing unsaturated organic compound
DE102008023801A1 (en) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituted imidazo and triazolopyrimidines, imidazo and pyrazolopyrazines and imidazotriazines

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2344817A (en) * 1998-12-15 2000-06-21 Clariant Gmbh Preparation of para-oxadiazolylphenylboronic acids
WO2000042213A1 (en) * 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
EP1236726A1 (en) * 1999-12-03 2002-09-04 Ono Pharmaceutical Co., Ltd. Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient
US20050250825A1 (en) * 2000-08-23 2005-11-10 Brooks Dawn A Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
WO2002057273A1 (en) * 2001-01-20 2002-07-25 Trigen Limited Serine protease inhibitors comprising a hydrogen-bond acceptor
EP1444981A1 (en) * 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
WO2004081008A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
WO2005080403A2 (en) * 2004-02-20 2005-09-01 Astrazeneca Ab Chemical process
WO2007028104A2 (en) * 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US20070129544A1 (en) * 2005-12-01 2007-06-07 Jean Ackermann Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors
WO2007078340A2 (en) * 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007088148A1 (en) * 2006-02-01 2007-08-09 Smithkline Beecham Corporation Derivatives of thiophene carboxilic acid as antiviral agent
WO2007095638A2 (en) * 2006-02-16 2007-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
WO2007146965A2 (en) * 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Compounds for the treatment of periodontal disease
WO2008002674A2 (en) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
WO2008020920A1 (en) * 2006-08-15 2008-02-21 Duke University Ros-sensitive iron chelators and methods of using the same
WO2008063300A2 (en) * 2006-10-10 2008-05-29 Infinity Pharmaceuticals, Inc. Boronic acids and esters as inhibitors of fatty acid amide hydrolase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNA MINKKILÄ, SUSANNA M. SAARIO, HEIKKI KÄSNÄNEN,JUKKA LEPPÄNEN,ANTTI POSO AND TAPOI NEVALAINEN: "Discovery of Boronic Acids as Novel and Potent Inhibitors of Fatty Acid Amide Hydrolase", JOURNAL OF MEDICAL CHEMISTRY, vol. 51, 11 May 2008 (2008-05-11), pages 7057 - 7060, XP002541905 *
MILLER M C ET AL: "THE HYPOLIPIDEMIC AND ANTI-INFLAMMATORY ACTIVITY OF BORONATED AROMATIC AMINO ACIDS IN CF MALE MICE", METAL-BASED DRUGS, FREUND PUBLISHING HOUSE, TEL AVIV, IL, vol. 6, no. 6, 1 January 1999 (1999-01-01), pages 337 - 344, XP007904657, ISSN: 0793-0291 *
SÉVERINE VANDEVOORDE: "Overview of the Chemical Families of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibitors", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 8, 2008, pages 247 - 267, XP002541906 *
TORU ASANO, HIROYUKI NAKAMURA, YOSHIMASA UEHARA AND YOSHINORI YAMAOTO: "Design, Synthesis, and Biological Evaluation of Aminoboronic Acids as Growth-Factor Receptor Inhibiors of EHFR and VEGFR-1 Tyrosine Kinases", CHEMBIOCHEM, vol. 5, 2004, Weinheim, pages 483 - 490, XP002541903 *
WENQIAN YANG, XINGMING GAO, BINGHE WANG: "Boronic Acids Compounds as Potential Pharmaceutical Agents", MEDICINAL RESEARCH REVIEWS, vol. 23, no. 3, 2003, pages 346 - 368, XP002541904 *
WINUM J Y ET AL: "Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 15, no. 13, 1 July 2005 (2005-07-01), pages 3302 - 3306, XP025313749, ISSN: 0960-894X, [retrieved on 20050701] *

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108989B2 (en) 2006-10-10 2015-08-18 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US7947663B2 (en) 2006-10-10 2011-05-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8957049B2 (en) 2008-04-09 2015-02-17 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660A1 (en) * 2009-04-07 2012-02-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660A4 (en) * 2009-04-07 2012-09-19 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
US8802119B2 (en) 2009-04-07 2014-08-12 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8802064B2 (en) 2009-04-07 2014-08-12 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9062116B2 (en) 2009-04-23 2015-06-23 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US20120184768A1 (en) * 2009-09-25 2012-07-19 Peking University Preparation method of aromatic boronate compounds
US9035084B2 (en) * 2009-09-25 2015-05-19 Peking University Preparation method of aromatic boronate compounds
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US9034849B2 (en) 2010-02-03 2015-05-19 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
US9951089B2 (en) 2010-02-03 2018-04-24 Infinity Pharmaceuticals, Inc. Methods of treating a fatty acid amide hydrolase-mediated condition
US11649230B2 (en) 2010-02-18 2023-05-16 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US10570126B2 (en) 2010-02-18 2020-02-25 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US12091407B2 (en) 2010-02-18 2024-09-17 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US11130753B2 (en) 2010-02-18 2021-09-28 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US10030011B2 (en) 2010-02-18 2018-07-24 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US10287284B2 (en) 2010-02-18 2019-05-14 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8859543B2 (en) 2010-03-09 2014-10-14 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
US9957275B2 (en) 2010-06-24 2018-05-01 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
US9238039B2 (en) 2010-06-24 2016-01-19 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US8809330B2 (en) 2010-06-24 2014-08-19 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US10314845B2 (en) 2010-10-06 2019-06-11 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9156797B2 (en) 2010-10-06 2015-10-13 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10660898B2 (en) 2010-10-06 2020-05-26 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9062003B2 (en) 2010-10-06 2015-06-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9872860B2 (en) 2010-10-06 2018-01-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9453007B2 (en) 2010-12-22 2016-09-27 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9567355B2 (en) 2010-12-22 2017-02-14 Abbvie Inc. Hepatitis C inhibitors and uses thereof
JP2012232924A (en) * 2011-04-28 2012-11-29 Tosoh Corp Novel naphthyl boronic acid compound, and manufacturing method of the same
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
US8946238B2 (en) 2011-12-22 2015-02-03 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
US9278975B2 (en) 2011-12-22 2016-03-08 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
US8980878B2 (en) 2012-04-17 2015-03-17 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US9504689B2 (en) 2012-04-17 2016-11-29 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US10174038B2 (en) 2012-04-17 2019-01-08 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
RU2625801C2 (en) * 2012-12-03 2017-07-19 Ф. Хоффманн-Ля Рош Аг Connections of substituted triazolbronic acid
CN104822689A (en) * 2012-12-03 2015-08-05 弗·哈夫曼-拉罗切有限公司 Substituted triazole boronic acid compounds
KR101782235B1 (en) 2012-12-03 2017-09-26 에프. 호프만-라 로슈 아게 Substituted triazole boronic acid compounds
WO2014086664A1 (en) * 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole boronic acid compounds
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
EP3134418A4 (en) * 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US10435418B2 (en) 2014-04-23 2019-10-08 The Research Foundation for the State University o Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
WO2015164213A1 (en) * 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US9758533B2 (en) 2014-04-23 2017-09-12 The Research Foundation For The State University Of New York Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
WO2015196258A1 (en) * 2014-06-26 2015-12-30 Monash University Enzyme interacting agents
US9828351B2 (en) 2014-06-26 2017-11-28 Monash University Enzyme interacting agents
AU2015281799B2 (en) * 2014-06-26 2019-11-28 Central Adelaide Local Health Network Incorporated Enzyme interacting agents
EP3164405A4 (en) * 2014-07-02 2018-05-23 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
JP2017522375A (en) * 2014-07-02 2017-08-10 ザビエル・ユニバーシティ・オブ・ルイジアナＸａｖｉｅｒ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｌｏｕｉｓｉａｎａ Boron-based prodrug strategy for increased bioavailability and lower required dose for drug molecules containing at least one phenol (or aromatic hydroxyl) group
US10898475B2 (en) 2014-12-01 2021-01-26 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10172840B2 (en) 2014-12-01 2019-01-08 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10463652B2 (en) 2014-12-01 2019-11-05 Vtv Therapeutics Llc Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
US10011594B2 (en) 2015-06-03 2018-07-03 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
US10336739B2 (en) 2015-06-03 2019-07-02 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists
US10328053B2 (en) 2016-08-26 2019-06-25 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US10874640B2 (en) 2016-08-26 2020-12-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US11420974B2 (en) 2018-02-26 2022-08-23 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11944622B2 (en) 2018-10-05 2024-04-02 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11919887B2 (en) 2019-12-06 2024-03-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11926643B2 (en) 2020-02-07 2024-03-12 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
US11492365B2 (en) 2020-02-07 2022-11-08 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
US11643394B2 (en) 2020-04-30 2023-05-09 Icahn School Of Medicine At Mount Sinai Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease
WO2021222637A1 (en) * 2020-04-30 2021-11-04 United States Government As Represented By The Department Of Veterans Affairs Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
KR102567789B1 (en) * 2021-06-08 2023-08-17 한국원자력의학원 Novel benzothiazole derivatives and use thereof in boron neutron capture therapy
KR20220165359A (en) * 2021-06-08 2022-12-15 한국원자력의학원 Novel benzothiazole derivatives and use thereof in boron neutron capture therapy
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer
US12084434B2 (en) 2021-06-14 2024-09-10 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators

Also Published As

Publication number Publication date
IL208536A0 (en) 2010-12-30
EP2282742A1 (en) 2011-02-16
AU2009233711A1 (en) 2009-10-15
PE20091838A1 (en) 2009-12-18
CN102046179B (en) 2015-01-14
CA2721060A1 (en) 2009-10-15
AU2009233711B2 (en) 2015-02-12
JP2011516564A (en) 2011-05-26
US8957049B2 (en) 2015-02-17
TW201000107A (en) 2010-01-01
JP5637982B2 (en) 2014-12-10
US20110172186A1 (en) 2011-07-14
AR072249A1 (en) 2010-08-18
CN102046179A (en) 2011-05-04
CL2009000870A1 (en) 2010-06-25
US20150368278A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
AU2009233711B2 (en) Inhibitors of fatty acid amide hydrolase
CA2666224C (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
JP6152167B2 (en) Ring-restricted analogs as arginase inhibitors
CA3042731A1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US8802119B2 (en) Inhibitors of fatty acid amide hydrolase
WO2013049332A1 (en) Inhibitors of monoacylglycerol lipase and methods of their use
US20180244700A1 (en) Methods of treating a fatty acid amide hydrolase-mediated condition
US8802064B2 (en) Inhibitors of fatty acid amide hydrolase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980119527.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09729529

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2009729529

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009729529

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2721060

Country of ref document: CA

Ref document number: 2011504146

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009233711

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009233711

Country of ref document: AU

Date of ref document: 20090408

Kind code of ref document: A